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Abstract 
 
Malaria is a vector-borne parasitic disease spread by a bite of an infected female Anopheles 
mosquito that accounts for high morbidity and mortality, mainly in sub-Saharan Africa. Of 
the five species that can cause malaria in humans, Plasmodium falciparum is regarded the 
most virulent species. Antimalarial drugs, unaltered for many decades, remain the mainstay 
for treating P. falciparum infection. In addition, despite intensive research there remain 
significant knowledge gaps in understanding of the biology of the malaria parasite P. 
falciparum. These deficiencies hinder the ability of scientists to identify new targets for 
drug discovery at a time when new targets are urgently required, such as in the case of 
newly emerging drug resistant parasite strains. Therefore, an understanding of the biology 
of P. falciparum is helpful in identifying new drug targets. Metabolomics, defined as the 
comprehensive analysis of all metabolites in a biological system, offers a feasible platform 
for highly sensitive and specific analysis of the metabolic pathways of P. falciparum. This 
is supported by the assumption that metabolites are important players in biological systems 
and that resistant parasite strains may operate or alter single or multiple metabolic 
pathways in order to adapt to the drugs being used. Therefore, a targeted metabolomics 
approach was developed and validated (Chapter 3) in order to better understand the 
metabolic roles of mitochondria and the digestive vacuole of P. falciparum. Metabolite 
detection and quantification were conducted using a targeted LC-MS/MS metabolomics 
approach (Chapter 3). It was shown that metabolic activities, particularly carbohydrate 
metabolism, in trophozoite stage P. falciparum-infected RBC were remarkably higher than 
that of non-infected RBC (Chapter 4). This lead the study to progress further, examining 
the metabolic role of two components of the P. falciparum; the mitochondria and the 
digestive vacuole. A number of mitochondrial inhibitors selective for specific electron 
transport chain complexes and mitochondrial transporters were used to assess 
mitochondrial function in asexually growing trophozoite stage P. falciparum (Chapter 5 
and 6). Despite the differing modes of action of the inhibitors, the metabolic fingerprints, 
which were carbamoyl-l-aspartate and dihydroorotate, from these experiments were 
consistent with the parasite mitochondrion playing a key role in pyrimidine biosynthesis at 
the point of dihydroorotate dehydrogenase (DHODH) (Chapter 5 and 6). This metabolic 
fingerprint, leading to parasite death, was quite distinct from fingerprints obtained from 
biologically distinct inhibitors such as heme-binding drugs (quinoline-containing 
antimalarials drugs) which primarily affected the metabolism of amino acids, perhaps in the 
digestive vacuole and parasite cytosol (Chapter 7). In contrast to genomic and proteomic 
approaches, metabolomics appears to better represent the parasites’ phenotype in response 
to drug perturbation. Pharmacometabolomics will therefore have significant utility in 
understanding the biological function of parasite components; and the mode of action, 
efficacy and toxicity of pharmaceutical drugs. 
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CHAPTER 1   
General Introduction  
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 Overview 1.1.
Malaria is a tropical disease of immense importance in many parts of the world. It 
continues to be one of the main causes of morbidity and mortality in the world particularly 
tropical countries (Bruce-Chwatt, 1987, Murray et al., 2012, Guerin et al., 2002). Malaria is 
transmitted by a bite of the infected female Anopheles mosquito. Malaria is caused by 
Plasmodium species parasite that lives one part of its life cycle in vertebrates (humans, 
animals, birds) and continues its life cycle in dipteran vectors (mosquitoes). Four major 
species of Plasmodium parasites can establish malaria in humans namely; Plasmodium 
falciparum, Plasmodium vivax, Plasmodium ovale and Plasmodium malariae.  The 
monkey’s  parasite, Plasmodium knowlesi, has been recently recognized as a fifth human 
malaria parasite (Cox-Singh and Singh, 2008, Cox-Singh et al., 2008, White, 2008a). 
Despite the fact that human malaria is not considered as a zoonotic disease, P. knowlesi can 
establish a malaria disease in monkeys and humans, and can be transmitted from monkeys 
to humans (White, 2008a, Singh et al., 2004). 
  
Malaria has had a greater impact on global history than any other infectious disease, 
impacting the outcome of wars, population travels and the development of various nations. 
It places a heavy economic burden on many endemic countries, contributing to the cycle of 
poverty and limiting economic development. In 1958, President of the United State of 
America Eisenhower announced in his speech for the State of the Union bold and 
enthusiastic plan to clear and end malaria in five years’ time: 
 
“Another kind of work of peace is cooperation on projects 
of human welfare. For example, we now have it within our 
power to eradicate from the face of the earth that age-old 
scourge of mankind: malaria. We are embarking with other 
nations in an all-out five-year campaign to blot out this 
curse forever. We invite the Soviets to join with us in this 
great work of humanity.” Eisenhower, USA President 
(1953 - 1961). 
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In 2013, fifty five years later, malaria still remains one of the deadliest infectious diseases 
today despite decades of enormous efforts to eradicate the disease during 1950s and 1960s.  
The failure of vaccine trials, the continued emergence of drug-resistant strains of 
Plasmodium, the appearance of insecticide resistance mosquitoes, global environmental 
changes and an ever increasing population makes the idea of malaria eradication an 
extremely challenging task for researchers, clinicians and politicians across the world.  
 
 Malaria as a Disease  1.2.
1.2.1. Malaria in Human History: Key Discoveries  
The trophozoite-derived P. falciparum histidine-rich protein-2 antigen (PfHRP-2) has been 
detected in skin, muscle, brain and lung samples from naturally desiccated  Egyptian 
mummies dating from 3200 BC (Miller et al., 1994). The first written description of 
characteristic poor health, periodic fevers and enlarged spleens were documented in China, 
around 2700 BC (Cox, 2002, Cox, 2010). This documentation was continuing through the 
writings of Greek, Roman, Assyrian, Indian, Arabic and European physicians up to the 
nineteenth century (Cox, 2002, Cox, 2010, Sterling, 1978, Bruce-Chwatt, 1987). In the 
seventh century, Italians were the first who called the disease associated with swamps near 
Rome “mal’ aria” meaning “spoiled air”. With the birth of microbiology and germ theory 
in the end of nineteenth century, the scientific understanding of malaria began. This new 
way of thinking in which microorganisms caused disease led Chalres Louis Alphonse 
Laveran, a French army physician in Algeria (North Africa) and Nobel Prize winner in 
1907, to discover the parasite causing malaria by examining the blood of infected patient 
who had malaria symptoms (Laveran, 1880). In 1884, Ettore Marchiafava and Angelo Celli 
subsequently confirmed Laveran’s germ and named the protozoan observed Plasmodium 
(Smith and Sanford, 1985).  
 
In 1894, Sir Patrick Manson, a Scottish physician and founder of tropical medicine field, 
postulated a theory to Sir Ronald Ross, a British physician in the Indian Medical Service 
and Nobel Prize winner in 1902, about the involvement of mosquitoes in malaria 
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transmission.  In 1897, Sir Ronald Ross proved Manson’s theory and made an important 
discovery by describing the full life cycle of Plasmodium inside the female mosquito 
(Ross, 1898). Ross’s discovery into malaria was immediately followed by a series of 
significant works carried out by Grassi and colleagues who demonstrated conclusively the 
whole life cycle of Plasmodium in human and mosquito (Grassi, 1900). From 1945 – 1948, 
Shortt and Garnham contributed in decoding the mystery of injected sporozoites destination 
by finding out that sporozoites development and division take place in liver (pre-
erythrocytic stages) prior their development in blood (erythrocytic stages) (Shortt and 
Garnham, 1948). The final brick was put in place when Wojciech Krotoski and his 
colleagues demonstrated the hyponozoite theory in P. vivax which can remain dormant in 
liver for several months after infection (Krotoski, 1985).       
 
1.2.2. Malaria Epidemiology  
Malaria is a major public health problem in over 100 malaria-endemic countries in tropical 
and sub-tropical regions (Figure 1.1) (WHO, 2012). It is considered one of the top three 
infectious disease killers, including tuberculosis and HIV/AIDS, in low income countries 
(WHO, 2012). It is also regarded as a disease of poverty and underdevelopment. According 
to WHO's latest estimates in 2011, approximately 216 million cases of malaria occur in the 
world and the disease kills about 655,000 people (WHO, 2012). This is translated to 
approximately a death from malaria every minute. However, malaria mortality rates have 
fallen by more than 25% globally since 2000, and by 33% in the WHO African Region 
(WHO, 2012). About 90% of malaria deaths occur in Africa and the majority of them are 
children under 5 years (Murray et al., 2012, WHO, 2012). However, the distribution of the 
disease varies greatly from country to country and within the countries themselves, 
depending on certain factors such as climate, politics, education, and economical means for 
the prevention of malaria transmission.   
 
To date, there are approximately 200 species of Plasmodium parasites that have been 
described from reptiles, rodents, birds and mammals (Perkins and Austin, 2009). Of these, 
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only five species of Plasmodium parasites are known until now to cause malaria in humans. 
These include:  
 
1- P. falciparum (Malignant Tertian Malaria): is found worldwide in tropical and 
subtropical areas predominantly in Africa (Snow et al., 2005). It is the most lethal 
Plasmodium species and causes the most severe form of malaria including cerebral malaria 
which can be fatal (Gunn, 2012). P. falciparum is responsible for the vast majority (around 
90%) of malaria deaths and cases worldwide (WHO, 2012). 
  
2-  P. vivax (Benign Tertian Malaria): is the most geographically widespread species and 
found mostly in Asia, Latin America, and in some parts of Africa (Gunn, 2012). It is 
responsible for a large number of cases and increasingly being recognized as a cause of 
severe malaria and even death (WHO, 2012, Kochar et al., 2005). However, P. vivax is not 
found in West Africa because it can only invade erythrocyte expressing Duffy blood group 
antigens (Fy
a
 and Fy
b
) which most West Africans do not have these antigens on their 
erythrocytes (Gunn, 2012).  P. vivax as well as P. ovale has dormant liver stages 
(hypnozoites) that can activate and invade the blood (relapse) several months or years after 
the infecting mosquito bite (Gunn, 2012). In addition, P. vivax parasites as well as P. ovale 
parasites are only able to develop in reticulocyte (Gunn, 2012).  
 
3-  P. ovale (Ovale Malaria): is found mostly in Africa (especially West Africa) and the 
islands of the Western Pacific (Collins and Jeffery, 2005). It is biologically and 
morphologically very similar to P. vivax. However, differently from P. vivax, it can infect 
individuals who are negative for the Duffy blood group, which is the case for many 
residents of sub-Saharan Africa (Gunn, 2012). This explains the greater prevalence of P. 
ovale (rather than P. vivax) in most of Africa (Collins and Jeffery, 2005).  
 
4-  P. malariae (Quartan Malaria): found worldwide and it is the only human malaria 
parasite species that has a quartan cycle (three-day cycle) (Collins and Jeffery, 2007). 
Natural infections are common in chimpanzees as well as in human and latent infections 
can persist in them for many years if untreated (Gunn, 2012, Hayakawa et al., 2009).  
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5- P. knowlesi (Simian Malaria): is found throughout Southeast Asia as a natural pathogen 
of long-tailed and pig-tailed macaques (Macaca fascicularis) (Gunn, 2012).  It has recently 
been shown to be a significant cause of zoonotic malaria in that region, particularly in 
Malaysia, as it is often mistaken for P. malariae but its infection consequences can be fatal 
(Cox-Singh and Singh, 2008, Cox-Singh et al., 2008). 
 
 
Figure 1.1. Geographical distribution of malaria. 
World map shows malaria affected countries in 2010. Amber colour indicates countries affected by 
malaria and of high transmission. Blue indicates countries preventing reintroduction of malaria but 
with limited risk. White colour indicates countries that are not affected by malaria. Grey colour is 
not applicable to any countries. (Adapted from WHO, 2012). 
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1.2.3. Malaria Pathogenesis and Symptoms 
Malaria pathogenesis is initiated when the parasites are released from the liver to the blood 
circulation. Therefore, the clinical manifestations of malarial infections are associated with 
the rupture of infected red blood cells (iRBC) during the blood stage of the parasites’s life 
cycle. These drastic morphological and biochemical changes of the iRBC are central to the 
malaria pathogenesis (Maier et al., 2009). Thus, these modifications may results in the 
ability of the iRBC (primarily seen in P. falciparum infections) to undergo a range of 
adhesive interactions (cytoadherence) such as binding of iRBC with endothelial cells 
(sequestration), interaction of iRBC with non-infected RBC (rosetting) and other iRBC 
(auto-agglutination) (Miller et al., 2002).  
 
Furthermore, the release of malaria antigens, pigment and toxins rise to a cascade of 
pathological events. These pathological events can range in severity from uncomplicated or 
mild malaria to complicated malaria or severe malaria. The clinical symptoms develop 
from classical symptoms of uncomplicated malaria including headache, fever, chills, 
sweating, and muscle pains (Laishram et al., 2012) to sometimes severely developed 
symptoms of complicated malaria including anemia, kidney failure, respiratory distress, 
cerebral malaria and often death in certain malarial patients (Warrell, 1997, Weatherall et 
al., 2002). These clinical manifestation of malarial infection is predominantly influenced by 
several factors which are (1) host age and immune status with regard to malaria and 
pregnancy, (2) the parasite species and its genotype and perhaps (3) the geographical, 
economical and social factors (Figure 1.2) (Miller et al., 2002).   
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Figure 1.2. The Clinical outcome malarial infection in human. 
Parasite, host, geographical and social factors determine the severity of the clinical outcome. 
(Adapted from Miller et al., 2002). 
 
1.2.4. Malaria prevention and control 
There are four main approaches to prevent and control malaria. These include (1) health 
education and primary health care, (2) malaria vaccine, (3) vector control and (4) 
antimalarial chemotherapy.  
1.2.4.1. Health education and primary health care  
Health education and primary health care is one of the important measures to control and 
prevent malaria. Malaria prevention and control has to be integrated into the basic health 
system of endemic country to improve health education and development of primary health 
care. The integration of this approach within antimalarial activities has been successfully 
test in some places (Bruce-Chwatt, 1987, Raccurt, 1997, O'Meara et al., 2009, Koram et al., 
1995).  
The availability of primary health care facilities in malaria-endemic areas has strong 
patterns in disease management through early diagnosis and prompt treatment. These 
facilities are also used to educate the local community in control malaria through personal 
protection measures. Health education helps affected people seek medical attention and it 
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promotes the use of insecticide-treated bed nets (Ayi et al., 2010). These methods are 
usually quite cheap and can provide a good first line of defence against the malaria vector. 
In addition, malaria has been contained quite affectively through personnel protection 
measures such as protective clothing, repellents and bed nets. The community protection 
measures has also involved in reducing the malaria transmission by the use of biological 
control methods such as the use of toxic agents (pyrethroids) against the mosquito vector 
(Kroeger et al., 1996).       
1.2.4.2. Malaria Vaccines  
Malaria vaccine development is a continuing area of research and unfortunately an 
effective and durable vaccine is not yet available. There are a number of targets that have 
been suggested for malaria vaccine to break the parasite life cycle. These vaccines are 
currently directed against three candidate stages of malaria parasite development include 
the pre-erythrocytic stage, erythrocytic stage and the sexual stage (Greenwood et al., 2008, 
Garcia-Basteiro et al., 2012).  
The pre-erythrocytic stage vaccine is directed to block the sporozoite from invading or 
developing within the hepatocyte; hence preventing of infection (Greenwood et al., 2008, 
Garcia-Basteiro et al., 2012). One of the pre-erythrocytic stage vaccine candidate is RTS,S 
which is currently in clinical phase III trials and the final results and conclusion about its 
efficacy will be revealed by the end of 2014 (Mian-McCarthy et al., 2012, Garcia-Basteiro 
et al., 2012).  
The erythrocytic stage vaccine is aimed to block merozoite invasion of RBC and inhibiting 
the development of schizont; therefore preventing the progression of malaria disease and 
eliminate or reduce the number of erythrocytic stage parasite (Greenwood et al., 2008, 
Girard et al., 2007). The erythrocytic stage vaccine candidates such as merozoite surface 
proteins 1 (MSP-1), 2 (MSP-2), 3 (MSP-3), the glutamate-rich protein (GLURP) and apical 
membrane antigen 1 (AMA-1) are currently in early clinical trials (Genton and Reed, 
2007). Additional antigens from merozoite surface antigens such MSP-4, -5, -8,    and -9, 
and P. falciparum erythrocyte protein 1 (PfEMP1) are under development as vaccine 
candidate (Girard et al., 2007).  
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The sexual stage vaccine is targeted to block human mosquito transmission by immunising 
against the sexual stages or gametes; thereby preventing sporozoite development in 
Anopheles mosquitoes (Garcia-Basteiro et al., 2012, Greenwood et al., 2008). Several 
candidates are in clinical development, including vaccines that target the Pfs25, Pvs25 and 
Pvs28 surface proteins, but the ISA51, an adjuvant, formulation of these vaccines turned 
out to be unacceptably reactogenic (Wu et al., 2008). In addition, a major challenge for this 
vaccine approach is proving true field efficacy (Saul, 2007).  
It appears that there are still many obstacles to overcome with the main difficulties 
resulting from the complex nature of parasite and its life cycle. The parasite multiple stages 
rise the antigenic diversity and polymorphism which allow the switch of the expression of 
the antigenic molecules, thus the parasite is able to evade the immune response of the 
host(Garcia-Basteiro et al., 2012). The result is an immune response generated against a 
specific allelic form, which may not recognize another one. These challenges also apply 
equally to all potential vaccines candidate making this a very slow process with no 
effective vaccine likely in the near future (Garcia-Basteiro et al., 2012). 
1.2.4.3. Vector Control 
Since the recognition that insects transmit infectious agents and the elucidation of the 
parasites life cycle in their vectors, vectors have been targeted through which disease 
control can be successfully achieved. The objective of vector control is to reduce malaria 
transmission through different control strategy approaches. These include (1) using 
insecticides, (2) personal protective measures, (3) larval control and (4) environmental 
control.  
Insecticides have been the most common form of vector control. The effectiveness of 
dichlorodiphenyltrichloroethane (DDT) against indoor resting mosquitoes led to the view 
that malaria could be eradicated through a combination of indoor residual spraying and 
disease surveillance to detect and treat any remaining diseases (Muturi et al., 2008). DDT is 
inexpensive and its effective use had resulted in successful malaria vector campaigns and 
eliminated the disease in North America, Europe and parts of Asia (Najera et al., 2011). 
However, DDT resistance has been reported from more than 50 species of anopheline 
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mosquitoes as the eradication programme for malaria vector was abandoned due to 
problems associated with administrative, political, logistic and financial constraints (van 
den Berg, 2009, Hemingway and Ranson, 2000). In addition, malaria mosquito vector has 
evolved resistance to another effective insecticide, synthetic pyrethroids, and there is now a 
need for developing new insecticide (Martinez-Torres et al., 1998).  
Personal protective measures are based on insecticide impregnated materials such as bed 
nets and curtains. The use of insecticide-treated bed nets (ITN) can significantly reduce the 
child mortality, severe pregnancy associated anaemia and low birth weight infants (Muturi 
et al., 2008, Phillips-Howard et al., 2003, ter Kuile et al., 2003, Gosoniu et al., 2008). 
However, the efficacy of ITN varies with the type of insecticide, duration of use and human 
behaviour (Gu and Novak, 2009). Therefore, the increased resistance to most of the 
presently available insecticide such as deltamethrin and permethrin demands for new 
classes of insecticide and other alternative control measures (Phillips-Howard et al., 2003, 
Muturi et al., 2008). 
 Larval control of malaria vector is another strategy for preventive measures. Chemical and 
biological agents can be used to kill larvae in breading sites. Larvivorous fishes or bacterial 
pathogens such as Bacillus thuringiensis israelensis have given a new scope for novel 
control measures in the present resistant vector population (Walker and Lynch, 2007, 
Takken and Knols, 2009).  
Environmental control is used to prevent breeding, nesting and feeding of malaria vectors. 
This can be achieved by various means such as eliminating the low spots where pools of 
water can be formed after rainy season, or applying locally grown plant materials to limit 
growth of mosquitos. In contrast, environmental changes from road, dam or pipeline 
construction, deforestation, agricultural and irrigation can generate new larval breeding 
sites. Therefore, environmental control can mostly be achieved in urban areas and require 
community participation and inter-sectorial collaboration.  
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1.2.4.4. Antimalarial Chemotherapy 
Antimalarial chemotherapy has been the defensive bastions against malaria for decades 
especially in the absence of an effective malaria vaccine. Fundamentally, the treatment of 
malaria involves in killing parasites in the liver and blood circulation while providing 
supportive therapy to the host (Winstanley, 2000). The available antimalarial drugs fall into 
five broad groups according to their chemical structure and biological activities (Table 1.1) 
(Antoine, 2013). These include (1) quinoline-containing antimalarial drugs, (2) artemisinin-
type compounds, (3) antifolates, (4) antibacterial agents and (5) hydroxynaphthoquinones. 
These drugs have different mode of action that interfere with the process of metabolic 
pathways within different subcellular organelles leading eventually to parasites death 
(Figure 1.3) (Greenwood et al., 2008, Biagini et al., 2003).   
It has been noted that human malaria parasites have developed resistance to almost every 
antimalarial drug due to inadequate drug administration, level of host defence, spontaneous 
mutations in the parasites and pharmacokinetics and pharmacodynamics of antimalarial 
drugs used (White, 2004). Therefore, the use of two or three combinational antimalarial 
drug therapy with different modes of action and molecular targets will perhaps reduce the 
risk of resistance and increase the treatment efficacy (Table 1.1) (Kremsner and Krishna, 
2004, White, 2004). 
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Table 1.1. Antimalarial drug classes, their target locations, parasite stages and their possible combinations. 
Drug 
Target location Parasite stage 
Combination 
C M DV A BS LS GS HS SS 
Quinoline-Containing Drugs 
Quinine   ●  ●  ●   + Sulfadoxine-pyrimethamine (SP); + Tetracycline; + Clindamycin; + Doxycycline 
Chloroquine   ●  ●  ●   + Sulfadoxine-pyrimethamine (SP) 
Amodiaquine   ●  ●  ●   + Sulfadoxine-pyrimethamine (SP) 
Piperaquine   ●  ●     + Dihydroartemisinin 
Primaquine    ●   ● ● ●   
Tafenoquine   ●   ● ●    
Mefloquine   ●  ●  ●   + Sulfadoxine-pyrimethamine (Fansimef®) 
Halofantrine   ●  ●      
Lumefantrine   ●  ●     + Artemether (Coartem®, Riamet®) 
Antifolates 
Pyrimethamine ●    ● ●   ● + Sulfadoxine (SP) 
Sulfadoxine ●    ●     + Pyrimethamine (SP) 
Proguanil ●    ● ●   ● + Atovaquone (Malarone®) 
Chloroproguanil ●    ●     + Dapsone + Artesunate (Dacart®); + Dapsone (LapDap®) 
Dapsone ●    ●     + Artesunate + Chloroproguanil (Dacart®); + Chloroproguanil (LapDap®) 
Hydroxynapthaquinones 
Atovaquone  ●   ●    ● + Proguanil (Malarone®) 
Antibiotics 
Doxycycline    ● ●     + Quinine 
Clindamycin     ● ●     + Quinine 
Tetracycline    ● ● ●    + Quinine 
Endoperoxide compounds 
Artemisinin ● ●?  ●  ●  ●?    
Artemether ● ●? ●  ●  ●?   + Lumefantrine (Coartem®, Riamet®) 
Artesunate 
● ●? ●  ●  ●?   + Dapsone + Chloroproguanil (Dacart®); + amadioquine (ASAQ); + Mefloquine (ASMQ); + Sulfadoxine-
pyrimethamine (SP) 
Dihydroartemisinin ● ●? ●  ●  ●?   + Piperaquine 
Abbreviations: C, cytosol; M, mitochondrion; DV, digestive vacuole; A, apicoplast; BS, blood stage; LS, liver stage; GS, gametocytes stage; HS, 
hypnozoites stage and SS, sporozoites stage. (Adapted from Antoine, 2013)
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Figure 1.3. Representation of some of the major classes of antimalarial drugs targeted at 
specific intracellular compartments of P. falciparum parasite.  
The 4-aminoquinolines (e.g chloroquine and amodiaquine), and the quinolinemethanols (e.g 
quinine and mefloquine) act inside the digestive vacuole of the parasite. The falcipain inhibitors 
targeted to the cysteine proteases. Antibiotics such as azithromycin, doxycycline and clindamycin 
act inside the apicoplast by inhibiting protein translation. Atovaquone and other selected 
compounds inhibit electron transport chain in the mitochondrion. The antifolate drugs act by 
disrupting folate biosynthesis in cytosol. The targets and sites of action of other antimalarials, 
including artemisinin and its derivatives, remain an area of active investigation. (Adapted from 
Greenwood et al., 2008).  
 
1.2.4.4.1. Quinoline-containing antimalarial drugs 
Quinoline-containing antimalarial drugs (QCDs) include some of the most common 
antimalarial drug families. Quinolines are aromatic nitrogen compounds characterized by a 
central solid-ring structure, essentially benzene fused to pyridine at two adjacent carbon 
atoms (Figure 1.4). However, there can be various functional groups on the main quinoline 
molecule that add to solubility and specificity of drug activity.  The main QCDs that are 
used as antimalarial drugs can be divided into groups based on their chemical class. These 
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include (1) type-1 drugs 4-aminoquinolines (chloroquine, amodiaquine, pyronaridine, bis-
quinoline piperaquine) are weak bases, deprotonated, and hydrophilic at pH 7.0, and (2) 
type-2 drugs aryl-amino alcohols (quinine, mefloquine, halofantrine, lumefantrine) are 
weaker bases and lipid soluble at neutral pH (Figure 1.4) (Olliaro, 2001, O’Neill et al., 
2012). Additional QCDs include the 8-aminoquinoline, primaquine (Figure 1.4). 
 
Figure 1.4. Chemical structures of some quinoline-containing antimalarial.  
(A) quinoline ring core structure. (B) Aryl-amino alcohols drugs include quinine and mefloquine. 
(C) 4-aminoquinolines drugs include chloroquine, amodiaquine and piperaquine. (D) 8-
aminoquinoline drug include primaquine.  
 
Recognition of the therapeutic value of the ‘fever bark tree’ cinchona dates back to the 17th 
century before the parasitic nature of malaria was understood (Achan et al., 2011). It was 
not until 19
th
 century when the active ingredient of the cinchona bark, quinine, was isolated 
and successfully synthesized to overcome the problem associated with the limited natural 
supplies (Seeman, 2007, Foley and Tilley, 1998, Woodward and Doering, 1944). The 
elucidation of quinine structure and then the identification of quinoline ring as key 
pharmacophore led to the development of synthetic drug families that include aryl-amino 
alcohol, 4-aminoquinolines and 8-aminoquinolines (Figure 1.4).  
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It is appropriate to start with the 4-aminoquinolines chloroquine which became available 
for several decades as a drug of choice for malaria treatment and prophylaxis (Muller and 
Hyde, 2010). The success of chloroquine has been based on its excellent clinical efficacy, 
limited host toxicity, ease of use and simple and cost-effective synthesis (Hyde, 2007a, 
Muller and Hyde, 2010, Biagini et al., 2003). Since chloroquine introduction in 1940s, it 
has saved countless millions of lives but its use against P. falciparum in now confined to 
limited areas of North Africa, Central America and the Caribbean region because its 
efficacy has decreased in the last two decades, mainly as a result of the development and 
the emergence of widespread of parasite resistance in every region where P. falciparum is 
prevalent such as sub-Saharan Africa (Muller and Hyde, 2010, Wellems and Plowe, 2001, 
O’Neill et al., 2012, Biagini et al., 2003, Payne, 1987). Therefore, the research into 4-
aminoquinoline antimalarials has led to synthesis of amodiaquine (a Mannich base) and 
piperaquine (a bisquinoline) which have been shown to be effective against chloroquine-
resistant strains of P. falciparum parasite (O’Neill et al., 2012, O'Neill et al., 1998, Biagini 
et al., 2003). In addition, a newer generation of aryl-amino alcohol quinine have been 
synthesised as response to the increasing problem of drug resistance. These include the 
development of mefloquine (a quinoline methanol), lumefantrine (also known as 
benflumetol) and halofantrine (a phenanthrene methanol). Nonetheless, quinine can be 
combined with an antibiotic (doxycycline or tetracycline) to enhance the treatment efficacy 
especially where some degree of quinine resistance may be present, such as in southeast 
Asia (Ejaz et al., 2007). In addition, 8-aminoquinolines drugs such as primaquine have 
been used to eradicate malaria hypnozoites from the liver as well as for malaria 
prophylaxis. 
The exact mode of action (MoA) of QCDs is not fully understood (O’Neill et al., 2012, 
Muller and Hyde, 2010). However, it has been thought that QCDs, with the exception of 8-
aminoquinoline primaquine (used primarily to act against hypnozoite and sexual stages 
infection), are thought to share a common target by interfering with the process of toxic 
heme polymerisation in the digestive vacuole of the asexual parasite stage although 
additional targets may also be involved in some cases (Figure 1.5) (Fitch, 2004, Muller and 
Hyde, 2010, Bray et al., 2005, O’Neill et al., 2012, Slater and Cerami, 1992). There is a 
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compelling evidence supporting the central role of a heme dependent mechanism in the 
action of 4-aminoquinoline and aryl-amino alcohol (Mungthin et al., 1998).  Chloroquine is 
a weak base that accumulates in the parasite’s acidic digestive vacuole and increase the pH 
and osmolality of the vesicles, leading to swelling and membrane leakiness (Krogstad and 
Schlesinger, 1987). Chloroquine becomes deprotonated in the digestive vacuole and 
trapped inside it (Olliaro, 2001). It appears that the most widely accepted theory about the 
MoA of chloroquine  is to directly inhibit the polymerization of toxic heme molecules 
(produced from hemoglobin degradation) into hemazoin, and monomeric heme 
accumulates to levels in the digestive vacuole that kill the parasite (Slater and Cerami, 
1992). However, there is a debate about chloroquine MoA which perhaps also include the 
interaction with the parasite DNA (Meshnick, 1990), impairment of lysosome function 
(Homewood et al., 1972) and inhibition of heme dependent protein synthesis (Surolia and 
Padmanaban, 1991).  Therefore, in order to elucidate the MoA of QCDs, chapter 7 presents 
new insights into these drugs MoA using pharmacometabolomics approach. 
The emergence of resistance to QCDs represents one of the predominant problems in 
malaria control. QCDs, such as chloroquine and quinine, resistance emerged in just 10 
years after its introductios to all regions where malaria is endemic including Thai-
Cambodian border in 1960s, Colombia-Venezuela border in 1970s and all sub-Saharan 
Africa in 1980s (Mita et al., 2009). Malaria parasites resistance to QCDs have been 
demonstrated by several studies showing that it is associated with point mutations in the 
transporter proteins that are located on the parasite digestive vacuole. Currently, genes 
associated with altered QCDs response are the P. falciparum chloroquine resistance 
transporter (pfcrt), the P. falciparum multidrug resistance transporter 1 (pfmdr1), and the P. 
falciparum Na
+
/H
+
 exchanger 1 (pfnhe1) (reviewed in (Petersen et al., 2011)). The 
involvement of pfcrt polymorphisms, particularly the K76T mutation, has been established 
for chloroquine and 4-aminoquinoline resistances (Lakshmanan et al., 2005, Fidock et al., 
2000). This chloroquine resistance may acts by enabling the active efflux of diprotonated 
chloroquine out of the digestive vacuole and hence reducing the DV chloroquine 
concentration (Martin et al., 2009, Martin and Kirk, 2004). Pfmdr1 has been associated to 
the altered susceptibility of malaria parasites to mefloquine, halofantrine and quinine but its 
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association remains unclear and other genetic factors may be involved such as pfcrt (Ward 
and Bray, 2000). Pfmdr1 is a homolog of the multidrug resistance (MDR) transporter 
family, which is associated with drug resistance in mammalian tumor cells (Foote et al., 
1989), that is thought to enable an increased drug efflux and decreased intracellular drug 
accumulation in parasite (Petersen et al., 2011). Pfmdr1 is associated with increased 
malaria parasite susceptibility responses to lumefantrine, quinine, mefloquine, halofantrine 
and chloroquine (reviewed in (Petersen et al., 2011)). Pfnhe1 is located in the plasma 
membrane and its function remains unclear but it is speculated to actively efflux protons to 
maintain a pH around 7.4 within the parasite (Bosia et al., 1993) . The association of 
Pfnhe1 mutations with quinine resistance has been proposed but remains controversial 
(Okombo et al., 2010, Henry et al., 2009, Briolant et al., 2011, Andriantsoanirina et al., 
2010).  
 
Figure 1.5. Proposed mode of action of quinoline-containing antimalarial drugs.  
QCDs are thought to interfere with the process of heme polymerisation process leading to 
accumulation of toxic heme and eventually parasite death. (Adapted from Antoine, 2013).  
  
1.2.4.4.2. Antifolates  
Antifolates are widely used antimalarial drugs although their role in malaria control in 
hindered by rapid emergence of resistance under drug pressure (Plowe et al., 1998). 
  
 
 
19 
 
Antifolates are widely used in fixed-ratio combinations, most commonly sulfadoxine-
pyrimethamine (SP, Fansidar
TM
), for treatment and prophylaxis against malaria infection in 
chloroquine-resistant regions of Africa as well as in malaria endemic areas without supplies 
of Artemisinin Combination Therapy (ACT) (Gutman et al., 2012, Winstanley and Ward, 
2006). There are two classes of antifolates drugs. Class I antifolates (sulfadoxine and 
dapsone) compete for the active site of dihydropteroate synthase (DHPS), preventing the 
formation of dihydropteroate (Figure 1.6)  (Muller and Hyde, 2010). Class II antifolates 
(pyrimethamine and biguanide proguanil) inhibit parasite dihydrofolate reductase (DHFR), 
preventing tetrahydrofolate (necessary for biosynthesis of deoxythymidylate (dTMP), 
pyrimidine and polyamine) from being formed (Figure 1.6) (Olliaro, 2001). Growth of 
malaria parasites requires folate derivatives (folic acid or folinic acid) which are important 
cellular cofactors for the production of deoxythymidylate (dTMP) and thus DNA synthesis 
through pyrimidine pathway (Figure 1.6). The folate synthesis is essential for the malaria 
parasite survival which relies on de novo dTMP synthesis because of its incapacity to 
salvage pyrimidine from the exogenous medium (Hyde, 2007b). Antifolate drugs result in 
decreased pyrimidine synthesis, leading to reduced DNA, serine, and methionine formation 
and therefore they exert high activity when DNA synthesis peaks (late trophozoites) in 
parasites (Gregson and Plowe, 2005, Hyde, 2007b). 
 
Unfortunately, antifolate resistance emerged rapidly after extensive administration of 
sulphadoxine/pyrimethamine (SP) combinations due to point mutations in both targeted 
enzymes (Mita et al., 2009). The quadruple mutant form of DHFR consists of three point 
mutations (S108N, N51I and C51R) whereas the double mutation form of DHPS consists 
of two points mutations (A437G and K540E); both enzymes mutations have been strongly 
associated with treatment failure (Kublin et al., 2002). PfMRP1 is also proposed to affect 
intracellular folate homeostasis in parasites in which point mutation (K1446R) has been 
proposed to increase exogenous folate efflux, decrease the competition with the incoming 
drugs for their targets and contribute to antifolate resistance (Dahlstrom et al., 2009). 
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Figure 1.6. Chemical structures of antifolate drugs and their mode of action.  
(A) Chemical structures of sulfadoxine, dapsone, proguanil and pyrimethamine. (B) Folate 
biochemical pathway in P. falciparum and mode of action for antifolate antimalarial drugs. 
Abbreviations: DHF, dihydrofolate; DHP, dihydropteroate; PABA, para-Aminobenzoic acid; THF, 
tetrahydrofolate; DHFR, dihydrofolate reductase; DHPS, dihydropteroate synthase; GTP, guanosine 
triphosphate; mTHF, methyltetrahydrofolate; dUMP, deoxy-urinidine monophosphate; HMP-PP, 
hydroxymethyl-pteridine-PP; dTMP, thymidine monophosphate. (Adapted from Antoine, 2013). 
 
1.2.4.4.3. Hydroxynaphthoquinone (Atovaquone) 
Atovaquone, a hydroxynaphthoquinone (2-[trans-4-(4’-chlorophenyl)cyclohexyl]-3 
hydroxy-1.4-napthoquinone),  has been developed twenty years ago and it shows  activity 
against Plasmodium species (Figure 1.7 A) (Hudson et al., 1991). However, atovaquone is  
not very effective when used alone, as resistance to the drug develops quickly 
(Looareesuwan et al., 1996). Therefore, atovaquone is combined with the antifolate 
proguanil (forming Malarone
®
) which displayed synergistic effects in vitro and in clinical 
trials (Looareesuwan et al., 1999a, Canfield et al., 1995, Looareesuwan et al., 1996). The 
combination of atovaquone-proguanil (Malarone
®
) produces a near 100% curative rate but 
due to its costly production Malarone
®
 is used mainly as chemoprophylaxis for travellers 
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visiting malaria endemic areas (Kessl et al., 2007, Looareesuwan et al., 1999b, 
Looareesuwan et al., 1999a).  
 
 
 
Figure 1.7. Chemical structure of atovaquone and its mode of action.  
(A) Chemical structure of atovaquone and its analogue, the coenzyme ubiquinone. (B) 
Representation of bc1 complex reactions and its inhibition with atovaquone (ATQ). Abbreviations: 
Q, ubiquinone; QH2, ubiquinol; bL, heme bL binding site; bH, heme bH binding site; Fe-S, iron-sulfur 
cluster; cyt c, cytochrome c; c1, cytochrome c binding site. (Adapted from Antoine, 2013). 
 
Atovaquone is an inhibitor of the ubiquinol oxidation site (Qo) of the P. falciparum bc1 
complex (Figure 1.7. B). The MoA of atovaquone alone and in combination with proguanil 
is comprehensively described in Chapters 5 and 6. In short, atovaquone inhibits the 
catalytic turnover of bc1 complex, collapsing the mitochondrial membrane potential and 
resulting in the loss of essential mitochondrial metabolic function such as pyrimidine 
biosynthesis (Painter et al., 2007). Interestingly, the action of proguanil in Malarone
®
 is not 
to inhibit DHFR in folate pathway (as when used by itself), but rather it lowers the 
effective dose needed to cause mitochondrial membrane potential collapse by atovaquone 
(Srivastava and Vaidya, 1999). Resistance to Malarone
® 
has been reported in different 
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point mutations at the Qo site (Musset et al., 2006, Korsinczky et al., 2000, Berry et al., 
2006).  Y268S, and less frequently Y268N, are the most common mutations observed, 
increasing the atovaquone IC50 by several hundred fold as compared to sensitive parasite 
strains (Barton et al., 2010).  
 
1.2.4.4.4. Artemisinin-type compounds 
Artemisinin (Qinghaosu; active compound) is an extract from the plant Artemisia annua 
(Chinese wormwood) that has been used as herbal remedies for the treatment of fevers in 
traditional Chinese medicine (White, 2008b). Artemisinin has low toxicity and high 
efficacy against all types of human malaria parasites including those resistant to 
conventional antimalarial treatment (Li et al., 1994, Krishna et al., 2008). A first generation 
of semi-synthetic artemisinin derivatives (known as dihydroartemisinin, artesunate and 
artemether) has been synthesized with higher antimalarial activity and better solubility 
owing to the cultivation growing demand to obtain high yields extract from A. annua 
(O'Neill and Posner, 2004). These semi-synthetic artemisinin derivatives were initially used 
as monotherapies and then in combination with a numerous of antimalarial drugs (refer to 
Table 1.1) known as artemisinin-based combination therapies (ACTs) (White, 2008b). 
ACTs are widely used to treat uncomplicated malaria as well as drug-resistant malaria 
strains with a high efficiency, rapid clearance and minimal toxicity in humans (Nosten and 
White, 2007, White, 2008b).  
 
Artemisinin and its derivatives have unique trioxane ring structure with an endoperoxide 
bridge (C-O-O-C), lacking the nitrogen containing ring system which is found in most 
antimalarial drugs such as chlolorquine (Figure 1.8) (Meshnick et al., 1996). The MoA of 
artemisinin and its derivatives is not fully understood and still debatable (Figure 1.9) (Ding 
et al., 2011). The absolute requirement of the trioxane as a pharmacophore subunit of 
artemisinin for activity has led researchers to focus on this for the MoA studies.  It has been 
proposed that artemisinins can exert their effect through the generation of reactive oxygen 
species, which can be enhanced in the presence of haem-iron that is found in parasites after 
hemoglobin digestion (Petersen et al., 2011). It is possible that these radicals may exert an 
effects by overwhelming parasite oxidative stress mechanisms (Krishna et al., 2004, 
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Olliaro, 2001). The trioxane pharmacophore acts as a source of hydroperoxide via the 
generation of an oxo-stabilised cation upon heterolysis of the peroxide bridge. This may 
lead to oxygenating species or hydroxyl or alkoxyl radicals which can have detrimental 
effects on biomolecules (Olliaro et al., 2001). Other studies found that artemisinin may acts 
by interference with heme detoxificatioin process in the digestive vacuole (Pandey et al., 
1999) or artemisinin derivatives accumulate within neutral lipid bodies in the digestive 
vacuole where they damage parasite membranes after oxidation reactions (Hartwig et al., 
2009). Artemisinins have also been found to inhibit mitochondrial function in Plasmodium 
parasite by interfering with the electron transport chain and by inducing reactive oxygen 
species leading to the loss of mitochondrial membrane potential loss, disrupting the normal 
function of mitochondria and eventually parasite death (Wang et al., 2010, Li et al., 2005). 
In addition, it has been reported that artemisinin inhibits PfATP6 (sarco/endoplasmic 
reticulum calcium-dependent ATPase SERCA) leading to the disruption of Ca
2+
 
homeostasis in the parasite (Eckstein-Ludwig et al., 2003).  
 
 
Figure 1.8. Chemical structure of artemisinin and its derivatives. 
  
 
 
24 
 
 
Figure 1.9. Proposed mode of action of artemisinin  and resistance factors in P. falciparum.  
It is believed that iron interacts with the peroxide bond of artemisinins (Art) resulting in active 
carbon centered radicals that might (i) interfere with the heme detoxification pathway; (ii) induce 
the alkylation of the translationally controlled tumor protein (PfTCTP) and other proteins; (iii) 
inhibit the sarco/endoplasmic reticulum membrane calcium ATPase 6 (PfATPase6); or (iv) interfere 
with Plasmodium mitochondrial functions through the production of reactive oxygen species 
(ROS).  Proteins, in which mutations (red dots) have been shown to increase (arrow) or to decrease 
(inhibition line) in vitro sensitivity to Art, are indicated. Putative targets or target mechanisms are 
labelled in orange and putative resistance factors in yellow. (Adapted from Ding et al., 2011).   
 
Artemisinin resistance has not been documented until 2010 on the Thai-Cambodian border 
(Dondorp et al., 2009). However, the direct evidence of the resistant mechanisms has not 
been well understood. The findings from the sequencing data did not show any correlation 
between artemisinin resistance and pfcrt, pfmdr1 or pfatp6 genes (Imwong et al., 2010). 
Interestingly, evidence from transcriptomic studies suggests that artemisinin resistance may 
be associated with reduced activity of basic metabolic (e.g. glycolysis and nucleotide 
metabolism) and cellular maturation (e.g. DNA replication) pathways in the parasites (Mok 
et al., 2011). 
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1.2.4.4.5. Antibacterial Agents 
Several antibiotics have shown an antimalarial effect targeting prokaryote-like organelles 
such as apicoplast and mitochondria (McFadden and Roos, 1999, Lim and McFadden, 
2010, Vaidya, 2004). Antibiotics exert their action by inhibiting the prokaryote-like 
processes in Plasmodium parasites such as protein synthesis and DNA/RNA replication 
(Dahl and Rosenthal, 2008, Johnson et al., 2011, Vaidya, 2004). Interestingly, antibiotics 
do not immediately kill malaria parasites, but they cause what is known as ‘‘delayed death 
phenotype’’ or ‘‘delayed kill effect’’ in the second erythrocytic cycle (Ramya et al., 2007). 
This effect equates to longer parasite clearance times and prolonged symptoms as 
compared with classical antimalarial (Lell and Kremsner, 2002). Therefore, antibiotics such 
as doxycycline and tetracycline are used in combination with quinine for non-immunes 
experiencing acute malaria to achieve faster acting effect by classical antimalarial drug and 
clearance of remaining parasites by antibiotic particularly those showing reduced 
sensitivity against antimalarial drug (Schlitzer, 2008).   
 
 Malaria parasite biology                                                 1.3.
Human malaria can be caused by five species of Plasmodium parasites, all of which 
undergo similar life cycles within the host although slight differences are observed. 
Research in recent decades has shed light on many aspects of Plasmodium biology, 
broadening understanding of how parasites interact with the host system, cause human 
disease. However, this fundamental area of research is essential parasite biology although 
there are numerous questions remain unanswered and new questions have arisen. In 
addition, knowledge of the detailed structure, physiology and biochemistry of the parasite 
can be helpful for identifying new potential antimalarial targets for the synthesis of new 
drugs and providing accurate immunolocalization of antigens for the design of vaccine.   
1.3.1. Human malaria parasite life cycle 
The human malaria parasite, Plasmodium species, undergoes over a dozen distinguishable 
stages of development as it moves from the mosquito vector to human host and back again. 
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One way to simplify this complex life cycle is to consider it in three distinct replicative 
stages include liver stage, blood stage and mosquito stage (Figure 1.10). 
The liver stage of malaria begins with the bite of an infected female anopheline mosquito, 
when sporozoites are introduced into the human host skin together with mosquito saliva 
during a blood meal. Following the mosquito injection, the sporozoites rapidly make their 
way to liver where they invade the liver cells (hepatocytes). Over a course of 5 to 15 days, 
depending on the Plasmodium species, the sporozoites undergo a process of asexual 
reproduction, known as exoerythrocytic schizogony (the splitting process), that results in 
the production of thousands daughter parasites called merozoites (Oaks Jr, 1991). The 
duration of liver stage schizogony is characteristic for each species. For instance, minimum 
maturation time of 5 days in P. falciparum and 15 days P. malariae (Hommel, 2005). 
However, P. vivax and P. ovale undergo dormant phase called hypnozoites, which can 
persist in the liver and cause relapses by invading the blood stream months or years later 
(Krotoski et al., 1982, Krotoski, 1985).  
The blood stage begins when the merozoites are released from the liver into the blood 
stream where they rapidly adhere to and invade erythrocytes to begin. Once inside the red 
blood cell (RBC), the parasite undergoes a 48 hours (or 72 hours for P. malariae) asexual 
blood stage reproduction known as erythrocytic schizogony. This blood stage of the 
Plasmodium life cycle consists of three distinctive developing forms of Plasmodium 
parasite including ring form, trophozoite form and schizont form. Following the merozoite 
invasion of RBC, it develops into a ring form over the first twelve hours post-invasion. 
Then, it develops into a trophozoite and remains at this stage for 14 hours. After that, the 
matured trophozoite is marked by multiple rounds of nuclear division resulting in the 
formation of schizont which is characterised by containing numerous of daughter 
merozoites. When the red blood cell burst, each mature schizont releases about 8-32 
merozoites which are ready to invade new red blood cells and the cycle within blood stage 
repeats itself which is known as asexual cycle (Oaks Jr, 1991, Hommel, 2005, Cowman et 
al., 2012). However, some released merozoites are committed to gametocytogenesis, where 
they develop either into male (microgametocyte) or female (macrogametocyte) 
gametocytes to continue their sexual cycle in the mosquito vector. Factors that has been 
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shown perhaps to induce gametocytogenesis rather than schizogonic development in  are 
hyperparasitemia, anemia and antimalarial drug treatment and it looks though the parasite 
sensing hostile conditions and by transforming into gametocytes they prepare to escape into 
new host (Hommel, 2005). Gametocytes undergo through five developing morphological 
stages to reach full maturity within approximately 12-14 days (Fivelman et al., 2007).  
The mosquito stage begins when gametocytes are taken up during the mosquito’s blood 
meal. Gametocytes are taken into the mosquito’s midgut where they can continue their 
differentiation to form macrogametes and microgametes. Male microgametes are released 
during a process called exflagellation. Fusion of the female macrogamete with a single 
microgamete results in fertilization and the formation of zygote. This zygote continuously 
divides to develop into a motile ookinete which migrate to the wall of the mosquito’s 
midgut, where it penetrates the peritrophic membrane, epithelium and comes to rest on the 
external surface of the stomach to mature and develop into an oocyst. Over a period of days 
(4-15 days), mature oocyst contains up to 10,000 motile sporozoites. When the occyst 
ruptures, the sporozoites enter the mosquito circulation and migrate to the salivary glands 
where they are injected into the human host when the mosquito takes the blood meal thus 
perpetuating the malaria life cycle (Oaks Jr, 1991, Sinden and Billingsley, 2001). 
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Figure 1.10. The life cycle of human malaria parasite, P. falciparum.  
The Anopheles mosquito bites a human and injects sporozoite forms. These move to the liver and 
invade hepatocytes, in which they develop to produce exoerythrocytic merozoite forms (liver stage) 
that are released into the blood stream. Merozoites invade erythrocytes and grow into trophozoites 
and mature schizonts (blood stage). Merozoites are released that reinvade new erythrocytes. 
Gametocytes, formed from the asexual blood stage, are taken up by a feeding mosquito into the gut 
where they mature to form male and female gametes. The fertilized zygote develops to an ookinete 
and an oocyst and finally sporozoites that migrate to the salivary glands (mosquito stage). (Adapted 
from Cowman et al., 2012).  
 
1.3.2. Structure of malaria parasite asexual blood stages 
This thesis focuses on the trophozoite stage of P. falciparum parasite. Nonetheless, the 
structure of major asexual blood stages including merozoite (the invader), ring stage, 
trophozoite stage (feeding and highly metabolic stage) and schizont stage (the dividing 
stage) will be highlighted. 
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1.3.2.1. Merozoite 
The invasive merozoite stage is immunologically important because it is briefly 
extracellular and hence exposed to host antibodies between leaving one RBC and invade 
other. It is a pear-shaped (1-2 µm) with a low flat-ended projection located at one end 
(Langreth et al., 1978, Bannister et al., 2000). Merozoite contains secretory vesicles, 
numerous ribosomes, a mitochondrion and a plastid that are located at apex whereas the 
nucleus is placed basally (Figure 1.11) (Bannister et al., 2000). The apical organelles 
containing rhoptries, micronemes, dense granules that are all membranous vesicles which 
discharge their contents during invasion and thus change the shape and composition of the 
invaded RBC membrane (Bannister et al., 2000). The secretions of rhoptries and 
micronemes might be essential for the attachement of merozoite to the surface of RBC 
leading to the formation of an invasion ditch that later develops into parasitophorous 
vacuole (Bannister et al., 2000). The dense granules lie separately and release their contents 
after invasion in order to perhaps increase the membrane area and possibly helping to 
facilitate the change in shape to that of a ring stage (Atkinson and Aikawa, 1990). 
 
Figure 1.11. Three-dimensional organization of P. falciparum merozoite showing the internal 
structure. Inset: relative sizes of merozoites and the invaded RBC. (Adapted from 
Bannister et al., 2000).  
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1.3.2.2. Ring stage 
Following merozoite invasion, it flattens into a thin discoidal, flat and cup-shaped ring 
form (Figure 1.12). This ring stage of the parasite is characterised by a thick circumference 
of cytoplasm that house the major organelles include nucleus, mitochondrion, plastid, 
ribosomes and endoplasmic reticulum whereas the centre of the disc is thin containing few 
structures (Figure 1.12) (Bannister et al., 2000). Pinocytosis is a process in which the 
parasite begins to feed on the surrounding RBC producing several small pigment vacuoles 
(Slomianny, 1990). As the ring stage develops into an early trophozoite, the cytostome 
appears, feeding intensifies, small pigment vacuoles fuse to form a single large central 
digestive vacuole and the area of the parasitophorous vacuole membrane (PVM) 
surrounding the parasite also increases and extends to narrow, finger-like projections that 
protrudes into the surrounding RBC (Elford et al., 1995, Atkinson and Aikawa, 1990). 
Therefore, the ring stage eventually changes the shape to a larger irregular shape 
trophozoite.  
 
Figure 1.12. Three-dimensional organization of P. falciparum ring stage showing the internal 
structure. Inset: ring stage as seen in a Giemsa-stained film by light microscopy 
(Adapted from Bannister et al., 2000).   
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1.3.2.3. Trophozoite stage 
There is no fundamental internal difference between the ring stage and trophozoite stage 
apart from the size and shape (Figure 1.13). Trophozoite stage feeds on the host RBC, 
primarily haemoglobin the predominant protein in the cell (Goldberg et al., 1990). It 
gradually alters RBC shape by exporting various parasite proteins into its cytoplasm and 
surface (Bannister et al., 2000). Several changing features are observed in the trophozoite 
stage. These include increasing in the numbers of free ribosomes and the enlargement of 
endoplasmic reticulum which denoting increased protein synthesis (Bannister et al., 2000) 
as well as the attachment of mitochondrion and plastid to each other which indicate perhaps 
metabolic interaction  (van Dooren et al., 2005, Seeber and Soldati-Favre, 2010, Lim and 
McFadden, 2010).  The PVM embraces the parasite membrane with the formation of 
irregular bulges and tubular invaginations. These various membranous structures 
correspond to the basophil-like dots seen in the Giemsa stained cytoplasm of infected RBC 
known as Maurer’s clefts (Bannister et al., 2000). 
 
 
Figure 1.13. Three-dimensional organization of P. falciparum trophozoite stage showing the  
internal structure. Inset: trophozoite stage as seen in a Giemsa-stained film by 
light microscopy (Adapted from Bannister et al., 2000). 
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1.3.2.4. Schizont stage  
The nuclear division of the malaria parasite takes place during the schizont stage (Figure 
1.14) although synthesis of molecules that are needed for parasite multiplication such as 
DNA, is known to begin in the trophozoite stage (Bannister et al., 2000, White and Kilbey, 
1996). RBC ingestion and parasite protein exportation at the surface of RBC continue till 
late in the life of schizont (Bannister et al., 2000). Numerous cytoplasmic changes occur 
upon the beginning of nuclear division include increasing in the multiplication of rough 
endoplasmic reticulum, free ribosomes, mitochondria and plastids (Bannister et al., 2000). 
A series of merozoites-forming foci (each with a set of rhoptreis) develop and appear 
spread out at systematic intervals around the circumference of the parasite (Jaikaria et al., 
1993, Bannister et al., 2000). Before complete separation nucleus, mitochondrion and 
plastid move into each merozoite from the central area of the schizont cytoplasm (Bannister 
et al., 2000).  
 
Figure 1.14. Three-dimensional organization of P. falciparum schizont stage showing the 
internal structure. Inset: schizont stage as seen in a Giemsa-stained film by light 
microscopy (Adapted from Bannister et al., 2000).   
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1.3.3. Physiology and biochemistry of malaria parasite  
1.3.3.1. Feeding process and haemoglobin degradation 
Feeding process in malaria parasites begins with ingestion of small portions of RBC 
cytosol by micropinocytosis in ring stage parasites (Slomianny, 1990). As the parasite 
matures (trophozoite stage), a larger volume of hemoglobin is ingested by the cytostomal 
system that is formed by invagination of the parasitophorous vacuolar membrane (PVM) 
and the parasite plasma membrane (PPM) (Slomianny, 1990). When the cytostomes ingest 
RBC cytosol, double membrane-delimited vesicles are formed by budding at the surface of 
cytostome (Slomianny, 1990, Oaks Jr, 1991). These vesicles fuse to form one large, single 
membrane-enclosed digestive vacuole, which is regarded as the primary site for 
haemoglobin degradation (Slomianny, 1990, Francis et al., 1997, Olliaro and Goldberg, 
1995).  
The digestive vacuole of malaria parasites is an acidic compartment with pH 5.0-5.4 
(Yayon et al., 1984a). Haemoglobin represents about 95% of the dry weight of RBC and 
about 75% of it, is consumed by P. falciparum during its brief intraerythrocytic cycle 
(Morrison and Jeskey, 1948, Ball et al., 1948). Therefore, haemoglobin degradation is a 
massive and rapid catabolic process where a number of potent digestive protease enzymes 
involved (Goldberg, 2005). These include a group of aspartic proteases called plasmepsins, 
a group of cysteine proteases called falcipains, a metalloprotease called falcilysin, and at 
least one dipeptidylpeptidase I (Francis et al., 1997). Aminopeptidases are thought to be 
involved in the final peptide degradation in the cytoplasm (Kolakovich et al., 1997, 
Skinner-Adams et al., 2010). The action of these degradative enzymes in digestive vacuole 
appears to be an ordered process, requiring plasmepsins to make the initial cleavage in 
intact haemoglobin followed by secondary cleavages by plasmepsins and falcipains (Figure 
1.15) (Goldberg et al., 1990). Falcilysin appears to recognize only short peptides generated 
by the upstream enzymes whereas dipeptidylpeptidases and aminopeptidases are proposed 
to function most efﬁciently in terminal degradation providing ultimately amino acid in the 
parasite cytosol (Goldberg et al., 1990, Goldberg, 2005, Francis et al., 1997).  It has been 
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demonstrated that protease inhibitors exert their antimalarial activities digestive vacuole 
proteases and therefore merit development as antimalarial drug targets (Moura et al., 2009).  
Early in the haemoglobin degradation pathway, free heme is released upon digestion of the 
globin chains (Francis et al., 1997). Free heme causes lethal changes to membranes and 
proteins and its efﬁcient disposal is of critical importance to the malaria parasite during the 
proteolysis process (Bray et al., 2005). Therefore, Plasmodium parasite developed 
biocrystallization process to overcome the toxicity of heme, which crystallized into an inert 
pigment called hemozoin (Figure 1.15) (Egan et al., 2002, Egan, 2008). Therefore, 
quinoline-containing antimalarial drugs appear to function by disrupting this sequestration 
processs, leading to an accumulation of toxic heme products (Bray et al., 2005).  
Plasmodium parasite feeds on RBC hemoglobin as an amino acids source for protein 
synthesis because of its limited capacity for de novo amino acids synthesis (Goldberg, 
2005). However, P. falciparum can survive in medium supplying just ﬁve amino acids 
(methionine, cysteine, glutamine, glutamate and isoleucine) that are in limited supply or 
absent from hemoglobin (Divo et al., 1985a). In addition, it has been shown that amino 
acids from radiolabeled haemoglobin are incorporated into parasite proteins providing an 
evidence for the importance of RBC haemoglobin for the parasite survival (Sherman and 
Tanigosh.L, 1970, McCormic.Gj, 1970). Amino acids utilization for the parasite growth 
appears to be pivotal because parasites grown in the ﬁve amino acids supplemented 
medium are more sensitive to haemoglobin degradation inhibitors than those grown in full 
medium (Francis et al., 1994). Intriguingly, it has been noted that a signiﬁcant portion of 
amino acids released from haemoglobin is excreted by the parasite (Zarchin et al., 1986, 
Krugliak et al., 2002). Therefore, it has been hypothesized that the reason behind the 
existence of digestive vacuole could be attributed as making room for the parasite in its 
host cell (Krugliak et al., 2002, Ginsburg, 1990) or to control RBC osmotic stability (Lew 
et al., 2003). More insights about the amino acids metabolism and the role of digestive 
vacuole are presented in chapters 4 and 7, respectively.  
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Figure 1.15. Representation of haemoglobin degradation pathway in P. falciparum.  
Digestion of host haemoglobin (Hb) by P. falciparum takes place within the acidic digestive 
vacuole. Red cell haemoglobin is transported to the DV (i) where a number of protease enzymes, 
including aspartic proteases (plasmepsins I, II and IV), cysteine proteinases (falcipains 2, 2′ and 3) 
(ii) and a metallo-protease (falcilysin), initiate catabolism (iii).  Dipeptidyl aminopeptidase I (DDP 
I) acts by further cleaving of generated peptides by upstream enzymes into dipeptides (iv). The 
small peptide fragments derived from haemoglobin degradation in the digestive vacuole are 
transported to the parasite cytosol (v) where they are further digested by aminopeptidases providing 
amino acids (vi). (Adapted with modification from Skinner-Adams et al., 2010). 
 
1.3.3.2. Nutrient access and metabolism 
The passage of nutrients from the extracellular space to the malaria parasite cytosol 
involves a transfer across the RBC membrane, PVM and PPM. Different mechanisms may 
involve in nutrients transport across these membranes including diffusion along a gradient 
of substrate and carrier-mediated transport (Hommel, 2005). Two groups of transporters 
protein involve in the nutrients transport mechanism including (i) carrier proteins that bind 
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solutes and then undergo conformational change to move them across a membrane and (ii) 
channel proteins that are essentially gated, water-filled pores (Figure 1.16) (Staines et al., 
2010, Kirk, 2001). Because of the rapid growth and replication of the parasite, the normal 
transport processes of the RBC are not sufficient to meet the parasite demand. Therefore, 
the parasite, alongside other transporters, evolved a transport process known as new 
permeation pathway (NPP) to increase the nutrients traffic across the membranes (Kirk, 
2001). Most nutrients required by the Plasmodium parasite originate from the extracellular 
space such as host plasma. These include carbon sources (e.g. glucose), purines (e.g. 
adenine), amino acids, anions, cations and vitamin (e.g. folate or B9) (Hommel, 2005).   
 
Figure 1.16. Diagram of transport protein classes and transport mechanisms of RBC and 
parasite transport processes in P. falciparum.  
Illustrated are erythrocyte plasma membrane (EPM), parasitophorous vacuole membrane (PVM) 
and parasite plasma membrane (PPM). (1) Channels: examples are the Gardos channel (Ca
2+
-
activated K
+
 channel) and the new permeability pathways (NPP) in the EPM. (2) Primary active 
carriers: examples are the Na
+
/K
+
 ATPase and the plasma membrane Ca
2+
 pump in the EPM, and a 
V-type H
+
 pump in the PPM and the digestive food vacuole. (3) Secondary active carriers: 
examples are the HCO3
–
/Cl
– 
exchanger and the H
+
-coupled monocarboxylate symporter (MCT1; 
which mediates the efflux of lactate (L
-
) in the EPM, and H
+
-coupled pantothenate (P
-
) and lactate 
symporters in the PPM. (4) Facilitative carriers: examples are the hexose transporters GLUT1 and 
PfHT in the EPM and PPM, respectively (they mediate the uptake of the sugar D-glucose (S). 
(Adapted from Staines et al., 2010). 
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1.3.3.3. Energy metabolism  
The intraethrythrocytic malaria parasites rely mainly on glycolysis for energy generation. 
Glucose from the plasma enters into the Plasmodium cytoplasm and is subsequently 
degraded to lactate via the anaerobic Embden-Meyerhoff-Parnas (EMP) pathway  as 
summarized in Figure 1.17 (Crawford, 2003). It has been shown that P. falciparum has 
increased activity of the glycolytic enzymes and of lactate dehydrogenase as compared to 
RBC (Roth et al., 1988). Likewise, the speciﬁc activity of the glycolytic enzymes and 
lactate dehydrogenase from isolated P. falciparum trophozoites is higher than that from 
RBC (Vanderjagt et al., 1990). Most of the P. falciparum enzymes used for glucose 
fermentation during its 48 h asexual cycle development have now been characterized 
antigenically, enzymatically, and/or genetically (reviewed in (Lang-Unnasch and Murphy, 
1998)) as well as they are encoded in the Plasmodium genome (Gardner et al., 2002) 
(Figure 1.17).  In addition, Plasmodium parasites can also utilize alternative carbon sources 
such as fructose albeit at a reduced proliferation rate (Woodrow et al., 2000). Studies 
showed that P. falciparum infected RBC use 100 fold more glucose (mainly during 
trophozoite and schizont stages) than those non-infected (Roth et al., 1988, Roth Jr, 1990). 
Glucose is used in Plasmodium metabolic pathways for nucleic acid biosynthesis, amino 
acid biosynthesis, TCA cycle (tricarboxylic acid) and lipid biogenesis (Figure 1.17). It has 
been estimated that 60-70% of the glucose consumed by P. falciparum is incompletely 
oxidised to lactate (Jensen et al., 1983) and only a small amount of glucose is oxidised to 
form CO2 (Scheibel and Pflaum, 1970). This reflects the increased flux of glucose carbon 
into parasite biomass (nucleic acids, lipids, proteins) required for parasite growth and 
replication as compared to more than 90% of glucose is converted to lactate in uninfected 
RBCs (Olszewski and Llinas, 2011). On the other hand, these findings may indicate the 
lack of a fully functional TCA as well as call into querying the role of mitochondrial 
electron transport chain for energy generation. Answers to this assumption are provided in 
the chapters 4, 5, and 6. Nonetheless, synopsis about TCA and mitochondria is highlighted 
below.  
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Figure 1.17: Glycolysis pathway in P. falciparum. 
The component enzymes of the glycolysis pathways are encoded in the Plasmodium genome 
(Gardner et al., 2002). Glucose from host plasma protein is transported into the parasite via the 
hexose transporter located on the surface of infected RBC or via NPP transporter. Glucose is 
degraded via fermentation process by the parasite glycolytic enzymes producing lactate as an end 
product. This glycolytic pathway produces 2 ATP molecules. The oxidation of phophoenolpyruvate 
(PEP) produces 2 molecules of pyruvate for the production of lactate and for lipid biogenesis in the 
apicoplast. Branching pathways include the pentose phosphate shunt, which generates NADPH 
critical for oxidative stress protection, and CO2 ﬁxation into oxaloacetate (by the action of 
carboxykinases) which is then followed by transaminases action leading to generation of three 
amino acids (alanine, glutamate and aspartate). (Adapted from Crawford et al., 2003). 
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It has been reported that P. falciparum consumes only minimal amount oxygen (Krungkrai 
et al., 1999) and it prefers microaerophilic conditions of ~5% oxygen, as its growth is 
inhibited by normal atmospheric oxygen concentrations (Scheibel et al., 1979). These 
studies suggest that asexual stages of P. falciparum rely primarily upon glucose 
fermentation for their energetic requirements. This is in keeping with the study 
demonstrating that inhibitors of mitochondrial respiration have only a small effect on the 
parasite ATP pools (Fry et al., 1990). One molecule of glucose is degraded into two 
molecules of pyruvate via the glycolysis pathway. In eukaryotic organisms, pyruvate 
dehydrogenase has been recognised as an essential enzyme responsible for connecting the 
glycolytic pathway and TCA cycle and hence it catalyses the conversion of pyruvate to 
acetyl-CoA in the mitochondrial matrix. However, pyruvate dehydrogenase in malaria 
parasite is located only in apicoplast not in the mitochondria and thus role of pyruvate 
dehydrogenase is solely to produce acetyl-CoA for lipid biogenesis in apicoplast (Foth et 
al., 2005). In addition, the P. falciparum genome encodes all the necessary enzymes for 
TCA cycle (Gardner et al., 2002) which are actively expressed during the asexual blood life 
stages (Bozdech et al., 2003). Although it has been recently published that P. falciparum 
possess a branched TCA pathway rather than conventional cycle (Olszewski et al., 2011), 
now the authors of this paper come to the retraction of the whole article stating that TCA 
metabolism in blood-stage P. falciparum is not branched but primarily oxidative (Figure 
1.18) (Olszewski et al., 2013). Human RBC has incomplete TCA cycle (Prankerd, 1955) 
and it was suggested Linas and Vaidya groups that the reductive flux occurs primarily in 
the RBCs and not in the parasite itself (Olszewski et al., 2013). Therefore, there was an 
excessive interference from surrounding uninfected RBCs which has led to incorrect 
interpretation of stating that P. falciparum operates reductive and oxidative pathways with 
2-oxoglutarate being the entry point to feed both pathways which converge to generate 
malate (Olszewski et al., 2013).  
However, the role of Plasmodium mitochondrion has not been fully understood. 
Plasmodium mitochondrion contains both conserved and unusual features. These include 
(1) an active electron transport chain that is thought to serve as electron disposal system to 
supply pyrimidine biosynthesis (Painter et al., 2007), as well as to generate the 
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mitochondrial membrane potential (ΔΨ m) across the inner mitochondrial membrane that is 
necessary for electron transport (2) participation in iron-sulphur cluster biosynthesis and 
unusual hybrid haem biosynthesis pathway, with enzymes localizing in both the 
mitochondrion and plastid organelles (reviewed in (Vaidya and Mather, 2009, van Dooren 
et al., 2006)). 
 
 
Figure 1.18. Illustration of TCA pathways in P. falciparum.  
The classical oxidative TCA cycle used by P. falciparum is indicated by green arrows, and the 
branched pathway which was incorrectly thought to be used by P. falciparum is shown in red. 
Dashed arrows indicate multiple steps. (Adapted from Ginsburg 2010). 
 
 
1.3.3.4. Nucleotide metabolism 
The synthesis of nucleotides by malaria parasite necessitates the availability of purines and 
pyrimidines (the constituents of the nucleotides) as well as an adequate supply of ribose 
sugars and phosphate. The biosynthesis of purines, pyrimidines and folate as well as 
mitochondrial electron transport chain are intimately linked (Figure 1.19) (Olliaro and 
Yuthavong, 1999). Table 1.2 below summarizes the major differences between 
Plasmodium parasite and human in purines, pyrimidines and folate metabolic pathways. 
Blood stage Plasmodium parasites are incapable of de novo purine synthesis unlike 
mammalian cells and therefore they depend on salvage pathway to obtain performed host 
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purine precursors (hypoxanthine, adenosine, guanine) from the extracellular milieu through 
a number of transporters, some of which have been identified and characterized (as 
reviewed in (Sherman, 1979, Downie et al., 2008)). In infected RBC, the influx of purines 
into RBC is increased and there is evidence suggesting that the ATP generated by RBC is 
broken down to AMP and hypoxanthine (Reyes et al., 1982, Cassera et al., 2008). The 
parasite scavenges AMP and hypoxanthine from the host cytosol as a purine source and it 
converts hypoxanthine into inosine monophosphate (IMP), which serves as the precursor 
for the synthesis of all adenosine and guanosine nucleotides and deoxynucleotides 
(reviewed in (Downie et al., 2008, Kirk et al., 2009, Gero and Osullivan, 1990)). 
 
In contrast, asexual stages of Plasmodium parasites are unable to salvage either pyrimidine 
bases or nucleoside and they have to synthesize pyrimidine nucleotide de novo whilst 
mammalian cells can either salvage or synthesize de novo pyrimidine nucleotides 
(Sherman, 1979, Krungkrai et al., 2003, Gero et al., 1984). The parasite has all enzymes 
required for the synthesis of uridine monophosphate (UMP) from glutamine, ATP and CO2 
(Gero and Osullivan, 1990). Pyrimidine biosynthesis in malaria parasite begins by fixing 
CO2 into carbamoyl phosphate, which then condenses with aspartate to form carbamoyl-l-
aspartate. This is subsequently converted into UMP, which serves as the precursor for all 
uridine, thymidine and cytidine (deoxy)-nucleotides (Rathod and Reyes, 1983, Krungkrai et 
al., 2003, Reyes et al., 1982). Interestingly, recent reports suggest that the only vital 
function of the parasite’s mitochondrial electron transport chain is to serve as an electron 
sink for dihydroorotate dehydrogenase, an enzyme in this pathway (Painter et al., 2007). 
However, more insights about P. falciparum mitochondria and its role in pyrimidine 
biosynthesis are discussed in details in chapters 5 and 6.  
 
Moreover, tetrahydrofolate (THF) is a key coenzyme in amino acid and nucleotide 
metabolism. In P. falciparum, it can be synthesized either via a de novo or salvage 
pathway (Krungkrai et al., 1989, Asawamahasakda and Yuthavong, 1993). The folate 
pathway is connected to the purine salvage through GTP, with GTP cyclohydrolase as the 
first enzyme in the de novo folate synthesis pathway (Figure 1.19) (Krungkrai et al., 1989). 
It is as well linked to the pyrimidine and amino acid biosynthesis via the dTMP synthesis 
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cycle and the methionine synthesis cycle, respectively (Figure 1.19) (Olliaro and 
Yuthavong, 1999). All the enzymes of the folate pathway have been studied in malaria 
parasites with particular interest on dihydrofolate reductase (DHFR) and dihydropteroate 
synthase (DHPS), which are the targets of two different classes of antifolates used as 
antimalarial drugs as previewed previously (section 1.2.4.4.2).  
 
Table 1.2. Nucleotides metabolism in Plasmodium parasite and Humans. (Adapted from 
Olliaro and Yuthavong, 1999). 
Pathway Plasmodium parasite Mammal 
Pyrimidines Synthesizes pyrimidines de novo; cannot 
salvage bases/nucleotides 
Can either synthesize or salvage 
pyrimidine nucleotides 
Purines No de novo synthesis; relies on host-
derived hypoxanthine as source of purine 
precursors 
Can either synthesize or salvage 
purine nucleotides—hypoxanthine 
waste product 
Folate 
cofactors 
Can either synthesize or salvage folate 
precursors 
No de novo synthesis; rely on 
external sources 
 
 
 
Figure 1.19. Schematic diagram shows the metabolic interconnection between purine, 
pyrimidine, folate synthesis pathways. (Adapted with modification from Olliaro 
and Yuthavong, 1999). 
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1.3.3.5. Protein and polyamine synthesis 
During malaria parasite asexual blood stage growth, it obtains most of the amino acids 
required for protein synthesis and other metabolic functions from the digestion of RBC 
protein (primarily haemoglobin) as viewed previously (section 1.3.3.1). However, 
haemoglobin is not the only source for amino acids although majority (>85%) of the 
amino acids produced via haemoglobin degradation are excreted as waste; but rather the 
parasite salvage from the free amino acids pool in the plasma while some amino acids 
(e.g. glutamate, alanine and aspartate) are biosynthesized by the parasite itself from 
glucose and CO2 (Sherman, 1977, Sherman, 1979). Plasmodium parasites uptake amino 
acids from the extracellular environment through a variety of transporters expressed to 
the surface of the RBC as well as via NPP (Elford et al., 1995, Ginsburg et al., 1985). 
These amino acids are used for protein synthesis as well as in a number of other 
metabolic pathways. More insights and details about amino acids metabolism are 
presented in chapters 4, 6 and 7. In short, glutamine and glutamate are incorporated in 
different metabolism such as pyrimidine biosynthesis pathway. In addition, arginine is 
rapidly degraded via a parasite arginase to urea and ornithine, although the parasite lacks 
a urea cycle (Olszewski et al., 2009). Ornithine is required precursor for polyamine 
synthesis.  Three steps are critical for polyamine biosynthesis including (1) the 
decarboxylation of ornithine to putrescine via ornithine decarboxylase (ODC), (2) the 
formation of S-adenosylemethionine (AdoMet) from methionine and ATP, and (3) the 
decarboxylation of AdoMet which provides the aminopropyl groups required for the 
sperimidine and spermine synthesis (Assaraf et al., 1984). Methionine cycle exists to 
supply the substrate for methylation reactions as well as polyamine biosynthesis 
(Asawamahasakda and Yuthavong, 1993, Assaraf et al., 1984). Amino acids and 
polyamines processes are critical for the survival of blood stage malaria parasites and 
hence might be targeted for developing antimalarial drugs.  
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 Metabolomics  1.4.
1.4.1. Overview 
Metabolomics is a post genomic research field concerned with developing analytical 
methods for the study of the entire repertoire of metabolites in biological systems such as 
cells, organs or organisms (Fiehn, 2002, Goodacre, 2005, Lakshmanan et al., 2011). This 
repertoire consists of many different classes of small molecules including carbohydrates, 
amino acids, nucleotides, antioxidants and fatty acids. These small molecules perform 
critical functions such as energy storage, signal transduction, maintaining cellular structure, 
and feedback regulation of gene expression. The identities, concentrations, and fluxes of 
these metabolites result from a complex interaction among gene expression, protein 
expression, and the environment (Figure 1.20) (Goodacre, 2005). However, the function of 
genes and proteins is subjected to epigenetic regulation and post-translational 
modifications, respectively, whilst metabolites serve as direct signatures of biochemical 
activity and are therefore easier to correlate with phenotype and function of cellular 
activities (Patti et al., 2012). This explains why metabolomics has become a powerful 
approach in recent years and therefore it has been applied in different areas of research. In 
contrast to classical biochemical approaches that often focus on single metabolite, single 
metabolic reaction and its kinetic properties, metabolomics involves in the collection of 
qualitative and quantitative data on a broad series of metabolites in order to gain an 
integrated understanding of the cellular response to environmental change (Kaddurah-
Daouk et al., 2008, Ryan and Robards, 2006). Metabolic changes can be regarded as the 
ultimate consequence of environmental perturbation and therefore analyzing metabolic 
differences between unperturbed and perturbed systems, such as drug treated and untreated 
P. falciparum parasites, can lead to insights into the underlying biology as well as drug 
mode of action. This example can be used in the context of pharmacometabolomic which is 
the use of the techniques of metabolomics to define metabolite signals that will provide 
insight into mode of drug action and mechanisms responsible for parasite variations in drug 
response phenotypes.  
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Figure 1.20. General schematic illustration of the omics organisation.  
The general profiles ﬂow from genes to transcripts to proteins to metabolites leading ultimately to 
cellular phenotype (function). Blue vertical arrows indicate interactions regulating the respective 
omic expression. (Adapted with modification from Goodacre 2005). 
 
1.4.2. Metabolomics process workflow 
A generic metabolomics workﬂow needs to be tailored according to sample types being 
studied. The metabolomics workﬂow is shown in (Figure 1.21) and can be described as a 
metabolomics pipeline. It addresses the need to have streamlines approach for sample 
preparation, analytical setup for data capturing and pre-processing, data analysis and 
knowledge assembling. Therefore, a combination of diﬀerent expertises is required in 
multi-disciplinary teams including biologist, analytical chemists, statisticians, modellers 
and bioinformaticians (Dunn et al., 2011). Each phase in the metabolomics workﬂow has 
multiple choices and hence choosing the correct option for speciﬁc experiments is critical 
to ensure the production of robust and valid results. Therefore, it is recommended to 
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undertake the development and validation of each component to ensure they are ﬁt-for-
purpose (Villas-Boas et al., 2005, Dunn et al., 2011). This process of development and 
validation has been undertaken in chapter 3.  
 
 
Figure 1.21. Metabolomics pipeline workflow components. 
 
Generally, there are two types of metabolomic workflows, which can be sub-divided into 
targeted and untargeted approaches. Targeted metabolomics refers to an analytical method 
in which pre-determined set of known compounds (authentic standards) is accurately 
detected and quantified using appropriate internal standards (commonly, isotopes) (Figure 
1.22 A) (Dudley et al., 2010). It is typically driven by a specific biochemical question or 
hypothesis on one or more related metabolic pathways of interest (Patti et al., 2012). 
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Therefore, targeted metabolomics approach is effective for measuring the effect of drugs or 
genetic modifications on a specific enzyme (Nicholson et al., 2002). This approach has 
been developed, validated and undertaken throughout this thesis to investigate the effect of 
drugs on a number of selected metabolic pathways in P. falciparum parasite as well as drug 
mode of action (refer to chapters 3-7).  
Untargeted metabolomics refers to a method in which the aim is to get global metabolic 
profiling in scope through simultaneously measuring, without bias, as many metabolites as 
possible within a certain mass range  including novel (unknown) metabolites from 
biological samples (Figure 1.22 B) (Patti et al., 2012, Vinayavekhin and Saghatelian, 
2010). Typically, untargeted metabolomics approach is required to  provide detection of 
100-1000s of metabolites in a valid and robust manner which is generally applied in the 
pharmaceutical industry in the study of drug metabolism (Dunn et al., 2011).   
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Figure 1.22. Schematic representation shows the differences between workflow of targeted 
and untartgetd metabolomics approaches.  
A) Targeted metabolomics workflow most often uses triple quadrupole mass spectrometry. 
Standard compounds for the metabolites of interest are first used to set up selected reaction 
monitoring methods. Here, optimal instrument voltages are determined and response curves are 
generated for absolute quantification. Samples are then analysed based on the established standard 
metabolites. The data output provides quantification only of those metabolites for which standard 
methods have been built. B) Untargeted metabolomics workflow uses mass analyser that enables of 
identify both known and unknown metabolites. Samples are analysed by liquid chromatography 
followed by mass spectrometry (LC/MS). After data acquisition, the results are processed by using 
bioinformatic software to perform nonlinear retention time alignment and identify peaks that are 
changing between the groups of samples measured. The m/z values for the peaks of interest are 
searched in metabolite databases to obtain putative identifications. Putative identifications are then 
confirmed by comparing tandem mass spectrometry (MS/MS) data and retention time data to that 
of standard compounds. The untargeted workflow is global in scope and outputs data related to 
comprehensive cellular metabolism. (Adapted from Patti et al., 2012). 
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1.4.2.1. Sample preparation 
Adequate methods for sample preparation are of outmost importance in metabolomics. The 
objective of sample preparation is to ensure that the extracted metabolites represent the 
metabolome in the sample. The process of sample preparation is typically divided into two 
steps: (1) quenching of metabolic activity and (2) extraction of metabolites into an 
appropriate solvent for analysis. Rapid quenching (arrest) of all biochemical processes has 
to be adequately preformed in the beginning of sample preparation because the metabolite 
levels reflect the physiologic state of the biological system particularly if it is exposed to 
genetic or an environmental change (Dunn et al., 2011, Villas-Boas et al., 2005). Following 
the quenching step, extraction step in conducted to separate the metabolites of interest from 
its cellular material (matrix species) (Dunn et al., 2011). However, the extraction process is 
often the most time-consuming step in metabolomics analysis, and it is also very 
challenging to avoid metabolite losses due to the large chemical diversity classes of the 
different metabolites containing polar (water-soluble) and non-polar (water-insoluble) 
metabolites as well as volatile ones (Moco et al., 2007, Besteiro et al., 2010). During the 
extraction of intracellular metabolites, inevitable extra variability results in a comparatively 
low reproducibility of any analytical method. In addition, most of the available extraction 
methods produce high sample dilutions that result in even lower concentrations of 
metabolites thus a concentration step is required using evaporation process by nitrogen 
stream flow (Dunn et al., 2011, Villas-Boas et al., 2005). Therefore, quenching and 
extraction steps should be validated for any losses or leakage of metabolites due to 
degradation, on-going biochemical reactions and/or sample mishandling (Villas-Boas et al., 
2005, Reaves and Rabinowitz, 2011). In addition, quenching and extraction can be 
performed in a single step (Lakshmanan et al., 2011). It has been found that acidic 
acetonitrile/methanol/water (40:40:20) gave superior in extraction of  many  cellular 
metabolites of E. coli metabolome, including most amino acids, nucleotide and components 
of central carbon metabolism (Rabinowitz and Kimball, 2007). Therefore, this mixture of 
solvents has been used for the extraction of P. falciparum metabolites in this thesis.   
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1.4.2.2. Analytical instruments 
Metabolite identification is a key step for metabolomics study. Metabolome analysis can be 
conducted on a variety of biological sample types and may utilize a number of different 
technology platforms. There are general specifications for metabolomic analytical 
instruments. These include (1) excellent sensitivity and resolution,  (2) capability handling 
wide range of concentrations (from pM to mM), (3) identification and quantification of 
different types of molecules and (4) reproducible measurement of many samples in short 
analysis time (Čuperlović-Culf et al., 2010, Khoo and Al-Rubeai, 2007). The main 
analytical platforms used for metabolomics applications are nuclear magnetic resonance 
spectroscopy (NMR) and hyphenated techniques such as gas chromatography (GC), 
capillary electrophoresis (CE) and liquid chromatography (LC) coupled to mass 
spectrometry (MS). In addition, fourier transform infrared spectroscopy (FT-IR) and direct 
infusion mass spectrometry (DIMS) have been applied without any prior separation, except 
for eventual sample preparation (Figure 1.23)  (Dunn and Ellis, 2005).  
 
NMR spectroscopy functions by the application of strong magnetic fields and radio 
frequency (RF) pulses to the nuclei of atoms. The presence of a magnetic field causes 
nuclear spin for different nuclei which include 
1
H, 
13
C, 
15
N and 
31
P. Absorption of RF 
energy allows then the nuclei to be promoted from low-energy to high-energy spin states, 
and the subsequent emission of radiation during the relaxation process is detected. The 
NMR spectrum (chemical shift) is determined as the difference in ppm (parts per million) 
between the resonance frequency of the observed atom and that of a reference atom present 
in a reference compound. The signal intensity depends on the number of identical nuclei 
(Dunn and Ellis, 2005).  
 
FT-IR is based on the principle that when the sample is interrogated with an IR beam, the 
functional groups within the sample will absorb the IR radiation and vibrate in one of the 
following ways including stretching, bending, deformation or combination vibrations. 
These absorptions/vibrations can then be correlated to (bio)chemical species and the 
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resultant IR absorption spectrum can be described as an IR fingerprint (Ellis and Goodacre, 
2006).      
 
The spectra obtained from NMR and FR-IR, are composed of the signals of many 
metabolites and therefore the elucidation of these complex spectra can be very complicated 
(Koek et al., 2011). Moreover, the limits of detection for NMR and FT-IR are much higher 
than for MS-based techniques, limiting the applications of NMR and FT-IR to the analysis 
of bulk metabolites (Koek et al., 2011, Zhang et al., 2012). Therefore, hyphenated 
techniques such as GC-MS, LC-MS and CE-MS, are generally favoured in metabolomics 
allowing identification and quantification of as many metabolites. However, none of the 
analytical methods will cover the full metabolome and thus parallel application of several 
techniques, e.g. GC-MS , LC-MS or NMR , is desirable to study the global metabolome 
which consists of metabolites with different polarity and molecular weight ranges (Koek et 
al., 2011). In addition, GC-MS is applied to the analysis of volatile organic metabolites 
whereas CE-MS and LC-MS is highly applicable to the analysis of a wide range of polar 
metabolites (Zhang et al., 2012). Although CE is very effective for hydrophilic metabolites, 
the buffers used for this chromatographic separation are not readily compatible with the ion 
source of the MS. Therefore, the development of new column chemistries such as 
hydrophilic interaction chromatography (HILIC) can be placed as an alternative to CE 
using LC/MS. Therefore, HILIC coupled to MS based metabolomics method has been 
undertaken in the study of this thesis aiming to investigate part of P. falciparum parasite 
metabolome.   
 
  
 
 
52 
 
 
Figure 1.23. Summary of the different metabolomics-based strategies for sample preparation 
and sample analysis.  
 
Mass spectrometry is focused on the measurement of an analyte mass. More precisely, it 
determines the mass-to-charge (m/z) ratio of electrically charged molecules. A molecule 
with a nominal molecular weight of 1000 and coupled to a single proton (positive 
ionization mode or protonation) will be detected with an m/z of 1001 [MW of molecule 
(1000) + H
+
]. A molecule with a molecular weight of 1000 and decoupled of a single 
proton (negative ionization mode or deprotonation) will be detected with an m/z of 999 
[MW of molecule (1000) - H
+
] (El-Aneed et al., 2009, Dunn, 2011).  
The role of MS in metabolomic research is constantly expanding in which it is capable of 
performing targeted and untargeted metabolomics analysis (Dettmer et al., 2007). There are 
five important requirements  that need to be considered in metabolomics analysis by MS 
including (1) efficient metabolites extraction, (2) separation or fractionation of the analytes 
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by chromatography, (3) molecules ionization, (4) mass signals detection and (5) metabolite 
identification and quantification (Čuperlović-Culf et al., 2010). Therefore, recent advances 
in chromatography separation sciences, ion sources and mass analyzers have considerably 
improved the sensitivity, selectivity, specificity and speed of metabolite identification and 
quantification by MS.  
A critical step in LC-MS approach is the conversion of the eluted metabolites from LC 
system into gas-phase ions (Rabinowitz, 2007). Generally, there are two popular ionization 
approaches namely electrospray ionization (ESI) and atmospheric pressure chemical 
ionization (APCI). Although APCI often provides better quantitative reproducibility and 
robustness, ESI generally offers considerably superior sensitivity particularly for water-
soluble cellular metabolites. Therefore, most LC-MS approaches for cellular metabolomics 
employ ESI (Rabinowitz, 2007, Lu et al., 2008) which has been undertaken as an ionization 
source for the P. falciparum metabolites in this thesis.  
The obtained gas-phase ions have to be directed to appropriate MS or tandem MS 
(MS/MS) analysers in order to generate the actual data. Major options for MS analysers 
include time-of-flight (TOF), ion trap and triple quadrupole MS. TOF offers high mass 
accuracy and the ability to identify known and unknown metabolites. Disadvantages are 
suboptimal sensitivity and dynamic range for known analytes. Ion traps operated in data-
dependent MS/MS mode can provide spectra for both known and previously unknown 
analytes. If they are coupled to a high mass accuracy detector such as an ion cyclotron 
resonance (ICR) (Marshall et al., 1998) or orbitrap MS (Hu et al., 2005), they can provide 
high mass resolution product ion spectra, high sensitivity and thus they are outstanding for 
identification of unknown metabolites (Rabinowitz, 2007). 
Triple quadrupole mass spectrometers operated in multiple reactions monitoring (MRM) 
mode enable quantitation of known metabolites with predetermined fragmentation patterns. 
At any given instant, the mass spectrometer detects only a single analyte using a selected 
reaction monitoring (SRM) scan: the first quadrupole (Q1) selects for the parent ion mass; 
the second quadrupole (Q2) conducts collision-induced dissociation (CID); and the third 
quadrupole (Q3) selects for the predetermined product ion mass (Figure 1.24). Each SRM 
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scan takes approximately 0.1 s, enabling quantitation of numerous metabolites during a 
single LC run. MRM scanning generally provides the best quantitative performance 
sensitivity and reproducibility for known analytes although it does not provide information 
on unknown analytes (Rabinowitz, 2007). This approach of tandem MS (MS/MS) using 
Triple quadrupole mass analyser has been undertaken in the study of 
pharmacometabolomics of P. falciparum in this thesis.  
 
 
Figure 1.24. LC triple quadrupole tandem mass spectrometers use ESI as inonization source. 
LC-ESI-MS/MS aims to detect and quantify known cellular metabolites. Q1 is first 
quadrupole that selects for the precursor ion mass; Q2 is the second quadrupole that 
conducts collision-induced dissociation (CID) to fragment the precursor ion mass; and Q3 
is the third quadrupole that selects for the predetermined fragmented ion mass.   
 
1.4.2.3. Data analysis 
Metabolomics experiment produces large volumes of data for each sample. Efficient data 
analysis is important in order to achieve accurate metabolite identification and 
quantification, which ultimately leads to generate biologically meaningful interpretations. 
There are a wide variety of data processing software and other tools that have been 
developed for data analysis in metabolomics (Katajamaa and Oresic, 2007). The mostly 
commonly used statistical tools for metabolomics include principal component analysis 
(PCA) and partial least squares discriminant analysis (PLS-DA) (Novotny et al., 2008). 
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PCA is a commonly used unsupervised technique. It requires no a priori knowledge of class 
of the sample hence, the term “unsupervised”. PCA is a statistical technique that 
determines the most optimal linear transformation for a collection of data points in such a 
manner that the properties of that sample are most clearly displayed along the coordinate 
(i.e. principal) axes. In other words, PCA allows one to plot, visualize, and cluster multiple 
metabolomic data sets based on linear combinations of their shared features (Wishart, 
2010). Similarly, PLS-DA uses supervised techniques to enable one to perform efficient 
classification and discrimination analysis of very large data sets containing a small number 
of samples. A variant of PLS-DA classifies the data into two blocks, one representing 
between-class variation and the other representing within class. Therefore, it separates the 
more meaningful data from the less meaningful (Xia et al., 2012, Xia et al., 2009). PCA 
and PLS-DA plot results are discussed in terms of component scores (the transformed 
variable values corresponding to a particular data point), and loadings (the weight by which 
each standardized original variable should be multiplied to get the component score). The 
Variable Influence on Projection (VIP) is a weighted sum of squares of the PLS-DA 
loadings taking into account the amount of explained Y-variation in each dimension. When 
more components are used to calculate the feature importance, the averages of the VIP 
scores are used (Xia et al., 2012, Xia et al., 2009). These statistical approaches have been 
undertaken in the data analysis of this thesis. 
 
1.4.3. Metabolomics of malaria parasite 
In the post-genomic era, metabolism of the malarial parasite has been mapped based on the 
current knowledge of parasite biochemistry and on pathways known to occur in other 
eukaryotes. Metabolomics of malaria parasite has just been started in the last recent years 
and only handful studies have been reported and reviewed (Lian et al., 2009, Lakshmanan 
et al., 2011, Olszewski and Llinas, 2011, van Brummelen et al., 2009, Kafsack and Llinas, 
2010, Olszewski et al., 2011, Bulusu et al., 2011, Teng et al., 2009). However, these studies 
have contributed significantly in understanding of malaria parasite metabolic functions and 
thus they illuminate new chemotherapeutic targets for drug development, including the 
identification of target for drugs in current use.  
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Teng et al., (2009) used proton (
1
H) NMR to identify and quantifiy more than 50 
metabolites, including amino acids, nucleotides, carboxylates and other molecules, from an 
extract of saponin-released P. falciparum trophozoites (Teng et al., 2009). Lian et al., 
(2009) used 
13
C NMR to study the glucose metabolism in P. falciparum-infected RBC, 
which showed that alongside the expected glucose end-products (pyruvate, alanine, 
lactate), glycerol and glycerol-3-phosphate were generated in the parasite suggesting the 
operation of a glycerol-3-phosphate shuttle in the parasite in response to growth under 
limited O2 and elevated CO2 (Lian et al., 2009). A LC-MS/MS based metabolomics was 
used to quantitatively measure of ∼200 known metabolites of P. falciparum during its 48 h 
blood-stage developmental cycle showing that the conversion of arginine to ornithine by 
parasite arginase, and the potential link between parasite-induced hypoargininemia and the 
development of cerebral malaria (Olszewski et al., 2009). Therefore, insights into P. 
falciparum parasite biology and drugs mode of action are provided in the subsequent 
chapters (4-7) using pharmacometabolomics approach.   
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 Thesis Objectives 1.5.
The general objective of this thesis was to take a targeted pharmacometabolomics approach 
to study some selected metabolic pathways of P. falciparum parasites in the presence and 
absence of a number of antimalarial drugs and some inhibitors and to infer from these data, 
the drugs’ mode of action. Towards this overall objective, the specific objectives are: 
1. To develop and validate a targeted metabolomic platform focusing on central 
carbon and amino acid metabolism. This objective has been achieved successfully 
as described later in chapter 3.    
2. To study the general differences in the metabolic profiles between uninfected 
human red blood cell (RBC) and those infected by P. falciparum (iRBC). This 
objective will enable the study in the subsequent chapters to focus only on P. 
falciparum-iRBC trophozoite stage in order to eliminate any bias coming from the 
background noise generated by RBC. This objective has been accomplished 
successfully as described later in chapter 4.    
3.  To assess the role of P. falciparum mitochondria and mitochondrial electron 
transport chain using a number of mitochondrial selected inhibitors and antimalarial 
drugs and show the likely mode of actions of each drug used. This work is 
described in chapters 5 and 6. 
4. To examine the role of P. falciparum digestive vacuole using quinolones-containing 
antimalarial drugs (QCDs) and demonstrate the similarities and differences in the 
probable mode of action of QCDs used. This work is described in chapter 7. 
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CHAPTER 2  
     General Experimental Protocols 
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 Introduction     2.1.
The aim of this chapter was to provide information on the routine system for Plasmodium 
falciparum parasite culture and on the instrumentation of LC-MS/MS technique which has 
been utilized to provide the data in this thesis. This chapter will provide step-by-step 
methodology of the general techniques used in this thesis allowing easy reproducibility. 
Details of methods used in more specific instances and modification or supplements to 
standard methods are provided at appropriate locations within the experimental chapters.  
 
 Culture system for P. falciparum maintenance 2.2.
The method used for culturing the P. falciparum parasite was adapted from (Trager and 
Jensen, 1976) and (Jensen and Trager, 1978). Parasite culturing was carried out using 
standard aseptic techniques in an Envair class II laminar flow safety cabinet. The laminar 
flow cabinet was thoroughly cleaned firstly with biocidal cleaner (Biocleanse Concentarte, 
TEKNON, UK) and then with 70% ethanol (Chemistry Department, Liverpool University, 
UK) before and after the parasite culturing work, to minimize contamination. All 
consumables used in the laminar flow cabinet were pre-sterilized unless otherwise stated. 
These include 75 cm² and 25 cm² Nunc™ polystyrene tissue culture flasks (Fisher 
Scientific, UK), 15 ml and 50 ml centrifuge tubes (UK), 2.5 ml bijou bottles (VWR, UK) 
and disposable cotton plugged plastic pipettes (Sterilin Limited, UK). All the solutions 
used for P. falciprum culture were prepared with distilled water (dH2O) and sterilized 
through a sterile bottle top filter unit with a 0.22 μm membrane (Fisher Scientific, UK). All 
Glassware, 1.5 ml eppendorf tubes, 10 μl, 200 μl and 1000 μl pipette tips were sterilized by 
autoclaving (121 ⁰C, 15 psi for 30 min) prior to use. Protective gloves were worn and 
regularly sprayed with 70% ethanol to minimize any chances of contamination. All the 
parasite-related centrifugations were carried out using Fisher Scientific accuSpin1 bench 
top centrifuge (Fisher Scientific, UK). Extra parasite culture flasks, supernatants, used 
pipettes, old uninfected red blood cell (RBC) and old RPMI-1640 complete culture medium 
were first thoroughly decontaminated in biocidal cleaner (Biocleanse Concentarte, 
TEKNON, UK) and then discarded in the designated waste garbage. 
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2.2.1. P. falciparum parasite strains 
Two strains of P. falciparum, chloroquine sensitive 3D7 and transgenic 3D7-yDHOD∙GFP, 
were used in the preliminary stages of this study (Chapter 5). However, the 3D7 strain was 
selected for the remaining experiments in this thesis on the basis of its robustness in 
continuous culture and sensitivity for various inhibitors and antimalarial drugs.  The 3D7 
strain was cloned from the isolate NF54 obtained from an airport worker in Amsterdam 
(Cowman et al., 1991).  
 
2.2.2. Culture medium 
RPMI-1640 (Roswell Park Memorial Institute) culture medium containing L-glutamine and 
sodium bicarbonate (NaHCO3) was purchased from Sigma (Sigma, UK). Complete culture 
medium was prepared by adding to a 500 ml bottle of RPMI-1640 culture medium the 
following: 12.5 ml of pre-sterilized 1 M HEPES (4-(2-hydroxyethyl)-1-piperazine ethane 
sulfonic acid) (Section 2.1.2.1), 200 μl of 50 mg/ml gentamicin (Sigma, UK) (Section 
2.1.2.2) and 50 ml of pooled human AB+ serum (Section 2.1.2.3). Complete culture 
medium was incubated at 37 ⁰C overnight prior to use with the purpose of checking for 
contamination. An occurrence of contamination was characterized by a colour change in 
the medium from red/orange to yellow and an increase in turbidity of the medium. 
Complete culture medium was always prepared fresh and only used for 1 week after which 
the medium was discarded to avoid the effects of medium deterioration. 
 
2.2.2.1. HEPES 
HEPES (4-(2-hydroxyethyl)-1-piperazine ethane sulfonic acid) was purchased from VWR 
International Ltd (UK). The preparation of 1 M stock of HEPES (MW = 238.03 g) was as 
follows: 238.03 g of HEPES was dissolved in 700 ml of distilled water and the pH was 
adjusted using 5 M NaOH to 7.4 after which the solution was made up to 1 L using distilled 
water. This 1 M stock of HEPES was then sterilized through a sterile bottle top filter unit 
  
 
 
61 
 
with a 0.22 μm membrane (Fisher Scientific, UK), labeled, and stored at 4 ⁰C for future 
use. 
 
2.2.2.2. Gentamicin 
Gentamicin 50 mg/ml was purchased from Sigma (Sigma, UK), aliquoted into 2.5 ml bijou 
bottles, labeled and stored at 4 ⁰C until required.   
 
2.2.3. Serum 
Human AB+ serum was kindly donated by Ward 7Y and the Gastroenterology Unit, Royal 
Liverpool Hospital, Liverpool, UK. Approximately 15-20 bags of irregular volume (100-
250 ml) were pooled aseptically in a previously autoclaved beaker. Human AB+ pooled 
serum was then aliquoted into 50 ml centrifuge tubes and stored at -20 ⁰C until required. 
Prior to usage, an aliquot of 50 ml centrifuge tube containing human serum was defrosted 
by placing it in a water path at 37 ⁰C for approximately 30 min. The tube was then rinsed 
with 70% ethanol to minimize contamination before the content was transferred aseptically 
into a 500 ml bottle RPMI-1640 culture medium.    
 
2.2.4. Preparation of uninfected red blood cell 
Uninfected red blood cells (RBC) used in the study was kindly donated by the North West 
Regional Blood Transfusion Service, Liverpool, UK.  RBC was whole human O+ blood. 
This blood, obtained no longer than 48 h after collection, was supplied in citrate-phosphate-
dextrose bags and had been tested for HIV and HBV antibodies. It was unsuitable for 
transfusion because of irregular bag volume. Upon receipt, the blood was aseptically 
aliquoted into sterile 50 ml centrifuge tubes and stored at 4 °C for only two weeks. It is 
important to note here that using freshly drawn blood provides better support for parasite 
growth.   
 
Serum and buffy coat layer were removed prior to usage as follows: 25 ml aliquot of whole 
blood was centrifuged aseptically at 3000 rpm for 5 min. The serum and buffy coat layer 
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were carefully removed using a pre-sterilized 10 ml pipette. The remaining 10 ml of packed 
RBC was washed three times with RPMI-1640 incomplete culture medium supplemented 
with 25 mM HEPES (pH 7.4) and 20 µM gentamicin and was collected by centrifugation at 
3000 rpm for 5 min. All supernatants were discarded after each wash. The washed packet 
erythrocytes were labeled and stored as packed cells at 4 °C for up to one week and 
discarded after one week, if unused.   
 
2.2.5. Gas phase 
It is well documented that prolonged parasite growth requires a gas condition with a lower 
O2 concentration and a higher CO2 concentration than atmospheric air (Scheibel et al., 
1979). The gas used in this study was supplied by British Oxygen Special Gases and was 
composed of 3% O2, 4% CO2 and 93% N2 (British Oxygen Special Gases, UK). Culture 
flasks were gassed aseptically inside the class II laminar flow safety cabinet as follows: the 
gas from the cylinder was delivered to the laminar flow safety cabinet through a length of 
pre-sterilized silicon rubber tubing fitted with a 0.2 µm pore size acrylic filter (Gelman 
Sciences Inc., UK), into a further length of pre-sterilized silicon rubber tubing terminated 
with another 0.2 µm acrylic filter. This terminal filter was replaced before the gassing of 
the culture flasks. Culture flasks were gassed individually via a pre-sterilized cotton 
plugged pipette fitted to the terminal acrylic filter for approximately 1 min per 75 cm² 
culture flask.   
 
2.2.6. Cryopreservation (freezing) of parasite cultures  
Parasite cultures were cryopreserved by a modified method that is similar to that of (Rowe 
et al., 1968, Wilson et al., 1977) in order to facilitate the rapid recovery of parasites after 
retrieval. This method is described below (sections 2.1.6.1 and 2.1.6.2). 
 
2.2.6.1. Procedure of cryopreservation (freezing) 
Parasite cultures of a high parasitaemia (greater than 5%), predominantly at  ring stage, 
were transferred aseptically into sterile 50 ml centrifuge tubes and centrifuged at 2500 rpm 
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for 5 min. The supernatant was discarded and an equal volume of cryoprotectant solution 
(section 2.1.6.2) was added to the parasite culture pellet. This suspension of parasite culture 
pellet and cryoprotectant was allowed to equilibrate for 5 min at room temperature. 
Aliquots of 500 – 1000 µl of the suspension were placed into screw-capped cryotubes 
(Nunc, UK), labeled appropriately and then transferred into liquid nitrogen tank for storage 
(British Oxygen Special Gases, UK). 
 
2.2.6.2. Preparation of cryoprotectant solution 
The cryoprotectant solution was prepared as follows: 1.9 g of sodium chloride (Sigma 
Chemical Co, UK) was dissolved in 200 ml of distilled water to get 0.95% (w/v) 
physiological saline. 8.4 g of sorbitol (Sigma Chemical Co, UK) was then dissolved in the 
prepared saline to get 4.2% (w/v) sorbitol. Thereafter, 70 ml of glycerol (Sigma Chemical 
Co, UK) was added to the solution. Subsequently, the cryoprotectant solution was sterilized 
through a sterile bottle top filter unit with a 0.22 μm membrane (Fisher Scientific, UK), 
labeled, and stored at 4 °C until required. 
 
2.2.7. Retrieval of parasite cultures 
Cultures cryopreserved using the method described above was retrieved as follows: 
cryotubes were removed from the liquid nitrogen storage tank and allowed to defrost at 
room temperature or quickly thawed at 37 °C. Prior to decanting the defrosted contents of 
cultures into a 15 ml centrifuge tube, 70% ethanol was used to wipe the rim of the vial to 
minimize any chances of culture contamination. An equal volume of ice cold 3.5% (w/v) 
sodium chloride (Sigma Chemical Co, UK) was then added and centrifuged at 2000 rpm 
for 5 min. The supernatant was removed and the cell pellet was washed in an equal volume 
of RPMI-1640 complete culture medium, and centrifuged as before. The final supernatant 
was removed and the cell pellet was re-suspended in 15 ml of RPMI-1640 complete culture 
medium which was then made up to the desired hematocrit with washed RBC. Cell pellet 
suspension was then transferred to a sterile 25 cm² culture flask, labeled, gassed and placed 
in an incubator at 37 ⁰C for 48 h.      
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2.2.8. Routine monitoring of culture parasitaemia 
The parasitaemia of the cultures were checked regularly day by day to ensure that the 
parasite cultures were healthy, well synchronised (section 2.1.8.1) and within the required 
limits of parasitaemia (usually, 5-12%). In order to monitor the culture parasitaemia, a thin 
blood film from every culture flask was prepared each day by spreading a drop of cultured 
cells on a clean, glass microscope slide (Fisher Scientific, UK). Blood films were then 
fixed for 5 s in 100% methanol (Fisher Scientific, UK) and placed into a 10% Giemsa stain 
solution (VWR International Ltd, UK) buffered at pH 7.2 for 15-20 min. Blood films were 
afterwards removed, washed carefully and thoroughly under running tap water. Slides were 
then dried and examined under oil immersion at x1000 magnification on a light microscope 
(Zeiss, Germany).  The parasitaemia of the culture was determined by counting the number 
of infected cells and expressing these as a percentage of the total number of cells counted 
in approximately 5-10 fields of the blood film as shown below: 
 
Parasitaemia (%) = (number of infected red blood cells / total number of red blood 
cells) x 100    
 
2.2.8.1. Synchronising parasite cultures 
Sorbitol (Sigma, UK), a sugar-based alcohol, is known to have a stabilizing effect on the 
RBC plasma membrane (Meryman and Hornblow.M, 1968) and alter the  permeability of 
the later stages of asexual developing parasites (Lambros and Vanderberg, 1979). The 
changes in the RBC compartment of the later stage parasites allow sorbitol to enter via the 
new permeability pathway (NPP) leading the parasites to swell due to osmotic effect and 
eventually lyse and die. This process allows selection of the young ring forms which are 
unaffected, thereby synchronising the culture. 
 
Highly synchronous parasite cultures were used throughout this thesis. Parasite cultures 
were synchronised regularly by the method of Lambros and Vanderberg (1979), described 
above.  The procedure of synchronising the parasite cultures was as follows: cultures with a 
high proportion of ring stage parasites were transferred aseptically to pre-sterelized 
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centrifuge tubes and centrifuged at 2500 rpm for 5 min at room temperature. The 
supernatant was removed and discarded, and the cell pellet was re-suspended in 5 ml of 5% 
(w/v) sorbitol (section 2.2.8.1.1). The suspension was left in the laminar flow safety cabinet 
to stand at room temperature for approximately 20 min, with occasional shaking of the 
tube, and then centrifuged as above. The supernatant was removed and discarded, and the 
cell pellet was washed twice in 10 ml  RPMI-1640 complete culture medium and 
centrifuged as above. The remaining cell pellet was re-suspended in 50 ml RPMI-1640 
complete culture medium for the continous culture for a minimum of 48 hours prior to use 
in the different experiments.   
 
2.2.8.1.1. 5% Sorbitol Preparation 
Sorbitol was purchased from Sigma (Sigma, UK). The preparation of 5% sorbitol was as 
follows: a 25 g of sorbitol was dissolved in 500 ml of distilled water.  This prepared 5% 
sorbitol solution was then sterilized through a sterile bottle top filter unit with a 0.22 μm 
membrane (Fisher Scientific, UK), labeled, and stored at 4 ⁰C until required. 
 
2.2.8.2. Cultivation procedure 
A modification of the method of (Trager and Jensen, 1976) and (Jensen and Trager, 1978, 
Jensen and Trager, 1977) was used to maintain the parasite in continuous culture in pre-
sterilized plastic 75 cm² flasks (Nunc, UK). The hematocrit in the culture flasks was 2% 
unless otherwise stated. Cultures were initiated by seeding a red cell/RPMI-1640 complete 
culture medium suspension with parasitized red cells from either another culture flask 
(section 2.2.8.3) or parasitised cells retrieved from cryopreserved stocks (section 2.2.7). 
The culture flask was then gassed as described above (section 2.2.4) and placed in an 
incubator at 37 ⁰C.  The culture medium was changed every 48 and 24 h when the 
parasitaemia was less than 1.5% and higher than 2%, respectively. The procedure for this 
was as follows: the parasite suspension was transferred aseptically to a 50 ml centrifuge 
tube and centrifuged at 2500 rpm for 5 min at room temperature. The spent medium was 
carefully removed and discarded. Pre-warmed RPMI-1640 complete culture medium was 
then added to make up the volume to 15 ml and 50 ml in 25 cm² and 75 cm² culture flasks, 
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respectively. The culture flasks were then gassed as described above (2.2.5) and placed in 
an incubator at    37 ⁰C.  The parasites were sub-cultured (section 2.2.8.3) when the target 
parasitaemia had been reached (usually at ~10% parasitaemia). 
 
2.2.8.3. Sub-culturing of parasites 
The purpose of sub-culturing the parasites in this study is to produce a large volume of 
parasite pellets for metabolomics experiments described in the next experimental chapters. 
The process of sub-culturing was as follows: the parasitised cell suspension was 
centrifuged at 2500 rpm for 5 min at room temperature. The supernatant was removed and 
discarded. An appropriate volume of parasitised cell pellet was added to a new sterile 
culture flask. Fresh uninfected erythrocytes and RPMI-1640 complete culture medium were 
added to create the required hematocrit (usually 2%) and parasitaemia depending on size of 
the flask used. The culture flask was then labeled, gassed (section 2.2.5) and incubated at 
37 ⁰C. The remainder of the parasitised cells were used either in an experiment, 
cryopreserved (section 2.2.6) or thoroughly decontaminated and discarded (section 2.2).    
 
 Analytical system for LC-MS/MS-based targeted metabolomics 2.3.
Liquid chromatography coupled to (tandem) mass spectrometry (LC-MS/MS) is defined as 
an analytical chemistry technique that combines the physical separation of one or more 
compounds before being ionized and characterized by mass-to-charge ratio (m/z) and 
relative abundance using MS/MS. In this section, the general materials and methods used 
for analytical LC-MS/MS experiments will be described. 
 
2.3.1. LC-MS/MS instrumentation  
High performance liquid chromatography (HPLC) was carried out throughout this thesis 
using Accela™ instruments which include the Accela Autosampler and the Accela Pump 
(Thermo Electron Corporation, San Jose, CA). The main function of Accela Autosampler 
and Accela Pump is to inject samples automatically to MS and provides the optimum 
performance in the flow rate ranges needed for LC and MS, respectively. The autosampler 
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contains a built-in column oven (5 to 95 ºC), provides tray/sample temperature control (0 to 
60 ºC), and is capable of performing automated sample preparation routines. The Accela 
Pump is a low-pressure mixing pump with built-in solvent degassing and pulse dampening 
system. A TSQ Quantum Access™ Triple Stage Quadrupole MS (Thermo Electron 
Corporation, San Jose, CA) equipped with external electrospray ionization (ESI) source 
was employed for detection and analysis of metabolites. This MS provides sample 
ionization and mass analysis of injected samples or samples eluted from a liquid 
chromatography. Xcalibar software (Thermo Electron Corporation, version 2.0.7 release) 
was used for controlling the LC-MS/MS instrument, data acquisition and analysis. 
 
2.3.2. Solvents and Chemicals 
Water (H2O), acetonitrile (CH3CN) and methanol (CH3OH) were all HPLC grade. 
Acetonitrile (CH3CN) and methanol (CH3OH) were obtained from Fischer Scientific (UK). 
Water (H2O) and ammonium acetate (C2H3O2NH4) were purchased from VWR 
International Ltd (UK). Mass spectroscopy grade formic acid (CH2O2, ≥98%) and 
ammonium hydroxide (NH4OH) were obtained from Sigma – Aldrich (UK).    
 
2.3.3. HPLC column installation 
A Luna aminopropyl column (250 mm × 2 mm with a 5 μm particle size, Phenomenex, 
USA) was selected for the metabolite separation throughout this study. This is because 
most of the metabolites that were targeted in this study were polar and therefore require 
hydrophilic interaction chromatography (HILIC) for effective separation of a broad range 
of cellular metabolites including amino acids, nucleosides, nucleotides, coenzyme A 
derivatives, carboxylic acids, simple sugar, and sugar phosphate (Bajad et al., 2006).  
 
Upon receipt of the aminopropyl column, it was checked for any physical damage which 
may have occurred during shipping. Prior to testing the column performance and quality, it 
was important to equilibrate the column. Column equilibration was performed as follows: 
Accela Pump HPLC system was purged thoroughly with filtered and degassed mobile 
phase (95:5 water: acetonitrile) without buffers for 20 min. The column was then connected 
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to the injector corresponding to the direction of the flow label that was located on the 
column and the column outlet was left unattached. The pump flow rate was set at            
100 µl/min and was increased to normal flow rate over 5 min. The flow was stopped when 
there was a free flow of solvent from the column outlet. The column outlet was thereafter 
wiped up and attached to the mass spectrometry detector. The column was then 
equilibrated by passing approximately 10-30 column volumes of mobile phase at flow rate 
150 µl/min. Column volume was calculated according to the following equation:   
 
V= π x r² x L 
V= Column volume in ml 
π= Constant factor equals to 3.14 
r= Column radius in cm 
L= Column length in cm  
 
2.3.4. Mobile phase preparation 
The mobile phase that was used throughout this study consisted of solvent A [20 mM 
ammonium acetate + 20 mM ammonium hydroxide in 95:5 water:acetonitrile (pH 9.45)] 
and solvent B (acetonitrile). The choice of this mobile phase was based on its 
appropriateness and suitability for the luna aminopropyl column as tested by the 
Rabinowitz lab (Bajad et al., 2006, Kimball and Rabinowitz, 2006, Rabinowitz and 
Kimball, 2007, Yuan et al., 2008, Lu et al., 2006).  
Prior to each LC-MS/MS process, the mobile phase was freshly prepared as follows: 950 
ml of HPLC grade water and 50 ml of HPLC grade acetonitrile were added in a clean glass 
beaker  resulting in a water:acetonitrile ratio of 95:5. In the fume hood cabinet, 20 ml of 1 
M ammonium acetate stock (section 2.3.4.1) and 20 ml of 1 M ammonium hydroxide stock 
(section 2.3.4.2) were added to the 95:5 water:acetonitile. The pH was checked and this 
mixture gave pH 9.45. The mobile phase was then filtered through sterile bottle top filter 
unit with a 0.22 μm membrane (Fisher Scientific, UK), sonicated and degassed using a 
sonicator (Fisher Scientific, UK) for 15 minutes. 
  
 
 
69 
 
2.3.4.1. Preparation of ammonium acetate 
The preparation of 1 M stock solution of ammonium acetate (C2H3O2NH4) (MW = 77.08 
g/mol) was as follows: 38.54 g of ammonium acetate was dissolved in 500 ml of HPLC 
grade water. The solution was then filtered through a sterile bottle top filter unit with a  
0.22 μm membrane (Fisher Scientific, UK), labeled, and stored at 4 ⁰C for future use. 
 
2.3.4.2. Preparation of ammonium hydroxide     
The preparation of 1 M stock solution of ammonium hydroxide (NH4OH) (MW= 35.05 
g/mol, density= 0.9 g/ml, weight percentage= 28% w/w and M= 7.190 M) was as follows: 
slowly 34.772 ml of 7.19 M ammonium hydroxide stock solution  was added to 62.5 ml of 
HPLC grade water. The final volume of ammonium hydroxide solution was adjusted 
to 250 ml with HPLC grade water to make 1 M ammonium hydroxide stock solution. The 
solution was then transferred into clean glass bottle, labeled, and stored at 4 ⁰C for future 
use. 
 
2.3.5. HPLC column cleaning and storage 
Appropriate HPLC column cleaning and storage conditions provide a better performance 
over the column lifetime. The cleaning and storage solvents consisted of HPLC grade water 
and acetonitrile. After analysis of samples by LC MS/MS, the luna aminopropyl column 
(250 mm × 2 mm with a 5 μm particle size, Phenomenex, USA) was cleaned as follows:  
Accela Pump HPLC lines system were purged thoroughly with filtered and degassed HPLC 
grade water and acetonitrile for 20 min. The column was then connected to the injector in 
reverse to the direction of the flow label that was located on the column and the column 
outlet was left unattached.  The column was initially rinsed with 95% HPLC grade water, 
5% ACN for about an hour then 95% ACN, 5% water overnight.  The column was 
thereafter stored in 65% ACN, 35% water. 
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2.3.6. Routine mass spectrometer maintenance  
To ensure the proper operation of TSQ Quantum Access™ Triple Stage Quadrupole MS, 
Thermo Fisher Scientific recommends daily performance of checks and cleaning of the 
TSQ system.  This includes procedures before and after operating the TSQ system. To do 
this, the argon, nitrogen and system vaccum levels were checked to ensure they were up to 
appropriate levels prior to operating the TSQ system. Cleaning ion transfer tube, ion sweep 
cone, and flushing the sample transfer line, sample tube, and ESI probe were subsequently 
performed after operating the TSQ system. The flushing procedure was carried out by 
passing methanol/water (50:50) solution (section 2.3.6.1) from LC through the ESI probe 
for 2 h. Cleaning procedures were carried out firstly by sonicating ion transfer tube, ion 
sweep cone in HPLC water containing formic acid for 1 hour, then in methanol for another 
hour. 
 
2.3.6.1. Preparation of methanol/water (50:50) 
The preparation of methanol/water (50:50) was made as follows: a 500 ml of HPLC grade 
methanol and a 500 ml of HPLC grade water were added in a 1 L bottle. Sonication and 
degassing was thereafter carried out for 15 minutes. This cleaning solution was then placed 
in the reservoir area of the HPLC tanks for future use.   
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CHAPTER 3  
Development and Validation of an Analytical Method for 
Targeted Metabolomics Plasmodium falciparum 
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 Introduction 3.1.
A key element to this thesis was the measurement of P. falciparum metabolites which 
require accurate and reliable detection and quantification. Therefore, development and 
validation of an analytical platform for the detection and quantification of P. falciparum 
metabolome was undertaken.  
 
Despite intensive research in the metabolomics area in recent years, it has still proved 
difficult to develop a generic analytical method to detect and quantify the P. falciparum 
metabolome which includes 616 metabolites and accounts for around a thousand reactions 
in the compartmentalized metabolic network (Plata et al., 2010). These metabolites consist 
of a wide variety of compound classes with different physical and chemical properties and 
are present at varying dynamic ranges of concentration (Weckwerth, 2003, Xiayan and 
Legido-Quigley, 2008, Koek et al., 2011, Goodacre, 2005). The chemical diversity and 
complexity of the metabolome make it extremely challenging to profile all of the 
metabolome simultaneously. Furthermore, the characteristics of the metabolite molecular 
structure are influenced not just by its milieu but also its interactions with other molecule 
structures leading to ion suppression or enhancement (Cubbon et al., 2010).  
 
Depending on the kind of metabolites to be extracted, metabolomic methods require the 
development of tailor-made strategies for sample preparation, metabolite extraction and 
separation, and ultimately data analysis (Lakshmanan et al., 2011). Therefore, to 
successfully develop a method, there are few steps that have to be considered. First, the 
scientific question in the area must be identified and addressed. Secondly, reviewing the 
scientific literature and selecting the metabolites of interest. Thirdly, optimization of the 
sensitivity and selectivity for liquid chromatography coupled to tandem mass 
spectrometry detection (LC-MS/MS). This includes choosing the right HPLC column for 
metabolite separation, selecting the best ionization mode (APCI or ESI), optimization of 
mass spectrometry (MS) configuration, and tuning the ion path. When an LC-MS/MS 
method is successfully developed and validated, sample preparation and metabolite 
extraction is then optimized. 
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Although metabolomics in malaria is still in its infancy, there are a number of robust 
analytical techniques that have been developed and reported to achieve an efficient and all-
encompassing metabolomic analysis (Kafsack and Llinás, 2010, Plata et al., 2010, Cassera 
et al., 2011, Lakshmanan et al., 2011, Olszewski and Llinás, 2011, Teng et al., 2009, 
Bulusu et al., 2011, Jayaraman et al., 2012, Mehta et al., 2006, Olszewski et al., 2009, van 
Brummelen et al., 2009, Besteiro et al., 2010, Olszewski et al., 2011, Lian et al., 2009). In 
addition, there are different approaches including metabolic profiling and metabolic 
fingerprinting to detect and investigate the metabolome in various fields of research (Fiehn, 
2002).  
Advanced MS analysis can identify hundreds to thousands of metabolites, providing a new 
and extremely powerful tool for studying cell system biology and a drugs mode of action 
(Reaves and Rabinowitz, 2011, Tiziani et al., 2009). However, it is important to note that 
due to the diversity in physical and chemical structures of the metabolites, a prior 
knowledge of the types of molecules to be explored will dictate the protocols to be used. 
Targeted metabolomics as described early (Chapter 1) aims to detect and quantify a 
predefined set of metabolites, typically dozens or hundreds of known compounds, based on 
metabolite-specific signals (Lu et al., 2008). In particular, in targeted metabolomics 
approaches, using triplequadrupole MS, a precursor ion and a fragment of the precursor 
ion, producing a molecular weight and structure-specific measurement for a single 
metabolite (referred to as transition), are used for the sensitive and accurate determination 
of the compound concentration over a wide dynamic range which eventually results in a 
single reaction monitoring (SRM) (Rabinowitz, 2007). Each SRM scan takes 
approximately 0.1 s which enable the detection and quantitation of numerous metabolites 
during a single LC-MS/MS run (Rabinowitz, 2007).  Simultaneous analysis of multiple 
transitions results in multiple reaction monitoring (MRM), where the collision energy and 
product ion mass-to-charge ratio (m/z) are pre-optimized for each metabolite of interest to 
give the best signal intensity (Lu et al., 2008). Therefore, the development of a targeted 
metabolomic approach was undertaken to profile a number of related metabolites for         
P. falciparum mitochondrion and digestive vacuole. In addition, in order to ensure that the 
developed method is reliable for metabolite detection and quantification analysis, adequate 
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analytical method validation was conducted. In general, analytical method validation 
includes studies on selectivity and carryover, metabolite recovery and stability, linearity 
and sensitivity (limit of detection, LOD), and performance reproducibility.    
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 Materials and Methods 3.2.
3.2.1. Solvents and Chemicals 
Solvents and chemicals used for LC-MS/MS were of HPLC grade as described previously 
unless otherwise stated (chapter 2, section 2.3.2). 
3.2.2. Targeted metabolomics method development 
Electrospray ionization mode (ESI) was selected for targeted metabolomics method in this 
thesis owing to the fact that most of the metabolites of interest targeted were polar. In 
addition, although heated ESI (HESI) provided enhanced sensitivity compared with the 
unheated ESI, HESI had increased noise in most cases and increase metabolite 
decomposition due to the heat effect in the ESI probe. Therefore, unheatd ESI was 
preferred over heated ESI (HESI) in this thesis.    
3.2.2.1. Preparation of primary stock solution standards for ion path tuning  
An appropriate amount (> 1 mg) of metabolite standard (Appendix I, Table 1) was weighed 
out from their solid powder and then dissolved in an appropriate solvent to give 1 mg/ml of 
primary stock solutions and stored at -80 ºC until required. Freshly prepared 10 µg/ml 
working (Appendix I, Table 1) stocks were then prepared from 1 mg/ml stock solutions and 
used for tuning the ion path.  
3.2.2.2. Ion path tuning 
Freshly prepared 10 µg/ml metabolite working stocks (section 3.2.2.1) were injected 
directly into the MS to determine if the metabolite of interest could be detected. It was 
sometimes necessary to vary the concentration of metabolite being injected, as well as to 
modify the mode of ESI ionization (positive or negative).  Once it was certain that the 
metabolite can be detected, MS configurations were subsequently optimized as described 
(section 3.2.2.3). 
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3.2.2.3. Mass spectrometry configurations optimization 
Like ion path tuning, optimizing the MS configurations involves direct infusion of the 
metabolite of interest into the MS/MS, without going through liquid chromatography.  
When optimizing the source parameters, it was sometimes necessary to run as much 
mobile solvent into the MS/MS system as would be expected when chromatography is 
developed.  The goal of optimizing the mass spectrometry configurations was to increase 
the sensitivity of the analysis.  This was performed through series modifications of 
different configurations including voltage, nitrogen gas flow, collision argon gas and 
temperatures. 
 
Therefore, a TSQ Quantum Access™ Triple Stage Quadrupole mass spectrometer (Thermo 
Electron Corporation) equipped with electrospray ionization (ESI) was employed for the 
metabolite detection and analysis of metabolites. ESI spray voltage was 4000 V and     
5500 V for positive and negative modes, respectively. Nitrogen was used as sheath gas at 
30 psi and as the auxiliary gas at 10 psi. Argon was used as the collision gas at 1.5 mTorr. 
The capillary temperature was 320 °C and 270 °C for positive and negative modes, 
respectively. Scan time for each single reaction monitoring (SRM) event transition was   
0.1 s with a scan width of 1 m/z. The instrument control, data acquisition, and data analysis 
were achieved applying the Xcalibar software (Thermo Electron Corporation, version 2.0.7 
release), which also controlled the chromatography system. 
  
3.2.2.4. Chromatographic separation optimization 
Once the source parameters were optimized, chromatography was then optimized. This 
involved using the appropriate chromatography column selection for separation. 
Hydrophilic interaction chromatography (HILIC)     [Luna aminopropyl column (250 mm × 
2 mm with a 5 μm particle size, Phenomenex, USA)] was selected on the bases that most 
metabolites of interest targeted in this thesis were polar and had been tested before (Bajad 
et al., 2006). In addition, appropriate flow rate and mobile phase gradient were adjusted for 
optimal resolution and detection.  
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Therefore, chromatographic separation was achieved using a Luna aminopropyl column 
(250 mm × 2 mm with a 5 μm particle size, Phenomenex, USA) connected to a security 
guard packed with double-cartridge (4 mm × 2 mm, Phenomenex, USA) to maximize 
contaminant removal and extend the half-life of the HPLC column. This HILIC column 
(described in chapter 2) was employed for the metabolites separation using an Accela 
Autosampler HPLC system (Thermo Fisher Scientific). The mobile phase consisted of 
solvent A [(20 mM ammonium acetate + 20 mM ammonium hydroxide) in 95:5 
water:acetonitrile (pH 9.45)] and solvent B (acetonitrile) which was prepared as described 
beforehand (chapter 2, section 2.3.4). The chromatographic gradients were as follows:        
t = 0, 15% A; t = 15 min, 100% A; t = 33 min, 100%  A; t = 35 min, 15% A; t = 45 min, 
15% A. Injection volume, flow rate, column temperature and autosampler temperature 
were set at 20 μL, 150 μL/min, 15 °C and 15 °C, respectively. The injection needle was 
washed with one volume of methanol/water (50:50) solution between injections to 
eliminate the problem of carryover between samples.   
 
3.2.2.5. Extraction optimization 
Metabolite extraction formed part of sample preparation and involved testing many 
different solvents and methods of extraction to yield the best recovery.  The purpose of an 
extraction was to extract the metabolites of interest from any interfering components (e.g. 
cellular matrix) and to concentrate them for detection.  Extraction method must yield a 
good recovery of the metabolites with minimum to zero matrix effect (Rabinowitz and 
Kimball, 2007). Different extraction solvents were test by Rabinowitz and his colleague 
and they found that mixtures of acidic 0.1 M formic acid containing 
acetonitrile/methanol/water (40:40:20) gave superior yields for cellular metabolites in 
addition to providing a protection for redox and nucleotide phosphate compounds 
(Rabinowitz and Kimball, 2007, Yuan et al., 2008). Therefore, acidic 
acetonitrile/methanol/water (40:40:20 + 0.1 M formic acid) spiked with 200 µM of each 
internal standards namely β-alanine and DL-arabinose (section 3.2.2.5.1) for positive and 
negative modes, respectively, was used in this thesis as the quenching solvent and without 
internal standards as the extraction solvent.  
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3.2.2.5.1. Quenching and Extraction Solution  
The quenching solution used to carry out the LC-MS/MS metabolomic experiments was 
acidic acetonitrile/methanol/water (40:40:20 + 0.1 M formic acid) solvent system spiked 
with 200 µM of each internal standards namely β-alanine and DL-arabinose for positive 
and negative modes, respectively. The addition of formic acid to a final concentration of 
0.1 M provides additional protection of nucleotide triphosphates against degradation. The 
extraction solution used to carry out the metabolites extraction was 
acetonitrile/methanol/water (40:40:20) solvent system. This extraction solvent was neither 
acidic nor spiked with internal standards and was used only to extract the metabolites in a 
manner so as to yield as much as possible of metabolites in the supernatant and discarding 
the cell debris.   
 
3.2.3. Targeted metabolomics method validation 
3.2.3.1. Preparation of primary stock solution standards for calibration curve 
standards and quality control (QC)  
Primary stock solutions were prepared in the appropriate solvent at specific (mM) 
concentration for each metabolite as indicated in Appendix (I, Table 2). From these stocks 
of primary solutions, a standard mixture of metabolites was prepared by adding 100 ul of 
each metabolite primary stock. Aliquots of this standard mixture were used for calibration 
standards, authentic quality control (QC) standards and spiking into parasite cell extracts 
for the recovery method. The calibration curve was obtained by analyzing the standard 
mixture of metabolite solution at sixteen concentrations. Standard levels were prepared by 
serially diluting the standard mixture solution in HPLC water as follows: 1:1, 1:2, 1:4, 1:8, 
1:16, 1:32, 1:64, 1:128, 1:256, 1:512, 1:1024, 1:2048, 1:4096, 1:8192, 1:16384 and 
1:32768, as indicated in appendix (I, Table 3) which show the corresponding concentration 
(µM) at each standard level for each metabolite. These concentrations were presented in 
molarity unit and were varied from metabolite to metabolite depending on molecular 
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weight. Calibration curves were constructed by plotting the area ratio of the metabolite 
standard (AUC of metabolite divided by AUC of internal standard) against its 
concentration. Linear regression was used to fit the calibration curve and the linearity for 
each metabolite was evaluated from it.  Three levels of authentic QC standard were 
prepared, high, medium and low in order to evaluate the accuracy of the calibration curve. 
High quality control (HQC) represents the standard mixture at initial concentration (i.e. the 
standards mixture that was prepared by adding 100 µl of primary stock) (Appendix1, Table 
4). Medium quality control (MQC) represents the HQC diluted by 1:10. Low quality 
control (LQC) represents the HQC diluted by 1:100 (Appendix1, Table 4).   
3.2.3.2. Selectivity 
The selectivity for the developed targeted metabolomics method was evaluated in the 
following parameters: consistency in the retention time for each metabolite 
chromatographic separation and a specific detection for the precursor ion and its 
corresponding product ion using the MRM scan.  Therefore, authentic metabolite mixture 
standards and blank samples (e.g. methanol) were prepared and examined using the 
developed metabolomics method.   
3.2.3.3. Carryover test 
Carryover tests were conducted by injecting a series of methanol blanks directly following 
the highest concentration of standards and between the metabolomics experiment for the   
P. falciparum parasite. 
3.2.3.4. Recovery (%)  
The recovery of the metabolites was evaluated from cellular extracts of P. falciparum 
parasite as follows: metabolite mixtures of the standard solution were spiked with cell 
extracts of P. falciparum parasite prior to lyophilisation at the level 1 concentration 
indicated in (Appendix I, Table 3) and extracted and prepared as described later  (Chapter 
4, sections 4.2.2 and 4.2.3.1). The response, area under the curve (AUC), of the metabolites 
in the cell extract was divided by the corresponding metabolites standard solutions at the 
same concentration and expressed as percentage. In addition, the recovery of internal 
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standards β-alanine and DL-arabinose was carried out at concentration of 200 µM. 
Typically, a metabolite recovery of 70% - 120% was considered satisfactory (Koek et al., 
2011, Koek et al., 2006). 
3.2.3.5. Stability studies 
The stability studies were conducted on the purified metabolites as follows: a mixture of 
metabolite standard solution at level 1 concentration indicated in (Appendix I, Table 3) was 
prepared and divided into four aliquots. One analysed immediately three times. Others 
were stored separately at 4 ºC, -20 ºC and -80 ºC. These samples were analysed in triplicate 
after a month to evaluate the metabolites stability during the period of a month. Normalized 
signals, corresponding to the AUC of the metabolite signal divided by AUC of the internal 
standard signal, were compared for the various storage conditions to the actual normalized 
signal value. The metabolite was considered stable at a specified temperature if the 
normalized signal after the corresponding storage had an RSD of less than 15%. 
3.2.3.6. Reproducibility studies 
The mixture of metabolite standard solution at level 1 concentration indicated in (Appendix 
I, Table 3) was plunged into the quenching solvent, acetonitrile/methanol/water (40:40:20 
+ 0.1 M formic acid) spiked with 200 µM of internal standards β-alanine and DL-
arabinose, and then extracted and prepared as described later (Chapter 4, sections 4.2.2 and 
4.2.3.1) for  the  sample  preparation. Afterwards, it was divided into three aliquots and 
stored at -80 ºC. The first sample was analysed three times on Day 1. The remaining two 
samples were analysed on Days 2 and 3, three times in each case.  The method was 
considered reproducible if the RSD was less than 15% 
3.2.3.7. Linearity, LOD, and calibration curve accuracy 
The linearity was determined for this targeted metabolomics method by generating a 
standard calibration curve for each metabolite. Calibration curves were generated by 
plotting the area ratio (AUC of the metabolite divided by the AUC of internal standard) 
against concentration (µM). Linear regression was then used to find the 
straight line that best fits the data points. This curve fitting was performed using Xcalibar 
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software (Thermo Electron Corporation, version 2.0.7 release).  Goodness of fit for the 
standard calibration curves were determined by the R
2
 value calculated from the software, 
an R
2
 better than 0.98 was considered acceptable. The limit of detection (LOD) for each 
metabolite was evaluated by determining the lowest concentration of metabolite level that 
has signal-to-noise ratio (S/N) > 3. Three levels of QCs (low, medium and high; n=3 at 
each level) were prepared and used to determine the accuracy the calibration curve 
generated. The accuracy of 100% ± 20% (80-120%) was considered satisfactory. The 
accuracy of the analytical method describes how close the mean of test results obtained by 
the method are to the nominal concentration of the metabolite. Accuracy was calculated by 
the following equation and expressed as a percentage: 
Accuracy (%) = (mean observed concentration/nominal concentration) x 100 
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 Results 3.3.
3.3.1. Selectivity  
Two types of sample, including the authentic mixture of metabolite standards and methanol 
as the blank sample, were processed equally using the metabolomics method to evaluate 
the sensitivity of the method in terms of retention time and accurately distinguishing the 
metabolites precursor ion and their product ions based on the MRM scan. The 
chromatogram peak findings showed that the LC-MS/MS of the standard mixture was able 
to distinguish between different metabolite peaks based on their retention time and MRM 
scan as shown in the example of dihydroorotate chromatogram (Figure 3.1). The remaining 
metabolite chromatograms are shown in the Appendix (II, Figures 1 – 58).  On the other 
hand,  LC-MS/MS  of methanol showed noisy chromatogram peaks suggesting that this 
metabolomics method was very selective (Figure 3.2).  Tables 3.1 and 3.2 summarize all 
the metabolites targeted in positive and negative ionization modes, respectively, the 
following LC-MS/MS parameters: metabolite precursor ion and its product ion, collision 
induced dissociation (CID) and expected retention time (RT).   
3.3.2. Carryover test 
A critical issue for the LC-MS/MS metabolomics method is the tendency of metabolites to 
get absorbed by the HPLC column packing materials, resulting in a memory effect. 
However, the analysis of the present method showed no detectable carryover effect was 
obtained when a series of methanol blanks were injected immediately after the highest 
calibration standard and between the different sets of metabolomic experiments for            
P. falciparum parasite.    
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Figure 3.1: LC-MS/MS chromatogram of dihydroorotate.  
A) Chromatographic separation of dihydroorotate peak shows retention time (RT) at ~14min. B) 
SRM scan of ionized dihydroorotate shows the detection of its product ion at mass-to-charge (m/z) 
of 113. 
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Figure 3.2: LC-MS/MS chromatogram of methanol blank.  
Dihydroorotate SRM setting was selected here to evaluate the selectivity of the present LC-MS/MS 
method. The chromatogram shows noisy peaks and dihydroorotate peak is not observed. 
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Table 3.1: LC-MS/MS parameters for metabolites detected in positive ESI mode (protonation, 
Molecule + H
+
)  
Metabolite MW (g/mol) Precursor mass CID Product mass RT (min) 
Alanine 89.09 90.1 14 44.1 12.8 
B-alanine 89.09 90.3 5 71.8 12.5 
Serine 105.09 106 10 60 13.1 
Proline 115.13 116 11 70 12.4 
Valine 117.15 118 11 55 12.1 
Threonine 119.12 120 11 74 13.3 
Cysteine 121.16 122 21 59 26.1 
(iso)-leucine 131.17 132 11 86 11.4 
Asparagine 132.12 133 17 74 13.4 
Ornithine 132.19 133 15 70 14.4 
Aspartate 133.1 134 15 74 16.4 
Glutamine 146.14 147 15 84 13.1 
Lysine 146.19 147 16 84 14.4 
Glutamate 147.13 148 15 84 16.5 
Methionine 149.21 150 10 133 12 
Histidine 155.15 156 12 110 13.6 
Phenylalanine 165.19 166 28 103 11.6 
Arginine 174.2 175 14 60 13.7 
Citrulline 175.19 176 12 159 12.9 
Carbamoyl-l-aspartate 176.12 177 17 74 21.5 
Tyrosine 181.19 182 26 77 13 
Tryptophan 204.23 205 16 146 11.9 
GSH 307.32 308 19 162 19.7 
UMP 324.18 325 12 97 22.3 
AMP 347.22 348 21 136 22.8 
UDP 404.16 405 19 97 23.1 
ADP 427.20 428 31 136 23.5 
TTP 482.16 483 25 81 27.3 
CTP 483.15 484 21 112 25.1 
UTP 484.14 485 30 97 27.7 
ATP 507.18 508 37 136 25.5 
GTP 523.18 524 37 152 27.8 
GSSG 612.63 613 33 231 22 
NAD 663.43 664 30 428 16.5 
NADH 664.43 666 26 514 27.1 
NADP 744.41 744 48 136 22.9 
NADPH 745.41 746 16 729 31.9 
FAD 785.55 786 24 348 22.9 
Acetyl-CoA 809.57 810 28 303 24 
Propionyl-CoA 823.60 824 33 317 24.2 
Succinyl-CoA 867.60 868 38 361 25 
Abbreviations: MW, Molecular Weight; CID, Collision Induced Dissociation; RT, retention time. 
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Table 3.2: LC-MS/MS parameter for metabolites detected in negative ESI mode 
(deprotonation, Molecule – H+)   
Metabolite MW (g/mol) Precursor mass CID Product mass RT (min) 
Lactate 90.08 89 11 43 14 
Fumarate 116.07 115 11 71 25.5 
Succinate 118.09 117 16 73 21.5 
Oxaloacetate 132.07 131 12 87 24.2 
Malate 134.09 133 12 115 21.6 
Hypoxanthine 136.12 135 16 92 13.4 
PABA 137.14 136 16 92 13.1 
Carbamyl 
phosphate 
141.02 140 38 79 25.7 
2-Oxoglutarate 146.11 145 11 101 26.6 
DL-arabinose 150.13 149.1 7 130.6 10.8 
Orotate 156.10 155 13 111 15.3 
Dihydroorotate 158.11 157 14 113 14.1 
PEP 168.04 167 20 79 23.3 
DHAP 170.06 169 43 79 29 
G-3-P 172.07 171 13 79 21.8 
Glucose 180.16 179 18 59 11.7 
(iso)-citrate 192.12 191 18 111 23.3 
Abbreviations: MW, Molecular Weight; CID, Collision Induced Dissociation; RT, retention time.
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3.3.3. Recovery studies 
Recovery studies were conducted for all 58 metabolites targeted in this metabolomics 
method including the internal standards. The area under the curve (AUC) for metabolites 
spiked with cellular extract of P. falciparum was divided by the AUC for the corresponding 
authentic metabolite standard and then expressed as a percentage. The results showed that 
~85% of the metabolites including internal standards that were targeted in this method had 
a satisfactory recovery (70% - 120%) (Figure 3.3). This highlighted that the present method 
yields a good recovery for most of the metabolites targeted in this study. Nonetheless, in 
the presence of parasite matrix or any cell matrix, the influence of molecule adsorption to 
the analytical system results in recovery differences (high or low) for some metabolites due 
to many factors such as ion suppression (Annesley, 2003, Koek et al., 2006, Koek et al., 
2011). Therefore, it is important to note here that proper cleaning and maintenance of the 
analytical system greatly enhances the quality of data output. Table 3.3 summarizes the 
recovery (%) for all the metabolites targeted in the method of this chapter.  
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Figure 3.3:  Histogram of the distribution of recovery (%) for all 58 metabolites investigated.  
The recovery range of 70% - 120% was considered satisfactory. Histogram showed that ~85% of 
the metabolites had a satisfactory recovery between 70% and 120%. The remaining 15% of the 
metabolites had unsatisfactory recovery in which the recovery was either high (>120%) or low 
(<70%). 
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   Table 3.3: Recovery (%) of authentic metabolite standards spiked to P. falciparum cellular 
extracts  
Metabolite Recovery (%) Metabolite Recovery (%) 
TTP 18 Carbamoyl-l-aspartate 100 
GTP 32 GSH 100 
PABA 43 AMP 101 
Cysteine 44 Glutamine 102 
ATP 77 Oxaloacetate 102 
Threonine 85 NADPH 102 
Ornithine 89 UMP 102 
2-Oxoglutarate 92 Arginine 103 
Citrulline 92 Malate 103 
Valine 93 Succinate 103 
G-3-P 94 NADP 103 
Hypoxanthine 94 Dihydroorotate 104 
Proline 95 Histidine 104 
GSSG 95 Acetyl-CoA 106 
Lysine 96 Lactate 107 
NAD 96 Phenylalanine 107 
Asparagine 97 DL-arabinose (IS)* 107 
Glutamate 97 Carbamyl phosphate 109 
Methionine 97 Tryptophan 109 
β-alanine (IS)* 97 Propionyl-CoA 111 
Alanine 98 CTP 111 
Orotate 98 PEP 112 
FAD 98 NADH 113 
(iso)-leucine 99 Glucose 118 
DHAP 99 ADP 121 
Fumarate 99 Serine 124 
Tyrosine 99 UDP 126 
(iso)-citrate 99 UTP 135 
Aspartate 100 Succinyl-CoA 180 
   *IS, Internal Standard 
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3.3.4. Stability studies 
The metabolites targeted in the metabolomics method were investigated in terms of their 
storage stability over a one month period. Different storage temperatures including 4 ºC,     
-20 ºC and -80 ºC were evaluated for each metabolite by comparing the metabolites 
normalized signal to that of the corresponding actual value. The relative standard deviation 
was then calculated from the triplicate LC-MS/MS runs for each storage temperature. The 
results showed that ~88% of the metabolites were stable and had an RSD less than 15% 
under a -80 ºC storage temperature (Figure 3.4). In addition, ~70% and ~51% of the 
metabolites were stable and had an RSD less than 15% under -20 ºC and 4 ºC  storage 
temperatures, respectively (Figure 3.4). On the other hand, ~12%, ~30% and ~49% of the 
metabolites were unstable and had an RSD greater than 15% under -80 ºC, -20 ºC and 4 ºC 
storage temperatures, respectively (Figure 3.4). These results indicate that -80 ºC storage 
temperature had the least effect on changing metabolite stability (i.e. it is the optimal 
condition for keeping the metabolites). Table 3.4 summarizes the %RSD for each 
metabolite under the different storage temperatures.  
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Figure 3.4:  Histogram of the distribution of different storage temperatures for stable and 
unstable metabolites.   
Stability was determined for all metabolites targeted in the present method. Stable (dark grey bar) 
and unstable (light grey bar) represent the percentage of metabolite distribution in -80ºC, -20ºC and 
4ºC storage temperatures. %RSD was calculated for each metabolite and a metabolite is considered 
stable at the indicated temperature if RSD is less than 15%.   
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Table 3.4: Stability of the authentic metabolite standards. Metabolite is considered stable at 
indicated temperature if RSD is less than 15%   
Metabolite  
Storage Temperature 
-80°C (% RSD) -20°C (% RSD) 4°C (% RSD) 
Tryptophan  1 5 4 
Lysine 1 10 8 
Succinyl-CoA 1 25 45 
Arginine 2 2 10 
Citrulline 2 3 7 
Histidine 2 12 13 
Phenylalanine 2 1 14 
Methionine 3 7 14 
Ornithine 3 4 12 
UMP 3 5 5 
NAD 3 7 18 
Threonine 3 12 14 
ATP 3 30 55 
Carbamoyl-l-aspartate 4 7 9 
Tyrosine 4 2 2 
GSSG 4 4 16 
Glutamate 4 8 18 
TTP 4 6 49 
Glutamine 6 9 11 
Alanine 7 5 12 
Serine 7 12 13 
UDP 8 11 18 
Valine 9 12 14 
Asparagine 9 13 13 
UTP 9 16 20 
Aspartate 10 12 20 
FAD 11 13 15 
Proline 12 13 15 
AMP 13 17 17 
NADP 14 16 18 
Propionyl-CoA 14 27 25 
Acetyl-CoA 14 17 22 
ADP 14 14 19 
(iso)-leucine 14 17 22 
CTP 14 16 18 
NADPH 16 18 42 
NADH  17 19 20 
Cysteine 24 47 105 
GSH 40 57 71 
GTP 103 105 106 
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Table 3.4: (Continued)  
Metabolite  
Storage Temperature 
-80°C (% RSD) -20°C (% RSD) 4°C (% RSD) 
Glycerol-3-phosphate 1 1 5 
Orotate 1 2 11 
Lactate 1 9 13 
Succinate 1 3 5 
(iso)-citrate 3 9 37 
Dihydroorotate 3 4 8 
PABA 4 6 9 
Malate 5 6 12 
Glucose 5 9 13 
Fumarate 7 8 11 
2-Oxoglutarate 7 9 13 
Hypoxanthine 12 13 18 
Oxaloacetate 13 12 42 
PEP 13 16 21 
DHAP 16 20 26 
Carbamoyl phosphate 33 39 71 
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3.3.5. Reproducibility studies 
The reproducibility of the method for metabolite mixtures, containing all 58 metabolites 
including internal standards at a specified concentration, was evaluated by measuring the 
RSD between LC-MS/MS runs, both within and between days. Intra-day reproducibility 
was determined by performing three repeat runs of LC-MS/MS on Day1. The analysis of 
Intra-day reproducibility showed that the RSD was less than 15% for ~90% of the 
metabolites selected for the method (Figure 3.5). In contrast, inter-day reproducibility was 
determined by conducting nine repeat runs of the LC-MS/MS including the intra-day data. 
The analysis of inter-day reproducibility showed that the RSD was less than 15% for ~75% 
of the metabolites targeted in the method (Figure 3.5). Nonetheless, an RSD of less than 
25% was found for ~16% of the metabolites that have been analysed for inter-day 
reproducibility including acetyl-CoA, ADP, cysteine, GSH, NADH, NADP, NADPH, 
oxaloacetate and propionyl-CoA (Table 3.5). Therefore, this highlights that the effect seen 
in the %RSD for inter-day reproducibility was perhaps due to a stability factor for the some 
of the metabolites. Overall, the analysis and findings described signifying that this 
developed metabolomics method is reproducible. 
 
  
 
 
94 
 
Relative Standard Deviations
(RSDs)
%
 o
f 
M
e
ta
b
o
li
te
s
 D
is
tr
ib
u
ti
o
n
 <15% >15%  <15%  >15%
0
20
40
60
80
100 Intra-day
Inter-day
 
Figure 3.5: Histogram of the distribution of relative standard deviation (RSD) for metabolites 
investigated in intra-day and inter-day reproducibility studies.  
Histogram showed that that ~90% and ~75% of the metabolites had an RSD of less than 15% in 
intra-day and inter-day reproducibility studies, respectively. In contrast,   ~10% and ~25% of the 
metabolites had an RSD of greater than 15% in intra-day and inter-day reproducibility studies, 
respectively.  
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Table 3.5:  Intra-day and inter-day reproducibility studies for authentic metabolite standards  
Metabolite 
Intra-day 
%RSD 
(n=3) 
Inter-day 
%RSD 
(n=9) 
Metabolite 
Intra-day 
%RSD 
(n=3) 
Inter-day 
%RSD  
(n=9) 
(iso)-citrate 13 12 Hypoxanthine 12 14 
(iso)-leucine 4 8 Lactate 10 14 
2-Oxoglutarate 14 14 Lysine 11 15 
Acetyl-CoA 2 22 Malate 6 14 
ADP 2 16 Methionine 2 2 
Alanine 1 9 NAD 4 12 
AMP 1 15 NADH 2 16 
Arginine 2 13 NADP 1 16 
Asparagine 4 8 NADPH 3 18 
Aspartate 3 14 Ornithine 2 9 
ATP 135 151 Orotate 9 12 
Carbamoyl phosphate 8 15 Oxaloacetate 13 21 
Carbamoyl-l-aspartate 3 15 PABA 11 15 
Citrulline 2 3 PEP 15 13 
CTP 88 82 Phenylalanine 3 9 
Cysteine 11 22 Proline 4 14 
Glucose 14 11 Propionyl-CoA 1 21 
DHAP 12 14 Serine 6 8 
Dihydroorotate 13 9 Succinate 10 14 
FAD 1 15 Succinyl-CoA 87 88 
Fumarate 11 13 Threonine 4 12 
G-3-P 13 11 Tryptophan 2 13 
Glutamate 5 12 TTP 86 80 
Glutamine 1 10 Tyrosine 3 5 
GSH 13 16 UDP 4 15 
GSSG 4 15 UMP 2 15 
GTP 90 201 UTP 87 78 
Histidine 2 6 Valine 3 11 
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3.3.6. Linearity, LOD and calibration curve accuracy  
Standard calibration curves were generated over sixteen serially diluted concentration 
points for each metabolite. One example of a standard calibration curve for dihydroorotate 
is shown in Figure 3.6. The remaining standard calibration curves for other metabolites are 
shown in Appendix (II, Figures 59 – 76). Signal saturation was observed for several 
metabolite points at higher concentrations resulting in a non-linear calibration curve. 
Therefore, points with signal saturation were omitted from linearity analysis as shown in 
the dihydroorotate standard calibration curve (Figure 3.6).  The standard calibration curves 
for all metabolite standards were satisfactory with regression coefficients R
2
 better than 
0.98 of area ratio against metabolite concentration, signifying that the method is linear for 
all the metabolites (Table 3.6) (Appendix II, Figures 59 – 77).  Three levels of authentic 
QC standards (high, medium and low) were prepared (section 3.2.3.1) and used to evaluate 
the calibration curve accuracy. The results showed that the accuracy of metabolite standard 
calibration curves determined by LQC was satisfactory (80-120%) for ~91% of the 
calibration curves. The accuracy of the metabolites standard calibration curve determined 
by MQC and HQC was also satisfactory (80-120%) accounting for ~99% of the calibration 
curves (Figure 3.8). 
The linearity range for each metabolite was also determined with the lower limit always 
being the limit of detection (LOD) (Table 3.6). The results of linearity range and LOD for 
each metabolite are summarized in Table 3.6. The distribution of LOD among all 
metabolites was shown in (Figure 3.7).  Over 65% and 15% of the metabolites targeted in 
this method showed a LOD of 1-50 nM and 51-100 nM, respectively, indicating the 
sensitivity of the present method (Figure 3.7).  
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Figure 3.6: Standard calibration curve for dihydroorotate showed R
2 
> 0.99. 
The line of best fit the calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Dihydroorotate concentration in experimental parasite samples was 
calculated from the resulting area ratio and the regression equation of the calibration curve.              
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Table 3.6: Regression coefficients R
2
, linearity range and limit of detection (LOD) for 
metabolites targeted in LC-MS/MS method 
Metabolite R² 
Linear Range 
(uM) 
LOD 
(nM) 
Metabolite R² 
Linear Range 
(uM) 
LOD 
(nM) 
Propionyl-CoA 0.99 0.003 – 108.41 3 AMP 0.99 0.025 – 102.86 25 
Tryptophan 0.98 0.005 – 174.87 5 NAD 0.99 0.026 – 53.83 26 
Phenylalanine 0.99 0.006 – 216.2 6 UMP 0.98 0.026 – 110.17 26 
Glucose 0.99 0.006 – 198.25 6 GSH 0.98 0.028 – 116.21 28 
Citrulline 0.99 0.006 – 203.86 6 GSSG 0.98 0.028 – 58.3 28 
Tyrosine 0.99 0.006 – 197.11 6 2-Oxoglutarate 0.99 0.029 – 244.45 29 
G-3-P 0.99 0.006 – 207.55 6 Valine 0.99 0.037 – 304.86 37 
(iso)-citrate 0.99 0.006 – 93 6 UDP 0.99 0.042 – 88.37 42 
Methionine 0.99 0.007 – 239.36 7 NADP 0.99 0.047 – 48.04 47 
Histidine 0.98 0.007 – 230.19 7 Succinyl-CoA 0.98 0.049 – 102.91 49 
Dihydroorotate 0.99 0.007 – 56.47 7 Hypoxanthine 0.99 0.063 – 262.61 63 
Lysine 0.99 0.007 – 244.3 7 GTP 0.99 0.066 – 68.26 66 
Orotate 0.98 0.007 – 57.2 7 CTP 0.99 0.072 – 73.92 72 
Glutamate 0.99 0.007 – 242.74 7 UTP 0.98 0.072 – 73.77 72 
Acetyl-CoA 0.99 0.007 – 220.58 7 Proline 0.99 0.074 – 310.21 74 
Ornithine 0.99 0.008 – 270.24 8 Alanine 0.99 0.096 – 400.87 96 
Aspartate 0.99 0.008 – 268.32 8 NADPH 0.99 0.096 – 47.9 96 
Malate 0.99 0.008 – 266.35 8 
Carbamoyl-l-
aspartate 
0.99 0.097 – 202.78 97 
Succinate 0.99 0.009 – 302.44 9 NADH 0.99 0.107 – 53.67 107 
FAD 0.99 0.011 – 45.46 11 PEP 0.99 0.206 – 212.53 206 
Glutamine 0.99 0.015 – 244.38 15 TTP 0.99 0.578 – 74.07 578 
(iso)-leucine 0.98 0.016 – 272.27 16 Fumarate 0.98 0.615 – 307.69 615 
Asparagine 0.98 0.016 – 270.32 16 Serine 0.99 0.68 – 339.84 680 
ATP 0.98 0.017 – 70.42 17 DHAP 0.99 0.84 – 420.17 840 
Threonine 0.99 0.018 – 299.82 18 Cysteine 0.98 1.179 – 589.73 1179 
ADP 0.99 0.020 – 83.6 20 Oxaloacetate 0.98 5.4 – 2704.14 5400 
Lactate 0.99 0.024 – 793.03 24 
Carbamoyl 
phosphate 
0.98 7.59 – 3799.39 7590 
Arginine 0.99 0.025 – 205.02 25 PABA 0.98 8.151 – 260.42 8151 
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Figure 3.7: Histogram of the distribution of limit of detection (LOD) for the metabolites 
investigated.  
Histogram shows that ~65% and ~15% of metabolites targeted in the present LC-MS/MS 
method have their LOD between 1-50nM and 51-100nM, respectively. The remaining ~15% of 
the targeted metabolites have their LOD greater than 101nM reaching sometimes up to uM and 
mM concentrations depending on each individual metabolite.    
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Figure 3.8: Histogram of the distribution of standard curve accuracy (%) as determined 
by three levels of QC (low, medium and high).  
The histogram shows that ~91% of the metabolite standard calibration curves obtained a 
satisfactory accuracy between 80-120% for LQC. ~99% of metabolite standard calibration 
curves obtained a satisfactory accuracy between 80-120% for both MQC and HQC. 
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Table 3.7: Accuracy of standard calibration curves of LC-MS/MS targeted metabolomics as determined by three levels (low, medium and high) of 
authentic QCs  
 
LQC MQC HQC 
Metabolite 
Nominal  
Conc. 
(uM) 
Mean 
conc. (uM) 
±SD 
Accuracy 
(%) 
Nominal  
Conc. 
(uM) 
Mean 
conc. (uM) 
±SD 
Accuracy 
(%) 
Nominal  
Conc. (uM) 
Mean 
conc. 
±SD 
Accuracy 
(%) 
Alanine 4.01 3.20 0.40 81.88 40.09 35.78 1.62 89.24 400.9 353.30 14.88 88.13 
Asparagine 2.7 3.04 0.15 112.63 27.03 31.54 1.93 116.67 270.3 270.95 31.29 100.23 
Aspartate 2.68 3.18 0.01 118.82 26.83 31.12 1.40 115.98 268.3 221.94 31.90 82.71 
Glutamine 2.44 2.29 0.23 93.73 24.44 24.68 3.24 100.98 244.4 227.26 27.91 92.99 
Glutamate 2.43 2.18 0.16 89.52 24.27 20.33 0.83 83.78 242.7 202.44 4.68 83.40 
Arginine 2.05 2.25 0.18 109.90 20.5 21.57 2.21 105.24 205 173.90 25.50 84.82 
Proline 3.1 2.73 0.32 88.03 31.02 25.62 0.81 82.61 310.2 284.64 15.03 91.76 
Serine 3.4 3.51 0.43 103.32 33.98 39.63 1.22 116.62 339.8 309.98 20.88 91.21 
Valine 3.05 2.91 0.43 95.41 30.49 29.12 3.66 95.50 304.9 252.91 4.90 82.96 
Threonine 3 3.20 0.14 106.51 29.98 33.89 0.70 113.03 299.8 277.37 16.70 92.51 
Cysteine 5.9 ND ND ND 58.97 49.95 3.57 84.70 589.7 613.47 65.31 104.03 
(iso)-leucine 2.72 2.77 0.34 101.79 27.23 24.98 0.19 91.73 272.3 229.64 19.44 84.34 
Lysine 2.44 2.00 0.18 81.82 24.43 26.96 0.09 110.35 244.3 203.32 3.30 83.22 
Methionine 2.39 1.98 0.02 82.96 23.94 21.00 2.51 87.73 239.4 191.67 0.26 80.08 
Histidine 2.3 2.68 0.04 116.72 23.02 26.20 1.22 113.80 230.2 210.38 15.38 91.39 
Phenylalanine 2.16 2.22 0.06 102.72 21.62 21.62 0.75 100.00 216.2 195.32 6.77 90.34 
Tryptophan 1.75 1.56 0.14 89.29 17.49 16.07 0.39 91.88 174.9 163.00 20.69 93.21 
Tyrosine 1.97 1.46 0.16 73.97 19.71 23.25 1.32 117.97 197.1 173.81 13.53 88.18 
Ornithine 2.7 2.84 0.27 105.06 27.02 25.46 2.56 94.23 270.2 258.95 56.61 95.82 
Citrulline 2.04 2.01 0.25 98.30 20.39 23.13 2.52 113.46 203.9 210.17 19.19 103.09 
NAD 0.54 0.48 0.05 88.23 5.38 4.91 0.12 91.27 53.8 51.97 7.46 96.55 
NADH 0.54 0.47 0.04 86.17 5.37 5.03 0.19 93.74 53.7 46.42 1.56 86.48 
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Table 3.7: (Continued) 
 
LQC MQC HQC 
Metabolite 
Nominal  
Conc. 
(uM) 
Mean 
conc. (uM) 
±SD 
Accuracy 
(%) 
Nominal  
Conc. 
(uM) 
Mean 
conc. (uM) 
±SD 
Accuracy 
(%) 
Nominal  
Conc. (uM) 
Mean 
conc. 
±SD 
Accuracy 
(%) 
GSH 1.16 1.09 0.14 94.30 11.62 10.17 0.79 87.56 116.2 121.86 17.42 104.86 
GSSG 0.58 0.48 0.01 82.87 5.83 5.58 0.17 95.78 58.3 60.28 9.52 103.39 
NADP 0.48 0.39 0.03 81.13 4.8 3.90 0.05 81.21 48 38.77 4.56 80.70 
NADPH 0.48 0.44 0.06 90.76 4.79 4.12 0.20 85.99 47.9 40.54 4.61 84.61 
FAD 0.45 0.44 0.06 98.75 4.55 4.14 0.25 90.92 45.5 42.41 7.64 93.28 
UMP 1.1 1.07 0.04 97.68 11.02 9.58 0.51 86.94 110.2 92.50 4.99 83.96 
UDP 0.88 0.82 0.19 93.38 8.84 7.70 2.26 87.05 88.4 80.96 6.35 91.61 
UTP 0.74 0.57 0.08 76.41 7.38 6.92 1.02 93.83 73.8 65.51 3.93 88.80 
CTP 0.74 0.67 0.27 90.67 7.39 6.20 0.71 83.94 73.9 68.09 8.49 92.12 
TTP 0.74 0.63 0.13 85.25 7.41 6.15 0.80 82.98 74.1 68.16 3.01 92.02 
AMP 1.03 1.03 0.08 100.33 10.29 10.16 1.19 98.75 102.9 104.64 9.10 101.73 
ADP 0.84 0.75 0.17 88.96 8.36 7.01 0.42 83.88 83.6 76.17 4.17 91.12 
ATP 0.7 0.60 0.00 85.30 7.04 5.93 0.26 84.18 70.4 70.99 10.48 100.80 
GTP 0.68 0.70 0.29 103.00 6.83 6.83 2.31 100.00 68.3 80.11 22.26 117.37 
Carbamoyl-l-
Aspartate 
2.03 1.95 0.25 96.01 20.28 20.36 2.97 100.39 202.8 186.70 8.52 92.07 
Acetyl-CoA 2.21 1.96 0.09 88.60 22.06 20.77 1.23 94.14 220.6 193.72 4.27 87.75 
Succinyl-CoA 1.03 ND ND ND 10.29 12.53 5.10 121.73 102.9 100.09 17.72 97.26 
Propionyl-CoA 1.08 0.96 0.05 88.97 10.84 8.90 0.34 82.13 108.4 101.39 6.50 93.53 
Glucose 1.98 1.76 0.42 89.00 19.82 17.97 2.16 90.67 198.2 180.81 4.17 91.20 
Fumarate 3.08 3.26 0.39 105.95 30.77 29.69 7.84 96.48 307.7 317.85 39.39 103.30 
Succinate 3.02 3.26 0.86 107.96 30.24 28.52 6.09 94.32 302.4 304.06 8.83 100.54 
Malate 2.66 2.30 0.08 86.47 26.64 30.73 4.40 115.36 266.4 291.07 56.37 109.28 
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Table 3.7: (Continued) 
 
LQC MQC HQC 
Metabolite 
Nominal  
Conc. 
(uM) 
Mean 
conc. (uM) 
±SD 
Accuracy 
(%) 
Nominal  
Conc. 
(uM) 
Mean 
conc. (uM) 
±SD 
Accuracy 
(%) 
Nominal  
Conc. (uM) 
Mean 
conc. 
±SD 
Accuracy 
(%) 
2-Oxoglutarate 2.44 2.75 0.13 112.80 24.45 26.27 1.53 107.45 244.5 271.48 9.60 111.06 
(iso)-Citrate 1.86 1.56 0.62 83.92 18.6 20.32 3.46 109.23 186 162.90 38.95 87.58 
PEP 2.13 2.51 0.04 118.03 21.25 20.07 4.50 94.44 212.5 198.17 12.47 93.24 
PABA 2.6 1.89 1.19 72.55 26.04 26.22 1.70 100.69 260.4 286.21 30.46 109.90 
G-3-P 2.08 2.21 0.31 106.25 20.76 24.05 2.23 115.86 207.6 213.59 16.52 102.91 
Hypoxanthine 2.63 2.43 0.38 92.30 26.26 26.87 3.36 102.31 262.6 308.55 111.09 117.49 
Orotate 2.29 2.08 0.50 90.65 22.88 21.69 2.88 94.79 228.8 225.95 43.81 98.75 
Dihydroorotate 2.26 2.23 0.16 98.61 22.59 24.45 2.03 108.23 225.9 185.08 10.21 81.94 
Lactate 7.93 9.20 1.69 115.98 79.3 70.83 4.81 89.32 793 705.64 81.44 88.98 
DHAP 4.20 4.70 1.56 111.90 42.02 34.73 15.96 82.64 420.20 494.80 20.91 117.76 
Oxaloacetate 27.04 27.51 4.47 101.74 270.42 238.00 49.55 88.01 2704.20 2521.45 624.88 93.24 
Carbamyl-P 37.99 31.01 4.75 81.62 379.94 312.38 60.53 82.22 3799.40 2858.47 397.91 75.23 
Abbreviations: ND, Not Determined. 
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 Discussion   3.4.
The main objective in this metabolomics approach was to determine the differences 
between the complete or part of the parasite cell metabolome. Although non-targeted 
metabolomics approaches have resulted in new insights into the functioning of 
biological systems, development of a sensitive, quantitative and reproducible 
comprehensive method is extremely challenging (De Vos et al., 2007). Therefore, a 
targeted metabolomics approach was selected for the study of P. falciparum in this 
thesis. The primary challenge in developing this analytical targeted metabolomics 
approach was balancing a comprehensive coverage of P. falciparum metabolome with 
high sensitivity and reliable quantification. Thus, an extensive method optimization and 
validation was required in order to determine the differences in the metabolites between 
parasite samples that have been collected hourly as described in the subsequent 
chapters. Triple-quadrupole LC-MS/MS was showed here to be used for the detection 
and quantification of numerous known metabolites in parallel by scanning repeatedly 
through different SRM events. This LC-MS/MS analytical method was successfully 
developed for targeted metabolomics enabling the effective detection and relative 
quantification of a broad range of 56 metabolites that account for ~10% of the P. 
falciparum metabolome. These metabolites are associated with several different 
metabolic pathways including glycolysis, TCA cycle, pyrimidine biosynthesis, purine 
salvage, amino acids metabolism and bioenergetics/redox couples. This targeted 
metabolomics approach was in accordance and similar to previous metabolomic 
approaches  in terms of performance and reliability  (Bajad et al., 2006, Rabinowitz and 
Kimball, 2007, Lu et al., 2008, Lu et al., 2006). The analytical performance of the 
present method was validated for selectivity, carryover, metabolite recovery, metabolite 
stability, reproducibility, linearity and limit of detection (LOD).  
 
The method was found to have a high selectivity that enables a sensitive and specific 
detection for the pre-determined metabolite. This was showed by the presence of no 
interference or carryover peaks from other endogenous metabolites as was observed at 
the retention time for dihydroorotate in the blank sample. Therefore, the present LC-
MS/MS method advantageously ensured the identification of each metabolite not only 
based on the metabolite’s molecular weight or precursor mass but also on its retention 
time and fragmentation properties. In addition, an external and internal calibration 
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standard was used for reliable quantification of the metabolites. Calibration curves for 
all metabolites targeted in this study were fitted by linear regression with R
2
 values 
better than 0.98 for all metabolites representing satisfactory standard calibration 
linearity. The accuracy of the calibration curves was determined by three levels of QC 
(high, medium and low) and it showed that a majority (~91% for LQC and ~99% for 
MQC and HQC) of metabolites obtained a satisfactory standard calibration curve with 
accuracy between 80-120%. The LOD of each metabolite was determined and it was 
found that the current method was very sensitive detecting more than 75% of the 
targeted metabolites in the nanomolar range, specifically, a range between 1–100 nM.   
The recovery (%) was determined for all metabolites including the internal standards. 
Satisfactory recovery (70% - 120%) was effectively achieved for most (~85%) of the 
metabolites targeted including the internal standards. Few (~15%) of the targeted 
metabolites did not display a satisfactory recovery due to either ion suppression or 
enhancement as observed in low and high recoveries, respectively.  In addition, the 
present method of performance reproducibility was investigated given generally a 
respectable RSD of less than 15% for most of the metabolites being investigated both 
intra- and inter- days. With regard to metabolite stability, it was noted that different 
storage temperatures had a considerable effect on metabolite stability. Therefore, it was 
observed that the appropriate storage temperature for less than a month period is -80 ºC 
which led to more than ~88% of the metabolites being stable. Unstable metabolites, 
including NADPH, NADH, cysteine, GSH, DHAP and carbamoyl phosphate were 
prepared from fresh solid stocks for every LC-MS/MS run and all the parasite samples 
need to be processed analytically in a period of less than a month. Overall, the 
validation showed that the LC-MS/MS targeted metabolomics had high selectivity, 
sensitivity, satisfactory recovery, efficient performance reproducibility and excellent 
linearity values for all metabolites.      
 
In regards to the limitations of this chapter, although this developed method had an 
efficient chromatographic separation for all the metabolites, the total running time of 
45.0 min per sample is considered long particularly for large batches of samples. This 
might have had an effect on some metabolite sample stability. In addition, QC samples 
were prepared from authentic metabolite standards for the purpose of checking the 
accuracy of the calibration curve. However, it should be noted that QC samples 
prepared from the cell extract will give a better idea about the influence of matrix 
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interferences with the different levels of QC (Koek et al., 2006, Koek et al., 2011). In 
addition, the internal standards (IS) for positive and negative mode were 
chromatographically eluted during the first ~13.0 min of the running time. 
Nonetheless, it is important to include more than one IS for each ionization mode that 
can be eluted in the beginning, middle and end of the chromatograph running time. In 
addition, for a highly sensitive quantitative analytical approach, the most suitable IS is 
the isotope-labelled form of each metabolite as it behaves identically to the metabolite 
in the sample preparation, separation and ionization processes (Bennett et al., 2008). 
However, isotope-labelled metabolites are very expensive and are not available for all 
metabolites. In addition, one major drawback of the present method was the inability of 
the LC-MS/MS approach to distinguish between metabolite isomers such as citrate and 
leucine because it is mainly based on an MRM scan. Therefore, citrate and leucine 
were written in this thesis as (iso)-citrate and (iso)-leucine. It is therefore 
recommended that future studies should be carried  using a mass spectrometer that can 
deliver a high-resolution accurate mass detection such as the “Exactive” Orbitrap mass 
spectrometry (Lu et al., 2010).  
 
Moreover, this LC-MS/MS method seems to be robust and generally applicable to 
samples from various biological sources as a PhD colleague was using the same 
approach for investigation into the Mycobacterium tuberculosis (MTB) metabolome. It 
was also shown that this method can be expanded for more metabolites than those that 
were targeted as seen in the metabolomics of MTB (personal communication). This 
method appears also a promising tool for investigating the        P. falciparum 
metabolome and the drug mode of actions as will be demonstrated in the subsequent 
chapters.  
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CHAPTER 4  
Targeted Metabolomics of Plasmodium falciparum 
Infected and Uninfected Red Blood Cells 
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 Introduction 4.1.
The main objective of this chapter was to investigate the general metabolic profiles 
between uninfected human red blood cell (RBC) and those infected by P. falciparum 
(iRBC) using the developed LC-MS/MS targeted metabolomics approach described 
previously (Chapter 3).   
It is well known that the primary physiological function of human RBC is the carriage 
of oxygen (O2) and carbon dioxide (CO2) between the lungs and tissues of the body, as 
well as maintaining homeostasis by  pH buffering (Surgenor, 1974).  One of the known 
features of human RBC is that it is non-nucleated, and therefore has evolved specific 
metabolic functions for its survival during its three to fourth month life span (Surgenor, 
1974, Walsh, 1998). This survival of RBC uses several metabolic pathways in order to 
maintain its haemoglobin, biconcave shape and the electrolyte concentrations (Prankerd, 
1955). These pathways are involved in the production of the necessary cofactors such as 
ATP, NADPH, and NADH by energy and redox metabolisms thus maintaining RBC 
osmotic balance, electro-neutrality and fighting oxidative stresses (Joshi and Palsson, 
1989, Wiback and Palsson, 2002, Bossi and Giardina, 1996). There are four known 
basic metabolic pathways of RBC metabolism namely; anaerobic glycolysis, the 
pentose phosphate shunt (PPS), adenosine nucleotide metabolism and the Rapoport-
Leubering shunt (Wiback and Palsson, 2002, Walsh, 1998). The absence of a 
mitochondria in mature human RBC means that  energy in the form of ATP is generated 
exclusively from anaerobic glycolysis (Schweiger, 1962).  This suggests that  glucose 
must always be freely available for the synthesis of ATP (Prankerd, 1955). The other 
two important cofactors that come from this glycolytic pathway are NADH and 2,3-
diphosphosglycerate (2,3-DPG). NADH is an essential cofactor for the enzyme 
methemoglobin reductase, which maintains heme iron in the ferrous (Fe
2+
) state, which 
is a reaction  necessary for the ligation of molecular oxygen by the haemoglobin 
molecule (Zerez et al., 1990). In addition, mature human RBC contain a considerable 
large amount (~5.0 mM) of  2,3-DPG, the function of which is believed to regulate the 
oxygen affinity of haemoglobin, generated through the Rapoport-Leubering shunt 
(Nikinmaa, 1990). Moreover, mature human RBC’s which lose their  nucleus and other 
organelles during  development  make these cells unable to synthesize RNA, protein, 
lipid, and purines (Bishop, 1964). Walsh et al., (1998) wrote that 10% of the carbon 
flow could be diverted to the PPS pathway producing two important metabolites; 
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NADPH for maintaining intercellular store of GSH, an oxidative damage protector, 
synthesized from the amino acids cysteine, glutamate and glycine, and ribulose 5-
phosphate (R5P) for linking the pathway with nucleotide metabolism. Furthermore, 
nucleotide metabolism acts primarily to regenerate intracellular store of ATP which go 
through a normal turnover into adenosine and inosine (Walsh, 1998). However, human 
RBC do not synthesize adenosine de novo but rather takes it up  from plasma and 
synthesizes AMP, ADP and ATP (Walsh, 1998). In general, it appears that RBC’s 
metabolism has been comprehensively examined and this has made it possible to be 
simulated by virtual methods using comprehensive kinetic models (Joshi and Palsson, 
1989, Jamshidi et al., 2001). 
In stark contrast to uninfected RBC glucose consumption rate (~5 µmol glucose/24 
h/10
9 
RBCs), P. falciparum-iRBC  is shown to rely on anaerobic glycolysis but with an 
estimation of 50-100 times increase in the glucose consumption rate particularly at       
P. falciparum’s active stages to include trophozoite and schizont, both of which are 
metabolically demanding (Roth Jr, 1990). Metabolic changes that occur in RBC upon 
Plasmodium parasite invasion drastically diverge the metabolic requirements of the 
combined Plasmodium/RBC system which necessities finding energy source for growth 
and proliferation every 48 h (Roth, 1987, Sherman, 1979, Olszewski and Llinas, 2011). 
Within this time frame,  parasite growth increases significantly in size and numbers 
during the asexual stages which demand the system to synthesize enough RNA, protein, 
and DNA for 12-24 new progeny (merozoites) which are subsequently released and 
reinvade fresh RBC (Moulder, 1948). P. falciparum  also make major alterations to 
RBC to allow the direct influx and efflux of specific metabolites (e.g. glucose) using 
new permeability pathways (NPPs) (Kirk et al., 2005). In addition, for protein synthesis, 
P. falciparum relies principally on amino acids generated from haemoglobin 
degradation in the acidic digestive vacuole as well as through uptake from the 
extracellular space (Francis et al., 1997, Gardner et al., 2002). Furthermore, the 
production of energy in Plasmodium is a result of the glucose fermentation process 
consequentially leading to the accumulation and secretion of lactate and pyruvate 
despite the parasite having mitochondria (Sherman, 1998, Roth et al., 1988). This calls 
into questioning the role of the parasite mitochondrion in energy metabolism. The role 
of mitochondrial metabolism is examined further in the subsequent chapters (5 and 6). 
Similarly, there are some unresolved questions concerning apicoplast metabolism. 
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Ralph et al  2004 described  the apicoplast, as  a plastid-like organelle, that plays a role 
in fatty acid, heme, and isoprenoid biosynthesis (Ralph et al., 2004). This discovery has 
led to several drug discovery projects targeting plastid metabolism, however the precise 
role in P. falciparum’s survival is still debated (Lim and McFadden, 2010).  
The above mentioned overview shows the metabolic functions between P. falciparum 
and it’s host’s RBC, indicating the metabolic complexity in the parasite in comparison 
to the RBC. Therefore, understanding the biological differences in metabolism between 
both invader and host is essential for drug development as it reveals mode of action 
(MoA). Metabolomics offers an attractive platform for the study and understanding of 
the biology of P. falciparum-iRBC as well as RBC. The usefulness and application of 
this approach in malaria research was explained in depth previously (Chapter 1). 
Generally, metabolomics technologies and strategies (Kell, 2004, Kell, 2006, Goodacre 
et al., 2004, Moco et al., 2007) have  iteratively improved the present understanding of 
systems biology of numerous model organisms. These include Archeae (Trauger et al., 
2008), bacteria (Rabinowitz, 2007), yeast (Brauer et al., 2006), plants (Fiehn, 2006, 
Lisec et al., 2008, Beale and Sussman, 2011), insect (Pedersen et al., 2008, Kamleh et 
al., 2008) rodent(Sun et al., 2007), and human cell culture (Khoo and Al-Rubeai, 2007).  
Kirk’s group was able to determine the intracellular concentrations of a range of 
metabolites using NMR metabolomics in saponin-permeabilized mature trophozite 
stage of P.falciparum (Teng et al., 2009).  Recently, Llinas’s laboratory was the first to 
apply metabolomics approach in 48 h developmental cycle of P. falciparum. This 
demonstrated the general variation of metabolite levels by the parasite, with numerous 
metabolite levels changing in each phase of the developmental cycle (Olszewski et al., 
2009). On this basis, the study of this chapter was carried out primarily to determine and 
investigate the general metabolomics modulation of P. falciparum-iRBC compared to 
that of RBC. Therefore, this study was conducted on enriched culture of trophozoite-
staged P. falciparum-iRBC because of its high metabolic rate in limited time (i.e. 
incubation time of 7 h).  
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 Materials and Methods 4.2.
4.2.1. High Gradient Magnetic separation (HGMS) for trophozoite-stage 
parasites enrichment 
HGMS offers a means to concentrate trophozoites, schizonts and gametocytes of          
P. falciparum from suspensions, by virtue of the para-magnetic properties of these later 
stages. Throughout the metabolomic experiments described in this thesis, the 
enrichment of trophozoite-iRBC parasites was carried out using a VarioMACS™ 
separation unit (Miltenyi Biotec, UK), that is separating the trophozoite-stage iRBC of 
the parasite from early rings and uninfected RBC. However, an RBC experiment in this 
chapter also went through the magnetic separation unit in order to limit any variation in 
experiments between RBC as a control and iRBC.   
 
The VarioMACS™ column matrix creates a high-gradient magnetic field, which 
attracts the iron in the trophozoite haemozoin  (Ribaut et al., 2008).  Poorly, but 
successful HGMS of late-stage iRBC from malaria parasite cultures was first described 
in 1981 (Paul et al., 1981). Recently, the commercially polymer coated HGMS columns  
have  demonstrated to provide a better improved purified late-stage malaria parasite 
(Trang et al., 2004, Ribaut et al., 2008). However, it has been noted that sorbitol-
pretreatment of the malaria parasite cultures was essential prior to carry out the HGMS 
procedure (Ahn et al., 2008). Therefore for the purpose of this work, the parasite 
cultures were synchronized with sorbitol as described earlier (chapter 2 section 2.2.7.1) 
for at least two cycles before purifying using the VarioMACS™ column.    
 
The enrichment of trophozoite-stage P. falciparum parasites was carried out as follows: 
VarioMACS™ separation unit was place inside a class II Enviar laminar flow cabinet 
which was decontaminated with 70% ethanol. VarioMACS™ column was then 
sterilized by washing once with 100% ethanol. The column was then placed between 
the pole magnet and equilibrated for 5 min. Afterwards, the column was pre-
equilibrated and filled with PBG buffer solution (1x phosphate-buffered saline (PBS), 
4% w/v bovine serum albumin (BSA), 20 mM Glucose) (section 4.2.1.1) by gently 
pushing the PBG buffer solution through the syringe to the column in upright position 
to evacuate air by upward displacement. A 20 G/1-inch injection needle was thereafter 
connected to the stopcock subsequently after removing remaining air bubbles by gentle 
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finger tapping. After opening the stopcock, PBG buffer solution was then allowed to 
flow through the column in downward displacement.  
 
Each metabolomic experiment replicate consisted of 15 - 20 flasks (~750 - 1000 ml) of 
synchronized parasite culture. Each parasite culture flask was contained 8-10% 
parasitaemia, >98% trophozoite-stage, which was harvested at 2500 rpm for 5 min at 
room temperature. The pelleted cells from each culture flask were suspended in 10 ml 
of PBG buffer solution. This suspension of cells was then applied on the top of the 
column. Without interrupting the flow or letting the column to dry, the column was 
rinsed with 50 ml of PBG buffer solution until the effluent was clear (no longer 
contained red blood cells). After this, the stopcock was closed and the column was 
removed from the magnet. The needle was removed from the stopcock and the column 
was flushed with 10-15 ml of PBG buffer solution to elute the trophozoite-stage 
parasites until the eluate was clear (no longer contained trophozoite). The eluate 
contained isolated trophozoite-staged parasite was collected in 50 ml centrifuge tube. 
This process was repeated again for next 14 parasite culture flasks. The pooled eluate 
was thereafter centrifuged at 2000 rpm for 5 min, washed twice with RPMI-1640 
culture media before starting the haemocytometer counting (section 4.2.2) and the 
metabolomics time points experiment (section 4.2.3).  
 
The ultimate step in enrichment procedure was to clean the column as follows: the 
column was washed three times with each of the following solutions namely PBG 
buffer solution, 1% (v/v) Tween 20 (section 4.2.1.2) and distilled water respectively. 
These washes were followed by a final wash with 100% ethanol. The column was then 
dried on a vacuum pump for one hour and covered with parafilm ready for next usage.   
  
4.2.1.1. PBG buffer solution preparation 
The PBG (1x Phosphate-buffered saline, 4% Bovine serum albumin (BSA), 20 mM 
Glucose) buffer solution was prepared as follows: a tablet of phosphate-buffered saline 
(Sigma-aldrich, UK) was dissolved in 200ml of distilled water to get 1x (w/v) 
physiological saline.4 g of BSA (Sigma-aldrich, UK) was then dissolved in the prepared 
saline to get 4 % (w/v) BSA. Thereafter, 720.6 mg of glucose (Sigma-aldrich, UK) was 
added to the above solution and stirred all together. Subsequently, the PBG buffer 
 112 
 
solution was sterilized through a sterile bottle top filter unit with a 0.22 μm membrane 
(Fisher Scientific, UK), labeled, and stored at 4 ⁰C until required. 
 
4.2.1.2. 1% (v/v) Tween 20 preparation 
Tween 20 was purchased from Sigma (Sigma, UK). The preparation of 1% Tween 20 
was as follows: 1 ml of Tween 20 was dissolved in 100 ml of distilled water.  This 
prepared 1% (v/v) Tween 20 solution was then labeled, and stored at room temperature 
until required. 
 
4.2.2. Haemocytometer counting for infected and uninfected red blood cells 
A haemocytometer (Bright-Line™ Hemacytometer, Sigma-Aldrich, UK), was used to 
count the parasite cells. However, the enriched trophozoite-stage parasite and packed 
RBC were very concentrated and presented in high numbers which made it difficult to 
count. A 1:50 serial dilution was thus carried out in RPMI-1640 culture media. 
Haemocytometer is unique in that it has a thick base and uses a special cover-glass 
which is thick enough to stay flat under the pull of surface tension from the solution in 
the counting chamber. After the haemocytometer was assembled with its cover-glass, a 
15 µl of serially diluted parasites solution was loaded into the loading notch of the 
haemocytometer (Figure 4.1A). The haemocytometer was set on the light microscope 
(Zeiss, Germany) ready for counting the parasites. The parasite counting was carried out 
initially at x10 magnification power to determine the grid and squares area (Figure 4.1B 
) and then under x40 magnification power to count all the parasites in five random 
squares (Figure 4.1C). The counted parasites were then averaged and multiplied by 5. 
This was to calculate the number of parasites in 25 squares. If a 1:50 dilution was used, 
then the outcome of calculated parasites was multiplied by 50 (dilution factor) and 
finally multiplied by 10
4
. This total gave number of parasites per ml. The equation to 
carry out the parasites calculation was as follows: 
 
The number of parasites/ml= average of parasites count in five square x number of 
square counted x dilution factor x 10
4 
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Figure 4.1: Haemocytometer chamber counting.  
(A) Haemocytometer showing the loading notch and coverslip position, (B) Haemocytometer 
gridlines showing under light microscope four corner squares and a middle square, (C) 
Haemocytometer gridlines showing the five random squares marked in red in the middle square.  
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4.2.3. Metabolism quenching and metabolite extraction for RBC and iRBC 
Briefly at this stage, the enriched trophozoite-stage iRBC and RBC were subjected to a 
metabolomics experiment where they were incubated in culture media at 37 °C.  
Subsequently, iRBC and RBC were removed in a time related manner for quenching 
metabolism and initiating extraction. Metabolites were then extracted, ready for the next 
stage of LC-MS/MS analysis (section 4.2.4).  
 
The metabolomics experimental protocol that was carried out throughout this thesis, 
with minor modification in each experimental chapter; was as follows: The enriched 
trophozoite-stage iRBC and RBC were incubated with RPMI-1640 culture media 
(R8758, glutamine, and sodium bicarbonate) supplemented with 10% pooled human 
serum, 25 mM HEPES (pH 7.4) (VWR), 40 μM hypoxanthine (Sigma), and 20 μM 
gentamicin sulfate (Sigma) at 37 °C under 3% O2/4% CO2 in N2 for 7 h time points 
course. At predetermined time intervals, one volume of incubated iRBC and RBC (~1 × 
10
8
 parasites/mL) was directly collected at t= 0 h interval for metabolically quenching 
into three volumes of -20 ºC quenching solvent system [acidic 
acetonitrile/methanol/water (40:40:20 + 0.1 M formic acid) spiked with internal 
standards] (chapter 3, section 3.2.2.5). After quenching, the sample was kept at -80 ºC 
for overnight. The sample was then centrifuged at 4500 rpm for 20 min with a rotor at   
4 ºC. The supernatant was carefully transferred into a new tube and kept in ice whereas 
the cell debris was washed twice with three volumes of extraction solvent system 
[acetonitrile/methanol/water (40:40:20)] (chapter 3, section 3.2.2.5). All the 
supernatants for each individual sample were thereafter collected and pooled together 
into each corresponding sample tube. Afterwards, metabolites extracted sample was 
concentrated under N2 gas flow in the fume hood by using the samples concentrator 
system (Techne sample concentrator, Bibby Scientific Ltd, UK) until the sample was 
totally dry. The sample was then kept at -80 °C ready for LC-MS/MS analysis. 
 
4.2.4. LC-MS/MS instrumentation 
Briefly at this stage, sample preparation including trophozoite-stage iRBC and RBC 
samples, external standards, authentic QCs, and blanks was carried out in this section 
aimed at LC-MS/MS. In addition, the chromatographic gradient conditions and mass 
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spectrometry configurations were set up as described previously in the developed 
method for LC-MS/MS targeted metabolomics (chapter 3).  
 
4.2.4.1. Samples preparation 
The parasite sample preparation was carried out as follows: dried sample was taken out 
from -80 °C freezer and resuspended in one volume of freshly prepared mobile phase 
[(20 mM ammonium acetate + 20 mM ammonium hydroxide) in 95:5 water:acetonitrile 
(pH 9.45)] (chapter 2, section 2.3.4). The resuspended sample was then transferred into 
an eppendorf tube and spun at high speed (17000 rpm) for 30 min at 4 °C. The 
supernatant was filtered using phenex-RC filters 0.2 µm into chromacol LC-MS/MS 
vial. The preparation of external standards, authentic QCs, and blanks was freshly 
carried out for each metabolomics experiment as described beforehand (chapter 3, 
section 3.2.3.1).    
 
4.2.4.2. Chromatographic separation  
Chromatographic separation was conducted as described earlier (chapter 3, section 
3.2.2.4).   
.   
4.2.4.3. Mass spectrometry configuration 
The configuration of mass spectrometry was set up for positive and negative modes as 
described previously (chapter 3, section 3.2.2.3). 
 
4.2.5. Data treatment and analysis 
The independent biological replicates from both RBC and trophozoite-stage iRBC were 
analyzed and the metabolite concentration was averaged at each time point. Metabolite 
concentration levels were quantified by applying standard curve using the known 
concentration of standards for each of the 34 selected reaction monitoring (SRM) 
because the remaining metabolites mentioned in Chapter 3 were below the limit of 
detection (LOD) where S/N was below than 3. The signal for each metabolite was 
defined as the area under the curve (AUC) of the integrated peak. Each metabolite 
signal was normalized to the signal of the internal standard DL-arabinose (negative 
mode) or β-alanine (positive mode) in the same sample. All data were expressed as the 
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normalized levels of metabolite in the sample at a particular time point to the number of 
cell counted in each experiment. In order to limit the variation in the metabolite 
concentrations for samples collected at time zero, fold change ratio was determined 
against time zero as follows: comparative metabolites fold change ratio represents the 
mean value for each time point in the sample divided by the mean value for the same 
sample collected at time zero. Data was further refined and plotted with GraphPad 
Prism 5.0 (GraphPad Software Inc.). The mean of fold change ratio for biological 
replicates was combined in a dataset file and imported into MetaboAnalyst web-based 
software (http://www.metaboanalyst.ca) (Xia et al., 2012, Xia et al., 2009), log2 
transformed and analyzed by different metabolomics analysis tools described below. 
 
Principal component analysis (PCA), an unsupervised method, is a type of clustering 
analysis that reduces the dimensionality and attempts to describe the data in as few 
components as possible (refer for details in definition to chapter 1, section 1.4.2.3) (Xia 
et al., 2009, Xia et al., 2012). With PCA, large quantities of data can be displayed 
graphically in a manner that makes it easy to analyze and recognize metabolic variations 
between different groups. This is in contrast to partial least square-discriminant analysis 
(PLS-DA), which is a supervised technique used to detect patterns in the data allowing 
for the prediction of class (or experimental condition) of the data set (refer for details in 
definition to chapter 1, section 1.4.2.3) (Xia et al., 2009, Xia et al., 2012). The 
distinction here is the ability of PLS-DA to classify the data based on a known variable 
such as time points, or survival.  
 
Generally, the log2 normalized dataset was subjected to the analysis of PCA and PLS-
DA and viewed as two and three dimensional score plots which followed thereafter by 
generating the loading plots. Metabolome profile analysis was then carried out based on 
a colouration method and visualized as a heat map. 
 
 
 
 
 
 117 
 
 Results 4.3.
Metabolomics experiments were conducted on enriched trophozoite-stage                     
iRBC and RBC as a control. The 56 metabolites targeted for this study were selected on 
the basis that they were the predominant metabolites involved in the core metabolism of 
the parasite as well as RBC. These metabolites are associated in the metabolic pathways 
including glycolysis, TCA cycle, pyrimidine de novo synthesis, purine salvage, amino 
acids metabolism and bioenergetics/redox couples. However, only 34 metabolites were 
detected and quantified using the metabolomics approach described previously (chapter 
3) whilst the remaining 22 metabolites were below LOD. The dynamic changes of 
metabolites from purified RBC and trophozoite stage of iRBC were monitored in a time 
related manner. The quantified 34 metabolites for each iRBC and RBC were included in 
one dataset. This dataset represented the mean of biological replicates for each group 
and presented as fold change ratio that was normalized by the corresponding sample for 
each group collected at time zero. The following findings were obtained from the 
metabolomics analysis of the dataset using metabolanalyst web-based software 
(http://www.metaboanalyst.ca) (Xia et al., 2009, Xia et al., 2012) and the plotted line-
graphs data were performed with GraphPad Prism 5.0 (GraphPad Software Inc.). 
 
4.3.1. Metabolomics analysis of iRBC and RBC 
Principal component analysis (PCA) and partial least squares-discriminant analysis 
(PLS-DA) was performed on the log2 transformed dataset using metabolanalyst web-
based software (http://www.metaboanalyst.ca).  
 
4.3.1.1. PCA and PLS-DA 
The 2-D and 3-D score plots from PCA showed distinct separation between iRBC and 
RBC reflecting the occurrence of essential differences in the metabolites generated 
(Figure 4.4 A and B). A corresponding loading plot indicated that the separation 
observed on PCA clustering was mainly based in the generation of pyrimidine 
intermediates including carbamyol-l-aspartate, dihydroorotate and orotate (Figure 4.4 
C).   
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Moreover, further discriminate analysis was used to indicate any further differences 
between RBC and iRBC. The 2-D and 3-D score plots from PLS-DA showed the same 
findings obtained for PCA. There was an evident clustering segregation between the 
clusters of RBC and iRBC in 2-D and 3-D PLS-DA score plots (Figure 4.5 A and B). In 
addition, the findings obtained for the corresponding loading plot for PLS-DA were 
similar to that obtained for PCA. PLS-DA loading plot indicated that the separation 
observed on 2-D and 3-D clustering was mainly based on the generation of pyrimidine 
intermediates including carbamyol-l-aspartate, dihydroorotate and orotate (Figure 4.5 
C). Similarly, Variable Influence on Projection (VIP) score was used in metabolomics 
analyses to further enhance the major metabolites differences between RBC and iRBC. 
VIP scores were calculated based on the variability explained in PLS-DA. Metabolites 
with VIP score > 1 were considered the most important metabolites responsible for the 
differentiation between RBC and iRBC. VIP scores showed that the most significant 
metabolites with score > 1 were orotate, DHAP, dihydroorotate, carbamoyl-l-aspartate 
and PEP (Figure 4.6). However, although lactate had a borderline VIP score, it indicates 
that differences between RBC and iRBC were also centred in glycolysis and pyrimidine 
pathway (Figure 4.6). Further observations will be described in the biochemical time-
dependent results (section 4.2.3)   
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Figure 4.4: PCA score and loading plots for RBC and iRBC.   
A) 2-D score plot shows divergence of two main clusters. One cluster includes the clustering of 
RBC (red circle) and the other cluster includes the clustering of iRBC by P. falciparum (green 
circle). Line boundary for each group represented a 95% confidence limit from each group 
centre. B) 3-D score plot shows the divergence of two main clusters. One cluster includes the 
clustering of RBC (red triangle) and the other cluster includes the clustering of iRBC by P. 
falciparum (green triangle). C) RBC and iRBC metabolites loading plot discriminate between 
various time points for the corresponding score plots (panel A and B) and reveals that the 
presence of metabolic fingerprints in carbamoyl-l-aspartate, dihydroorotate and orotate. Black 
arrow indicates the time zero (t=0) for RBC and iRBC in Panel A and B. 
t=0 
t=0 
t=0 
t=0 
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Figure 4.5: PLS-DA score and loading plots for RBC and iRBC.  
A) 2-D score plot shows divergence of two main clusters. One cluster includes the clustering of 
RBC (red circle) and the other cluster includes the clustering of iRBC by P. falciparum (green 
circle). Line boundary for each group represented a 95% confidence limit from each group 
centre. B) 3-D score plot shows the divergence of two main clusters. One cluster includes the 
clustering of RBC (red triangle) and the other cluster includes the clustering of iRBC by P. 
falciparum (green triangle). C) RBC and iRBC metabolites loading plot discriminate between 
various time points for the corresponding score plots (panel A and B) and reveals that the 
presence of metabolic fingerprints in carbamoyl-l-aspartate, dihydroorotate and orotate. Black 
arrow indicates the time zero (t=0) for RBC and iRBC in Panel A and B. 
t=0 
t=0 
t=0 
t=0 
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Figure 4.6: Variable Influence on Projection (VIP) score plot for RBC and iRBC. 
Metabolite with VIP score > 1 was considered the most important metabolite responsible for the 
differentiation among RBC and iRBC. The coloured boxes on the right indicate the relative 
ratios of the corresponding metabolite in each group under study. Colour scale shows the 
colours gradient for the VIP score with dark red and dark green being the colours for high and 
low changed metabolites, respectively. VIP score plot shows that the most important 
metabolites responsible for differentiation were orotate, DHAP, dihydroorotate, carbamoyl-l-
aspartate and PEP. Lactate was having borderline VIP score around 1. 
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4.3.1.2. Heat map for iRBC and RBC metabolome profiling 
The similarity and closest measures for the log2 transformed dataset of this chapter were 
analysed by metaboanalyst web-based software and presented as a heat map for visual 
aids.  
Heat map showed visually in a colouration method the relative difference of the 
dynamic changes of RBC and iRBC by P. falciparum (Figure 4.7). It was remarkably 
obvious that the metabolomic profiles of iRBC showed the occurrence of production 
trends in the intermediates of pyrimidine, purine, glycolysis, TCA pathways and some 
amino acids (Figure 4.7). An iRBC showed the incidence of consumption trends in 
glucose as well as some amino acids including asparagine, glutamine, arginine, serine, 
valine, (iso)-leucine, lysine, methionine, tryptophan, tyrosine and threonine (Figure 
4.7). In contrast, the metabolomics profile of RBC showed no obvious production trends 
in the intermediates of pyrimidine, purine, glycolysis, TCA pathways and some amino 
acids except alanine (Figure 4.7). In addition, there was the presence of either low or no 
consumption in glucose as well as some amino acids including asparagine, glutamine, 
arginine, serine, valine, (iso)-leucine, lysine, methionine, tryptophan, tyrosine and 
threonine (Figure 4.7). Moreover, the heat map presented in (Figure 4.7) summarized 
the relative metabolites fold changes ratio in RBC and iRBC. Major and evident 
metabolite changes were highlighted as mentioned above. However, detailed and 
specific explanation is presented as time-dependent graphs in the next section (4.3.2).       
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Figure 4.7: Heat map representation of RBC and iRBC dynamics metabolome. 
Heat map shows dynamic changes of 34 metabolites in RBC and iRBC. Average values at each 
time-point obtained, using uninfected RBC and enriched trophozoite-staged P.falciparum-iRBC 
from three independent biological replicates, were divided by the corresponding average values 
derived from samples harvested at time (0hr) to generate the corresponding ratios. Ratios were 
log₂ transformed and plotted on a colour dynamic range scale. Rows correspond to metabolites 
measured by LC-MS/MS. Columns correspond to the time course from 0hr to 7hr for each of 
the two blocks. Green and red colours represent decreases and increases, respectively. Black 
colour indicates the baseline. Abbreviations: DHAP, dihydroxyaceton phosphate; G-3-P, 
glycerol-3-phosphate; PEP, phosphoenol pyruvate.    
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4.3.2. Biochemical time-dependent of metabolites profile in RBC and iRBC 
The findings described in the previous metabolomics analysis section (section 4.3.1) 
were basically used to distinguish the general metabolomics modulation between RBC 
and iRBC by P. falciparum. In this section, average concentration values at each time-
point obtained using RBC and enriched trophozoite-stage P. falciparum-iRBC from 
independent biological replicates were divided by the corresponding average values 
derived from samples collected at time zero to generate the corresponding fold change 
ratio. Time-dependent graphs for RBC and iRBC were plotted using GraphPad Prism 
5.0 (GraphPad Software Inc.). 
 
The glucose utilization in iRBC was notably double that of RBC at 7 hr timepoint 
(Figure 4.8 A). Consequently, the production of dihydroxyaceton phosphate (DHAP), 
glycerol-l-phosphate (G-3-P), phosphoenol pyruvate (PEP) and lactate was remarkably 
higher in iRBC than those of RBC by at least 15 fold at 7 hr timepoint (Figure 4.8 B, C, 
D and E). 
 
Tricarboxylic Acid (TCA) intermediates were detected in iRBC and RBC. These 
include 2-oxoglutarate, (iso)-citrate, oxaloacetate, succinate, fumarate and malate. The 
levels of these TCA intermediates were considerably higher in iRBC than those in RBC 
by at least 1 fold at 7 hr timepoint (Figure 4.9 A, B, C, D, E and F).   
 
The amino acid trends were different in RBC and iRBC. Specifically, iRBC showed a 
substantial utilization of glutamine and asparagine compared to RBC by at least 0.5 fold 
at 7 hr timepoint (Figure 4.10 A and C). In addition, there was a variable increase trend 
in the production of glutamate, aspartate, alanine and histidine in iRBC compared to 
RBC during the 7 hr time point incubation time (Figure 4.10 B, D, E and F). Moreover, 
iRBC demonstrated an increase in the generation of proline, ornithine and citrulline 
compared to RBC (Figure 4.11 B, C and D). An iRBC showed an increase in the 
utilization of arginine, methionine and lysine as compared to RBC during at least the 
last three hours of incubation (Figure 4.11 A, E and F). Furthermore, there was an 
obvious trends in the utilization of (iso)-leucine, threonine, phenylalanine, tryptophan 
and tyrosine in iRBC compared to RBC by at least 0.5 fold at 7 hr time point (Figure 
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4.12 A, C, E, F and G). There were no obvious changes observed in valine and serine 
levels between RBC and iRBC (Figure 4.12 B and D).    
 
Pyrimidine intermediates were detected in iRBC but not in RBC. Carbamoyl-l-asparate 
was utilized whilst dihydroorotate and orotate were produced in iRBC (Figure 4.13 A, B 
and C). There was no significant change noted in the production of purine intermediate, 
hypoxanthine, between RBC and iRBC except at the last two hours of incubation when 
hypoxanthine started to upsurge (Figure 4.13 D).  
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Figure 4.8: Time-dependent curves of anaerobic glycolysis intermediates in RBC and 
iRBC.  
Anaerobic glycolysis intermediates level including (A) glucose, (B) DHAP (C) G-3-P (D) PEP 
and (E) Lactate were determined in RBC (open circle) and trophozoite-stage P. falciparum-
iRBC (closed circle) by LC-MS/MS. Time-dependent curve of (A) glucose showed notable 
increase in its consumption in iRBC compared to RBC. As a result, remarkable production of 
glycolysis intermediates including (B) DHAP (C) G-3-P (D) PEP and (E) Lactate were observed 
in iRBC as compared to RBC. The points represent the mean ± SEM of at least duplicate 
independent experiments. 
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Figure 4.9: Time-dependent curves of TCA intermediates in RBC and iRBC.  
TCA intermediates level including (A) 2-oxoglutarate, (B) (iso)-citrate (C) oxaloacetate (D) 
succinate, (E) fumarate and (F) malate were determined in RBC (open circle) and trophozoite-
stage P. falciparum-iRBC (closed circle) by LC-MS/MS. Data showed the existence and 
prominent increase of all TCA intermediates targeted in iRBC compared to RBC. The points 
represent the mean ± SEM of at least duplicate independent experiments.  
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Figure 4.10: Time-dependent curves of amino acids in RBC and iRBC.  
Amino acids level of (A) glutamine, (B) glutamate, (C) asparagine, (D) aspartate, (E) alanine 
and (F) histidine that were determined in RBC (open circle) and trophozoite-stage P. 
falciparum-iRBC (closed circle) by LC-MS/MS.  Data showed an increase in the production of 
(B) glutamate, (D) aspartate, (E) alanine and (F) histidine in iRBC compared to RBC. In 
addition, iRBC showed an increase in the utilization of (A) glutamine and (C) asparagine 
compared to RBC. The points represent the mean ± SEM of at least duplicate independent 
experiments. 
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Figure 4.11: Time-dependent curves of amino acids in RBC and iRBC.  
Amino acids level including (A) arginine, (B) proline, (C) ornithine, (D) citrulline, (E) 
methionine and (F) lysine were determined in RBC (open circle) and trophozoite-stage P. 
falciparum-iRBC (closed circle) by LC-MS/MS. Data showed increase in the production of (B) 
proline, (C) ornithine and (D) citrulline in iRBC compared to RBC. In addition, iRBC showed 
an increase in the utilization of (A) arginine, (E) methionine and (F) lysine as compared to 
RBC. The points represent the mean ± SEM of at least duplicate independent experiments.  
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Figure 4.12: Time-dependent curves of amino acids in RBC and iRBC.  
Amino acids level including (A) (iso)-leucine, (B) valine, (C) threonine, (D) serine, (E) 
phenylalanine, (F) tryptophan and (G) tyrosine were determined in RBC (open circle) and 
trophozoite-stage P. falciparum-iRBC (closed circle) by LC-MS/MS. Data showed an 
utilization trends of (A) (iso)-leucine, (C) threonine, (E) phenylalanine, (F) tryptophan and (G) 
tyrosine in iRBC compared to RBC. There was no obvious differences observed in (B) valine 
and (D) serine levels between RBC and iRBC. The points represent the mean ± SEM of at least 
duplicate independent experiments.  
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Figure 4.13: Time-dependent curves of pyrimidine and purine intermediates in RBC and 
iRBC.  
Pyrimidne intermediates level including (A) carbamoyl-l-aspartate, (B) dihydroorotate and (C) 
orotate; and purine intermediate level including (D) hypoxanthine were determined in RBC 
(open circle) and trophozoite-stage P. falciparum-iRBC (closed circle) by LC-MS/MS. Data  
showed the existence and an increase in the utilization of (C) carbamoyl-l-aspartate alongside an 
increase production of  (E) dihydroorotate and (F) orotate in iRBC as compared to RBC. There 
were no changes in (D) hypoxanthine level between RBC and iRBC expect at the last two hours 
of incubation. The points represent the mean ± SEM of at least duplicate independent 
experiments.  
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 Discussion 4.4.
The metabolomics studies in this chapter and the subsequent chapters (5, 6 and 7) were 
carried out in accordance with the Metabolomics Standards Initiative (MSI) guidelines 
for the in vitro biology/microbiology context http://msi-workgroups.sourceforge.net/.  
The metabolomics analysis PCA and PLS-DA demonstrated the occurrence of distinct 
clustering separation between RBC and iRBC by P. falciparum suggesting the 
differences and perhaps uniqueness of overall metabolism in RBC and iRBC. In 
addition, loading plots for PCA and PLS-DA revealed the major metabolites that could 
be attributed to the separation seen in PCA and PLS-DA. These include carbamoyl-l-
aspartate, dihydroorotate and orotate. Therefore, it appears that the major difference 
between RBC and iRBC is in the existence of pyrimidine intermediates. This was 
further strengthened by VIP score showing that pyrimidine intermediates, carbamoyl-l-
aspartate, dihydroorotate and orotate had VIP score > 1 indicating that they were the 
prominent metabolites differentiating RBC and iRBC. This is consistent with what has 
been clearly established about RBC in that it does not synthesize pyrimidine  (Tax et al., 
1979) and iRBC by P. falciparum synthesizes pyrimidine de novo (Walsh and Sherman, 
1968a, Walsh and Sherman, 1968b, Gutteridge and Trigg, 1970, Gutteridge et al., 1979, 
Gero et al., 1984, Gero and Osullivan, 1990). In addition, the biochemical time-
dependent profile of orotate biosynthesis showed this by the constant conversion of 
carbamoyl-l-aspartate to dihydroorotate which is then catalysed to orotate. This 
demonstrates the demand required for DNA and RNA synthesis during the transition 
stage from trophozoite to schizont. This demonstration is in agreement with a 
transcriptomic study of P. falciparum cycle showing that pyrimidine and purine 
enzymes transcript peak at approximately 18-22 hpi (hour post-invasion) (Bozdech et 
al., 2003). Additionally, only hypoxanthine as purine intermediate was detected by the 
LC-MS/MS while the remaining purine intermediates were below LOD. It has been 
noted that RBC could be an important source of purines for the synthesis of 
Plasmodium nucleic acid (Bungener, 1967). RBC contains relatively high concentration 
of purines that its metabolism acts primarily to regenerate intracellular stores of ATP 
(Walsh, 1998, Sherman, 1979). This ATP undergoes normal turnover to adenosine and 
inosine (Walsh, 1998). When RBCs are deteriorated due to age or upon invasion by 
Plasmodium, ATP is catalysed through sequential biochemical reactions leading to 
significant amounts of hypoxanthine (Sherman, 1979, Bishop, 1960, Bishop, 1961). 
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This explains what was observed in the biochemical time-dependent findings that there 
were no changes in the hypoxanthine levels between iRBC and RBC except in the last 
two hours of the time course. This is due to the extra requirements of parasite during the 
transition stage from trophozoite to schizont to salvage hypoxanthine for DNA and 
RNA synthesis in purine metabolism. 
Furthermore, it is well documented that mature human RBCs do not consume oxygen 
and do not have mitochondria (Schweiger, 1962). Instead, RBCs carry  out anaerobic 
glycolysis to meet their energy needs (Prankerd, 1955, Bishop, 1964). It was noted from 
this chapter that both RBC and iRBC carried out fermentation of glucose leading to 
lactate as the major end-product. However, it was observed from the biochemical time-
dependent findings that iRBC by P. falciparum consumed more glucose than that of 
RBC. It has been reported that  P. falciparum-iRBC consumed glucose up to 100 times 
as compared to RBC (Roth Jr, 1990). The upsurge of glucose consumption observed in 
the findings of iRBC in this chapter resulted in an increase in the generation of expected 
major end-products including lactate, glycerol-3-phosphate (G-3-P) and alanine. This 
findings is consistent with results obtained showing that NMR analysis of P. falciparum 
parasite incubated in 
13
C-glucose-supplemented media enabled the detection of  five 
major end-products including pyruvate, lactate, alanine, G-3-P and glycerol (Lian et al., 
2009). However, pyruvate and glycerol could not be detected by the present LC-
MS/MS-based system because of their poor ionization potential. Therefore, it could be 
suggested here that a combinatorial approach (NMR and LC-MS/MS) is critical to 
attaining the most comprehensive analysis of small metabolites in a biological sample. 
Additionally, it appears from the results presented here that the proportional increase of 
G-3-P over time indicates that P. falciparum possess a G-3-P shuttle which converts 
dihydroxyacetone phosphate (DHAP) to G-3-P by a cytosolic glycerol-3-phosphate 
dehydrogenase (G3PDH) leading to reoxidation of cytosolic NADH, a glycolysis by-
product (Lian et al., 2009, Danne et al., 2013). G-3-P is then converted to DHAP in the 
mitochondria by a membrane bound mitochondrial G3PDH which contributing to the 
generation of reduced form of ubiquinone in the mitochondrial respiratory chain (Danne 
et al., 2013). Therefore, it could be supposed here that the G-3-P shuttle functions as 
link between glycolysis and mitochondrial respiratory chain.  
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Moreover, carbon dioxide (CO2) fixation has been studied in P. falciparum (Blum and 
Ginsburg, 1984), P. knowlesi (Sherman and Ting, 1968) and P. lophurae  (Sherman and 
Ting, 1966) demonstrating that radiolabeled CO2 was fixed into three major amino acids 
namely alanine, aspartate and glutamate probably through concerted enzymatic action 
of carboxykinases followed by transaminases. This was supported by the findings in 
biochemical time-dependent experiments demonstrating that there was a distinguished 
increase in the production of alanine, glutamate and aspartate in P. falciparum-iRBC 
when compared to RBC. However, it has been found recently that fumarate is converted 
to aspartate then incorporated into proteins and nucleic acid synthesis of P. falciparum 
(Bulusu et al., 2011, Jayaraman et al., 2012). This finding is interesting because it 
explains why aspartate level in P. falciparum-iRBC increased at the first few hours of 
the time course and then decreased in the last few hours of the incubation owing to the 
high need for DNA and RNA synthesis during the transition stage from trophozoite to 
schizont. In addition, iRBC showed significant utilization for asparagine compared to 
RBC suggesting, perhaps a similar demand in nucleic acid synthesis as noted in the 
production of aspartate. Furthermore, the notable increase observed in the production of 
alanine and histidine is consistent with the recent metabolomics study showing that 
alanine and histidine were increased significantly in trophozoite stage indicating the 
initiation of hemoglobin digestion (Olszewski et al., 2009). Nevertheless, it has been 
noted that alanine and histidine were also significantly accumulated in the extracellular 
media suggesting that the parasite only incorporates a fraction of the haemoglobin-
derived amino acids into protein while it excreting the excess as waste (Olszewski et al., 
2009). Therefore, it might be that the amino acids produced through CO2 fixation are 
not readily incorporated into proteins because these amino acids, which have been 
generated through transamination reactions, can interact with pathways 
contributing perhaps in energy metabolism to serve as a fuel source. In addition, some 
amino acids might also serve as precursors or components in other metabolic pathways 
such as aspartate, which involves in pyrimidine and purine metabolism.  
In contrast, a metabolomic studies conducted recently on human RBC has shown that 
there are three possible pathways contributing to the de novo synthesis of glutamate via 
alanine aminotransferase, aspartate aminotransferase and glutamine aminohydrolase 
(Ellinger et al., 2011). Additionally, it has been shown that glucose consumption by 
RBC is devoted to de novo alanine production (Ellinger et al., 2011, Lewis et al., 2009). 
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On the other hand, it has been found that there are few stages of TCA cycle in human 
RBC and this cycle is incompletely represented in RBC (Prankerd, 1955). Human RBC 
has been shown to possess high activities of malate dehydrogenase and fumarase 
(Shrago, 1965, Quastel, 1931). Although TCA intermediates including 2-oxoglutarate, 
(iso)-citrate, oxaloacetate, succinate, fumarate and malate were detected in RBC, their 
levels were noticeably lower than that of iRBC. This gives two indications; one is that 
RBC possesses the enzymes required for generating these TCA intermediates but not 
necessarily a functional TCA cycle because of a lack of mitochondria in human RBC. 
The other indication is that P. falciparum-iRBC has functional TCA cycle represented 
by the high production in TCA intermediates as compared to RBC. Both indications are 
correct and they are consistent with the recent retracted article of ‘‘branched TCA 
metabolism in P. falciparum’’ from Llinas’s group (Olszewski et al., 2013). In other 
words, it was thought that P. falciparum operates bifurcated TCA cycle with part of it 
being oxidative and the other part being reductive, and this cycle is largely disconnected 
from glycolysis (Olszewski et al., 2011). However, this is not valid any longer because 
Llinas and his co-worker stated in their retraction that the reductive flux, which was 
thought to be occurred in the parasite, was due to an excessive interference from the 
RBC (Olszewski et al., 2013). This explains why some of TCA intermediates were seen 
in RBC experiments of this chapter. In addition, it has therefore been confirmed that P. 
falciparum operates an oxidative TCA cycle (Olszewski et al., 2013). Moreover, it has 
been postulated that the main metabolic functions of the TCA cycle in the malaria 
parasite is the production of succinyl-CoA for haem biosynthesis (Ginsburg, 2010). 
However, because  P. falciparum cannot convert citrate to acetyl-CoA, RBC possess the 
appropriate enzyme (ATPdependent citrate lyase) for this conversion resulting in 
generation of acetyl-CoA that is shuttled back to the parasite (Ginsburg, 2010).  
Moreover, the role of human RBC in amino acids metabolism remains obscure. It has 
been thought that RBC neither utilize amino acids for protein synthesis nor having the 
capacity for the degradation (Harris, 1979). Nonetheless, RBC has been shown to have 
a dynamic role that involves in the compartmentation of amino acids between RBC and 
plasma in addition to perhaps transporting amino acids between tissues (Aoki et al., 
1976, Pozefsky et al., 1969). The data showed that RBC might participate in the 
production of ornithine suggesting the ability of RBC to convert arginine to ornithine. 
This data is in agreement with the studies conducted on intact human RBC showing the 
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functionality of arginase in converting arginine to ornithine (Williams and Phang, 
1982).  Also, it has been reported that although RBC contributes to the production of 
ornithine, it is unlikely it has a significant role in urea formation because of the absence 
of urea-cycles enzymes such as ornithine carbamoyltransferase (Williams and Phang, 
1982). Therefore, it has been suggested that ornithine is secreted by the RBC and then 
converted by the peripheral tissues to proline, a critical constituent of proteins in 
peripheral tissues such as collagen (Phang et al., 1975, Smith and Phang, 1978). 
Recently, it has been shown that RBC can synthesis nitric oxide (NO) using arginine as 
a substrate (Ulker et al., 2009, Kleinbongard et al., 2006). In contrast to RBC, the 
results demonstrated that P. falciparum-iRBC utilized arginine as a precursor for 
ornithine and citrulline synthesis. The results showed a notable increase in the 
utilization of arginine in iRBC as compared to RBC. As a result, there was an increase 
in the production of ornithine and citrulline levels in iRBC as compared to RBC. This is 
in agreement with a recent metabolomics observation demonstrating that incubating          
P .falciparum-iRBC in culture media supplemented with uniformly 
13
C
15
N-labeled L-
arginine resulted in depleting arginine to almost undetectable level which is coinciding 
in the generation of fully labelled ornithine and citrulline (Olszewski et al., 2009). 
Therefore, the results obtained in this chapter for arginine utilization and ornithine and 
citrulline production suggest the existence of urea cycle in P. falciaprum parasite. 
However, it has not been predicted in the P. falciparum genome that it is encoding nitric 
oxide synthase (NOS) or arginine deiminase for catalysing arginine to citrulline 
(Gardner et al., 2002). Conversely, previous biochemical study conducted on P. 
falciparum-iRBC showed that the parasite exhibit a high NOS for the synthesis of NO 
measured as citrulline and nitrate production (Ghigo et al., 1995). Therefore, it appears 
that the parasite has two pathways for catalysing arginine. One pathway is through 
arginase yielding ornithine, an important precursor for polyamines as well as proline. 
The other one is producing NO through the oxidation of arginine to citrulline. In 
addition, the significant formation of proline in iRBC indicates the involvement of 
ornithine aminotransferase in the ultimate production of proline from ornithine.  
Moreover, the data of iRBC showed an evident trends of the utilization of several amino 
acids including methionine, lysine, (iso)-leucine, threonine, phenylalanine, tryptophan 
and tyrosine compared to RBC. It has been noted that human haemoglobin is a poor 
source of methionine, glutamine, glutamate, cysteine and contains no (iso)-leucine 
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(Francis et al., 1997). In addition, it has been previously found that P. falciparum-iRBC 
can be maintained only when the culture media is provided with the five amino acids, 
including cysteine, glutamine, glutamate, methionine and (iso)-leucine, that are lacking 
or present in insignificant amount in the haemoglobin (Divo et al., 1985a). Therefore, 
this explains the parasite need for exogenously acquisition of several amino acids 
particularly (iso)-leucine. Consistent with a previous report (Liu et al., 2006), it has 
been shown that the trophozoite stage of P. falciparum can grow and develop in a 
medium containing a single amino acid, (iso)-leucine. Moreover, as in agreement with 
the previous study, it has been reported that new permeability pathway (NPP) is induced 
at the trophozoite stage of P. falciparum in order to increase the  permeability of several 
amino acids including valine, serine, threonine, (iso)-leucine (Ginsburg et al., 1985). In 
addition, the high utilization observed in the iRBC for (iso)-leucine is also consistent 
with observation of Kirk’s lab showing that the rate of transport of (iso)-leucine into 
mature trophozoite stage of P. falciparum-iRBC is increased to ~5-fold than that of 
RBC (Martin and Kirk, 2007).  
Overall, it appears that the metabolomics approach revealed that P. falciparum-iRBC 
modulates and alters the metabolism of the host RBC by exploiting to its own end. In 
addition, the aforementioned discussion of the results suggests that P. falciparum-iRBC 
parasite developed an extremely specialized metabolic system wherein the main source 
of cellular ATP in asexual stages of the parasite comes from anaerobic glycolysis and 
the mitochondria appears to play a minimal biochemical metabolic role in the parasite. 
Therefore, recent advances in metabolomics research expand further the current 
understanding of parasite biology as well as the malaria disease status. Furthermore, 
metabolomic studies are a highly useful approach in determining the metabolic 
differences between phenotypically divergent strains and in revealing the mode of 
action for poorly characterized antimalarial drugs and inhibitors. Moreover, integrated 
approaches of concurrent transcriptomic, proteomic and metabolomic profiles will 
allow investigating of the interconnections between enzyme expression, protein and 
metabolite levels. Likewise, the data of this chapter as well as the metabolomics 
platform will provide a powerful tool to a further investigation of important metabolic 
pathways and elucidate P. falciparum metabolome response to physiologically relevant 
perturbations such as drug exposures. Therefore, in order to get a holistic view about the 
biology of P. falciparum parasite, a pharmacomatabolomics approach has been 
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undertaken in the subsequent chapters to investigate the role of two essential organelles 
namely; mitochondria and digestive vacuole.  
With regards to the limitation of this chapter, although the metabolomics platform used 
in this chapter was optimized (refer to chapter 3) to a higher sensitivity than that of used 
for the next chapter (5), the detection of bioenergetics/redox couples, UMP, UDP, UTP, 
TTP, CTP, and GTP was under the limit of detection in the parasite samples as well as 
RBC. This is could be explained as the presence of inadequate parasite materials. In 
addition, it has been noted that core metabolites intermediate and cofactors are required 
to be biosynthesized by the organism itself making these metabolites present in low 
levels, often more than 10,000-fold less than the most abundant metabolites (Reaves 
and Rabinowitz, 2011, Bennett et al., 2009). Moreover, the use of HGMS in 
metabolomics studies for P. falciparum is hampered by limited column capacity, 
inconsistent separation purities and high costs.  
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CHAPTER 5  
Pharmacometabolomics Study of Plasmodium 
falciparum Mitochondria: I 
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 Introduction 5.1.
Having developed a metabolomics platform for analysis of core P. falciparum 
metabolism, in this chapter, the interplay of the parasite mitochondrion with core 
metabolism was investigated. This work was aided by the availability of transgenic 
strains resistant to atovaquone and in house ETC-specific inhibitors. 
The role of P. falciparum mitochondria has long been a matter of dispute due to the fact 
that malaria parasites rely on glucose fermentation for their ATP production (Roth et al., 
1988, Roth Jr, 1990). There is also evidence that malaria parasite is microaerophilic 
growing in low O2 tension and elevated CO2 (Oaks Jr, 1991, Scheibel et al., 1979). The  
importance  of  mitochondrial  function  to parasite  growth  and  viability is uncertain 
because it has been thought that parasite  mitochondria   lack a  functional  Krebs  cycle 
(TCA cycle) and  other  mitochondrial  enzymes albeit there is an indication for the  
presence  of  a  rudimentary  ETC (Homewood et al., 1972, Blum and Ginsburg, 1984, 
Scheibel and Miller, 1969, Sherman, 1979). Malaria parasites possess a single acristae 
mitochondrion during their asexual blood cycle (Slomianny and Prensier, 1986, Divo et 
al., 1985b) which undergoes  distinct morphologies at different asexual and sexual 
stages (van Dooren et al., 2005) (Figure 5.1). The Plasmodium mitochondrion carries 
the smallest sequenced mitochondrial genome to date (6-kb in length) which encodes 
only three mitochondrial proteins, including cytochrome b, cytochrome c oxidase 
subunit I and cytochrome c oxidase subunit III; in addition to fragmented rRNA genes 
(Aldritt et al., 1989, Vaidya et al., 1989, Johnson et al., 2011, Feagin et al., 1997, 
Feagin, 1992). Therefore, the Plasmodium mitochondrion  must import from the cytosol 
the majority of proteins and tRNA to serve the physiological functions of protein 
synthesis and also for the upkeep of its separate genetic system (Vaidya and Mather, 
2009, Vaidya and Mather, 2005). However, the metabolic role of Plasmodium 
mitochondria has been a longstanding conundrum as it is thought to lack a functional 
TCA cycle and the main source of energy for these parasites is glycolysis (Sherman, 
1979, Bryant et al., 1964, Scheibel and Pflaum, 1970). However, genomic studies have 
revealed the presence of the genes necessary for a functional TCA cycle in Plasmodium 
and metabolite profiling has identified TCA intermediates, providing direct evidence of 
an active mitochondrion (Teng et al., 2009, Gardner et al., 2002, Olszewski et al., 
2009). In addition, the findings observed in chapter (4) confirm this by representing a 
prominent production increase in the TCA intermediates in P. falciparum-iRBC. This  
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is also supported by further metabolomics investigation that has recently been retracted 
that P. falciparum parasite operates an oxidative TCA cycle (Olszewski et al., 2013).  
 
 
Figure 5.1: Plasmodium falciparum mitochondrial morphology during asexual and sexual 
parasite stages.  
Development of the mitochondrion during the different stages of asexual cycle including ring, 
trophozoite, schizont and merozoite stages.  The mitochondrion is typically small and tubular in 
appearance during the early stages of asexual cycle but by mid schizogony, it becomes highly 
branched in its appearance after which the mitochondrion divides late in schizogony and a 
single mitochondrion segregates into each daughter merozoite. In contrast, there are several 
forms of mitochondria during the sexual stages of Plasmodium falciparum including the 
following forms: single, branched, and as a cluster of mitochondrial lobes towards the centre of 
the cell. (Adapted from Van Dooren et al., 2006)  
 
Additionally, perhaps because the RBC host loses its ability to synthesize 
pyrimidines de novo, Plasmodium parasites cannot salvage pyrimidines and therefore it 
is dependent on de novo pyrimidine biosynthesis (Hyde, 2007b, Cassera et al., 2011). 
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A number of early observations suggested that the malaria parasite mitochondrion is 
involved in this pyrimidine biosynthesis and the dihydroorotate dehydrogenase 
(DHODH) enzyme, which carries out  the fourth sequential step in this pathway, 
appears to be present in the mitochondrial electron transport chain (mtETC) and it is 
sensitive to a variety of mtETC inhibitors (Gutteridge et al., 1979, Gero et al., 1984, 
Gero et al., 1981a, Gero et al., 1981b, Prapunwattana et al., 1988, Ittarat et al., 1994, 
Scott et al., 1986, Heikkila et al., 2006, Heikkila et al., 2007). Therefore, it has been 
hypothesized that one of the vital roles of the Plasmodium parasite mitochondrion is to 
catalyze the oxidation of dihydrooroate to orotate for pyrimidine biosynthesis through 
the activity of DHODH (Figure 5.2). Several lines of evidence support this assumption 
wherein atovaquone, a specific bc1 complex inhibitor of the respiratory chain (Fry and 
Pudney, 1992), had shown a secondary effect on DHODH resulting  in the increase of 
carbamoyl-l-aspartate and a reduction in UTP, CTP, and dTTP (Hammond et al., 1985, 
Seymour et al., 1994, Seymour et al., 1997). A more recent study also confirmed this 
involvement between mitochondrial function and pyrimidine biosynthesis by the 
generation of an atovaquone-resistant phenotype in a transgenic P. falciparum parasite 
expressing ubiquinone-independent yeast DHODH (Painter et al., 2007). In addition, a 
further link between mitochondrial functions and purine pathway has been shown by the 
treatment of free-parasites with atovaquone which resulted in the inhibition of the 
conversion of fumarate to aspartate (Jayaraman et al., 2012, Bulusu et al., 2011). 
It was also noted that P. falciparum favours living in the low oxygen tension 
environment of the host cell (Scheibel et al., 1979). Nonetheless, Plasmodium parasites 
have a functional mitochondrial respiratory chain and an oxygen-requiring system that 
is essential for parasite development and survival. Consistent with this, the rate of 
oxygen consumption of P. falciparum and P. yoelii yoelii free parasites was affected by 
mtETC selective inhibitors demonstrating the functionality of mtETC during the 
asexual and sexual stages of the parasite (Krungkrai et al., 2000, Uyemura et al., 2004, 
Krungkrai et al., 1999) – although it is not clear from these studies whether the 
inhibition of O2-consumption was specific or a result of parasite death.  
In stark contrast to mammalian mitochondrial respiratory chain, the Plasmodium 
respiratory chain contains five different dehydrogenases including type II NADH 
dehydrogenase (PfNDH2 or rotenone-insensitive complex I), succinate:quinone 
oxidoreductase (SDH or complex II), malate:quinone oxidoreductase (MQO), 
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dihydroorotate dehydrogenase (DHODH) and glycerol-3-phosphate dehydrogenase 
(G3PDH) (Figure. 5.2). Each dehydrogenase potentially donates electrons to the ETC 
via redox reactions involving the oxidation of reducing-equivalent substrates coupled to 
the reduction of coenzyme ubiquinone (Q) to ubiquinol (QH2). The redox pair 
ubiquinone/ubiquinol can then shuttle back and forth in the bi-layer of the 
mitochondrial inner membrane creating what is called the Q-cycle. The downstream re-
oxidation reaction for ubiquinol (QH2) is then carried out by ubiquinol:cytochrome c 
oxidoreductase (cytochrome bc1 or complex III) resulting in the transfer of electrons 
from ubiquinol to a reduced form of cytochrome c,  which is then oxidized by a 
cytochrome c oxidase (Complex IV) resulting in the vectorial translocation of protons 
(H
+
) from the matrix, generating a transmembrane electrochemical potential (ΔΨm) and 
molecular oxygen to yield water (Fisher et al., 2009) (Figure 5.2). The transmembrane 
proton gradient is operated by an ATP synthase (complex V) to synthesize ATP 
although its contribution to the cellular ATP pool is believed to be minimal (Fry et al., 
1990) (Figure. 5.2).  
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Figure 5.2: Schematic drawing of the mitochondrial electron transport chain of 
Plasmodium falciparum.  
The chain consists of Complex I (PfNDH-type II NADH: quinone oxidoreductase), DHODH 
(dihydroorotate dehydrogenase), G3PDH (glycerol-3-phosphate dehydrogenase), MQO (malate 
quinone oxidoreductase), Complex II (succinate dehydrogenase), Complex III (cytochrome bc1 
complex), Cyt c (cytochrome c), Complex IV (cytochrome c oxidase) and Complex V 
(F1F0ATPase). Electrons are generated by mitochondrial dehydrogenases and passed to 
ubiquinone (Q). Re-oxidation of QH2 releases 2 H
+ 
to mitochondrial intermembrane space and 
passes electrons to bc1 complex. The electrons are continuously passed to cytochrome c. Finally, 
the cytochrome c uses the electrons and H
+
 to reduce O2 to H2O. The Plasmodium genome lacks 
F0 the subunit (subunits a and b) which is essential for ATP generation. Fisher et al., (2007) 
described the presence of a proton leak via the Plasmodium F1F0 respiratory chain to enable the 
maintenance of high transmembrane proton potential (ΔΨm). 
 
Since DHODH is known to be critical for growth of the parasites, it has been studied 
extensively as a target for drug development in the last decade (Baldwin et al., 2002, 
Heikkilä et al., 2007, Davies et al., 2009, Baldwin et al., 2005, Patel et al., 2008). 
DHODH, one of the mtETC dehydrogenases, is known to be a critical key enzyme in 
the pyimidine biosynthesis pathway, which is essential in the parasites because they 
cannot salvage pyrimidines. A study undertaken by (Painter et al., 2007) showed that 
transgenic P. falciparum parasites expressing yeast DHODH (non-ubiquinone 
dependent) can independently synthesize the pyrimidine precursors in the presence of 
mtETC inhibitors such as atovaquone (Painter et al., 2007). Therefore, it has been 
concluded that the major specific role of the mtETC in blood stages of P. falciparum 
parasites is to solely serve as an electron disposal system for DHODH and pyrimidine 
synthesis and hence DHODH is the only dehydrogenase in the mtETC viable as a 
chemotherapeutic target (Painter et al., 2007, Vaidya et al., 2008) (Figure. 5.3).  
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On the other hand, it has been reported and reviewed that P. falciparum type II NADH 
dehydrogenase (PfNDH2 or rotenone-insensitive complex I) has been a promising 
subject for the development of a chemotherapeutic drug because PfNDH2 is missing the 
conventional large multisubunits of complex I that are found in most mammalian 
mitochondria and also it is not directly involved in proton pumping (Fisher et al., 2009, 
Dong et al., 2009, Biagini et al., 2006, Fisher et al., 2007). Therefore, it has been 
demonstrated that PfNDH2 inhibition resulted in the collapse of ΔΨm by starving the 
bc1 of the reduced form of ubiquinone (Biagini et al., 2006).  Fry and Beesley (1991) 
showed  previously that NADH-dependent respiration contributes ∼50% of the 
ubiquinol flux to the bc1 complex at maximal capacity compared to only 1% by 
DHODH (Fry and Beesley, 1991). 
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Figure 5.3: Schematic metabolic pathway of pyrimidine de novo synthesis and 
mitochondrial electron transport chain in Plasmodium falciparum.   
The diagram depicts that pyrimidine de novo synthesis is linked to the mitochondrial electron 
transport chain (mtETC) through dihydrooroate dehydrogenase enzyme. Enzymes involved in 
the de novo pyrimidine biosynthesis are indicated in orange-coloured boxes. Abbreviations: 
CPSII, Carbomoyl phosphate synthatase II; ACT, Aspartate carbamoyl transferase; DHO, 
Dihydroorotase; DHODH, Dihydroorotate dehydrogenase; OPRT, Orotate 
phosphoribosyltransferase; OMPDC, Orotidine 5'-monophosphate decarboxylase. 
 
In this regard, it seems from the aforementioned description of P. falciparum 
mitochondria and ETC that there are gaps and disagreement in understanding the 
metabolic role of this organelle which includes the function of certain components of 
the respiratory chain in the ETC and their link to other mitochondrial-related 
metabolism (e.g. pyrimidine biosynthesis). Therefore, the aim of this chapter was to 
determine whether using atovaquone (Figure 5.4A) as a proof-of-concept inhibitor to 
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perturb bc1 complex of mtETC in both sensitive and transgenic P. falciparum strains 
will result in the generation of the same metabolic fingerprints. Similarly, if the findings 
between sensitive and transgenic parasite strains were distinct, then a new lead 
compound (CK-2-68) (Figure 5.4B), that has been shown to have dual-target mode of 
action (MoA) effects on PfNDH2 and bc1 complex in nanomolar concentration 
(Pidathala et al., 2012), will be used in this study  to confirm the findings of 
atovaquone.  
                                             
 
Figure 5.4: Chemical Structure of (A) Atovaquone and (B) CK-2-68. 
 
To investigate this hypothesis, pharmacometabolomics approach was undertaken to 
examine the metabolic differences between sensitive and transgenic parasite strains 
upon drug addition.  
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 Materials and Methods 5.2.
5.2.1. Parasite culture  
P. falciparum sensitive 3D7 and transgenic 3D7-yDHOD∙GFP strains were maintained 
in synchronous cultures at 2% hematocrit as described previously (Trager and Jensen, 
1976). A transgenic derivative of parental strain P. falciparum 3D7, 3D7-
yDHODH·GFP, containing yeast DHODH gene was generated through electroporation 
of purified pHHyDHOD–GFP plasmid into ring stages of P. falciparum using a BioRad 
GenePulser (BioRad, UK) and was prepared by Dr. David Johnson, (Parasitology 
Department, Liverpool School of Tropical Medicine, UK). Purified pHHyDHOD∙GFP 
plasmid was generously provided by Professor Akhil Vaidya (Drexel University 
College of Medicine, Philadelphia, USA). This plasmid contains a human dihydrofolate 
reductase gene as a WR99210-selectable marker (Painter et al., 2007).  The transgenic 
parasites were grown and maintained in complete RPMI-1640 culture medium 
containing 2.5 nM of WR99210 (section 5.2.1.1) for the purpose of selectivity. Routine 
parasite culture system was thereafter followed as described in chapter 2 section 2.2.  
5.2.1.1. Preparation of WR99210-selectable marker 
WR99210, antifolate inhibitor, was purchased from Sigma-Aldrich (UK). The 
preparation of 10 mM stock of WR99210 (MW = 394.68 g/mol) was as follows:  3.9468 
mg of WR99210 was dissolved in 1 ml of DMSO. This 10 mM stock of WR99210 was 
further diluted to 250 uM stock after which it was labeled, and stored at -20 ⁰C for 
future use. 
5.2.2. High-Gradient Magnetic separation (HGMS) for trophozoite-stage parasite 
enrichment 
HGMS was conducted for trophozoite-stage P. flaciparum parasites as described 
previously (chapter 4, section 4.2.1).   
5.2.3. Haemocytometer for parasite counting  
Haemocytometer counting for the purified P. falciparum trophozoite-stage parasites 
was carried out as described previously (chapter 4, section 4.2.2).   
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5.2.4. Parasite cell metabolism quenching and metabolite extraction 
Briefly at this stage, the purified trophozoite-stage parasites (section 5.2.2) were 
subjected to a metabolomics experiment where they were incubated in culture media at 
37 °C. Subsequently, the parasites were exposed to a sub-lethal concentration (IC90) of 
perspective drugs. Afterwards, the parasites were removed and metabolically quenched 
in a time related manner. Metabolites were then extracted to be ready for the next stage 
of LC-MS/MS analysis (section 5.2.5).  
This metabolomics experimental protocol was carried out throughout this thesis, 
however, with minor modification in each experimental chapter. The enriched 
trophozoite-stage parasites (section 5.2. 2) were incubated with RPMI-1640 culture 
media (R8758, glutamine, and sodium bicarbonate) supplemented with 10% pooled 
human serum, 25 mM HEPES (pH 7.4) (VWR), 40 μM hypoxanthine (Sigma), and 20 
μM gentamicin sulfate (Sigma) at 37 °C under 3% O2/4% CO2 in N2 (described in 
chapter 2 sections 2.2.2 and 2.2.4) for a 7 hour time course. At predetermined time 
intervals, one volume of enriched-culture (~1 × 10
8
 parasites/mL)  was directly 
collected at t= 0 h and t= 0.5 h  intervals for metabolic quenching into three volumes of 
-20 ºC quenching solvent system [acidic acetonitrile/methanol/water (40:40:20 + 0.1M 
formic acid) spiked with internal standards] (section 5.2.2.1) (Rabinowitz and Kimball, 
2007). The IC90 concentrations of drugs was choosen for this chapter and the 
subsequent chapters because the IC50   from the preliminary data did not show any 
effect on the purified parasites. This is may be due to the highly parasitaemia (~95%) 
present for the experiment. The IC90 concentrations of atovaquone (2.5 nM) and CK-2-
68 (50 nM) (section 5.2.4.1) were then added at t= 1 h time point for corresponding 
drug-treated enriched-cultures. DMSO was added to untreated controls in an equivalent 
amount to that of the drug added. After quenching, the sample was kept at -80 ºC 
overnight. The sample was then centrifuged at 4500 rpm for 20 min with a pre-cooled 
rotor at 4 ºC. The supernatant was carefully transferred into a new tube and kept on ice 
whereas the cell debris was washed twice with three volumes of extraction solvent 
system [acetonitrile/methanol/water (40:40:20)] (chapter 3, section 3.2.2.5.1). All the 
supernatants for each individual sample were thereafter collected and pooled together 
into the corresponding sample tube. Afterwards, the extracted metabolite sample was 
concentrated under N2 gas flow in the fume hood by using the sample concentrator 
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system (Techne sample concentrator, Bibby Scientific Ltd, UK) until the sample was 
completely dry. The sample was then kept at -80 °C ready for LC-MS/MS analysis. 
 
5.2.4.1. Solvent and Drug Preparation 
All the solvents used to carry out the LC-MS/MS metabolomics experiments were 
HPLC grade as described in Chapter 2 unless otherwise stated. The solvents used for 
drug preparation depend on the solubility of the perspective drug. In this chapter, two 
drugs were used, namely atovaquone (MW = 366.84 g/mol) and CK-2-68 (MW = 
443.85 g/mol) which were weighed from solid powders to an appropriate amount in a 
previously autoclaved eppendorf tube. Stocks of 10 mM were prepared for atovaquone 
and CK-2-68 as follows:  3.66 mg of atovaqoune and 4.44 mg of CK-2-68 were 
dissolved in a 1 ml of dimethyl sulfoxide (DMSO, Sigma, UK). Both drug stocks were 
then labeled and stored at -20 ºC for no longer than a month. Final dilutions were 
performed with RPMI-1640 culture media and freshly made prior to commencing 
metabolomics experiment studies. 
5.2.5. LC-MS/MS instrumentation 
Briefly at this stage, sample preparation including parasite samples, external standards, 
authentic QCs, and blanks was carried out in this section aimed at LC-MS/MS. In 
addition, the chromatographic gradient condition and mass spectrometry tuning was 
initially set up for this chapter. Final improved LC-MS/MS platform is described in 
chapter 3 and was used throughout this thesis.     
5.2.5.1. Sample preparation 
The parasite sample preparation was carried out as follows: dried sample was taken out 
from -80 °C freezer and resuspended in one volume of freshly prepared mobile phase 
[(20 mM ammonium acetate + 20 mM ammonium hydroxide) in 95:5 water:acetonitrile 
(pH 9.45)] (Chapter 2, section 2.3.4). The resuspended sample was then transferred into 
an eppendorf tube and spun at high speed for 30 min at 4 °C. The supernatant was 
thereafter filtered using phenex-RC membrane filters (0.2 µm pore size, Phenomenex, 
USA) into a chromacol LC-MS/MS vial (Chromacol, Thermo Fisher Scientific Inc., 
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UK). The preparation of external standards, authentic QCs and blank was freshly 
carried out for each metabolomics experiment as described previously (chapter 3).   
5.2.5.2. Chromatographic separation  
Chromatographic separation was achieved using Luna aminopropyl column (250 mm × 
2 mm with a 5 μm particle size, Phenomenex, USA) connected to security guard packed 
with double-cartridge (4 mm × 2 mm, Phenomenex, USA) to maximize contaminant 
removal and extend the half-life of the HPLC column. HILIC column (described in 
chapter 2 and 3) was employed for the metabolite separation using an Accela 
Autosampler HPLC system (Thermo Fisher Scientific). The mobile phase consisted of 
solvent A [(20 mM ammonium acetate + 20 mM ammonium hydroxide) in 95:5 
water:acetonitrile (pH 9.45)] and solvent B (acetonitrile). The chromatographic 
gradients were as follows: t = 0, 15% A; t = 7 min, 100% A; t = 14 min, 100% A; t = 
16min, 15% A; t = 35 min, 15% A. Injection volume, flow rate, column temperature 
and autosampler temperature were set at 20 μL, 150 μL/min, 15 °C and 15 °C, 
respectively. The injection needle was washed with one volume of methanol/water 
(50:50) solution between injections to eliminate the problem of carryover between 
samples.   
5.2.5.3. Mass spectrometry configuration  
A TSQ Quantum Access™ Triple Stage Quadrupole mass spectrometer (Thermo 
Electron Corporation) equipped with electrospray ionization (ESI) was employed for 
the detection and analysis of metabolites. ESI spray voltage was 3,200 V. Nitrogen was 
used as sheath gas at 50 psi and as the auxiliary gas at 10 psi, and argon as the collision 
gas at 1.5 mTorr, with the capillary temperature at 320 °C. Scan time for each single 
reaction monitoring (SRM) event transition was 0.1 s with a scan width of 1 m/z. The 
instrument control, data acquisition, and data analysis were achieved by applying the 
Xcalibar software (Thermo Electron Corporation, version 2.0.7 release), which also 
controlled the chromatography system. 
5.2.6. Data treatment and analysis 
The independent biological replicates from both drug-treated and untreated controls 
were analyzed and the metabolite concentration was averaged at each time point. 
Metabolite concentration levels were quantified by applying a standard calibration 
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curve using standards of known concentration for each of the 23 selected reaction 
monitoring (SRM). However, the remaining metabolites described in Chapter 3 were 
below the limit of detection in the parasite samples for the method of this chapter. The 
signal for each metabolite was defined as the area under the curve (AUC) of the 
integrated peak. Each metabolite signal was normalized to the signal of the internal 
standard DL-arabinose (negative mode) or β-alanine (positive mode) in the same 
sample. All data were expressed as the normalized levels of a metabolite in the sample 
at any one time point to the number of purified trophozoite-stage parasites in untreated 
and drug-treated experiments. The metabolite concentrations in drug-treated parasites 
were divided by their corresponding concentration in the untreated control to present the 
untreated controls as a baseline. This ratio was combined in a dataset file and imported 
into MetaboAnalyst web-based software (http://www.metaboanalyst.ca) (Xia et al., 
2012, Xia et al., 2009), log2 transformed and analyzed by the different metabolomics 
analysis tools described previously (Chapter 4, section 4.2.5). 
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 Results 5.3.
Part of the findings obtained in this chapter was published in (Biagini et al., 2012). The 
metabolomics experiments carried out were conducted on two strains namely P. 
falciparum sensitive 3D7 and transgenic P. falciparum 3D7-yDHOD∙GFP. Both strains 
were exposed equally to a sub-lethal concentration of atovaquone (2.5 nM, IC50 0.8 ± 
0.1) after 1 h of incubation. Untreated parasite controls were exposed to equivalent 
DMSO concentrations to the drug treated experiments. In addition, the P. falciparum 
3D7 sensitive strain was also exposed to a sub-lethal concentration of CK-2-68 (50 nM, 
IC50 31 ± 3).    
The 23 metabolites targeted for this study were selected on the basis that they were the 
predominant metabolites involved in mitochondrial and related metabolism. These 
metabolites were associated with metabolic pathways including glycolysis, TCA cycle, 
pyrimidine biosynthesis, purine salvage, and amino acid metabolism. The dynamic 
changes of metabolites from purified parasites were monitored in a time related manner 
and the subsequent metabolite detection and comparative quantification were carried 
out using the LC-MS/MS targeted metabolomics approach. The quantified 23 
metabolites for each drug-treated and untreated group were included in one dataset. This 
dataset represented the ratio of normalized concentration of drug-treated/untreated 
parasites. The following findings were obtained from the metabolomics analysis of the 
dataset using metabolanalyst web-based software.   
5.3.1. Metabolomics analysis of P. falciparum parasites 
5.3.1.1. PCA and PLS-DA 
The 2-D score plot from PCA of normalized dataset revealed separate clusters of P. 
falciparum sensitive 3D7 and transgenic 3D7-yDHOD∙GFP strains, reflecting essential 
differences in the metabolites generated.  It reveals cluster overlap between atovaquone 
and CK-2-68 treated parasites, indicating commonalities in the mode of action (MoA) 
effect on the targeted metabolites (Figure 5.5 A). The 3-D score PCA plot was created 
to further examine the interrelation between atovaquone, CK-2-68 treated sensitive 
parasites and atovaquone-treated transgenic parasites. The 3-D score PCA plot 
demonstrated distinct separation among sensitive and transgenic treated parasite groups 
but not clear discrimination between atovaquone treated and CK-2-68 treated sensitive 
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parasites (Figure 5.5 B). A corresponding loading plot indicated that the divergence 
observed on PCA clustering was mainly based on differences in the relative amounts of 
carbamyol-l-aspartate and dihydroorotate, upstream intermediates of the pyrimidine 
biosynthesis pathway (Figure 5.5 C).   
The supervised clustering method PLS-DA was carried out to improve any occurrence 
of poor separation obtained within the PCA model for the atovaquone treated, CK-2-68 
treated sensitive parasites; and atovaquone-treated transgenic parasite. Yet again, a 
distinct clustering separation was observed in the 2-D PLS-DA between atovaquone 
treated and CK-2-68 treated sensitive parasites; and atovaquone-treated transgenic 
parasite (Figure 5.6 A). Interestingly, a clear divergence and separation was 
demonstrated in the 3-D PLS-DA among the three groups in the dataset: atovaquone 
treated, CK-2-68 treated sensitive parasites and atovaquone-treated transgenic parasite 
(Figure 5.6 B). A resultant loading plot showed that the distinguished divergence on 
PLS-DA clustering was consistent with that observed in the PCA loading plot which 
indicated carbamyol-l-aspartate and dihydroorotate as metabolic fingerprints (Figure 5.6 
C).   
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Figure 5.5: PCA score and loading plots for P. falciparum 3D7 sensitive and transgenic 
strains treated with atovaquone and CK-2-68.  
A) 2-D score plot shows the clustering of P. falciparum 3D7 sensitive strain treated with 
atovaquone (ATQ) (red circle) and CK-2-68 (green circle); and the clustering of P. falciparum 
3D7 transgenic strain treated with atovaquone (ATQ) (blue circle). Line boundary for each 
group represented a 95% confidence limit from each treatment centre.  B) 3-D score plot shows 
the clustering of P. falciparum 3D7 sensitive strain treated with atovaquone (ATQ) (red 
triangle) and CK-2-68 (green triangle); and the clustering of P. falciparum 3D7 transgenic strain 
treated with atovaquone (ATQ) (blue triangle). Panels A and B show distinctive separation of 
the transgenic strain from the sensitive strain. C) P. falciparum metabolites loading plot 
discriminate between various time points for the corresponding score plots (panel A and B) and 
reveal the metabolic fingerprints in carbamoyl-l-aspartate and dihydroorotate.   
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Figure 5.6: PLS-DA score and loading plots for Plasmodium falciparum 3D7 sensitive and 
transgenic strains treated with atovaquone and CK-2-68.  
A) 2-D score plot shows the clustering of P. falciparum 3D7 sensitive strain treated with 
atovaquone (ATQ) (red circle) and CK-2-68 (green circle); and the clustering of P. falciparum 
3D7 transgenic strain treated with atovaquone (ATQ) (blue circle). Line boundary for each 
group represented a 95% confidence limit from each treatment centre. B) 3-D score plot shows 
the clustering of P. falciparum 3D7 sensitive strain treated with atovaquone (ATQ) (red 
triangle) and CK-2-68 (green triangle); and the clustering of P. falciparum 3D7 transgenic strain 
treated with atovaquone (ATQ) (blue triangle). Panels A and B show distinctive separation of 
the transgenic strain from the sensitive strain in addition to clear segregation between 
atovaquone-treated and CK-2-68-treated P. falciparum 3D7 sensitive strain parasites. C) P. 
falciparum metabolites loading plot discriminate between various time points for the 
corresponding score plots (panel A and B) and reveal the metabolic fingerprints in carbamoyl-l-
aspartate and dihydroorotate. 
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5.1.1.1. Heat map for P. falciparum metabolome profiling    
The ratio of drug-treated/untreated dataset among all the three groups, atovaquone, CK-
2-68 treated sensitive parasites and atovaquone-treated transgenic parasite, were 
analysed by metaboanalyst web-based software and presented as a heat map for visual 
aids.  
The heat map highlights visually, by the use of colour, the relative difference among 
atovaquone, CK-2-68 treated sensitive parasites and atovaquone-treated transgenic 
parasites (Figure 5.7). It is visibly evident that the metabolomic profiles presented by 
heat map show that carbamoyl-l-aspartate and dihydroorotate in atovaquone-treated and 
CK-2-68-treated sensitive parasites display very similar increasing trends (Figure 5.7). 
However, it appears that DHAP, G-3-P and PEP profiles were different in atovaquone 
treated than that of CK-2-68 treated parasites. On the other hand, the trends observed in 
the profiles of carbamoyl-l-aspartate and dihydroorotate for atovaquone-treated 
transgenic parasites were entirely opposite to those seen in atovaquone-treated and CK-
2-68-treated sensitive parasites (Figure 5.7). There were no other clear metabolomic 
profile trends observed in other metabolites selected for this experiment.  
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Figure 5.7: Heat map of metabolome dynamics following the addition of drug at time 1hr 
(50 nM CK -2–68 or 2.5 nM atovaquone) to P. falciparum 3D7 and 3D7-
yDHODH·GFP parasites.  
Fold changes are relative to untreated controls.  Metabolite levels during the drug exposure 
course of atovaquone and CK-2-68 were normalized by purified parasite cell volume and 
expressed relative to the levels measured in the untreated controls. Ratios were log₂ transformed 
and plotted on a colour scale. Rows correspond to metabolites measured by LC-MS/MS. 
Columns correspond to hours post drug exposure for each of the three metabolomics 
experiments time courses. Green and red colours represent the log₂ ratio of drug-
treated/untreated decreases and increases, respectively. Black colour indicates the baseline. 
Values are averages of triplicate independent biological experiments. Abbreviations: DHAP, 
dihydroxyaceton phosphate; G-3-P, glycerol-3-phosphate; PEP, phosphoenol pyruvate.    
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5.1.2. Biochemical time-dependent metabolic fingerprinting in P. falciparum 
It was clear from the findings noted in loading plots of PCA and PLS-DA in addition to 
the results seen in the heat map that the metabolic fingerprints of P. falciparum 
mitochondria were carbamoyl-l-aspartate and dihydroorotate. The time course for the P. 
falciparum untreated controls and atovaquone and CK-2-68 treated parasite strains was 
carried out for 7 h and assayed metabolically. The comparative concentrations of 
metabolic fingerprints observed in the findings of metabolomics analysis were plotted 
using time-line graphs (Excel-microsoft office, 2010) and published as (Biagini et al., 
2012).   
The results showed that there was a notable accumulation in the amounts of carbamoyl-
l-aspartate and dihydroorotate following atovaquone and CK-2-68 addition to P. 
falciparum sensitive 3D7 strain (Figure 5.8). Conversely, there were no changes in 
carbamoyl-l-aspartate and dihydroorotate levels in atovaquone-treated transgenic 3D7-
yDHODH·GFP parasites (Figure 5.8). In addition, all the untreated parasite controls 
showed no variations in the concentration of carbamoyl-l-aspartate and dihydroorotate.     
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Figure 5.8: Time-dependent curves of (A) carbamoyl-l-aspartate and (B) dihydroorotate in 
drug-treated and untreated sensitive and transgenic strains of P. falciparum 
parasites.  
A) Carbamoyl-l-aspartate B) Dihydroorotate concentration levels were determined in 3D7 
untreated parasites (open brown triangle), atovaquone-treated 3D7 (closed brown triangle), 
untreated 3D7-yDHODH·GFP transgenic parasites (open red square), atovaquone-treated 3D7-
yDHODH·GFP transgenic parasites (closed red square), 3D7 untreated parasites (open blue 
circle) and CK-2-68-treated 3D7 (closed blue circle). 
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 Discussion  5.4.
The metabolic function of P. falciparum mitochondria has long been thought to be 
minimal because of the existence of anaerobic glycolysis in malaria parasites as they 
require low O2 and high CO2 for growth and they have acristae mitochondria (Scheibel 
and Miller, 1969, Sherman, 1979, Slomianny and Prensier, 1986). However, the seminal 
discovery of DHODH in malaria parasites showed that it was intimately connected to 
the ETC at the ubiquinone level (Gutteridge et al., 1979). A study carried out by 
Hammond el al (1985) showed that P. falciparum treated with atovaquone resulted in 
the inhibition of pyrimidine de novo synthesis (Hammond et al., 1985). The malaria 
parasite mitochondrion has been validated as a drug target after the discovery of 
atovaquone which target the mtETC at the level of the bc1 complex (Fry and Pudney, 
1992). Therefore, the findings described in this chapter show that the two metabolic 
fingerprints, carbamoyl-l-aspartate and dihydrooroate, generated following atovaquone 
addition to a sensitive strain of P. falciparum, resulted from the collapse in the ΔΨm 
leading to the indirect effect of atovaquone by disrupting DHODH. This is direct 
biochemical evidence for the site and MoA of atovaquone. In addition, the metabolic 
fingerprint findings for the atovaquone treated sensitive P. falciparum strain was 
consistent with the results observed previously when investigating the cytotoxicity 
effects of atovaquone on pyrimidine biosynthesis (Seymour et al., 1997, Seymour et al., 
1994, Hammond et al., 1985). This highlighted the significant linkage between mtETC 
and pyrimidine biosynthesis to the DHODH enzyme.         
Painter el at., (2007) carried out a transfection study to generate a transgenic                
P. falciparum strain expressing cytosolic yeast DHODH which is independent of 
mtETC (Painter et al., 2007). The transgenic P. falciparum strain was shown to be 
completely resistant to mtETC inhibitors (Painter et al., 2007). A metabolomics study 
was conducted on this transgenic 3D7-yDHOD∙GFP P. falciparum strain to examine the 
main metabolic differences between the sensitive and transgenic strains of P. 
falciparum upon atovaquone addition. Remarkably, both dimensions (2-D and 3-D) of 
PCA and PLS-DA analysis revealed a distinct segregation between sensitive and 
transgenic P. falciparum parasite strains treated with atovaquone, indicating the 
occurrence of a significant metabolic fingerprint producing this divergence of the 
strains. This divergence was examined further by loading plot to indicate the major 
metabolic fingerprints in both strains. Loading plots of PCA and PLS-DA indicated that 
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the major metabolic fingerprints were carbamoyl-l-aspartate and dihydroorotate 
signifying the metabolic link between pyrimidine biosynthesis and mtETC. In addition, 
the pyrimidine biosynthesis in the transgenic P. falciparum strain was not affected by 
the addition of atovaquone because of the presence of an alternative route of synthesis 
for orotate. Therefore, this cytosolic bypass provided by yDHODH was adequate to 
serve the critical step in pyrimidine de novo biosynthesis allowing the parasite to be 
independent of the mtETC. This was supported by conducting heat map analysis which 
showed clearly the clustering and metabolomics profiles of the parasites, demonstrating 
a distinct phenotypic signature between sensitive and transgenic parasites which 
occurred mainly in the upstream intermediates of the pyrimidine biosynthesis pathway.     
Painter et al (2007) and Vaidya et al (2008) concluded from their work on transgenic P. 
falciparum expressing yeast DHODH that the only dehydrogenase component of the 
mtETC with potential as a drug target is DHODH (Painter et al., 2007, Vaidya et al., 
2008). Therefore, atovaquone was used as a proof-of-concept antimalarial drug that is 
known to specifically target the bc1 complex in the mtETC and the findings show 
essential differences between sensitive and transgenic P. falciparum strains following 
atovaquone addition. An in-house lead compound, CK-2-68, that has been shown to 
have dual-target MoA effects on PfNDH2 and bc1 complex in  nanomolar concentration 
(Pidathala et al., 2012) was used in this metabolomics study to confirm the findings of 
atovaquone. The 2-D of both the PCA and the PLS-DA findings showed that CK-2-68-
treated and atovaquone-treated sensitive P. falciparum were grouped closely together 
(line boundary for each group represented a 95% confidence limit from each treatment 
centre) suggesting the commonalities in the MoA between atovaquone and CK-2-68. 
Further PCA and PLS-DA analysis was presented in 3-D plots which showed the 
noticeable aggregation of time points following the addition of CK-2-68 and 
atovaquone and each group was separated from each other. This shows the differences 
in the mode of action of each drug confirming that CK-2-68 targets a component in the 
mtETC other than bc1 which is PfNDH2 (Pidathala et al., 2012, Biagini et al., 2012). 
However, loading plots showed that the major metabolic fingerprints for CK-2-68 and 
atovaquone were carbamyol-l-aspartate and dihydroorotate. Nonetheless, the relative 
differences in the fumarate, succinate, DHAP, G-3-P and PEP profiles between CK-2-
68-treated and atovaquone-treated sensitive P. falciparum seems to be the cause for the 
divergence between both drugs. This suggests that atovaquone and CK-2-68 have 
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perhaps different indirect MoAs on glycolysis metabolism and some of the TCA 
intermediates. Furthermore, the biochemical time course for the generated metabolic 
fingerprints showed an accumulation in carbamoyl-l-aspartate and dihydroorotate 
following CK-2-68 and atovaquone addition to the sensitive parasite strain compared to 
the atovaquone-treated transgenic parasite strain and untreated controls.  
Overall, this pharmacometabolomics approach demonstrated the evidence that                   
P. falciparum mitochondrion is tightly linked to the pyrimidine biosynthesis pathway 
through a critical step centralized in one of the mtETC dehydrogenase components, 
DHODH. The findings of this chapter which presented a systemic perturbation of 
mitochondria by atovaquone and CK-2-68 aroused questions about the role of other 
mtETC components in pyrimidine biosynthesis. Therefore, the next chapter (6) will 
investigate further this link by targeting different mtETC components.     
The major limitation of this chapter was in analyzing the bioenergetics\redox couples, 
pyruvate, UMP, UDP, UTP, dCTP, CTP, GTP, carbamyol phosphate as they were 
below the limit of detection. 
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CHAPTER 6  
Pharmacometabolomics Study of Plasmodium 
falciparum Mitochondria: II 
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 Introduction 6.1.
The aim of this chapter is to further explore the findings obtained in the preceding 
chapter (5).  The metabolic role of the P. falciparum mitochondria under the influence 
of number of selective mitochondrial inhibitors is investigated and the mode of actions 
(MoAs) of these inhibitors are highlighted. 
 
The malaria parasite mitochondrion is a vital organelle comprising several essential 
enzymes. These enzymes were found to be important in sustaining a functional TCA 
cycle and in maintaining the membrane potential of the electron transport chain (ΔΨm) 
(Gardner et al., 2002, Krungkrai, 2004, Olszewski et al., 2013). The mitochondrial 
respiratory chain consists of five dehydrogenases which generate reduced coenzyme Q 
(CoQ).  CoQ in turn is re-oxidized by bc1 complex to feed the electron transport chain 
(Vaidya and Mather, 2005). Among these dehydrogenases is DHODH which appears, 
from the preliminary findings in chapter 5, to form a tight link between the pyrimidine 
biosynthesis pathway and mtETC (Figure 6.1). Therefore, it is likely this link is 
essential for the development and survival of asexual stages of malaria parasites as they 
cannot salvage pyrimidine (Gutteridge et al., 1979). 
 
Malaria parasites harbour DHODH type II. This enzyme is a mitochondrial membrane 
associated protein which catalyzes the oxidation of dihydroorotate to orotate and 
couples the pyrimidine biosynthesis to the respiratory chain by reducing the coenzyme 
ubiquinone (CoQ) to ubiquinol (Figure 6.1) (Krungkrai, 1995, Malmquist et al., 2008). 
It has been postulated that the major function of the P. falciparum respiratory chain is to 
regenerate CoQ required as an electron acceptor for DHODH and to maintain ΔΨm 
(Malmquist et al., 2008, Painter et al., 2007, Vaidya et al., 2008). Consistent with this, 
the inhibition of pyrimidine biosynthesis at DHODH level is suggested, from the 
observations obtained in Chapter 5, to be an indirect MoA of atovaquone. Atovaquone 
causes the loss of ΔΨm (and thus DHODH activity) via inhibition of the bc1 complex, 
eventually leading to parasite death (Figure 6.2). In addition, the metabolomics findings 
in Chapter 5 shows transgenic                   P. falciparum expressing cytosolic yeast 
DHODH became resistant to bc1 inhibitor (atovaquone) by synthesizing pyrimidine 
precursors independently to the mtETC. This is in accordance with a study by Painter et 
al. (2007) and highlights the essential role of PfDHODH which has become an 
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attractive potential drug target for the development of novel antimalarials (Phillips et 
al., 2008, Heikkilä et al., 2007, Baldwin et al., 2005, Patel et al., 2008). However, this 
raises several questions as to whether the inhibition of mitochondria with a number of 
selective inhibitors will lead to the same metabolic effect observed previously at the 
level of DHODH. 
 
 
 
 
Figure 6.1: Schematic representation of the contribution of mitochondrial electron 
transport chain in the pyrimidine biosynthesis pathway in P. falciparum.  
Enzymes involved in the de novo pyrimidine biosynthesis pathway are in pink boxes in red 
type. Abbreviations: CPSII, Carbomoyl phosphate synthatase II; ACT, Aspartate carbamoyl 
transferase; DHO, Dihydroorotase; DHODH, Dihydroorotate dehydrogenase; OPRT, Orotate 
phosphoribosyltransferase; OMPDC, Orotidine 5'-monophosphate decarboxylase; UMP, 
Uridine monophosphate. 
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Figure 6.2: Schematic representation of the indirect effect of atovaquone on pyrimidine 
biosynthesis pathway in P. falciparum.   
Atovaquone (ATQ) targets bc1 complex in the mitochondrial electron transport chain (mtETC) 
leading to the depolarization of mitochondrial membrane potential (ψm) and eventually parasite 
death. 
 
A handful of studies reported the indirect metabolic effect of atovaquone on pyrimdine 
biosynthesis and all of them were consistent in showing disruption of the pathway at the 
point of DHODH (Seymour et al., 1997, Seymour et al., 1994, Hammond et al., 1985). 
In addition, polarographic studies showed that the rate of mitochondrial oxygen 
consumption in P. falciparum was inhibited to various degrees by inhibitors that target 
each component of respiratory chain complexes I-IV in addition to targeting DHODH 
by 5-fluoroorotic acid (Krungkrai et al., 1999). In contrast, there is no study that shows 
the contribution of mtETC dehydrogenases and complexes I-IV on mitochondrial 
related metabolism (e.g. pyrimidine biosynthesis). In addition, Vaidya and his 
coworkers insist that DHODH is the only valid drug target in the mitochondria of         
P. falciparum (Painter et al., 2007, Vaidya et al., 2008). Conversely, both Biagini and 
Mozote propose that there are multiple drug targets within the P. falciparum 
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mitochondria (Biagini et al., 2006, Fisher et al., 2007, Biagini et al., 2008, Fisher et al., 
2008, Monzote and Gille, 2010, Biagini et al., 2012). In this regards, there is a gap in 
the current knowledge about the role of mtETC dehydrogenases and complexes I-IV in                  
P. falciparum mitochondrial related metabolism. 
 
P. falciparum was shown to express an ADP/ATP transporter that is located in the inner 
mitochondrial membrane (Hatin et al., 1992). Bongkrekic acid was shown to 
specifically inhibit the adenine nucleotide translocase (ADP/ATP translocase) of the 
mitochondria (Henderson and Lardy, 1970). Whether this mitochondrial transporter is 
vital to the P. falciparum mitochondrial related metabolism is yet to be explored in this 
study. In addition, fusidic acid (a potent inhibitor of the translation component of 
elongation factor G  which leads to the arresting of mitochondrial protein synthesis) has 
been suggested to have antimalarial activity but not as active as the known therapeutic 
antimalarial agents (e.g. chloroquine) (Black et al., 1985). Recently, fusidic acid was 
shown to specifically target P. falciparum mitochondria by arresting the parasite 
development. This confirmed reports using protein-reporter fusion which suggest that 
elongation factor G is a component of P. falciparum parasite mitochondria (Johnson et 
al., 2011). In addition, P. falciparum mitochondria rely on importing protein and tRNA 
for protein synthesis because mitochondrial genome lacks many genes typically found 
on the genome of other organisms including tRNA genes and subunits of NADH 
dehydrogenase (van Dooren et al., 2006). Therefore, the role of P. falciparum 
mitochondrial protein machinery synthesis in the mitochondria and mitochondrial 
related metabolism remains obscure.  
 
In this chapter, biologically selective inhibitors for specific electron transport chain 
complexes I-IV, mitochondrial ADP/ATP transporter and mitochondrial machinery 
protein synthesis were used to perturb metabolic pathways generating fingerprints of 
metabolite concentrations and fluxes in a time-related manner. Specifically, the 
inhibitors used were atovaquone, atovaquone-proguanil, CK-2-68, 5-fluoroorotic acid, 
potassium cyanide, thenoyltrifluoroacetone, bongkrekic acid and fusidic acid. Tables 
6.1 and 6.2 summarize the inhibitors used in this chapter and their proposed MoA as 
well as their IC90 values which were obtained from in-house laboratory data and used to 
carry out the pharmacometabolomic experiments of this chapter. Metabolite detection 
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and quantitation were conducted using LC-MS/MS targeted metabolomics approach as 
described previously (Chapter 3). 
 
Table 6.1: Drugs used and their proposed mode of action 
Compound Proposed Mode of Action 
Atovaquone Inhibits complex III (bc1)  
Atovaquone-Proguanil Inhibits complex III (bc1)  and sensitize ΔΨm 
CK-2-68 Inhibits alternative complex I (PfNDH2) and complex III (bc1) 
Proguanil Inhibits dihydrofolate reductase via its metabolite cycloguanil 
5-Flouroorotic acid Inhibits DHODH 
Thenoyltrifluoroacetone Inhibits complex II (succinate dehydrogenase) 
Potassium Cyanide Inhibits complex IV 
Bongkrekic acid Inhibits ADP/ATP mitochondrial transpoter 
Fusidic acid Inhibits elongation factor G in the mitochondrial protein synthesis machinery 
 
Abbreviations: ΔΨm mitochondrial membrane potential; DHODH, Dihydroorotate 
Dehydrogenase 
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 Materials and Methods  6.2.
6.2.1. High-Gradient Magnetic separation (HGMS) for trophozoite-stage 
parasites enrichment 
The parasite cultures followed by high gradient magnetic separation (HGMS) were 
conducted for trophozoite-stage P. flaciparum parasites as described previously (chapter 
4, section 4.2.1).   
.   
6.2.2. Haemocytometer for parasite counting  
Haemocytometer counting for the purified P. falciparum trophozoite-stage parasites 
was carried out as described previously (chapter 4, section 4.2.2).   
 
6.2.3. Parasite cells metabolism quenching and metabolites extraction 
Briefly at this stage, the purified trophozoite-stage parasites (section 6.2.1) were 
subjected to a metabolomics experiment where they were incubated in culture media at 
37 °C and subsequently exposed to drug pressure. After this the parasites were removed 
and metabolically quenched in a time related manner and finally the metabolites 
extracted to be ready for the next stage of LC-MS/MS analysis (section 6.2.4). This 
metabolomic experiment was conducted as described earlier (chapter 4 section 4.2.3) 
with the exception of the addition of drug in the study of this chapter. The IC90 
concentrations of atovaquone (2.5 nM), atovaquone-proguanil combination (2.5 nM + 1 
uM), CK-2-68 (50 nM), 5-flouroorotic acid (15 nM), bongkrekic acid (5 uM), 
potassium cyanide (1 mM), thenoyltrifluoroacetone (10 uM), proguanil (70 uM) and 
fusidic acid (200 uM) were added at 1 h time point for each set of the experiments (n= 
at least two independent replicates for each drug used) (Table 6.1). Untreated parasite 
controls were prepared in at least two independent biological experiments. The parasite 
metabolites sampling, quenching, extraction, drying and storing were performed as 
described beforehand (chapter 4, section 4.2.3) 
 
6.2.3.1. Solvents and Drugs Preparation 
All the solvents used to carry out the LC-MS/MS metabolomics experiments were 
HPLC grade as described in Chapter 2 unless otherwise stated. The solvents used for 
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drug preparation were different and depended on the solubility of the drug. 10mM 
stocks were prepared for the drugs listed in Table 6.2. These were labeled and stored at 
-20 ºC for no longer than a month. Final dilutions were performed with RPMI-1640 
culture media which was freshly made prior to the experiment. 
 
Table  6.2: Drugs used and their IC90 values. 
Drugs MW (g/mol) 
IC90 3D7 P.falciparum 
(nM)* 
Solvent Source 
ATQ 366.83 2.5 DMSO Sigma Aldrich 
CK-2-68 443.85 50 DMSO 
Prof.O’Neill, Chemistry Department, 
Liverpool University 
PG 290.19 70 
X 
10
3 
DMSO Sigma Aldrich 
5-FOA 174.09 15 DMSO Sigma Aldrich 
TTFA 222.18 10 
X 
10
3
 DMSO Sigma Aldrich 
KCN 65.12 1 
X 
10
6
 H2O Sigma Aldrich 
BK 486.60 5 
X 
10
3
 DMSO Sigma Aldrich 
FA 516.71 200 
X 
10
3
 DMSO Sigma Aldrich 
 
Abbreviations: ATQ, Atovaquone; PG, Proguanil; 5FOA, 5-flouroorotic acid; TTFA, 
Thenoyltrifluoroacetone; KCN, Potassium Cyanide; BK, Bongkrekic acid; FA, Fusidic acid; 
MW, Molecular Weight. *IC90 values were obtained from in-house laboratory data.. 
 
6.2.4. LC-MS/MS instrumentation 
Sample preparation including parasite samples, external standards, authentic QCs 
sample, and blanks were carried out in this section aimed at LC-MS/MS. In addition, 
chromatographic conditions and mass spectrometry configurations were set up ready for 
the samples processing. 
 
6.2.4.1. Samples preparation 
The parasite sample preparation was carried out as described previously (chapter 4, 
section 4.2.4.1). The preparation of external standards, authentic QC samples and 
blanks were freshly carried out for each metabolomics experiment as described 
previously (chapter 3, section 3.2.3.1).   
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6.2.4.2. Chromatographic separation  
Chromatographic separation was conducted as described earlier (chapter 3, section 
3.2.2.4).   
 
6.2.4.3. Mass spectrometry configuration 
The configuration of mass spectrometry was set up for positive and negative modes as 
described previously (chapter 3, section 3.2.2.3).  
 
6.2.5. Data treatment and analysis 
Metabolomics data of the biological replicates from all drugs treated parasites and 
untreated controls were analyzed as described previously (chapter 4 section 4.2.5).  
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 Results 6.3.
The metabolomics experiments carried out in this chapter were conducted only on the 
P. falciparum 3D7 strain. This strain was selected because of its robustness in 
continuous culture and sensitivity to various inhibitors and antimalarial drugs. Sets of 
metabolomic experiments were conducted on purified trophozoite-stage P. falciparum. 
After one hour of incubation, the enriched trophozoite-stage P. falciparum parasites 
were exposed to a sub-lethal concentration of one of the following inhibiotrs:  
atovaquone (2.5 nM), atovaquone-proguanil (2.5 nM + 1 µM), CK-2-68 (50 nM), 5-
fluoroorotic acid (15 nM), potassium cyanide (1 mM), bongkrekic acid (5 µM), 
thenoyltrifluoroacetone (10 µM), proguanil (70 µM) and fusidic acid (200 µM). 
Nothing was added to the untreated parasite controls.  
 
The 56 metabolites targeted for this study were selected on the basis that they are 
predominant metabolites in the mitochondria and mitochondrial related metabolism. 
These metabolites are associated with metabolic pathways including glycolysis, TCA 
cycle, pyrimidine biosynthesis, purine salvage, amino acids metabolism and 
bioenergetics/redox couples. However, only 34 metabolites were detected and 
quantified using the metabolomics approach described in chapter (3) whilst the 
remaining 22 metabolites were below the limit of detection. The dynamic changes of 
metabolites from purified parasites were monitored in a time related manner. The 
quantified 34 metabolites for each drug-treated and untreated group were included in 
one dataset. This dataset represented the mean of the biological replicates for each 
group and presented as fold change ratio that was normalized by the corresponding 
sample for each group collected at time zero. The following findings were obtained 
from the metabolomics analysis of the dataset using metabolanalyst web-based software 
(http://www.metaboanalyst.ca) (Xia et al., 2009, Xia et al., 2012) and the plotted line-
graphs data were performed with GraphPad Prism 5.0 (GraphPad Software Inc.). 
 
6.3.1. Metobolomics analysis of P. falciparum parasites 
Multivariate statistical analysis using principal component analysis (PCA) and partial 
least squares-discriminant analysis (PLS-DA) was performed on the log2 transformed 
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dataset (http://www.metaboanalyst.ca) generated by LC-MS/MS and normalized at time 
zero.  
 
6.3.1.1. PCA and PLS-DA 
The 2-D score plot from PCA and PLS-DA of normalized dataset revealed divergence 
between P. falciparum parasites treated with atovaquone, atovaquone-proguanil, CK-2-
68, 5-fluoroorotic acid, potassium cyanide and bongkrekic acid; and those treated with 
thenoyltrifluoroacetone, proguanil, and fusidic acid as well as untreated parasites 
controls (Figure 6.4A). This indicates the important differences in the inhibitors MoAs 
resulted in discrete separation by the different metabolites generated. In addition, the 2-
D score plot from PCA and PLS-DA showed that time course points of parasites treated 
with atovaquone, atovaquone-proguanil, CK-2-68, 5-fluoroorotic acid, potassium 
cyanide and bongkrekic acid were clustered very closely to each other suggesting the 
similarity in the MoA of these inhibitors on the parasite mitochondria (Figure 6.4A and 
6.5A). In contrast, time course points of untreated parasites and parasites treated with 
proguanil, thenoyltrifluoroacetone and fusidic acid  were also clustered near each other 
suggesting either these drugs had no specific MoA effect on mitochondria or the MoA 
effect was not strong as the separated groups mentioned above.  Further analysis was 
carried out using the 3-D of PCA and PLS-DA to observe a better clustering and 
positioning. The 3-D of PCA showed that the parasites treated with inhibitors that 
specifically target the different components of mtETC and ADP/ATP transporter were 
clustered almost together (Figure 6.4B). On the other hand, untreated parasites were 
grouped together with parasites treated with proguanil (Figure 6.4B). Parasites treated 
with fusidic acid were distinctly clustered almost separately from other treatments and 
untreated control indicating the specific MoA effect on different mitochondrial target 
other than respiratory chain (Figure 6.4B).  In contrast, the 3-D of PLS-DA showed 
distinctively four major clusters indicting the incidence of specific discrimination 
between the different inhibitors treated parasites as well as untreated control parasites 
(Figure 6.5B). Specifically, the 3-D of PLS-DA demonstrated that CK-2-68, cyanide 
and bongkrekic acid treated parasites were aggregated adjacently to each other although 
these inhibitors have different MoAs and also different specific targets including 
PfNDH2/bc1, complex IV and ADP/ATP translocase transporter, respectively. 
Conversely, parasites treated with atovaquone, atovaquone-proguanil and 5-fluoroorotic 
 175 
 
acid were shown to be grouped nearby each other although 5-fluoroorotic acid 
specifically targets DHODH while atovaquone does not, suggesting the commonalities 
in the overall MoAs of the drugs effect either directly or indirectly (Figure 6.5B). On 
the other hand, two more clusters were observed in the 3-D PLS-DA plot and both of 
them were distinctively separated from each other. This includes one cluster of 
untreated parasite controls and parasites treated with thenoyltrifluoroacetone, and in the 
other cluster parasites treated with fusidic acid and proguanil (Figure 6.5B). Overall, it 
was clearly noted in the 3-D PLS-DA plot that parasites treated with atovaquone, 
atovaquone-proguanil, CK-2-68, 5-fluoroorotic acid, potassium cyanide and bongkrekic 
acid were clustered in one side of the plot and untreated parasites control alongside 
parasites treated with thenoyltrifluoroacetone, proguanil, and fusidic acid were clustered 
in the opposite side (Figure 6.5B). 
 
The corresponding loading plots for PCA and PLSDA revealed that carbamoyl-l-
aspartate and dihydroorotate were the major metabolic fingerprints which accounted for 
the aforementioned differences in the clustering of different inhibitor treated parasites 
alongside the untreated parasite control (Figure 6.4C and 6.5C). Similarly, Variable 
Influence on Projection (VIP) score was used in metabolomics analysis to further 
enhance the major metabolites differences among all treatments and controls. VIP 
scores were calculated using the variability explained in PLS-DA. Metabolites with VIP 
score > 1 were considered the most important metabolites responsible for the 
differentiation of the parasites exposed to different inhibitors (Figure 6.6). VIP score 
showed that the most significant metabolites with score > 1 were DHAP, orotate, 
alanine, fumarate, carbamoyl-l-aspartate and dihydroorotate (Figure 6.6). However, 
carbamyol-l-aspartate and dihydroorotate were the merely metabolites with VIP score 
exceeding 3 whilst DHAP, orotate, alanine, fumarate had just borderline VIP score < 
1.5 suggesting that carbamoyl-l-aspartate and dihydroorotate were the prominent 
metabolic fingerprints (Figure 6.6).  
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Figure 6.4: PCA score and loading plots for P. falciparum 3D7 upon exposure to different 
drugs and inhibitors.   
A) 2-D score plot shows divergence of two main clusters. One cluster includes the P. 
falciparum treated with 5-flouroorotic acid (5-FOA, light blue circle), atovaquone (ATQ, dark 
blue circle), atovaquone-proguanil (ATQ+PG, green circle), bongkrekic acid (BK, light brown 
circle), CK-2-68 (red circle) and potassium cyanide (KCN, dark amber circle). The other cluster 
includes the untreated P. falciparum control (UN, dark brown circle) and P. falciparum treated 
with fusidic acid (FA, light amber circle), proguanil (PG, purple circle), thenoyltrifluoroacetone 
(TTFA, beige circle). Line boundary for each group represented a 95% confidence limit from 
each treatment centre. B) 3-D score plot shows the divergence of three main clusters. One 
cluster includes the clustering of P. falciparum treated with 5-flouroorotic acid (5-FOA, light 
blue triangle), atovaquone (ATQ, dark blue triangle), atovaquone-proguanil (ATQ+PG, green 
triangle), bongkrekic acid (BK, light brown triangle), CK-2-68 (red triangle), potassium cyanide 
(KCN, dark amber triangle) and thenoyltrifluoroacetone (TTFA, beige triangle). Second cluster 
includes the clustering of untreated P. falciaprum control (UN, dark brown triangle) and P. 
falciparum treated with proguanil (PG, purple triangle). Third cluster includes the clustering of 
P. falciparum treated with fusidic acid (FA, light amber triangle). C) P. falciparum metabolites 
loading plot discriminate between various time points for the corresponding score plots (panel A 
and B) and reveals the major metabolic fingerprints in carbamoyl-l-aspartate and 
dihydroorotate. Black arrow indicates the time zero (t=0) for untreated control and other drugs 
treatment that are all confined in the same position of 2-D and 3-D score plots. 
t=0 
t=0 
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Figure 6.5: PLS-DA score and loading plots for P. falciparum 3D7 upon exposure to 
different drugs and inhibitors.  
A) 2-D score plot shows divergence of two main clusters. One cluster includes the clustering of 
P. falciparum treated with 5-flouroorotic acid (5-FOA, light blue circle), atovaquone (ATQ, 
dark blue circle), atovaquone-proguanil (ATQ+PG, green circle), bongkrekic acid (BK, light 
brown circle), CK-2-68 (red circle) and potassium cyanide (KCN, dark amber circle). The other 
cluster includes the clustering of untreated P. falciparum control (UN, dark brown circle) and P. 
falciparum treated with fusidic acid (FA, light amber circle), proguanil (PG, purple circle), 
thenoyltrifluoroacetone (TTFA, beige circle). Line boundary for each group represented a 95% 
confidence limit from each treatment centre. B) 3-D score plot shows the divergence and 
discrimination of four main clusters. First cluster includes the clustering of untreated P. 
falciaprum control (UN, dark brown triangle) and P. falciparum treated with 
thenoyltrifluoroacetone (TTFA, beige triangle). Second cluster includes the clustering of P. 
falciparum treated with proguanil (PG, purple triangle) and fusidic acid (FA, light amber 
triangle). Third cluster includes the clustering of P. falciparum treated with 5-flouroorotic acid 
(5-FOA, light blue triangle), atovaquone (ATQ, dark blue triangle) and atovaquone-proguanil 
(ATQ+PG, green triangle). Fourth cluster includes the clustering of P. falciparum treated with 
bongkrekic acid (BK, light brown triangle), CK-2-68 (red triangle) and potassium cyanide 
(KCN, dark amber triangle). C) P. falciparum metabolites loading plot discriminate between 
various time points for the corresponding score plots (panel A and B) and reveals the major 
metabolic fingerprints in carbamoyl-l-aspartate and dihydroorotate.  Black arrow indicates the 
time zero (t=0) for untreated control and other drugs treatment that are all confined in the same 
position of 2-D and 3-D score plots. 
t=0 
t=0 
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Figure 6.6: Variable Influence on Projection (VIP) score plot for Plasmodium falciparum 
3D7 upon exposure to different drugs and inhibitors.  
Metabolite with VIP score > 1 was considered the most important metabolite responsible for the 
differentiation among the different drugs and inhibitors used to treated P. falciparum parasites. 
The coloured boxes on the right indicate the relative ratios of the corresponding metabolite in 
each group under study. Colour scale shows the colours gradient for the VIP score with dark red 
and dark green being the colours for high and low changed metabolites, respectively. VIP score 
plot shows that the most important metabolites responsible for differentiation were 
dihydroorotate and carbamoyl-l-aspartate. Fumarate, alanine, orotate and DHAP had borderline 
VIP score around 1. 
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6.3.1.2. Heat map for P. falciparum metabolome profiling    
The heat map visually demonstrates the relative difference of the dynamic changes of 
the P. falciparum metabolome upon exposure to different drugs and inhibitors including 
atovaquone, atovaquone-proguanil, CK-2-68, 5-flouroorotic acid, potassium cyanide, 
bongkrekic acid, thenoyltrifluoroacetone, proguanil and fusidic acid (Figure 6.7). It is 
visibly evident from the heat map that increasing trends in carbamoyl-l-aspartate and 
dihydroorotate occurs in P. falciparum parasites treated with mtETC selective drugs 
including atovaquone, atovaquone-proguanil, CK-2-68, 5-flouroorotic acid and 
potassium cyanide in addition to ADP/ATP translocase inhibitor, bongkrekic acid 
(Figure 6.7). In contrast, the trends observed in the profiles of carbamoyl-l-aspartate and 
dihydroorotate in the untreated control P. falciparum and P. falciparum parasites treated 
with thenoyltrifluoroacetone, proguanil and fusidic acid were entirely opposite to that of 
seen in aforementioned mtETC drugs and inhibitors (Figure 6.7).  
Interestingly, P. falciparum parasites treated with fusidic acid showed markedly 
cumulative changes in amino acids including glutamine, serine, asparagine, lysine, 
phenylalanine, tryptophan, tyrosine, threonine, valine, alanine, ornithine, citrulline and 
methionine (Figure 6.7). On the other hand, glutamate dynamic levels were noticeably 
diminished upon treating the parasite with fusidic acid (Figure 6.7). In addition, P. 
falciparum parasites treated with fusidic acid prominently showed a reduction in the 
dynamic levels of TCA intermediates including 2-oxoglutarate, (iso)-citrate, fumarate, 
succinate and malate (Figure 6.7).  
Moreover, the heat map presented in (Figure 6.7) summarized the relative fold changes 
ratio in P. falciparum following the addition of different drugs and inhibitors. Major and 
evident metabolite changes were highlighted in the aforementioned paragraphs. 
Detailed and specific explanations are presented as time-dependent graphs in the next 
section (6.3.2).       
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Figure 6.7: Heat map representation of P.falciparum 3D7 dynamics metabolome. 
Heat map shows a dynamic changes of 34 metabolites in untreated P. falciparum control and P. falciparum parasites treated after one hour of incubation with 
atovaquone (ATQ), atovaquone-proguanil (ATQ+PG), CK-2-68, 5-flouroorotic acid (5-FOA), potassium cyanide (KCN), bongkrekic acid (BK), 
thenoyltrifluoroacetone (TTFA), proguanil (PG) and fusidic acid (FA). Average values at each time-point obtained using purified trophozoite-staged from 
three independent biological replicates were divided by the corresponding average values derived from parasites harvested at time (0 hr) to generate the 
corresponding ratios. Ratios were log₂ transformed and plotted on a colour dynamic range scale. Rows correspond to metabolites measured by LC-MS/MS. 
Columns correspond to the time course from 0hr to 7hr for each of the ten blocks. Green and red colours represent decreases and increases, respectively. 
Black colour indicates the baseline. Abbreviations: DHAP, dihydroxyaceton phosphate; G-3-P, glycerol-3-phosphate; PEP, phosphoenol pyruvate.    
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6.3.2. Biochemical time–dependent of metabolites profile in P. falciparum parasite  
The findings described previously in the analysis section (section 6.3.1) were used to 
distinguish the MoAs of the drugs and inhibitors used to perturb the biological system 
of P. falciparum. Average concentration values at each time-point were obtained using 
purified trophozoite-stages from three biological replicates. These were divided by the 
corresponding average values derived from parasites collected prior to the addition of 
the respective drug to generate the corresponding fold change ratio. Time-dependent 
graphs for P. falciparum untreated control and P. falciparum treated with the addition of 
atovaquone, atovaquone-proguanil, CK-2-68, 5-flouroorotic acid, potassium cyanide, 
bongkrekic acid, thenoyltrifluoroacetone, proguanil and fusidic acid were plotted using 
GraphPad Prism 5.0 (GraphPad Software Inc.). 
 
It is clear that glucose level was notably utilized in untreated P. falciparum and P. 
falciparum treated with atovaquone, atovaquone-proguanil, CK-2-68, 5-flouroorotic 
acid, potassium cyanide, bongkrekic acid, thenoyltrifluoroacetone, proguanil and fusidic 
during the 7 hours incubation time (Figure 6.8 A, B, C, D, E, F, G, H and I). The 
production of phosphoenol pyruvate (PEP) among all drug treatments was higher than 
that of the untreated by at least 50 fold at 7 hr time point (Figure 6.11 A, B, C, D, E, F, 
G, H and I). Lactate production was also higher among all drug treatments except 
fusidic acid than that of untreated parasites by at least 15 fold at 7 hr timepoint (Figure 
6.12 A, B, C, D, E, F, G, H and I). In addition, the level of dihydroxyaceton phosphate 
(DHAP) was noticeably decreased upon treating the parasite with atovaquone, 
atovaquone-proguanil, potassium cyanide, thenoyltrifluoroacetone, proguanil and 
fusidic acid by at least 200 fold at 7 hr timepoint compared to untreated (Figure 6.9 A, 
B, E, G, H and I). In contrast, there was a slight upsurge in the level of DHAP in parasites 
treated with CK-2-68, 5-fluoroorotic acid and bongkrekic acid (Figure 6.9 C, D and F). The 
level of glycerol-3-phosphate (G-3-P) was increased by more than 10 fold at 7 hr 
timepoint in parasites treated with atovaquone, atovaquone-proguanil, bongkrekic acid, 
proguanil and fusidic acid as compared to untreated parasites (Figure 6.10 A, B, F, H and 
I). G-3-P was notably decreased by more than 20 fold in parasite treated with 
thenoyltrifluoroacetone as compared to untreated parasites (Figure 6.10 G). There were 
no obvious changes in the G-3-P levels between untreated parasites and parasites treated 
with CK-2-68, 5-fluoroorotic acid and potassium cyanide (Figure 6.10 C, D and E).   
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The mitochondrial selective drugs and inhibitors, including atovaquone, atovaquone-
proguanil, CK-2-68, 5-flouroorotic acid, potassium cyanide, bongkrekic acid, 
thenoyltrifluoroacetone and fusidic acid showed different patterns in the   Tricarboxylic 
Acid (TCA) intermediates compared to untreated. Specifically, P. falciaprum parasites 
treated with atovaquone and atovaquone-proguanil showed a notable increase in the 
levels of 2-oxoglutarate and succinate as compared to untreated parasites (Figure 6.13 & 
6.15 A and B). An evident increase of (iso)-citrate, fumarate and malate was observed  
in parasites following the addition of atovaquone-proguanil  (Figure 6.14, 6.16 & 6.18, 
B) but no clear changes were noted in the levels of fumarate, oxaloacetate and malate in 
parasites treated with atovaquone (Figure 6.16, 6.17 & 6.18 A). As expected, there were 
not any changes observed in the TCA intermediates in parasite treated with proguanil 
(Figures 6.13, 6.14, 6.15, 6.16, 6.17 & 6.18, H). CK-2-68 treated parasites showed 
marked reduction in the levels of 2-oxoglutarate and succinate (Figure 6.13 and 6.15, C) 
but there were no changes seen in the levels of (iso)-citrate, fumarate, oxaloacetate and 
malate (Figures 6.14, 6.16, 6.17 & 6.18, C). There were not any obvious alterations 
noted in TCA intermediates in parasites treated with 5-flouroorotic acid, potassium 
cyanide, bongkrekic acid (Figures 6.13, 6.14, 6.15, 6.16, 6.17 & 6.18, D, E and F). 
However, parasite treated with thenoyltrifluoroacetone showed a clear reduction in the 
levels of succinate, fumarate and malate by at least 5 fold at 7 hr time point (Figures 
6.15, 6.16 & 6.18, G) but not in 2-oxoglutarate, (iso)-citrate and oxaloacetate (Figures 
6.13, 6.14 & 6.17, G). Surprisingly, parasites treated with fusidic acid showed a marked 
reduction in 2-oxoglutarate, (iso)-citrate, succinate, fumarate and malate by at least 5 
fold at 7 hr time point as compared to untreated parasites (Figure 6.13, 6.14, 6.15, 6.16 
& 6.18, I). In contrast, there was not any apparent change observed in oxaloacetate level 
following the addition of fusidic acid (Figure 6.17 I).  
 
With the exception of thenoyltrifluoroacetone, P. falciaprum treated with mtETC 
selective inhibitors including atovaquone, atovaquone-proguanil, CK-2-68, 5-
flouroorotic acid and potassium cyanide showed a distinguished accumulation of 
carbamoyl-l-aspartate and dihydroorotate and a subsequent reduction in orotate (Figure 
6.19, 6.20 & 6.21, A, B, C, D and E ). In addition, P. falciaprum treated with 
bongkrekic acid showed a notable increase in carbamoyl-l-aspartate and dihydroorotate 
and a clear reduction in orotate (Figure 6.19, 6.20 & 6.21, F). There were no changes 
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observed in the levels of carbamoyl-l-aspartate, dihydroorotate and orotate upon treating 
P. falciaprum parasites with of thenoyltrifluoroacetone, proguanil and fusidic acid 
compared to untreated (Figure 6.19, 6.20 & 6.21, G, H and I).  
 
The trend in amino acids varied upon the addition of mitochondrial selective drugs and 
inhibitors of P. falciparum parasites in particular fusidic acid. With the exception of 
fusidic acid, P. falciparum parasites treated with atovaquone, atovaquone-proguanil, 
CK-2-68, 5-flouroorotic acid, potassium cyanide, bongkrekic acid,  
thenoyltrifluoroacetone and proguanil showed no obvious changes in the levels of 
glutamine, glutamate, arginine, proline, ornithine, citrulline, serine, asparagine, lysine, 
methionine, histidine, phenylalanine, tryptophan, threonine and (iso)-leucine (Figures 
6.23, 6.24, 6.25, 6.26, 6.27, 6.28, 6.29, 6.30, 6.32, 6.33, 6.34, 6.35, 6.36, 6.38 & 6.39;  
A, B, C, D, E, F, G and H). In contrast, there was a notable increase in the level of 
alanine in P. falciparum treated with all mitochondrial selective drugs and inhibitors 
mentioned above as well as in parasite treated with proguanil (Figure 6.22, A, B, C, D, 
E, F, G and H). Aspartate levels in P. falciparum treated with aforementioned selective 
mtETC inhibitors were notably lower than that of untreated control parasite (Figure 
6.31, A, B, C, D, E and G). On the other hand, P. falciparum parasites treated with 
bongkrekic acid, proguanil and fusidic acid showed no obvious changes in aspartate 
levels compared to untreated controls (Figure 6.31, F, H and I). There was a slight 
increase in tyrosine and a noticeable accumulation of valine in P. falciparum treated 
with atovaquone, atovaquone-proguanil and CK-2-68 (Figure 6.37 & 6.40, A, B and C).  
 
As stated above, most of the changes in the amino acid trends were observed in P. 
falciparum treated with fusidic acid. There was a distinguished accumulation in 
glutamine, ornithine, citrulline, phenylalanine, tryptophan, tyrosine, threonine and 
valine following fusidic acid addition to the P. falciparum parasites (Figure 6.23, 6.27, 
6.28, 6.35, 6.36, 6.37, 6.38 & 6.40, I). Moreover, there were a notable invariable 
changes observed in the levels of serine, asparagine, lysine and methionine (Figure 
6.29, 6.30, 6.32 & 6.33, I). P. falciparum treated with fusidic acid showed no changes in 
the levels of arginine, proline, histidine and (iso)-leucine compared to untreated (Figure 
6.25, 6.26, 6.34 & 6.39, I).  
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P. falciparum parasites treated with atovaquone, atovaquone-proguanil, CK-2-68, 5-
flouroorotic acid, potassium cyanide, bongkrekic acid, thenoyltrifluoroacetone, 
proguanil and fusidic acid showed no obvious changes in the level of hypoxanthine 
compared to untreated parasite control ( Figure 6.41, A, B, C, D, E, F, G, H and I) .   
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Figure 6.8: Glucose metabolism in drug-treated and untreated P. falciparum 3D7 parasites over time.  
Glucose levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed clearly the utilization of glucose in drugs treated and untreated parasites. The points represent the mean ± SEM of at least 
duplicate independent experiments.  
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Figure 6.9: Time-dependent curves of dihydroxyaceton phosphate (DHAP) in drug-treated and untreated P. falciparum 3D7 parasites.  
DHAP levels were measured in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. Data 
showed clear reduction of DHAP after one hour of incubation in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (E) 
1 mM potassium cyanide, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 200 µM fusidic acid. On the other hand, there was a slight 
increase in the level of DHAP after one hour of incubation in parasites treated with (C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, and (F) 5 µM 
bongkrekic acid. The points represent the mean ± SEM of at least duplicate independent experiments.  
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Figure 6.10: Time-dependent curves of glycerol-3-phosphate (G-3-P) in drug-treated and untreated P. falciparum 3D7 parasites.  
G-3-P levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. Data 
showed an increase in the G-3-P level after one hour of incubation in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, 
(F) 5 µM bongkrekic acid, (H) 70 µM proguanil and (I) 200 µM fusidic acid. On the other hand, parasites treated with (G) 10 µM thenoyltrifluoroacetone 
showed a notable reduction in G-3-P level. There were no differences in parasites treated with (C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM 
potassium cyanide as compared to untreated parasites. The points represent the mean ± SEM of at least duplicate independent experiments.  
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Figure 6.11: Time-dependent curves of phosphoenol pyruvate (PEP) in drug-treated and untreated P. falciparum 3D7 parasites.  
PEP levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. Data showed 
a noticeable increase in PEP levels after one hour of incubation in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, 
(C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid and (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 
µM proguanil and (I) 200 µM fusidic acid. The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.12: Time-dependent curves of lactate production in drug-treated and untreated P. falciparum 3D7 parasites.  
Lactate levels were measured in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. Data 
showed a notable increase in production of lactate after one hour of incubation in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 
µM proguanil, (C) 50 nM CK-2-68,  (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM 
thenoyltrifluoroacetone and (H) 70 µM proguanil. Parasites treated with (I) 200 µM fusidic acid showed no differences compared to untreated parasites. The 
points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.13: Time-dependent curves of 2-oxoglutarate in drug-treated and untreated P. falciparum 3D7 parasites.  
2-oxoglutarate levels were determined in untreated (opened circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. 
The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM 
CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil 
and (I) 200 µM fusidic acid. Data showed that parasites treated with (A) 2.5 nM atovaquone and (B) 2.5 nM atovaquone + 1 µM proguanil had a notable 
increase of 2-oxoglutarate whereas that of treated with (C) 50 nM CK-2-68 and (I) 200 µM fusidic acid showed a distinguished reduction. The points 
represent the mean ± SEM of at least duplicate independent experiments. There were no clear changes observed in others drugs-treated parasites. 
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Figure 6.14:. Time-dependent curves of (iso)-citrate in drug-treated and untreated P. falciparum 3D7 parasites.  
The (iso)-citrate levels were determined in untreated (opened circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-
MS/MS. The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 
50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM 
proguanil and (I) 200 µM fusidic acid. Data showed that parasites treated with (B) 2.5 nM atovaquone + 1 µM proguanil had a substantial increase of (iso)-
citrate while that of treated with (I) 200 µM fusidic acid showed a notable decrease. There were no changes observed in others drugs-treated parasites. The 
points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.15: Time-dependent curves of succinate in drug-treated and untreated P. falciparum 3D7 parasites.  
Succinate levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed a distinguished increase of succinate in parasites treated with (A) 2.5nM atovaquone, (B) 2.5 nM atovaquone + 1 µM 
proguanil whereas parasites treated with (C) 50 nM CK-2-68, (G) 10 µM thenoyltrifluoroacetone and (I) 200 µM fusidic acid showed a notable reduction. The 
points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.16: Time-dependent curves of fumarate in drug-treated and untreated P. falciparum 3D7 parasites.  
Fumarate levels were determined in untreated (open circle) and drug-treated (closed circle) P. falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed a notable increase of  fumarate in parasites treated with (B) 2.5 nM atovaquone + 1 µM proguanil whereas it showed an 
evident reduction of fumarate in parasites treated with (G) 10 µM thenoyltrifluoroacetone and (I) 200 µM fusidic acid. There were no clear changes observed 
in others drugs-treated parasites. The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.17: Time-dependent curves of oxaloacetate levels in drug-treated and untreated P. falciparum 3D7 parasites.  
Oxaloacetate levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. There were no changes observed between drugs-treated and untreated parasites. The points represent the mean ± SEM of at least 
duplicate independent experiments.  
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Figure 6.18: Time-dependent curves of malate production in drug-treated and untreated P. falciparum 3D7 parasites.  
Malate levels were measured in untreated (open circle) and drug-treated (closed circle) P. falciparum trophozoite-staged parasites by LC-MS/MS. There were 
no differences in malate levels after one hour of  incubation in parasites treated with (A) 2.5 nM atovaquone, (C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic 
acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, and (H) 70 µM proguanil. Conversely, data showed a slight increase of malate in parasites 
treated with (B) 2.5 nM atovaquone + 1 µM proguanil while there was an evident reduction in malate levels in parasites treated with (G) 10 µM 
thenoyltrifluoroacetone and (I) 200 µM fusidic acid. The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.19: Time-dependent curves of carbamoyl-L-aspartate in drug-treated and untreated P. falciparum 3D7 parasites.  
Carbamoyl-L-aspartate levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-
MS/MS. The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 
50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM 
proguanil and (I) 200 µM fusidic acid. Data showed a distinguished accumulation of carbamoyl-L-aspartate in parasites treated with (A) 2.5 nM atovaquone 
and (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide and (F) 5 µM bongkrekic 
acid.  There were no changes observed in parasites treated with (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 200 µM fusidic acid. The 
points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.20: Time-dependent curves of dihydroorotate in drug-treated and untreated P. falciparum 3D7 parasites.  
Dihydroorotate levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. 
The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM 
CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil 
and (I) 200µM fusidic acid. Data showed a notable accumulation of dihydroorotate in parasites treated with (A) 2.5nM atovaquone and (B) 2.5 nM 
atovaquone + 1 µM proguanil, (C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide and (F) 5 µM bongkrekic acid. There were 
no changes observed in parasites treated with (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 200 µM fusidic acid. The points represent the 
mean ± SEM of at least duplicate independent experiments. 
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Figure 6.21: Time-dependent curves of orotate in drug-treated and untreated P. falciparum 3D7 parasites.  
Orotate levels were determined in untreated (opened circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200µM fusidic acid.  Data showed an evident reduction of orotate in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, 
(C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide and (F) 5 µM bongkrekic acid. There were no changes observed in others 
drugs-treated parasites. The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.22: Time-dependent curves of alanine accumulation in drug-treated P. falciparum 3D7 parasites.  
Alanine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. Data 
showed a distinguished accumulation of alanine after one hour of incubation in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM 
proguanil, (C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, 
(H) 70 µM proguanil and (I) 200 µM fusidic acid. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.23: Time-dependent curves of glutamine in drug-treated and untreated P. falciparum 3D7 parasites.  
Glutamine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS.  There 
were no changes observed after one hour of incubation in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1µM proguanil, (C) 50 nM 
CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone and (H) 70 µM 
proguanil. Data showed a notable accumulation of glutamine in parasites treated with (I) 200 µM fusidic acid. Data represent the mean ± SEM of at least 
duplicate independent experiments. 
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Figure 6.24: Time-dependent curves of glutamate in drug-treated and untreated P. falciparum 3D7 parasites.  
Glutamate levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. 
Notable invariable changes were observed in glutamate after one hour of incubation in parasites treated with (I) 200 µM fusidic acid. There were no changes 
observed in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 
1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone and (H) 70 µM proguanil. Data represent the mean ± SEM of at least 
duplicate independent experiments. 
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Figure 6.25: Time-dependent curves of arginie degradation in drug-treated and untreated P. falciparum 3D7 parasites.  
Arginine degradation levels were measured in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-
MS/MS. The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 
50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM 
proguanil and (I) 200 µM fusidic acid. There were no changes between drugs-treated and untreated parasites. The points represent the mean ± SEM of at least 
duplicate independent experiments. 
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Figure 6.26: Time-dependent curves of proline in drug-treated and untreated P. falciparum 3D7 parasites.  
Proline levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. There were no changes observed between drugs-treated and untreated parasites. The points represent the mean ± SEM of at least 
duplicate independent experiments. 
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Figure 6.27: Time-dependent curves of ornithine production in drug-treated and untreated P. falciparum 3D7 parasites.  
Ornithine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed a marked increase in ornithine level in parasite treated with (I) 200 µM fusidic acid. There were no changes observed 
between other drugs-treated and untreated parasites. The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.28: Time-dependent curves of citrulline in drug-treated and untreated P. falciparum 3D7 parasites.  
Citrulline levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed an evident accumulation of citrulline in parasites treated with (I) 200 µM fusidic acid. There were no changes observed 
between other drugs-treated and untreated parasites. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.29: Time-dependent curves of serine in drug-treated and untreated P. falciparum 3D7 parasites.  
Serine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed notable invariable changes of serine in parasites treated with (I) 200 µM fusidic acid. There were no changes among other 
drugs-treated parasites as compared to untreated parasites. The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.30: Time-dependent curves of asparagine in drug-treated and untreated P. falciparum 3D7 parasites.  
Asparagine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed distinguished invariable changes of asparagine in parasites treated with (I) 200 µM fusidic acid. There were no changes 
observed among other drugs-treated parasites as compared to untreated parasites. The points represent the mean ± SEM of at least duplicate independent 
experiments. 
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Figure 6.31: Time-dependent curves of aspartate in drug-treated and untreated P. falciparum 3D7 parasites.  
Aspartate levels were determined in untreated (opened circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed a slight reduction in the level of asparate in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM 
proguanil, (C) 50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid and (E) 1 mM potassium cyanide. There were no changes between drugs-treated and untreated 
parasites. The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.32: Time-dependent curves of lysine degradation in drug-treated and untreated P. falciparum 3D7 parasites.  
Lysine degredation levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-
MS/MS. The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 
50 nM CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM 
proguanil and (I) 200 µM fusidic acid. Data showed notable invariable changes of lysine in parasites treated with (I) 200uM fusidic acid. There were no 
changes between drugs-treated and untreated parasites. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.33: Time-dependent curves of methionine in drug-treated and untreated P. falciparum 3D7 parasites.  
Methionine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Data showed notable invariable changes in the methionine level in parasites treated with (I) 200 µM fusidic acid. There were no changes 
observed between others drugs-treated and untreated parasites.  The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.34: Time-dependent curves of histidine in drug-treated and untreated P. falciparum 3D7 parasites.  
Histidine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. There were no changes observed between drugs-treated and untreated parasites. The points represent the mean ± SEM of at least 
duplicate independent experiments. 
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Figure 6.35: Time-dependent curves of phenylalanine in drug-treated and untreated P. falciparum 3D7 parasites.  
Phenylalanine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. 
The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM 
CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil 
and (I) 200 µM fusidic acid. Phenylalanine was slightly accumulated after one hour of incubation in parasites treated with (I) 200 µM fusidic acid. There were 
no changes observed between others drugs-treated and untreated parasites. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.36: Time-dependent curves of tryptophan in drug-treated and untreated P. falciparum 3D7 parasites.  
Tryptophan levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. Tryptophan was slightly accumulated after one hour of incubation in parasites treated with (I) 200 µM fusidic acid. There were no 
changes observed between others drugs-treated and untreated parasites.  Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.37: Time-dependent curves of tyrosine in drug-treated and untreated P. falciparum 3D7 parasites.  
Tyrosine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. There was an evident accumulation of tyrosine after one hour of incubation in parasites treated with (I) 200 µM fusidic acid. There were 
no changes observed between others drugs-treated and untreated parasites. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.38: Time-dependent curves of threonine in drug-treated and untreated P. falciparum 3D7 parasites.  
Threonine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200 µM fusidic acid. There was a notable accumulation of threonine after one hour of incubation in parasites treated with (I) 200 µM fusidic acid. There were 
no changes observed between others drugs-treated and untreated parasites. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 6.39: Time-dependent curves of (iso)-leucine in drug-treated and untreated P. falciparum 3D7 parasites.  
The (iso)-leucine levels were determined in untreated (open circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. 
The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM 
CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil 
and (I) 200 µM fusidic acid. There were no changes observed between drugs-treated and untreated parasites. The points represent the mean ± SEM of at least 
duplicate independent experiments. 
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Figure 6.40: Time-dependent curves of valine in drug-treated and untreated P. falciparum 3D7 parasites.  
Valine levels were determined in untreated (opened circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The 
following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM CK-2-
68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil and (I) 
200µM fusidic acid. Data showed a distinguished accumulation of valine in parasites treated with (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM 
proguanil, (C) 50 nM CK-2-68 and (I) 200 µM fusidic acid. There were no changes observed between others drugs-treated and untreated parasites. Data 
represent the mean ± SEM of at least duplicate independent experiments. 
B 
A 
F
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
I 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
H
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
G
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
D
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
E
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
C
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
l
s 
i
n 
d
r
u
g
A
F
i
g
u
r
e 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
l
s 
i
 218 
 
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0
1
2
3
4
Drug Addition
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0
1
2
3
Drug Addition
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0.0
0.5
1.0
1.5
2.0
2.5
Drug Addition
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0.0
0.5
1.0
1.5
2.0
2.5
Drug Addition
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0.0
0.5
1.0
1.5
2.0
2.5
Drug Addition
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0.0
0.5
1.0
1.5
2.0
2.5
Drug Addition
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0.0
0.5
1.0
1.5
2.0
2.5
Drug Addition
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0.0
0.5
1.0
1.5
2.0
2.5
Drug Addition
Time (hr)
Fo
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0.0
0.5
1.0
1.5
2.0
2.5
Drug Addition
 
Figure 6.41: Time-dependent curves of hypoxanthine in drug-treated and untreated P. falciparum 3D7 parasites.  
Hypoxanthine levels were determined in untreated (opened circle) and drug-treated (closed circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. 
The following drugs were added to the parasites after one hour of incubation (A) 2.5 nM atovaquone, (B) 2.5 nM atovaquone + 1 µM proguanil, (C) 50 nM 
CK-2-68, (D) 15 nM 5-fluoroorotic acid, (E) 1 mM potassium cyanide, (F) 5 µM bongkrekic acid, (G) 10 µM thenoyltrifluoroacetone, (H) 70 µM proguanil 
and (I) 200µM fusidic acid. There were no changes observed between drugs-treated and untreated parasites. The points represent the mean ± SEM of at least 
duplicate independent experiments.
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 Discussion 6.4.
The aims and hypotheses of this chapter were to dissect the role of mtETC components 
on the basis of the findings of the previous chapter (chapter 5) and to investigate 
whether the P. falciparum mitochondria can be regarded as containing multiple drug 
targets. It was markedly noted from the analysis of PCA and PLS-DA that the selective 
mitochondrial inhibitors and some antimalarial drugs used to specifically perturb P. 
falciparum mitochondria in trophozoite-stage have different MoAs.  
 
In this regards, P. falciparum parasites treated with mtETC selective drugs and 
inhibitors including atovaquone, atovaquone-proguanil, CK-2-68, 5-flouroorotic acid, 
potassium cyanide, and thenoyltrifluoroacetone showed similar MoA in PCA analysis. 
Nevertheless, further discriminate analysis (PLS-DA) demonstrated different 
divergence clusters. This suggests strongly that these mtETC selective drugs and 
inhibitors act upon different components of P. falciparum mtETC. With the exception 
of thenoyltrifluoroacetone, P. falciparum parasites treated with selective inhibitors for 
the mtETC components including atovaquone, atovaquone-proguanil, CK-2-68, 5-
fluoroorotic acid and potassium cyanide generate prominent metabolic fingerprints in 
the upstream pyrimidine biosynthesis pathway including carbamoyl-l-aspartate and 
dihydroorotate. Despite the fact that the MoA of atovaquone, atovaquone-proguanil, 
CK-2-28 and potassium cyanide is not directly linked to the dihydrooroate 
dehydrogenase (DHODH), the metabolic fingerprint findings from metabolomic 
experiments was in accordance with the parasite mitochondrion playing a key role in 
pyrimidine biosynthesis. Therefore, shutdown of the mtETC completely arrests crucial 
metabolic pathways within the parasite leading to parasite death. Consistent with these 
findings, previous studies reported that the inhibition of the  mtETC in malaria parasite 
at cytochrome bc1  (complex III) by atovaquone results in the accumulation of 
carbamoyl-l-aspartate and dihydroorotate and a reduction in UTP, CTP, and dTTP 
(Hammond et al., 1985, Seymour et al., 1994). Although UTP, CTP and TTP were 
included in the list of the targeted metabolomics analytical platform (Chapter 3); they 
were under the limit of detection in the parasite materials. This means there is a 
necessity for either an increase in adequate parasite material or a more sensitive method 
of detection. The reduction in orotate levels following the addition of  atovaquone 
confirms the previous hypothesis that atovaquone has an effect on pyrimidine 
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intermediates (Hudson et al., 1991). Moreover, the accumulation of  valine observed 
upon the addition of atovaquone, atovaquone-proguanil and CK-2-68 indicates that 
these drugs had an indirect MoA effect on the branched chain α-ketoacid dehydrogenase 
complex (BCKDH) that is located in the mitochondria (Gunther et al., 2005, Seeber et 
al., 2008, Storm and Mueller, 2012). Atovaquone is known to be a competitive inhibitor 
of ubiquinone binding to Plasmodium mitochondrial bc1 (Fry and Pudney, 1992). 
Although atovaquone acts by inhibiting electron transfer in the bc1 complex (complex 
III) and thereby collapsing the ΔΨm (Srivastava et al., 1997, Biagini et al., 2006), its 
disruption of pyrimidine de novo biosynthesis  would indicate the involvement of 
atovaquone ( a ubiquinone (CoQ) analoge) in the reaction of DHODH. Consequently, it 
is conceivable that the depolarization effect of atovaquone on ΔΨm results in the 
disturbance of vital metabolic pathway, pyrimidine biosynthesis, by the indirect 
inhibition of DHODH. Unsurprisingly, the effect of an atovaquone-progaunil 
combination on the levels of carbamyol-l-aspartate and dihydroorotate accumulation 
was higher than the effect produced by atovaquone alone suggesting the role of 
progaunil in potentiating and enhancing  atovaquone’s effect when they used in 
combination is correct.  This also indicates a secondary MoA for proguanil. However, 
this observation was not the case when parasites treated only with proguanil. As shown 
in PCA and PLS-DA, the clustering of parasites treated with proguanil was entirely 
separated from parasites treated with atovaquone-proguanil. The biguanide proguanil by 
its self does not have any effect on either the ΔΨm or dihydrofolate reductase (DHFR), a 
critical enzyme in folate pathway, but rather it becomes metabolized and converted to 
cycloguanil, a potent inhibitor of dihydrofolate reductase (DHFR) in folate biosynthesis 
(Carrington et al., 1951, Crowther and Levi, 1953, Canfield et al., 1995). Moreover, 
there was no clear metabolic fingerprint indication of proguanil addition although P. 
falciparum parasites were exposed to high levels of proguanil (70 µM). In contrast, 
exposing P. falciparum parasites to 1 µM proguanil in combination with sub-lethal 
concentration of atovaquone resulted in strong biochemical evidence of mitochondrial 
membrane depolarization as made evident by the two pyrimidine metabolic fingerprints 
discussed above. This suggests that proguanil has no direct MoA on the ΔΨm but rather 
acts to sensitize the parasite ΔΨm to depolarization  by atovaquone without disturbing 
the mtETC (Srivastava and Vaidya, 1999). Furthermore, it was found that progunail had 
a small effect on P. falciparum parasites’ oxygen consumption in polarographic assays 
when used alone or in combination with atovaquone or salicylhydroxamic (SHAM), 
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suggesting that proguanil potentiate atovaquone by indirect inhibition of the branched 
respiratory pathway including a cytochrome chain and an alternative terminal oxidase 
(Murphy et al., 1997, Murphy and Lang-Unnasch, 1999).  
 
A 5-fluoroorotic acid, an orotate analog, has potent activity (IC50 in nM range) against 
both human and mouse malaria parasites in vitro and in vivo, respectively (Rathod et al., 
1989, Queen et al., 1990, Gomez and Rathod, 1990). Malaria parasites were treated with 
nanomolar concentration of 5-fluoroorotic acid as a proof-of-concept for potency and if 
successful, to confirm biochemically the metabolic link between mitochondria and 
pyrimidine biosynthesis. As expected, the findings showed clearly a notable increase in 
carbamoyl-l-aspartate and dihydroorotate and a reduction in orotate. However, the 
findings of the metabolic effects of 5-fluoroorotic acid are inconsistent with the results 
observed by earlier studies which showed that 5-fluoroorotic acid incorporated in a 
significant accumulation of 5-fluoro-UMP, 5-fluoro-UDP and 5-fluoro-UTP but not of a 
pyrimidine intermediates suggesting that the accumulated 5-fluoro-UTP acts as a potent 
inhibitor on carbamoyl phosphate synthase leading to hampering the pyrimidine 
biosynthesis pathway at its’ first step (Seymour et al., 1994, Seymour et al., 1997). 
Conversely, a biochemical pharmacology study performed on orotate analogs showed 
that 5-fluoroorotic acid was the most effective inhibitor for dihydrooroate orotase and 
dihydrooroate dehydrogenase leading to a 50% inhibition in P. falciparum growth at 10 
nM (Krungkrai et al., 1992). Therefore, the results obtained for P. falciparum parasites 
treated with 5-fluoroorotic acid suggesting that this inhibitor acts upon DHODH 
component of the mtETC leading to the observed accumulation in the upstream 
pyrimidine intermediates, carbamoyl-l-aspartate and dihydroorotate, which are in 
keeping with the findings of Krungkrai and his colleagues  (Krungkrai et al., 1992).  
 
The results obtained for CK-2-68, a bisaryl quinolones type compound that is 
synthesized in-house and displayed potency in the nanomolar range against P. 
falciparum parasites (Pidathala et al., 2012), showed a parallel MoA of atovaquone and 
atovaquone-proguanil having its effect on the DHODH choke point (Biagini et al., 
2012). It was pointed out in the literature that  Plasmodium parasites lack the canonical 
proton motive NADH dehydrogenase (Complex I) but instead it harbors a bacterial-like 
type II NADH:ubiquinone oxidoreductase, P. falciparum NDH2 (Fisher et al., 2007). 
CK-2-68 was shown to have dual-targeting MoA (PfNDH2/bc1) effect on P. falciparum 
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respiratory chain (Biagini et al., 2012, Pidathala et al., 2012). The development of 
PfNDH2/bc1 dual-acting lead antimalarial compound (CK-2-68) was evidenced by a 
rapid and selective depolarization of the parasite ΔΨm. This leads to the disruption of 
pyrimidine biosynthesis, organelle dysfunction and eventually parasite death (Biagini et 
al., 2012).  Moreover, the findings of PLS-DA clustering showed that the P. falciparum 
parasites treated with atovaquone, arovaquone-progaunil and 5-flouroorotic acid was in 
one cluster and that of P. falciparum parasites treated with CK-2-68, potassium cyanide 
and bongkrekic acid was in another cluster. The metabolites caused this divergence 
were clearly detected in the VIP score for each drug treatment and they had different 
profiles following the addition of each drug. These metabolites include fumarate, 
alanine, orotate and DHAP in addition to the major metabolic fingerprints which are 
carbamoyl-l-aspartate and dihydroorotate. However, it appears that fumarate is the only 
metabolite that had different profile in parasites treated with atovaquone, arovaquone-
progaunil and 5-flouroorotic acid from those treated with CK-2-68, potassium cyanide 
and bongkrekic acid. This suggests that the P. falciapurm mitochondria houses a 
number of drug targets. Moreover, potassium cyanide is known to specifically and 
selectively inhibit cytochrome c oxidase (complex IV) (Way, 1984). It is conceivable 
that the detrimental effect of cyanide on the ΔΨm may produce the same pyrimidine 
metabolic fingerprint observed with the other mtETC inhibitors. 
Thenoyltrifluoroacetone is known to specifically inhibit succinate dehydrogenase 
(complex II) (Sun et al., 2005).  Thenoyltrifluoroacetone treated parasites occupied an 
entirely unique position from other mtETC inhibitors in the 3-D of PLS-DA suggesting 
the weak role of complex II in the mtETC of P. falciparum. However, a suppression and 
rescue study carried out on complex II of P. falciparum showed that the disruption of 
complex II caused growth retardation of the intra-erythrocytic forms and was rescued 
by addition of succinate but not fumarate suggesting that complex II in malaria parasites 
functions as a quinol-fumarate reductase (QFR) to produce succinate from fumarate  
(Tanaka et al., 2012).  
 
Remarkably, the findings for bongkrekic acid treated parasites showed that it also had 
an indirect effect on DHODH resulting in a significant accumulation of carbamoyl-l-
aspartate and dihydrooroate even though it targets ADP/ATP transporter in the 
mitochondria. Therefore, this result confirms a role for the ATP synthase complex 
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(complex V). However, the exact role of ATP synthase complex in parasite remains 
unclear although there is some evidence suggesting the essentiality of this complex to 
the survival of malaria parasites and that it is perhaps a valid drug target (Nina et al., 
2011, Basco and Lebras, 1994). Moreover, bongkrekic acid treated parasites initially 
clustered with mtETC selective drugs and inhibitors in PCA and were differentiated 
further in PLS-DA to be clustered only with CK-2-68 and potassium cyanide treated 
parasites. This indicates that bongkrekic acid had a commonality in the MoA with CK-
2-68 and potassium cyanide. Overall, this highlights that mitochondrial inhibition with a 
range of independent electron transport inhibitors results consistently in a specific and 
significant accumulation of two pyrimidine intermediates, carbamoyl-l-aspartate and 
dihydroorotate. 
 
Fusidic acid is an antibiotic that is known to inhibit the elongation factor G (EF-G), a 
GTPase critical to the translocation step of protein synthesis, in the mitochondrial 
machinery protein synthesis. This leads to a disruption in the protein synthesis, 
organelle malfunction and eventually parasite death (Black et al., 1985, Johnson et al., 
2011). Unexpectedly, the findings showed that upon treating the parasites with fusidic 
acid, there was no effect in the upstream pyrimidine intermediates indicating that ΔΨm 
was not affected as it is observed with other mitochondrial inhibitors (e.g. atovaquone). 
This was clearly shown in the metabolomics analysis (PCA and PLS-DA) in that the 
clustering of P. falciparum parasite treated with fusidic acid was entirely segregated 
from those of mtETC inhibitors and ADP/ATP transporter inhibitors suggesting that 
fusidic acid had a different MoA. Nonetheless, the findings demonstrated a notable 
reduction in TCA intermediates including succinate, fumarate, malate, (iso)-citrate and 
2-oxoglutarate when parasites were treated with fusidic acid. This suggests an indirect 
or secondary MoA in the intermediary fluxes of mitochondrial TCA intermediates. In 
addition, the MoA of fusidic acid in this study was also extended to affect a number of 
amino acids as it appeared in the accumulation of glutamine, ornithine, citrulline, 
phenylalanine, tryptophan, tyrosine, threonine and valine. Fusidic acid acted indirectly 
to hamper the degradation of serine, asparagine, methionine and lysine showing notable 
invariable changes compared to untreated control.  Several lines of evidence pointed out 
that exposing malaria parasite to known mitochondrial protein synthesis inhibitors (e.g. 
tetracycline and chloramphenicol) results in a reduction of amino acids incorporation 
into protein synthesis (Geary and Jensen, 1983, Blum et al., 1984, Ginsburg et al., 
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1986). It is likely that the effect of fusidic acid on a number of amino acids up-take, 
including glutamine, serine, asparagine, lysine, phenylalanine, tryptophan, tyrosine, 
threonine, and valine, was caused by a direct  disruption in the mitochondrial protein 
synthetic machinery resulting in the inhibition of EF-G. Specifically, fusidic acid binds 
to EF-G on the ribosome and prevents the EF-G:GDP complex from leaving the 
ribosome leading it to obstruct the amino acid translocation to the growing polypeptide 
chain and effectively stalling protein synthesis by steric inhibition (Besier et al., 2003). 
The results obtained in this chapter for fusidic acid are in agreement with the view that 
it acts by inhibiting protein synthesis as reported in an early study which demonstrated 
that the incorporation of tyrosine, lysine, phenylalanine and alanine into protein was 
inhibited upon fusidic acid addition in cell-free systems from Escherichia coli 
(Vazquez, 1966). Furthermore, the result obtained for (iso)-leucine showed that after 
three hours of fusidic acid exposure, the parasite’s up-take level was altered from 
decrease to a steady state suggesting that fusidic acid is active against late trophozoite 
and possibly schizont parasite stages. This finding is consistent with the results obtained 
by (Blum et al., 1984) showing that exposing the ring-staged of P. falciparum parasite 
to chloramphenicol (mitochondrial protein synthesis inhibitor) resulted in the inhibition 
of [
3
H] iso-leucine incorporation into protein after  21 h indicating that chloramphenicol 
is a stage-specific inhibitor. On the other hand, the effect seen on alanine, glutamate, 
ornithine, citrulline was possibly an indirect MoA effect of fusidic acid resulting from 
the perturbation of the mitochondrial metabolism (e.g. alanine as an end-product from 
glysolysis pathway). Overall, there is clear pharmacometabolomics evidence that the P. 
falciaprum mitochondria carries out protein synthesis although the P. falciaprum 
mitochondria genome only encodes a fragmented rRNA molecules. Therefore, it 
appears that mitochondria import all proteins and tRNAs needed for translation of 
mitochondrial-encoded transcripts, and it is unclear if its fragmented rRNA is functional 
(Jackson et al., 2011). This view is supported by the MoA of fusidic acid showing that 
the large effect occurred towards the end points of the time course indicating that the 
synthesis of the parasite’s mitochondrial protein machinery is active in the transition 
stage between trophozoite and schizont.     
 
Interestingly, it was noted in the metabolomic experiments carried out in this chapter 
that glucose was dramatically utilized in drug-treated P. falciparum parasites leading to 
a notable elevation in as phosphoenol pyruvate (PEP) and lactate as compared to the 
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untreated. This could be explained as the effect of drug pressure on the perturbation of 
the P. falciparum parasites metabolic system biology. However, the effect on the rate of 
glucose utilization and lactate production depends on the MoA of the drug. For instance, 
P. falciparum parasites treated with atovaquone alone was demonstrated to take up 
glucose and produce lactate at a relatively lower rate than that of the parasites treated 
with atovaquone-proguanil and/or CK-2-68. Overall, the finding that P. falciparum 
parasites are voracious glucose consumers is consistent with the earlier studies and 
investigations of Plasmodium biochemistry wherein glucose was demonstrated to be an 
essential nutrient for survival, growth and reproduction (Bass and Johns, 1912, Hegner 
and MacDougall, 1926, Johns, 1931). In addition, (Sherman, 1979) noted that 
biochemical experiments carried out on a variety of malaria species to investigate the 
glucose utilization revealed lactate as a major end product of glucose catabolism 
together with a variety of other organic acids such as pyruvate, acetate, formate, 
succinate, aspartate, glutamate, alanine and CO2. However, metabolites like pyruvate, 
acetate and formate could not be detected in the metabolomics analytical platform of 
this thesis due to the fact that they were not properly eluted and poorly ionized by LC-
MS/MS. Nonetheless, lactate, succinate, aspartate, glutamate and alanine were detected 
using this metabolomics analytical platform and showed an increase trend over time in 
untreated P. falciparum parasites. These findings are parallel to the early reported 
studies on different species of malaria parasites (Bowman et al., 1960, Bowman et al., 
1961, Bryant et al., 1964, Nagaraja.K, 1968). Overall, it was clearly shown that P. 
falciparum displayed different glucose metabolism phenotypes when exposing to 
antimalarial drugs and inhibitors. 
  
To conclude, for a number of ETC components, their inhibitions results in a 
convergence in terms of the cellular response leading to parasite death.  However, for 
other ETC components there appears to be a distinct cellular response suggesting 
multiple roles for the mitochondrion in the cell. With regards to the limitation of this 
chapter, the analytical limitation is similar to what has been discussed previously 
(chapter 4, section 4.4). This includes the under limit of detection of bioenergetics/redox 
couples, UMP, UDP, UTP, TTP, CTP, and GTP in the parasite samples. With regards to 
future experiments, it can be generally stated that P. falciparum mitochondria is a valid 
drug target (e.g. Malarone™) and according to the findings of this chapter it is still 
considered susceptible target for many drugs that act specifically on different 
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mitochondrial targets (e.g. transporters, protein synthesis machinery and mtETC 
components). Therefore, it could be suggested that future experiments could be carried 
out in the same means using specific drugs and inhibitors. For example, using 
antibiotics such as chloramphenicol and cycloheximide will enhance the current 
understanding of mitochondrial machinery protein synthesis. In addition, atractyloside, 
specific mitochondrial ADP/ATP transporter inhibitor, can be used to further confirm 
the existence of oxidative phosphorylation in P. falciparum mitochondria.  
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CHAPTER 7  
Pharmacometabolomics Study of Inhibitors Targeting 
the Digestive Vacuole of Plasmodium falciparum 
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 Introduction 7.1.
The aim of this chapter was to investigate the P. falciparum cellular metabolite response 
following sub-lethal exposure to digestive vacuole-targeting quinoline-containing 
antimalarial drugs (QCDs); chloroquine, amodiaquine, piperaquine, quinine and 
mefloquine. The analytical approach for this work has been described previously in 
Chapter 3.  
 
As mentioned previously in the general introduction (Chapter 1), there are three sources 
available to the parasite in which it can acquires the amino acids necessary to carry out 
various metabolic functions. These include; (i) biosynthesis of amino acid from carbon 
sources, (ii) uptake of preformed free amino acids and (iii) proteolysis of haemoglobin 
with the release of amino acids. The trophozoite stage of P. falciparum ingests and 
degrades the host RBC haemoglobin in the digestive vacuole (Tilley et al., 2011). The 
Plasmodium parasite has a limited capacity for the de novo synthesis of amino acid 
(Sherman, 1979). Therefore, it appears that haemoglobin digestion is essential for the 
survival of the parasite. Haemoglobin degradation is capable of providing all essential 
amino acids with the exception of (iso)-leucine, which is absent in human haemoglobin, 
and a limited supply of cysteine, methionine, glutamate and glutamine (Francis et al., 
1997, Divo et al., 1985a). In addition, The Plasmodiun digestive vacuole is a complex 
organelle that is evolutionally well adapted to haemoglobin metabolism. The digestive 
vacuole of Plasmodium is believed to be the site of haemoglobin degradation, 
detoxification of oxygen radicals, acidification, generation of free iron and drugs 
accumulation (Olliaro and Goldberg, 1995). The process of haemoglobin degradation 
releases globin and heme (Francis et al., 1997). Haemoglobin degradation in malaria 
parasite appears to be an ordered process (Goldberg et al., 1990). This degradation 
process is preceded by endocytosis of the host haemoglobin which is then transported to 
an acidic digestive vacuole where a concerted action of groups of aspartic and cysteine 
protease enzymes and a metalloprotease break down haemoglobin initially into large 
peptide and later into small peptides (Bray et al., 2005). Consequently, the small peptide 
is then transported to the parasite cytosol where it is hydrolysed by aminopeptidase to 
derive amino acids that are incorporated into protein synthesis (Kolakovich et al., 1997, 
Rosenthal, 1998). Moreover, heme (reactive free toxic substance to the parasite) 
crystallization into hemozoin (an inert crystalline substance) is a parasite-specific 
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process that enables the detoxification of heme following its generation upon 
haemoglobin digestion in the digestive vacuole (Olliaro and Goldberg, 1995, Francis et 
al., 1997, Egan et al., 2002, Fitch et al., 1982). This crystallization process represents 
both an essential and a unique pharmacological drug target in malaria parasite 
(Kurosawa et al., 2000).  
 
The MoA of QCD is still not properly understood, with several knowledge gaps 
pertaining to the exact pharmacodynamics mechanisms leading to parasite death 
(Ginsburg and Krugliak, 1992). Nonetheless, it has generally been supposed that QCD 
interfere with haemoglobin digestion (Foley and Tilley, 1998) by preventing the process 
of heme sequestration into a non-toxic hemozoin (Muller and Hyde, 2010, Fitch, 2004). 
However, QCDs can be classified on the basis of the drug chemical structure leading 
perhaps to distinct MoA for each drug class. In other word, QCDs class comprise most 
of the common antimalarial drugs that include (1) type-1 drugs 4-aminoquinolines 
including chloroquine, amodiaquine and piperaquine; and (2) type-2 drugs aryl-amino 
alcohols including quinine, mefloquine, quinidine and halofantrine (O’Neill et al., 2012, 
Olliaro, 2001). The two groups differ in that type-1 drugs are weak bases, deprotonated 
and hydrophilic at neutral pH whereas type-2 drugs are weaker bases and lipid soluble 
at neutral pH (Olliaro, 2001).  
 
Chloroquine and other QCDs such as amodiaquine, piperaquine, quinine and 
mefloquine have been mainstays of malaria chemotherapy for decades (Biagini et al., 
2003). Chloroquine is the most widely studied aminoquinoline however its MoA is still 
a matter of some controversy. The proposed MoAs of chloroquine include the effects on 
parasite DNA and RNA synthesis (Meshnick, 1990, Cohen and Yielding, 1965),  the 
inhibition of digestive vacuole lysosomal phospholipases (Ginsburg and Geary, 1987), 
the inhibition of digestive vacuole proteases (Vancer Jagt et al., 1986), the inhibition of 
protein synthesis (Surolia and Padmanaban, 1991)  and the inhibition of hemozoin 
formation by blocking heme polymerase enzyme leading to the accumulation of toxic 
heme which is lethal to the parasite (Slater and Cerami, 1992). However, the latter 
seems to be the most widely accepted hypothesis not only for chloroquine but also for 
other members of quinoline-containing antimalarial drugs. Although QCD members are 
thought to act in a similar way to chloroquine in that they all bind to heme (Foley and 
Tilley, 1998, Sullivan, 2002, Mungthin et al., 1998), their effects on the feeding process 
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appears to be subtly different. For instance, 4-aminoquinoline drugs, including 
chloroquine, amodiaquine and piperaquine, cause an accumulation of undigested 
haemoglobin in the parasite (Yayon et al., 1984b) whereas aryl-amino alcohol drugs, 
including quinine and mefloquine do not (Famin and Ginsburg, 2002). Therefore, it has 
been proposed that 4-aminoquinoline drugs inhibit the digestion of the haemoglobin 
whereas aryl-amino alcohol drugs inhibit the ingestion of the host cell haemoglobin 
perhaps by interfering with the endocytosis process (Bray et al., 2005).  
 
Given the described debate surrounding the MoA of QCDs, in this chapter, a 
pharmacometabolomic approach has been used to determine whether parasite exposure 
to sub-lethal concentrations of the described set of antimalarials results in a convergent 
or divergent metabolite fingerprint. The results are then discussed in the context of the 
various hypotheses supporting the MoA of the drugs. 
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 Materials and Methods 7.2.
7.2.1. High-Gradient Magnetic separation (HGMS) for trophozoite-stage 
parasites enrichment 
The parasite cultures followed by high gradient magnetic separation (HGMS) were 
conducted for trophozoite-stage P. flaciparum parasites as described previously (chapter 
4, section 4.2.1).   
 
7.2.2. Haemocytometer for parasite counting  
Haemocytometer counting for the purified P. falciparum trophozoite-stage parasites 
was carried out as described previously (chapter 4, section 4.2.2).   
 
7.2.3. Parasite cells metabolism quenching and metabolites extraction 
Briefly at this stage, the purified trophozoite-stage parasites (section 7.2.1) were 
subjected to a metabolomics experiment wherewith they were incubated in culture 
media at 37 °C and subsequently exposed to a drug pressure. Thereafter, the parasites 
were removed and metabolically quenched in a time related manner. The metabolites 
were then extracted to be ready for the next stage of LC-MS/MS analysis (section 
7.2.4). This metabolomics experiment was conducted as described earlier (chapter 4 
section 4.2.3) with the exception of drugs addition in the study of this chapter. The IC90 
concentrations of chloroquine (50 nM), amodiaquine (50 nM), piperaquine (80 nM), 
quinine (100 nM) and mefloquine (50 nM) were added at 1 h time point for each set of 
the experiments (n= at least two independent replicates for each drug used). Untreated 
parasite controls were prepared in at least two independent biological experiments. The 
parasite metabolites sampling, quenching, extraction, drying and storing were 
performed as described beforehand (chapter 4, section 4.2.3) 
 
7.2.3.1. Solvents and Drugs Preparation 
All the solvents used to carry out the LC-MS/MS metabolomics experiments were 
HPLC grade as described in Chapter 2 unless otherwise stated. The solvents used for 
drug preparation were of different depending on the solubility of the perspective drug. 
A 10 mM stocks were prepared for the drugs listed in (Table 7.1) , labeled and stored at  
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-20 ºC for no longer than a month. Final dilutions were performed with RPMI-1640 
culture media and freshly made prior to commencing metabolomics experiment studies. 
 
Table  7.1: Drugs used and their IC90 values. 
Drugs MW (g/mol) 
IC90 3D7 P. falciparum 
(nM)* 
Solvent Source 
CQ 319.872 50 H2O Sigma Aldrich 
AQ 355.861 50 DMSO Sigma Aldrich 
PPQ 535.51 80
 
DMSO Sigma Aldrich 
QN 324.417 100 DMSO Sigma Aldrich 
MQ 378.312 50 DMSO Sigma Aldrich 
 
Abbreviations: CQ, Chloroquine; AQ, Amodiaquine; PPQ, Piperaquine; QN, Quinine; MQ, 
Mefloquine; MW, Molecular Weight. *IC90 values were obtained from in-house laboratory data. 
 
7.2.4. LC-MS/MS instrumentation 
Samples preparation including parasite samples, external standards, authentic QCs 
sample, and blanks were carried out in this section aimed at LC-MS/MS. In addition, 
chromatographic conditions and mass spectrometry configurations were set up ready for 
the samples processing. 
 
7.2.4.1. Samples preparation 
The parasite sample preparation was carried out described previously (chapter 4, section 
4.2.4.1). The preparation of external standards authentic QCs sample and blank were 
freshly carried out for each metabolomics experiment as described previously (chapter 
3, section 3.2.3.1).   
  
7.2.4.2. Chromatographic separation  
Chromatographic separation was conducted as described earlier (chapter 3, section 
3.2.2.4).   
 
7.2.4.3. Mass spectrometry configuration 
The configuration of mass spectrometry was set up for positive and negative modes as 
described previously (chapter 3, section 3.2.2.3).  
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7.2.5. Data treatment and analysis 
Metabolomics data of the biological replicates from all drugs treated parasites and 
untreated controls were analyzed as described previously (chapter 4 section 4.2.5).  
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 Results 7.3.
7.3.1. Metobolomics analysis of P. falciparum parasites 
Multivariate statistical analysis using principal component analysis (PCA) and partial 
least squares-discriminant analysis (PLS-DA) was performed on the log2 transformed 
dataset (http://www.metaboanalyst.ca) generated by LC-MS/MS and normalized at time 
zero.  
 
7.3.1.1. PCA and PLS-DA 
The 2-D score plot from PCA revealed distinct divergence between P. falciparum 
parasites treated with quinoline-containing antimalarial drugs (QCDs) including 
amodiaquine, chloroquine, mefloquine, piperaquine and quinine; and untreated parasites 
controls (Figure 7.1 A). This indicates the commonality in the MoAs of QCDs resulted 
in clustering in on direction of the 2-D PCA plot. In addition, the 3-D score plot from 
PCA showed a better representation and positioning of the points in which it 
demonstaes the presence of three separated clusters (Figure 7.1 B). These include (1) 
the clustering of P. falciparum parasites treated with chloroquine, (2) the clustering of 
P. falciparum parasites treated with amodiaquine, piperaquine, quinine and mefloquine, 
and (3) the clustering of untreated P. falciparum parasites controls (Figure 7.1 B).  
 
Therefore, further discriminate analysis was carried out to examine the differences 
between QCD members. The findings showed that 2-D and 3-D score plot from PLS-
DA revealed five distinctive separation clusters (Figure 7.2 A and B). These include (1) 
the clustering of P. falciparum parasites treated with amodiaquine, (2) the clustering of 
P. falciparum parasites treated with chloroquine, (3) the clustering of P. falciparum 
parasites treated with piperaquine and mefloquine, (4) the clustering of P. falciparum 
parasites treated with quinine and (5) the clustering of untreated P. falciparum parasites 
controls (Figure 7.2 A and B). In addition, it appears from the 3-D PLS-DA plot that the 
time course points of parasites treated with chloroquine and amodaiquine were clustered 
towards one direction side whereas that of treated with quinine was clustered in another 
direction (Figure 7.2 B). This suggests that the MoA of QCDs are different and it might 
be drug class-related.  
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The corresponding loading plots for PCA and PLSDA were not very informative to 
indicate the major metabolic fingerprints accounted for the aforementioned differences 
in the clustering among different members of QCD treated parasites alongside the 
untreated parasites control (Figure 7.1 and 7.2, C). However, Variable Influence on 
Projection (VIP) score was used in metabolomics analysis to further enhance the major 
metabolites differences among different members of QCD treatments and untreated 
control. VIP score was calculated based on the variability explained in PLS-DA. 
Metabolites with VIP score > 1 were considered the most important metabolites 
responsible for the differentiation of the parasites exposed to different members of 
quinoline-containing antimalarial drug. VIP score showed that the most significant 
metabolites with score > 1 were alanine, asparagine, glutamine, lysine, orotate, DHAP 
and citrulline (Figure 7.3). In addition, succinate, G-3-P and phenyalanine had a 
borderline VIP score close to 1 (Figure 7.3). However, alanine, asparagine and 
glutamine were the merely metabolites with VIP score exceeding 2 whilst lysine, 
orotate, DHAP and citrulline had just borderline VIP score < 1.5 (Figure 7.3). This 
suggests that alanine, asparagine and glutamine were the prominent metabolic 
fingerprints. 
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Figure 7.1: PCA score and loading plots for P. falciparum 3D7 upon exposure to quinoline-
containing antimalarial drugs (QCDs).   
A) 2-D score plot shows divergence of two main clusters. One cluster includes the clustering of 
P. falciparum treated with QCDs including amodiaquine acid (AQ, red circle), chloroquine 
(CQ, green circle), mefloquine (MQ, blue circle), piperaquine (PPQ, turquoise circle), quinine 
(QN, pink circle). The other cluster includes the clustering of untreated P. falciparum control 
(UN, yellow circle). Line boundary for each group represents a 95% confidence limit from each 
treatment centre. B) 3-D score plot shows the divergence of three main clusters. One cluster 
includes the clustering of P. falciparum treated with chloroquine (CQ, green triangle). Second 
cluster includes the clustering of untreated P. falciaprum control (UN, yellow triangle). Third 
cluster includes the clustering of P. falciparum treated with mefloquine (MQ, blue triangle), 
piperaquine (PPQ, turquoise triangle) and quinine (QN, pink triangle). C) P. falciparum 
metabolites loading plot discriminate between various time points for the corresponding score 
plots (panel A and B) but it was not informative. Black arrow indicates the time zero (t=0) for 
untreated control and other drugs treatment that are all confined in the same position of 2-D and 
3-D score plots. 
t=0 
t=0 
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Figure 7.2: PLS-DA score and loading plots for Plasmodium falciparum 3D7 upon 
exposure to quinoline-containing antimalarial drugs (QCDs).  
A) 2-D score plot shows divergence of five main clusters. First cluster includes the clustering of 
P. falciparum treated with amodiaquine (AQ, red circle). Second cluster includes the clustering 
of P. falciparum treated with chloroquine (CQ, green circle). Third cluster includes the 
clustering of P. falciparum treated with quinine (QN, pink circle). Fourth cluster includes the 
clustering of P. falciparum treated with mefloquine (MQ, blue circle) and piperaquine (PPQ, 
turquoise circle). Fifth cluster includes the clustering of untreated P.falciparum control (UN, 
yellow circle). Line boundary for each group represents a 95% confidence limit from each 
treatment centre. B) 3-D score plot shows the divergence and discrimination of five main 
clusters. First cluster includes the clustering of P. falciparum treated with amodiaquine (AQ, red 
triangle). Second cluster includes the clustering of P. falciparum treated with chloroquine (CQ, 
green triangle). Third cluster includes the clustering of P. falciparum treated with quinine (QN, 
pink triangle). Fourth cluster includes the clustering of P. falciparum treated with mefloquine 
(MQ, blue triangle) and piperaquine (PPQ, turquoise triangle). Fifth cluster includes the 
clustering of untreated P. falciparum control (UN, yellow triangle). C) P. falciparum 
metabolites loading plot discriminate between various time points for the corresponding score 
plots (panel A and B) but it was not informative.  Black arrow indicates the time zero (t=0) for 
untreated control and other drugs treatment that are all confined in the same position of 2-D and 
3-D score plots. 
t=0 
t=0 
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Figure 7.3 Variable Influence on Projection (VIP) score plot for P. falciparum 3D7 upon 
exposure to quinoline-containing antimalarial drugs (QCDs).  
Metabolite with VIP score > 1 was considered the most important metabolite responsible for the 
differentiation among the different members of QCDs used to treat P. falciparum parasites. The 
coloured boxes on the right indicate the relative ratios of the corresponding metabolite in each 
group under study. Colour scale shows the colours gradient for the VIP score with dark red and 
dark green being the colours for high and low changed metabolites, respectively. VIP score plot 
shows that the most important metabolites responsible for differentiation were alanine, 
asparagine, glutamine, lysine, orotate, DHAP and citrulline. 
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7.3.1.2. Heat map for P. falciparum metabolome profiling  
The heat map demonstrated visually the relative difference of the dynamic changes of 
the P. falciparum metabolome upon exposure to different members of QCD including 
chloroquine, amodiaquine, piperaquine, quinine and mefloquine (Figure 7.4). The 
metabolomic profiles presented by the heat map showed no major differences between 
the members of QCD treated parasites and untreated in the glycolysis intermediates 
(Figure 7.4).  However, TCA intermediates showed variable profiles upon the addition 
of chloroquine, amodiaquine, piperaquine, quinine and mefloquine particularly in (iso)-
citrate profile as compared to the untreated parasites (Figure 7.4). In addition, the 
metabolic profile of pyrimidine intermediates were variable as well following the 
addition of chloroquine, amodiaquine, piperaquine, quinine and mefloquine particularly 
in dihydroorotate profile as compared to the untreated parasites (Figure 7.4).  Purine 
intermediate, hypoxanthine, showed no evident changes upon the addition of QCD 
members to the parasites as compared to untreated (Figure 7.4).  Moreover, the 
metabolic profile observed for amino acids following the addition of chloroquine, 
amodiaquine, piperaquine, quinine and mefloquine is of particular interest (Figure 7.4). 
It appears that the changes observed for amino acids metabolic profile is dependent 
upon the class of drug used. For instance, P. falciparum parasite treated with 
chloroquine showed prominent increasing trends in a number of amino acids as 
compared to other drugs and untreated as well. These amino acids include valine, 
ornithine, citrulline, alanine, threonine, asparagine, glutamine, methionine, lysine, 
phenylalanine, tryptophan and tyrosine (Figure 7.4).   
Moreover, the heat map presented in (Figure 7.4) summarized the relative fold changes 
ratio in P. falciparum following the addition of different members of QCD including 
chloroquine, amodiaquine, piperaquine, quinine and mefloquine. Major and evident 
metabolite changes were highlighted in the aforementioned paragraphs. However, 
detailed and specific explanation was presented as time-dependent graphs in the next 
section (7.3.2).   
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Figure 7.4: Heat map representation of P. falciparum 3D7 dynamics metabolome. 
Heat map shows a dynamic changes of 34 metabolites in untreated P. falciparum control and P. falciparum parasites treated after one hour of incubation with 
chloroquine (CQ), amodiaquine (AQ), piperaquine (PPQ), quinine (QN) and mefloquine (MQ). Average values at each time-point obtained using purified 
trophozoite-staged from three independent biological replicates were divided by the corresponding average values derived from parasites harvested at time 
(0hr) to generate the corresponding ratios. Ratios were log₂ transformed and plotted on a colour dynamic range scale. Rows correspond to metabolites 
measured by LC-MS/MS. Columns correspond to the time course from 0hr to 7hr for each of the six blocks. Green and red colours represent decreases and 
increases, respectively. Black colour indicates the baseline. Abbreviations: DHAP, dihydroxyaceton phosphate; G-3-P, glycerol-3-phosphate; PEP, 
phosphoenol pyruvate.    
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7.3.2. Biochemical time–dependent of metabolites profile in P. falciparum parasite  
The findings described in the previous metabolomics analysis section (section 7.3.1) 
were used to distinguish between the MoAs of QCD members used to perturb the 
biological system of P. falciparum. Average concentration values at each time-point 
obtained using purified trophozoite-stage from biological replicates were divided by the 
corresponding average values derived from parasites collected prior to the addition of 
the respective drug to generate the corresponding fold change ratio. Time-dependent 
graphs for P. falciparum untreated control and P. falciparum treated with the addition of 
chloroquine, amodiaquine, piperaquine, quinine and mefloquine were plotted using 
GraphPad Prism 5.0 (GraphPad Software Inc.). 
 
The data showed that the rate of glucose consumption in P. falciparum following the 
addition of chloroquine, amodiaquine, piperaquine, quinine and mefloquine was slightly 
higher than that of untreated control particularly in the first few hours of drugs exposure 
by 0.5 fold at time 3 hr time point (Figure 7.5 A, B, C, D and E). Consequently, the 
production of phosphoenol pyruvate (PEP) and lactate for parasites treated with 
chloroquine, amodiaquine, piperaquine, quinine and mefloquine was also marginally 
higher than that of untreated; with variations in their production rate depending on the 
drug used (Figure 7.6 and 7.7; A, B, C, D and E). In addition, the level of 
dihydroxyacetone phosphate (DHAP) was notably decreased upon treating the parasite 
with chloroquine, amodiaquine, piperaquine, quinine and mefloquine when compared to 
untreated (Figure 7.8 A, B, C, D and E). The level of glycerol-l-phosphate (G-3-P) was 
noticeably increased in parasites treated with chloroquine, amodiaquine, piperaquine, 
quinine and mefloquine as compared to the untreated parasites (Figure 7.9 A, B, C, D 
and E).  
 
The QCD showed different patterns and trends in Tricarboxylic Acid (TCA) 
intermediates compared to untreated. Specifically, P. falciparum parasites treated with 
chloroquine showed a noticeable increase in the levels of 2-oxoglutarate but no obvious 
changes were observed in 2-oxoglutarate for the reminder of QCDs treatment (Figure 
7.10 A, B, C, D and E). A distinguished reduction of (iso)-citrate was observed in 
parasites following the addition of chloroquine, amodiaquine, piperaquine, quinine and 
mefloquine (Figure 7.11 A, B, C, D and E). With the exception of piperaquine, there 
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was a notable reduction in the level of succinate in parasites treated with chloroquine, 
amodiaquine, quinine and mefloquine (Figure 7.12 A, B, D and E). There were no clear 
changes in the level of fumarate between parasites treated with amodiaquine, 
piperaquine, quinine and mefloquine and untreated parasites (Figure 7.13 B, C, and E) 
but a notable reduction was observed in fumarate level in parasites treated with 
chloroquine and quinine (Figure 7.13 A and D). Moreover, parasites treated with 
amodiaquine, quinine and mefloquine showed a reduction in the level of oxaloacetate 
whereas those treated with chloroquine and piperaquine do not (Figure 7.14 A, B, C, D 
and E). Parasites treated with amodiaquine and quinine showed a notable reduction in 
malate levels while those treated with chloroquine, piperaquine and mefloquine showed 
a slight reduction in malate as compared to untreated parasites (Figure 7.15 A, B, C, D 
and E ).     
 
With regards to pyrimidine intermediates, there were no obvious changes noted in the 
levels of carbamoyl-l-aspartate in parasites treated with chloroquine, amodiaquine, 
piperaquine, quinine and mefloquine as compared to untreated parasites (Figures 7.16 
A, B, C, D and E). However, with the exception of mefloquine, P. falciaprum treated 
with chloroquine, amodiaquine, piperaquine and quinine showed a notable reduction in 
the levels on dihydroorotate (Figure 7.17 A, B, C, D and E). Orotate level was notably 
decreased in parasites treated with chloroquine and amodiaquine as compared to 
untreated parasites but there were no obvious changes in its level in parasites treated 
with piperaquine, quinine and mefloquine (Figure 7.18 A, B, C, D and E ). With regards 
to purine intermediate, hypoxanthine, parasites treated with chloroquine, amodiaquine 
and piperaquine showed no clear changes when compared to untreated parasites (Figure 
7.19 A, B and C). However, parasites treated with quinine and mefloquine showed a 
slight increase in the hypoxanthine level as compared to untreated parasites (Figure 7.19 
D and E).   
 
Amino acids profile were different upon the addition of QCDs to P. falciparum 
parasites. Following the addition of chloroquine, amodiaquine, piperaquine, quinine and 
mefloquine to P. falciparum parasites, there was a notable accumulation in the level of 
alanine (Figure 7.20 A, B, C, D and E) and there was a little or no utilization in 
glutamine and asparagine (Figure 7.21 and 7.23; A, B, C, D and E). In addition, the 
level of glutamate in parasites treated with all members of QCDs mentioned above 
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showed a noticeable of invariable changes compared to untreated parasites (Figure 7.22 
A, B, C, D and E) whereas there was a notable reduction in the level of aspartate 
compared to untreated parasites following the addition of QCDs (Figure 7.24 A, B, C, D 
and E).    
 
Moreover, there were no obvious changes in the levels of arginine and proline upon the 
addition of chloroquine, amodiaquine, piperaquine, quinine and mefloquine to the P. 
falciparum parasites as compared to the untreated (Figures 7.25 and 7.26; A, B, C, D 
and E). Interestingly, there was a distinguished accumulation in the level of ornithine in 
parasites treated with chloroquine (Figure 7.27 A) but no evident changes were 
observed in ornithine levels in parasites treated with amodiaquine, piperaquine, quinine 
and mefloquine (Figure 7.27 B, C, D and E). Additionally, there was a little or no 
utilization in the level of methionine in parasites treated with chloroquine (Figure 7.29 
A) but no clear changes were observed in methionine levels in parasites treated with 
amodiaquine, piperaquine, quinine and mefloquine (Figure 7.29 B, C, D and E). P. 
falciparum parasites treated with chloroquine, amodiaquine, piperaquine, quinine and 
mefloquine showed a notable accumulation of citrulline as compared to untreated 
parasite (Figure 7.28 A, B, C, D and E). 
 
There was little or no utilization of lysine upon the addition of chloroquine and 
amodiaquine to the P. falciparum parasites as compared to the untreated (Figure 7.30 A 
and B). In contrast, parasites treated with piperaquine, quinine and mefloquine showed 
no obvious changes in the level of lysine compared to untreated parasites (Figure 7.30 
C, D and E). Moreover, there were no clear changes in the level of serine and histidine 
upon the addition of chloroquine, amodiaquine, piperaquine, quinine and mefloquine to 
the P. falciparum parasites as compared to the untreated (Figure 7.31 and 7.32; A, B, C, 
D and E). 
 
Furthermore, P. falciparum parasites treated with chloroquine showed a slight increase 
in the phenyalanine level whereas those treated with amodiaquine, piperaquine, quinine 
and mefloquine showed little or no utilization of phenylalanine as compared to 
untreated parasites (Figure 7.33 A, B, C, D and E). In addition, P. falciparum parasites 
treated with chloroquine, amodiaquine, piperaquine and mefloquine showed little or no 
utilization of tryptophan (Figure 7.34 A, B, C and E) whereas those treated with quinine 
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showed a notable increase in tryptophan level as compared to untreated parasites 
(Figure 7.34 D). Moreover, there was a trend of increase in the level of tyrosine in 
parasites treated with chloroquine, quinine and mefloquine (Figure 7.35 A, D and E). 
On the other hand, parasites treated with amodiaquine and piperaquine did not show 
notable changes in tyrosine level as compared to untreated parasites (Figure 7.35 B and 
C).  
 
In addition, the P. falciparum parasites treated with chloroquine and quinine showed a 
notable increase in the level of threonine (Figure 7.36 A and D) whereas those treated 
with amodiaquine, piperaquine and mefloquine showed little or no utilization of 
threonine as compared to untreated (Figure 7.36 B, C and E). In addition, parasites 
treated with chloroquine, amodiaquine, piperaquine, quinine and mefloquine showed a 
notable increase in the valine level by at least 0.5 fold at 7 hr time point as compared to 
untreated (Figure 7.37 A, B, C, D and E). There was no obviuos changes observed in 
the level of (iso)-leucine in parasites treated with chloroquine, amodiaquine, 
piperaquine, quinine and mefloquine as compared to untreated parasites (Figure 7.38 A, 
B, C, D and E).     
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Figure 7.5. Time-dependent of glucose fermentation in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Glucose levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data showed clearly the 
utilization of glucose in drugs treated and untreated parasites. The points represent the mean ± 
SEM of at least duplicate independent experiments. 
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Figure 7.6. Time-dependent curves of phosphoenol pyruvate (PEP) in drug-treated and 
untreated P. falciparum 3D7 parasites.  
PEP levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data showed slight increase in 
PEP levels after one hour of incubation in parasites treated with (A) 50  nM chloroquine, (B) 50 
nM amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine as 
compared to untreated parasites.  The points represent the mean ± SEM of at least duplicate 
independent experiments.                      
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Figure 7.7. Time-dependent curves of lactate production in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Lactate levels were measured in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data showed slight increase in 
lactate levels at 7 hr time point in parasites treated with (A) 50  nM chloroquine, (B) 50 nM 
amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine as 
compared to untreated parasites.  The points represent the mean ± SEM of at least duplicate 
independent experiments. 
B 
A 
A
F
i
g
u
r
e 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
l
s 
i
n 
d
r
u
g
-
t
r
e
a
t
e
d 
a
n
d 
u
n
t
r
e
C
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
l
s 
i
n 
d
r
u
g
-
t
r
e
a
t
e
D
 
6
.
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
l
s 
i
n 
d
r
u
g
-
t
r
e
a
t
e
E
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
e 
l
e
v
e
l
 248 
 
Time (hr)
F
o
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0
200
400
600
Drug Addition
Time (hr)
F
o
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0
200
400
600
Drug Addition
Time (hr)
F
o
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0
200
400
600
Drug Addition
Time (hr)
F
o
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0
200
400
600
Drug Addition
Time (hr)
F
o
ld
 C
ha
ng
e
0 1 2 3 4 5 6 7
0
200
400
600
Drug Addition
 
Figure 7.8. Time-dependent curves of dihydroxyaceton phosphate (DHAP) in drug-treated 
and untreated P. falciparum 3D7 parasites.  
DHAP levels were measured in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. Data showed a notable reduction of 
DHAP after one hour of incubation in parasites treated with (A) 50 nM chloroquine, (B) 50 nM 
amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. The 
points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.9. Time-dependent curves of glycerol-3-phosphate (G-3-P) in drug-treated and 
untreated P. falciparum 3D7 parasites.  
G-3-P levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. Data showed a notable increase in G-3-P 
after one hour of incubation in parasites treated with (A) 50 nM chloroquine, (B) 50 nM 
amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. The 
points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.10. Time-dependent curves of 2-oxoglutarate in drug-treated and untreated P. 
falciparum 3D7 parasites.  
2-oxoglutarate levels were determined in untreated (open circle) and drug-treated (closed circle) 
P. falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to 
the parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 
80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data showed a notable 
increase in 2-oxoglutarate in parasite treated with (A) 50 nM chloroquine compared to 
untreated. There were no clear changes between others drug-treated and untreated parasites. The 
points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.11. Time-dependent curves of (iso)-citrate in drug-treated and untreated P. 
falciparum 3D7 parasites.  
The (iso)-citrate levels were determined in untreated (open circle) and drug-treated (closed 
circle) P. falciparum trophozoite-stage parasites by LC-MS/MS. Data showed a distinguished 
reduction in (iso)-citrate after one hour of incubation in parasites treated with (A) 50 nM 
chloroquine, (B) 50 nM amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 
nM mefloquine. The points represent the mean ± SEM of at least duplicate independent 
experiments. 
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Figure 7.12. Time-dependent curves of succinate in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Succinate levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-staged parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. With the exception of (C) 
piperaquine, data showed an evident reduction in the level of succinate in parasites treated with 
(A) 50 nM chloroquine, (B) 50 nM amodiaquine, (D) 100 nM quinine and (E) 50 nM 
mefloquine. The points represent the mean ± SEM of at least duplicate independent 
experiments. 
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Figure 7.13. Time-dependent curves of fumarate in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Fumarate levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-staged parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. There were no clear changes 
in the level of fumarate between parasites treated with (B) 50 nM amodiaquine, (C) 80 nM 
piperaquine, and (E) 50 nM mefloquine but a notable reduction was observed in fumarate level 
in parasites treated with (A) 50 nM chloroquine and (D) 100 nM quinine. The points represent 
the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.14. Time-dependent curves of oxaloacetate levels in drug-treated and untreated 
P. falciparum 3D7 parasites.  
Oxaloacetate levels were determined in untreated (open circle) and drug-treated (closed circle) 
P. falciparum trophozoite-staged parasites by LC-MS/MS. The following drugs were added to 
the parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 
80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data showed a notable 
reduction in the level of oxaloacetate in parasites treated with (B) 50 nM amodiaquine, (D) 100 
nM quinine and (E) 50 nM mefloquine whereas no clear changes were observed in others drug 
used. The points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.15. Time-dependent curves of malate production in drug-treated and untreated 
P. falciparum 3D7 parasites.  
Malate levels were measured in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-staged parasites by LC-MS/MS. The following drugs were added to 
the parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 
80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data showed an evident 
reduction in the level of malate in parasites treated with (B) 50 nM amodiaquine and (D) 100 
nM quinine while those treated (A) 50 nM chloroquine, (C) 80 nM piperaquine and (E) 50 nM 
mefloquine showed a slight reduction in malate as compared to untreated parasites. The points 
represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.16. Time-dependent curves of carbamoyl-L-aspartate in drug-treated and 
untreated P. falciparum 3D7 parasites.  
Carbamoyl-L-aspartate levels were determined in untreated (open circle) and drug-treated 
(closed circle) P. falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs 
were added to the parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM 
amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. There 
were no obvious changes between drugs-treated and untreated parasites. The points represent 
the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.17. Time-dependent curves of dihydroorotate in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Dihydroorotate levels were determined in untreated (open circle) and drug-treated (closed 
circle) P. falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were 
added to the parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM 
amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data 
showed a notable reduction in dihydroorotate levels in parasites treated with A) 50 nM 
chloroquine, (B) 50 nM amodiaquine, (C) 80 nM piperaquine and (D) 100 nM quinine. The 
points represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.18. Time-dependent curves of orotate in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Orotate levels were determined in untreated (opencircle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data showed a notable 
reduction in orotate level in parasites treated with (A) 50 nM chloroquine and (B) 50 nM 
amodiaquine. There were no obvious changes observed between other drugs-treated and 
untreated parasites. The points represent the mean ± SEM of at least duplicate independent 
experiments. 
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Figure 7.19. Time-dependent curves of hypoxanthine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Hypoxanthine levels were determined in untreated (open circle) and drug-treated (closed circle) 
P. falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to 
the parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 
80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. A slight elevation was 
observed in parasites treated with (D) 100 nM quinine and (E) 50 nM mefloquine. There were 
no clear changes observed between other drugs-treated and untreated parasites. The points 
represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.20. Time-dependent curves of alanine accumulation in drug-treated P. 
falciparum 3D7 parasites.  
Alanine levels were determined in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-stage parasites by LC-MS/MS. Data showed a distinguished 
accumulation of alanine after one hour of incubation in parasites treated with (A) 50 nM 
chloroquine, (B) 50 nM amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 
nM mefloquine. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.21. Time-dependent curves of glutamine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Glutamine levels were determined in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-stage parasites by LC-MS/MS.  Data showed a little or no utilization 
of glutamine after one hour of incubation in parasites treated with (A) 50 nM chloroquine, (B) 
50 nM amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. 
Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.22. Time-dependent curves of glutamate in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Glutamate levels were determined in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-stage parasites by LC-MS/MS. Notable invariable changes were 
observed in glutamate after one hour of incubation in parasites treated with (A) 50 nM 
chloroquine, (B) 50 nM amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 
nM mefloquine. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.23. Time-dependent curves of asparagine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Asparagine levels were determined in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-staged parasites by LC-MS/MS. Data showed little or no utilization of 
asparagine after one hour of incubation in parasites treated with (A) 50 nM chloroquine and (B) 
50 nM amodiaquine. Significant invariable changes was observed in parasites treated with (C) 
80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data represent the mean ± 
SEM of at least duplicate independent experiments. 
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Figure 7.24. Time-dependent curves of aspartate in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Aspartate levels were determined in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-stage parasites by LC-MS/MS. Data showed a notable reduction of  
aspartate levels after one hour of incubation in parasites treated with (A) 50 nM chloroquine, 
(B) 50 nM amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM 
mefloquine. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.25. Time-dependent curves of arginie degradation in drug-treated and untreated 
P. falciparum 3D7 parasites.  
Arginine degradation levels were measured in untreated (open circle) and drug-treated (closed 
circle) P. falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were 
added to the parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM 
amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. There 
were no obvious changes observed between drugs-treated and untreated parasites. The points 
represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.26. Time-dependent curves of proline in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Proline levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. There were no obvious 
changes observed between drugs-treated and untreated parasites.  The points represent the mean 
± SEM of at least duplicate independent experiments. 
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Figure 7.27. Time-dependent curves of ornithine production in drug-treated and 
untreated P. falciparum 3D7 parasites.  
Ornithine levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data showed a distinguished 
accumulation of ornithine in parasites treated with (A) 50 nM chloroquine but not with other 
drugs treated as compared to untreated. The points represent the mean ± SEM of at least 
duplicate independent experiments. 
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Figure 7.28. Time-dependent curves of citrulline in drug-treated and untreated P. 
falciparum 3D7 parasites.  
The citrulline levels were determined in untreated (open circle) and drug-treated (closed circle) 
P. falciparum trophozoite-stage parasites by LC-MS/MS. Data showed a notable accumulation 
of citrulline after one hour of incubation in parasites treated with (A) 50 nM chloroquine, (B) 50 
nM amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data 
represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.29. Time-dependent curves of methionine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Methionine levels were determined in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-stage parasites by LC-MS/MS. Data showed little or no utilization  of  
methionine levels after one hour of incubation in parasites treated with (A) 50 nM chloroquine. 
No obviuos changes were observed in parasites treated with (B) 50 nM amodiaquine, (C) 80 nM 
piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. Data represent the mean ± SEM of 
at least duplicate independent experiments. 
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Figure 7.30. Time-dependent curves of lysine degradation in drug-treated and untreated 
P. falciparum 3D7 parasites.  
Lysine degredation levels were determined in untreated (open circle) and drug-treated (closed 
circle) P. falciparum trophozoite-stage parasites by LC-MS/MS. Data showed little or no 
utilization of  lysine after one hour of incubation in parasites treated with (A) 50 nM 
chloroquine and (B) 50 nM amodiaquine. Parasites treated with  (C) 80 nM piperaquine, (D) 
100 nM quinine and (E) 50 nM mefloquine showed no clear changes. Data represent the mean ± 
SEM of at least duplicate independent experiments. 
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Figure 7.31. Time-dependent curves of serine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Serine levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. There were clear changes 
observed among drugs-treated parasites as compared to untreated. The points represent the 
mean ± SEM of at least duplicate independent experiments. 
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Figure 7.32. Time-dependent curves of histidine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Histidine levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. The following drugs were added to the 
parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 
nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. There were clear changes 
observed among drugs-treated parasites as compared to untreated. The points represent the 
mean ± SEM of at least duplicate independent experiments. 
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Figure 7.33. Time-dependent curves of phenylalanine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Phenylalanine levels were determined in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-stage parasites by LC-MS/MS. Phenylalanine was slightly 
accumulated after one hour of incubation in parasites treated with (A) 50 nM chloroquine. 
Parasites treated with (B) 50 nM amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine, (E) 
50 nM mefloquine showed little or no utilization of phenylalanine as compared to untreated. 
Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.34. Time-dependent curves of tryptophan in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Tryptophan levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. Data showed a notable accumulation of 
tryptophan levels after one hour of incubation in parasites treated with (D) 100 nM quinine. 
Parasites treated with (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 nM piperaquine 
and (E) 50 nM mefloquine illustrated little or no utilization of tryptophan as compared to 
untreated. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.35. Time-dependent curves of tyrosine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Tyrosine levels were determined in untreated (open circle) and drug-treated (closed circle) P. 
falciparum trophozoite-stage parasites by LC-MS/MS. Data showed a notable increasing trend 
of tyrosine after one hour of incubation in parasites treated with (A) 50 nM chloroquine, (D) 
100 nM quinine and (E) 50 nM mefloquine. Parasites treated with (B) 50 nM amodiaquine, (C) 
80 nM piperaquine illustrated no obvious changes as compared to untreated. Data represent the 
mean ± SEM of at least duplicate independent experiments. 
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Figure 7.36. Time-dependent curves of threonine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Threonine levels were determined in untreated (open circle) and drug-treated (closed circle) 
P.falciparum trophozoite-staged parasites by LC-MS/MS. Data showed a notable increase in the 
threonine levels after one hour of incubation in parasites treated with (A) 50 nM chloroquine 
and (D) 100 nM quinine whereas little or no utilization was observed in parasites treated with 
(B) 50 nM amodiaquine, (C) 80 nM piperaquine and (E) 50nM mefloquine as compared to 
untreated. Data represent the mean ± SEM of at least duplicate independent experiments. 
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Figure 7.37. Time-dependent curves of valine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
Valine levels were determined in untreated (opened circle) and drug-treated (closed circle) 
P.falciparum trophozoite-staged parasites by LC-MS/MS. Data showed a notable increase in the 
valine level by at least 0.5 fold at 7 hr time point as compared to untreated in parasites treated 
with (A) 50 nM chloroquine, (B) 50 nM amodiaquine, (C) 80 nM piperaquine (D) 100 nM 
quinine and (E) 50 nM mefloquine. Data represent the mean ± SEM of at least duplicate 
independent experiments. 
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Figure 7.38. Time-dependent curves of (iso)-leucine in drug-treated and untreated P. 
falciparum 3D7 parasites.  
The (iso)-leucine levels were determined in untreated (open circle) and drug-treated (closed 
circle) P.falciparum trophozoite-staged parasites by LC-MS/MS. The following drugs were 
added to the parasites after one hour of incubation (A) 50 nM chloroquine, (B) 50 nM 
amodiaquine, (C) 80 nM piperaquine, (D) 100 nM quinine and (E) 50 nM mefloquine. There 
were no obvious changes observed between drugs-treated and untreated parasites. The points 
represent the mean ± SEM of at least duplicate independent experiments. 
B 
A 
A
F
i
g
u
r
e 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
l
s 
i
n 
d
r
u
g
-
t
r
e
a
t
e
d 
a
n
d 
u
n
t
r
e
C
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
l
s 
i
n 
d
r
u
g
-
t
r
e
a
t
D
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
e
l
s 
i
n 
d
r
u
g
-
t
r
e
a
t
E
 
6
.
1
. 
T
i
m
e 
c
o
u
r
s
e 
o
f 
a
l
a
n
i
n
e 
l
e
v
 279 
 
 Discussion 7.4.
In this chapter, a pharmacometabolomics approach was used to determine the MoA of 
quinoline-containing antimalarial drugs (QCDs) in order to study the role of digestive 
vacuole in P. falciparum. Two classes of QCDs, including type-1 drugs 4-
aminoquinolines and type-2 drugs aryl-amino alcohols, were investigated in this study. 
Type-1 drugs 4-aminoquinolines include chloroquine, amodiaquine and piperaquine 
while type-2 drugs aryl-amino alcohols include quinine and mefloquine. The 
metabolomics analysis performed using PCA and PLS-DA demonstrated interesting 
findings. The 2-D of PCA showed the divergence of two main clusters including one 
cluster of untreated P. falciparum parasite and another cluster of P. falciparum parasite 
treated with chloroquine, amodiaquine, piperaquine, quinine and mefloquine. This 
finding showed clearly that the parasite metabolism phenotype was altered upon 
apparently the perturbation caused by the addition of QCD members. The 3-D of PCA 
showed better representation and positioning of the drugs-treated and untreated 
parasites points. It demonstrated that the cluster of parasite treated with chloroquine was 
distinctly separated from the clusters of untreated parasites and parasites treated with 
amodiaquine, piperaquine, quinine and mefloquine. This finding suggests that the MoA 
of chloroquine is different from that of amodiaquine, piperaquine, quinine and 
mefloquine. Nonetheless, further discriminate analysis (PLS-DA) was conducted to 
investigate whether the MoA of QCD members are similar or at least related. 
Interestingly, the findings of 2-D and 3-D PLS-DA showed the separation of five main 
clusters. These include cluster of parasites treated with chloroquine, cluster of parasite 
treated with amodiaquine, clusters of parasites treated with piperaquine and mefloquine, 
cluster of parasites treated with quinine and cluster of untreated parasites. These results 
showed clearly that the MoA of QCD members, including chloroquine, amodiaquine, 
piperaquine, quinine and mefloquine, is probably drug class dependent. Specifically, it 
appears that the parasites treated with chloroquine and amodiaquine had their clusters 
together in the 2-D and 3-D PLS-DA plots. This indicates that chloroquine and 
amodiaquine had a similar MoA effects on the parasite because they are from the same 
drug class. In contrast, parasites treated with quinine had its cluster in different direction 
of those treated with chloroquine and amodiaquine suggesting that quinine had different 
effects on parasites than other members of QCD. However, it was noteworthy that 
although parasites treated with two different drugs class; including piperaquine and 
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mefloquine, of QCDs had their clusters overlapping each other suggesting perhaps the 
commonality in the MoA of both antimalarial drugs. This finding is of particular 
interest as it indicates that piperaquine, bisquinolines, and mefloquine shared possibly a 
common target.  
Moreover, the VIP score plot showed that the most important metabolites that had VIP 
score > 1 were alanine, asparagine, glutamine, lysine, orotate, DHAP and citrulline 
indicating that the effects of QCD are involved in the disruption of more than one 
metabolic pathway which may include the haemoglobin digestion, glycolysis pathway, 
pyrimidine biosynthesis and perhaps exogenously acquired amino acids. The hypothesis 
of the interaction of chloroquine and perhaps other QCD members with haemoglobin 
digestion is supported by other studies that have provided evidence of undigested 
haemoglobin in parasites treated with chloroquine (Krugliak et al., 2002, Roberts et al., 
2008, Yayon et al., 1984c). It has been ultra-structurally demonstrated that chloroquine 
inhibited the last step of the feeding process (i.e. vacuolar degradation) in trophozoite 
stage of P. falciparum manifested by the accumulation of intact vesicles bounded by 
single membranes within the vacuolar space (Yayon et al., 1984c). In addition, a recent 
study has shown an increase in free heme and decrease in hemozoin upon quinoline-
related antimalarials exposure to P. falciparum parasites (Combrinck et al., 2013). 
However, this increase and decrease in heme and hemozoin, respectively, is 
significantly less than that for parasites treated with chloroquine (Combrinck et al., 
2013).  This either indicates the multiple MoA of these drugs and/or differences in the  
toxicity of heme-drug complexes (Combrinck et al., 2013). This indication is supported 
by the metabolomic findings obtained for parasites treated with different members of 
QCD demonstrating clear discrimination and clustering of each drug being used. In 
addition, it was also demonstrated by the biochemical time-dependent result that 
following the addition of chloroquine, amodiaquine, piperaquine, quinine and 
mefloquine to P. falciparum parasites, the level of glutamate was noticeably invariable. 
This finding suggests that the MoA effect of these drugs paralyzed the metabolism of 
glutamate which might be as well affecting other metabolic pathway linked to glutamate 
such as TCA cycle, pyrimidine de novo synthesis, CO2 fixation process, protein 
synthesis, redox metabolism and porphyrin metabolism. Therefore, glutamate is this 
case could be regarded as a central hub to different metabolic network in the parasite. 
However, this hypothesis is required to be further analysed and confirmed using 
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bioinformatic tools for system biology (currently underway in the LSTM). Intriguingly, 
aspartate levels upon QCDs exposure were notably decreased which could be explained 
as the presence of high demand needed for making DNA and RNA under drug pressure 
as well as a transition state from trophozoite to schizont.   
As noted in the introduction, amino acids such as glutamine, glutamate, cysteine, 
proline, tyrosine, (iso)-leucine and methionine are rare or absent in human haemoglobin 
(Divo et al., 1985a). Cysteine was below the limit of detection for the current 
metabolomics approach. Glutamine, glutamate, proline, tyrosine, (iso)-leucine and 
methionine were supplied in the culture media and it appears that the untreated parasite 
utilized some of these amino acids to conduct several metabolic biosynthetic pathways. 
In addition, It has been reported that the P. falciparum parasite digested up to 65% of 
the RBC haemoglobin but up to 16% of digested haemoglobin is converted to parasite 
protein (Krugliak et al., 2002). On the other hand, it has been shown previously that 
when radiolabelled RBCs were transfused into P. lophurae- and P. berghei-infected 
RBC and the parasites were allowed to invade and grow in these tagged RBC, the 
amino acids in the radioactive haemoglobin became incorporated into the parasite 
proteins (Sherman and Tanigosh.L, 1970, Theaksto.Rd et al., 1970). Therefore, given 
that pharmacometabolomic experiments were conducted on P. falciparum parasite 
incubated with culture media, it is probably that the availability of amino acids in the 
parasite cytosol is governed by a dynamic equilibrium between haemoglobin 
degradation, efflux of generated amino acids and influx of amino acids from the 
extracellular media in order to incorporate them into proteins and other metabolic 
pathways. Therefore, it appears that actions of quinoline-containing antimalarial drugs 
used in this study were primarily concerted on two main targets: haemoglobin 
degradation process in digestive vacuole and other amino acids metabolic pathways 
including amino acids acquisition through new permeability pathway (NPP). Indeed, 
chloroquine treated parasites showed a distinguished accumulation in ornithine 
suggesting that the MoA of chloroquine is also extended to the parasite cytosol which 
may further leads to inhibition of polyamine metabolism. This result is consistent with 
previous study showing that incubation of P. falciparum-iRBC with 1 µM chloroquine 
inhibited the ornithine decarboxylase activity by 63% as compared to untreated controls 
(Konigk and Putfarken, 1983). In addition, it has been suggested that free heme escapes 
from the digestive vacuole and is degraded in the parasite cytosol by reduced 
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glutathione (GSH) (Ginsburg et al., 1998). Therefore, it has been hypothesized that 
chloroquine and amodiaquine competes for this process leading to the disruption of 
parasite plasma membrane as free heme builds up in the cytosol (Ginsburg et al., 1998). 
This hypothesis was supported by the study showing that manipulation the external 
concentration of GSH alters the sensitivity of the parasite to chloroquine (Raj et al., 
2009). Accordingly, methionine levels were notably not changed in chloroquine treated 
parasite as compared to untreated parasites indicating perhaps dual-inhibitions which 
include the blocking of polyamine synthesis by targeting ornithine decarboxylase and 
targeting the NPP preventing the accesses to the methionine available in the 
extracellular medium. Interestingly, citrulline levels were noticeably increased upon the 
addition of chloroquine, amodiaquine, piperaquine, quinine and mefloquine suggesting 
possibly the extensive production of nitric oxide (NO) via the oxidation of arginine to 
citrulline as a consequence of instant drug pressure. This was observed as well in the 
slightly excessive utilization of arginine in QCDs treated parasites particularly in the 
first few hours of the incubation as compared to untreated.   
Furthermore, chloroquine and amodiaquine treated parasites showed little or no 
utilization of lysine particularly in the first few hours of incubation compared to 
untreated parasite control. This indicates the commonality in the MoA of chloroquine 
and amodiaquine possibly in targeting the same route of lysine metabolic pathway. 
There was also a notable increase in threonine levels following the addition of 
chloroquine and quinine as compared to untreated. However, parasites treated with 
chloroquine, amodiaquine, piperaquine, quinine and mefloquine showed a notable 
increase in the valine as compared to untreated. This indicates probably the direct or 
indirect involvement of chloroquine and quinine in the interference of metabolism of 
threonine and valine. However, it is difficult to explain or propose why there was such 
an effect seen on threonine and valine upon chlolorquine and quinine addition as well as 
for others QCD effects on valine; which are remained to be explored.    
Moreover, the slight increase seen in the level of phenylalanine upon the addition of 
chloroquine suggesting its interaction with phenylalanine metabolism and/or transport. 
However, other members of QCDs including amodiaquine, piperaquine, quinine and 
mefloquine showed little or no utilization of phenylalanine indicating may be the less 
involvement in the interaction with phenylalanine. In addition, since chloroquine, an 
amphiphilic compound, is able to gain entry into cells without the assistance of 
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membrane transporters (Ferrari and Cutler, 1991), this may explains why other 
members of QCD had not shown a similar effect as chloroquine. Additionally, P. 
falciparum parasites treated with quinine showed remarkable accumulation in the level 
of tryptophan whereas those treated with chloroquine, amodiaquine, piperaquine and 
mefloquine showed little or no utilization of tryptophan. This finding suggests that these 
QCDs commonly interact with tryptophan but with different efficacy or activity. This is 
consistent with the recent study showing that quinine interferes with tryptophan 
metabolism in the malaria parasite and yeast model through inhibiting tryptophan 
uptake competitively (Islahudin et al., 2012, Khozoie et al., 2009). In addition, parasites 
treated with chloroquine, quinine and mefloquine showed a notable increase in tyrosine 
level but not with amodiaquine and piperaquine as compared to untreated parasites. As 
noted above, this may indicates the mode of chloroquine, quinine and mefloquine 
toxicity to the parasite resulting in the tyrosine starvation. This finding of tyrosine 
accumulation upon quinine exposure is consistent with the clinical study showing that 
the level of tyrosine in plasma of malaria patients increased ≥2- fold during quinine 
therapy (Islahudin et al., 2012). 
The notable consumption of glucose, marginal elevation of phosphoenolpyruvate and 
lactate and the notable decrease and increase in DHAP and glycerol-3-phosphate, 
respectively, upon treating P. falciparum parasites with chloroquine, amodiaquine, 
piperaquine, quinine and mefloquine indicates that these QCD members may exert 
indirect MoA effect on glycolysis metabolic pathway and probably on glycerol-3-
phosphate shuttle between cytosol and mitochondria. This indirect effect of these drugs 
might be resulted from the accumulation of free toxic heme leading to imbalance 
perturbation effect of metabolic system biology of the parasite. These findings are 
inconsistent with the previous studies carried out on P. falciparum (Menting et al., 
1997, Read et al., 1999) and yeast (Lenz and Holzer, 1984) showing that chloroquine 
acts as competitive inhibitor in the NADH binding pocket of P. falciparum lactate 
dehydrogenase (Pf LDH) and it causes a rapid and drastic decrease of the ATP content 
of the yeast by preventing the fermentation of glucose and formation of ethanol, 
respectively. However, the concentration of chloroquine used in these studies (Lenz and 
Holzer, 1984, Read et al., 1999, Menting et al., 1997) was in the millimolar range while 
that of used in this study was in nanomolar range. Moreover, the variable (decrease 
and/or increase) notable changes seen in a number of TCA intermediates such as 2-
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oxoglutarate, (iso)-citrate, succinate, oxaloacetate and malate as well as pyrimidine 
dihydroorotate intermediate following the QCDs addition to the P. falciparum parasite 
could be explained again as discussed above as an indirect effect of these QCD drugs.   
Overall, it appears that P. falciparum digestive vacuole plays a pivotal role in 
maintaining the biological function of the parasite. It provides amino acids for protein 
synthesis that are responsible for cellular structure and function. However, this 
pharmacometabolomics study suggests that in addition to this, quinolone-based drugs 
are acting on the parasite cytosol and membrane which resulting in blocking other vital 
metabolic pathways leading to parasite death.  
With regards to the limitation of this study, it is almost the same as the limitation 
discussed in the preceding chapters in terms of inability of the current metabolomics 
method to detect a number of metabolites which the bioenergetics/redox couples, UMP, 
UDP, UTP, TTP, CTP, and GTP perhaps due to the presence of inadequate parasite 
materials. With regards to future experiments, it can be underlined that P. falciparum 
digestive vacuole has a vital and essential biological role in the maintenance of amino 
acids abundance and toxic detoxification. It might be of interest to explore this 
organelle further by using drugs such as artemisinin as well as specific inhibitors to the 
digestive vacuole degradation enzyme such as pepstatin for proteases.   
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CHAPTER 8   
Summary, Conclusions, Limitations and Future 
Perspectives 
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 Summary and conclusions  8.1.
The aim of this chapter is to present the main findings of this thesis and place them in 
the broader context of the current understanding of P. falciparum parasite biology, 
particularly, to provide comprehensive views about the metabolic roles of the P. 
falciparum mitochondria and digestive vacuole using known antimalarial drugs, and 
some inhibitors.  
  
Malaria remains one of the leading causes of disease and death in the world, particularly 
in tropical countries. Malaria treatment remains the cornerstone of patient management 
and, in the absence of a fully effective vaccine, will likely remain so for the foreseeable 
future. However, in order to introduce an effective antimalarial drug therapy, prior 
knowledge of malaria parasite biology needs to be thoroughly understood. This can then 
be translated into identifying the vital and critical functions of malaria parasite 
biological systems for the development and discovery of effective and potent drugs. 
Metabolomics offers an attractive modern methodology for fast and comprehensive 
determination of parasite systems biology metabolites, and for establishing metabolic 
phenotypes, for instance in drug treated versus untreated parasites.   
 
Therefore, targeted metabolomics platform was set out (as described in Chapter 3) for 
studying the P. falciparum metabolome in order get new insights into the parasite 
biology, as well as exploring the likely drug MoAs. The development and validation of 
this was carried out in accordance with a number of criteria that include selectivity and 
carryover, metabolite recovery and stability, linearity and sensitivity (limit of detection, 
LOD), and performance reproducibility. Overall, this metabolomics platform was able 
to detect and quantify accurately ~10% of the P. falciparum metabolome with LOD 
ranging from low nM to µM concentrations. This is an important aspect in the 
metabolomics field because there are several biosynthetic metabolic pathways, making 
the biosynthesized metabolites present in low levels, that P. falciparum parasite depends 
on to carry an essential metabolic function such as pyrimidine de novo synthesis. As 
indicated previously in Chapter 3, there are few limitations in the developed targeted 
metabolomics method which are discussed below. 
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Moreover, metabolomics data analysis software such as MetaboAnalyst web-based 
software (http://www.metaboanalyst.ca) (Xia et al., 2012; Xia et al., 2009) has the 
ability to cluster drug candidates according to their common MoAs. Based on a 
metabolomic analysis, principal component analysis (PCA), and partial least squares 
discriminant analysis (PLS-DA) of compound profiles for drug candidates can be 
performed. The ability to cluster drug candidates according to their common MoAs has 
been proven for the study in this thesis to be very useful in predicting the mode of 
unknown drug candidates such as CK-2-68, which has been shown to have similar MoA 
to potassium cyanide and bongkrekic acid and a different MoA of atovaquone although 
all these drugs shared general metabolic fingerprints in the upstream intermediates of 
pyrimidine biosynthesis, carbamoyl-l-aspartate and dihydroorotate (Chapter 6). This 
interesting finding is an example of the power of this type of analysis, demonstrating the 
significant benefits and practicality of the pharmacometabolomics approach for 
prioritizing drug candidates.  
 
Furthermore, the application of the pharmacometabolomics approach in this thesis has 
enabled the identification and reliable prediction of the physiological functions of P. 
falciparum parasite, particularly the roles of mitochondria and digestive vacuole. P. 
falciparum, like any eukaryotic cell, requires the metabolism of a wide range of 
metabolites including amino acids, carbohydrates, nucleotides, redox, vitamins and 
other substances in order to sustain life. It has been shown and discussed (Chapter 4) 
that P. falciparum-iRBC had higher metabolic activity than non-infected RBC, 
particularly in the glucose fermentation process, and also in other vital metabolic 
process to the parasite, such as pyrimidine biosynthesis, amino acids metabolism, and in 
operating TCA cycle metabolic pathway. 
 
It has been shown that the mitochondrion of malaria parasites is highly divergent from 
its mammalian counterpart, and its physiology has been validated as a target for anti-
malarial drugs such as atovaquone (Mather and Vaidya, 2008; Vaidya and Mather, 
2005, 2009). In the study of this thesis, P. falciparum mitochondria and its electron 
transport chain (ETC) were biochemically analysed using a number of selective 
inhibitors and some antimalarial drugs as described previously (Chapters 5 and 6). The 
primary metabolic fingerprint differences observed between P. falciparum sensitive 
3D7 and transgenic 3D7-yDHOD∙GFP strains following atovaquone and CK-2-68 
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addition were in the upstream intermediates of pyrimidine biosynthesis, carbamoyl-l-
aspartate and dihydroorotate (Chapter 5, and Biagini et al., 2012). This supports the 
hypothesis that the P. falciparum mtETC acts as electron disposal system for the 
mitochondrially-located dihydroorotate dehydrogenase (DHODH) and thus supporting 
essential pyrimidine biosynthesis (Painter et al., 2007). Further examination into the P. 
falciparum mtETC components using a selective inhibitor for each one revealed an 
indirect effect as a consequence of mtETC collapse leading to the disruption of mtETC 
at the point of DHODH (Chapter 6). Intriguingly, perturbing the P. falciparum 
mitochondrion at the level of the ADP/ATP transporter using bongkrekic acid 
demonstrated a remarkable effect on mtETC as displayed by the accumulation of two 
metabolic fingerprints, carbamoyl-l-aspartate and dihydroorotate. This observation, 
together with the findings obtained for mtETC components, suggests that the P. 
falciparum mitochondrion may serve as a multi-target for drug discovery. In addition, 
these results suggest that ATP/ADP exchange is a vital bioenergetic process. In the 
absence of oxidative phosphorylation it has been previously postulated that this 
exchange is required to allow H+ leak (Fisher et al., 2007). Some potential P. 
falciparum mitochondrion drug targets may include PfNDH2, DHODH, ADP/ATP 
transporter, cytochrome bc1 (complex III) and cytochrome c oxidase (complex IV). 
Moreover, it is well known that elongation factor G plays a crucial role in the 
mitochondrial protein synthesis machinery and it has been shown recently that this 
factor is a component of malaria parasite mitochondria, as demonstrated by its 
sensitivity to the action of fusidic acid (Johnson et al., 2011). Interestingly, the addition 
of fusidic acid to P. falciparum had no effect on mtETC as there were no changes 
observed in the pyrimidine intermediates. In contrast, fusidic acid exerted its action on 
the mitochondrial protein synthesis machinery as primarily shown in the profile of 
several amino acids including: (1) the accumulation of glutamine, ornithine, citrulline, 
phenylalanine, tryptophan, tyrosine, threonine and valine; and (2) blocking the 
degradation of serine, asparagine and lysine (Chapter 6).   
 
The malaria parasite digestive vacuole is regarded as a headquarters for the parasite’s 
metabolic activities (Olliaro and Goldberg, 1995). A number of heme-binding drugs 
(quinolone-containing antimalarial drugs, QCDs) were used in order to perturb the 
metabolic processes in the digestive vacuole and hence assign the similarities and 
differences in QCDs MoA. It was clear that the metabolic fingerprints generating from 
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QCDs were distinct from those obtained for mitochondrial inhibitors. Furthermore, it 
was clearly shown, by using the PCA and PLS-DA metabolomics analysis, that the 
MoA of QCD members, including chloroquine, amodiaquine, piperaquine, quinine and 
mefloquine, were probably drug class dependent. The different metabolic profiles 
observed in amino acids upon the addition of QCDs suggests that these QCD members 
primarily target the metabolism of amino acids, which could be acquired from the 
digestion of hemoglobin as well as exogenously through perhaps targeting the new 
permeability pathway (NPP) (Chapter 7). Therefore, it appears that the digestive 
vacuole of P. falciparum has many possible roles which include: (1) providing amino 
acids for protein synthesis; (2) heme detoxification processes; (3) prevent RBC lysis by 
creating a niche for itself during the parasite development; and (4) participate together 
with other parasite metabolic functions in the control of RBC osmotic stability through 
a dynamic equilibrium between hemoglobin degradation, efflux of generated amino 
acids and influx of amino acids from the extracellular media (Chapter 7). 
 
To conclude, it appears that the pharmacometabolomics approach is a useful method in 
the understanding of malaria parasite physiological functions and identification of drug 
MoAs. The P. falciparum mitochondrion and digestive vacuole appear to be 
physiologically central to many related metabolic processes in the parasite. The 
unraveling of the complexities of mitochondrial functions are an immense challenges 
but these challenges must be met in order to determine whether mitochondrial 
manipulation can be harnessed therapeutically. Therefore, continued biological 
approaches, such as pharmacometabolomics in parallel with bioinformatics, genomics 
and proteomics, are critical and thus scientists can understand known pathways on a 
molecular level and characterize new pathways and components behaviour and 
functions that impact on the parasite system biology.  
 
 Limitations and future perspectives  8.2.
Although the study of this thesis contributes to the understanding of the biological 
functions of P. falciparum parasite and gives new insights into drug MoAs, there were 
some limitations in the study which need to be considered for the future experiments. 
These include:  
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1- The study was primarily carried out using targeted metabolomics approach.  
Despite its reproducibility, sensitivity and robustness, it is only limited to 
analysing small portions of the parasite metabolome. Therefore, metabolites that 
are not included in the list of targeted metabolomics platform will not be 
analysed by the LC-MS/MS and hence any effects on these metabolites upon 
drugs addition will not be observed. In this case, untargeted metabolomics 
approaches well as a combination of different analysers (e.g. NMR, FT-IR and 
MS); will greatly enhance a comprehensive coverage of parasite metabolome.    
2- The targeted metabolomics approach was developed using two internal 
standards (ISs) namely β-analine for positive mode and DL-arabinose for 
negative mode.  Both ISs become eluted in the first 15 min of the LC run 
whereas the total LC run is 45 min. This might hide any unseen problems in LC 
run after 15 min. Therefore, including three ISs with different elution times 
(preferentially one IS become eluted at beginning of LC run, second IS become 
eluted at middle of LC run and third IS become eluted at end) will enhance the 
precision and accuracy of the analytical producer. In addition, absolute 
metabolite quantification can be carried out using isotopes. However, isotopes 
are expensive and not always available for each individual metabolite.  
3- One problem with LC-MS/MS triple quadrupole mass analyser is an inability to 
differentiate between isomers. Therefore, a combinational approach is 
recommended as noted above. 
4- The detection of bioenergetics/redox couples, UMP, UDP, UTP, TTP, CTP, and 
GTP was below the limit of detection (LOD) in the parasite samples, although 
their LOD were in nanomolar range as described in Chapter 3. This could be 
justified as the presence of inadequate parasite materials, as these metabolites 
are required to be biosynthesized by the parasite leading them to be present in 
very low levels. Therefore, increasing the sensitivity of detection for these 
metabolites, as well as preparation of adequate parasite materials may help in 
solving this issue in these metabolite detections.  
5- All the experiments carried out in this thesis were performed using high gradient 
magnetic separation (HGMS) for trophozoite stage P. falciparum. In addition to 
a highly synchronous parasite culture, magnetic isolation of trophozoite stage 
can concentrate the culture to a parasitemia more than 95%. However, this 
procedure is hindered by limited column capacity, inconsistent separation 
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purities and high costs.  Therefore, carefully following the magnetic separation 
protocol is critical to the quality of the experiments. 
6- It is noted that all the findings included in this thesis were obtained from 
trophozoite stage P. falciparum parasite. Whilst there is nothing wrong with this, 
it would be a more comprehensive analysis and a broader picture could be drawn 
if this was performed on the developmental asexual cycle of the parasite. This 
could be suggested for the future experiments to examine the temporal metabolic 
profiles in ring, trophozoite and schizont stages following the addition of drugs.  
7- It appears from several recent studies and reviews (Jayaraman et al., 2012, 
Bulusu et al., 2011, Wrenger et al., 2012) that aspartate bridges a number of 
metabolic pathways that include pyrimidine biosynthesis, purine salvage, protein 
synthesis and carbohydrate metabolism and mtETC. It would be of particular 
interest to investigate the inhibition effect of aspartate aminotransferase, whose 
biochemical function is the reversible catalysis of aspartate and 2-oxoglutarate 
to oxaloactetate and glutamate, in the abovementioned metabolic pathways. In 
addition, aspartate aminotransferase offers a high potential for the development 
of novel drug to tackle the emergence of drug resistant malaria parasites because 
it functions in multiple metabolic pathways. 
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APPENDIX I 
 
Table 1: Metabolite primary and working stocks concentration for ion path tuning.  
Metabolites 
Primary Stock 
Concentration 
(mg/ml) 
Working Stock 
Concentration 
(ug/ml) 
Solvent Source 
Alanine 1 10 H2O Sigma-Aldrich, UK 
Asparagine 1 10 H2O Sigma-Aldrich, UK 
Aspartate 1 10 H2O Sigma-Aldrich, UK 
Glutamine 1 10 H2O Sigma-Aldrich, UK 
Glutamate 1 10 H2O Sigma-Aldrich, UK 
Arginine 1 10 MeOH Sigma-Aldrich, UK 
Proline 1 10 H2O Sigma-Aldrich, UK 
Serine 1 10 H2O Sigma-Aldrich, UK 
Valine 1 10 H2O Sigma-Aldrich, UK 
Threonine 1 10 H2O Sigma-Aldrich, UK 
Cysteine 1 10 H2O Sigma-Aldrich, UK 
(Iso)-leucine 1 10 H2O Sigma-Aldrich, UK 
Lysine 1 10 H2O Sigma-Aldrich, UK 
Methionine 1 10 H2O Sigma-Aldrich, UK 
Histidine 1 10 DMSO Sigma-Aldrich, UK 
Phenylalanine 1 10 MeOH Sigma-Aldrich, UK 
Tryptophan 1 10 H2O Sigma-Aldrich, UK 
Tyrosine 1 10 H2O Sigma-Aldrich, UK 
Ornithine 1 10 MeOH Sigma-Aldrich, UK 
Citrulline 1 10 H2O Sigma-Aldrich, UK 
NAD 1 10 H2O Sigma-Aldrich, UK 
NADH 1 10 DMSO Sigma-Aldrich, UK 
GSH 1 10 H2O Sigma-Aldrich, UK 
GSSG 1 10 H2O Sigma-Aldrich, UK 
NADP 1 10 H2O Sigma-Aldrich, UK 
NADPH 1 10 DMSO Sigma-Aldrich, UK 
FAD 1 10 MeOH Sigma-Aldrich, UK 
UMP 1 10 H2O Sigma-Aldrich, UK 
UDP 1 10 H2O Sigma-Aldrich, UK 
UTP 1 10 H2O Sigma-Aldrich, UK 
CTP 1 10 MeOH Sigma-Aldrich, UK 
TTP 1 10 H2O Sigma-Aldrich, UK 
AMP 1 10 H2O Sigma-Aldrich, UK 
ADP 1 10 H2O Sigma-Aldrich, UK 
ATP 1 10 H2O Sigma-Aldrich, UK 
GTP 1 10 H2O Sigma-Aldrich, UK 
Carbamoyl-l-
Aspartate 1 10 MeOH Alfa-Aesar lab, UK 
Acetyl-CoA 1 10 MeOH Sigma-Aldrich, UK 
Succinyl-CoA 1 10 H2O Sigma-Aldrich, UK 
Propionyl-CoA 1 10 H2O Sigma-Aldrich, UK 
Glucose 1 10 H2O Sigma-Aldrich, UK 
Fumarate 1 10 H2O Sigma-Aldrich, UK 
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Table 1: (Continued) 
Metabolites 
Primary Stock 
Concentration 
(mg/ml) 
Working Stock 
Concentration 
(ug/ml) 
Solvent Source 
Succinate 1 10 H2O Sigma-Aldrich, UK 
Malate 1 10 H2O Sigma-Aldrich, UK 
2-oxoglutarate 1 10 MeOH Sigma-Aldrich, UK 
(iso)-Citrate 1 10 MeOH Sigma-Aldrich, UK 
PEP 1 10 H2O Sigma-Aldrich, UK 
PABA 1 10 H2O Sigma-Aldrich, UK 
G-3-P 1 10 H2O Sigma-Aldrich, UK 
Hypoxanthine 1 10 DMSO Sigma-Aldrich, UK 
Orotate 1 10 DMSO Sigma-Aldrich, UK 
Dihydroorotate 1 10 MeOH Sigma-Aldrich, UK 
Lactate 1 10 H2O Sigma-Aldrich, UK 
DHAP 1 10 H2O Sigma-Aldrich, UK 
Oxaloacetate 1 10 H2O Sigma-Aldrich, UK 
Carbamoyl-P 1 10 DMSO Sigma-Aldrich, UK 
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Table 2: Metabolite primary stocks concentration for calibration curve standards and QC samples  
Metabolites 
Primary Stock 
Concentration (mg/ml) 
MW 
(g/mol) 
Primary Stock 
Concentration (mM) 
Solvent 
Alanine 2 89.09 22.44 H2O 
Asparagine 2 132.12 15.13 H2O 
Aspartate 2 133.1 15.02 H2O 
Glutamine 2 146.14 13.68 H2O 
Glutamate 2 147.13 13.59 H2O 
Arginine 2 174.2 11.48 MeOH 
Proline 2 115.13 17.37 H2O 
Serine 2 105.09 19.03 H2O 
Valine 2 117.15 17.07 H2O 
Threonine 2 119.12 16.78 H2O 
Cysteine 2 121.16 33.02 H2O 
(Iso)-leucine 2 131.17 15.24 H2O 
Lysine 2 146.19 13.68 H2O 
Methionine 2 149.21 13.40 H2O 
Histidine 2 155.15 12.89 DMSO 
Phenylalanine 2 165.19 12.10 MeOH 
Tryptophan 2 204.23 9.79 H2O 
Tyrosine 2 181.19 11.03 H2O 
Ornithine 2 132.19 15.13 MeOH 
Citrulline 2 175.19 11.41 H2O 
NAD 2 663.43 3.01 H2O 
NADH 2 664.43 3.00 DMSO 
GSH 2 307.32 6.50 H2O 
GSSG 2 612.63 3.26 H2O 
NADP 2 744.41 2.69 H2O 
NADPH 2 745.41 2.68 DMSO 
FAD 2 785.55 2.54 MeOH 
UMP 2 324.18 6.16 H2O 
UDP 2 404.16 4.94 H2O 
UTP 2 484.14 4.13 H2O 
CTP 2 483.15 4.13 MeOH 
TTP 2 482.16 4.14 H2O 
AMP 2 347.22 5.76 H2O 
ADP 2 427.20 4.68 H2O 
ATP 2 507.18 3.94 H2O 
GTP 2 523.18 3.82 H2O 
Carbamoyl-l-
Aspartate 
2 176.12 11.35 MeOH 
Acetyl-CoA 10 809.57 12.35 MeOH 
Succinyl-CoA 5 867.60 5.76 H2O 
Propionyl-CoA 4 823.60 6.07 H2O 
Glucose 2 180.16 11.10 H2O 
Fumarate 2 116.07 17.23 H2O 
Succinate 2 118.09 16.93 H2O 
Malate 2 134.09 14.91 H2O 
2-oxoglutarate 2 146.11 13.68 MeOH 
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Table 2: (Continued) 
Metabolites 
Primary Stock 
Concentration (mg/ml) 
MW (g/mol) 
Primary Stock 
Concentration (mM) 
Solvent 
(Iso)-Citrate 2 192.12 10.41 MeOH 
PEP 2 168.04 11.90 H2O 
PABA 2 137.14 14.58 H2O 
G-3-P 2 170.05 11.62 H2O 
Hypoxanthine 2 136.12 14.70 DMSO 
Orotate 2 156.10 12.81 DMSO 
Dihydroorotate 2 158.11 12.64 MeOH 
Lactate 4 90.08 44.40 H2O 
DHAP 4 170.06 23.52 H2O 
Oxaloacetate 20 132.07 151.43 H2O 
Carbamoyl-P 30 141.02 212.76 DMSO 
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      Table 3: Mixture of standards concentration levels for plotting calibration standard curves  
  
Standard 
mixture 
conc.(uM) Sixteen levels of serial dilution of standard mixture solution concentration (uM) 
Metabolite 
Primary 
Stock 
Conc. 
(mM) 
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LEVEL
1 
1:1 
LEVEL
2 
1:2  
LEVEL
3 
1:4 
LEVEL
4 
1:8 
LEVEL
5 
1:16 
LEVEL 
6 
1:32 
LEVEL
7 
1:64 
LEVEL
8 
1:128 
LEVEL
9 
1:256 
LEVEL
10 
1:512 
LEVEL 
11 
1:1024 
LEVEL 
12 
1:2048 
LEVEL 
13 
1:4096 
LEVEL 
14 
1:8192 
LEVEL 
15 
1:1638
4 
LEVEL 
16 
1:3276
8 
Alanine 22.45 400.9 200.4 100.2 50.1 25.05 12.53 6.26 3.13 1.57 0.78 0.39 0.20 0.098 0.049 0.024 0.012 
Asparagine 15.14 270.3 135.2 67.6 33.8 16.90 8.45 4.22 2.11 1.06 0.53 0.26 0.13 0.066 0.033 0.016 0.008 
Aspartate 15.03 268.3 134.2 67.1 33.5 16.77 8.39 4.19 2.10 1.05 0.52 0.26 0.13 0.066 0.033 0.016 0.008 
Glutamine 13.69 244.4 122.2 61.1 30.5 15.27 7.64 3.82 1.91 0.95 0.48 0.24 0.12 0.060 0.030 0.015 0.007 
Glutamate 13.59 242.7 121.4 60.7 30.3 15.17 7.59 3.79 1.90 0.95 0.47 0.24 0.12 0.059 0.030 0.015 0.007 
Arginine 11.48 205.0 102.5 51.3 25.6 12.81 6.41 3.20 1.60 0.80 0.40 0.20 0.10 0.050 0.025 0.013 0.006 
Proline 17.37 310.2 155.1 77.6 38.8 19.39 9.69 4.85 2.42 1.21 0.61 0.30 0.15 0.076 0.038 0.019 0.009 
Serine 19.03 339.8 169.9 85.0 42.5 21.24 10.62 5.31 2.66 1.33 0.66 0.33 0.17 0.083 0.041 0.021 0.010 
Valine 17.07 304.9 152.4 76.2 38.1 19.05 9.53 4.76 2.38 1.19 0.60 0.30 0.15 0.074 0.037 0.019 0.009 
Threonine 16.79 299.8 149.9 75.0 37.5 18.74 9.37 4.68 2.34 1.17 0.59 0.29 0.15 0.073 0.037 0.018 0.009 
Cysteine 33.03 589.7 294.9 147.4 73.7 36.86 18.43 9.21 4.61 2.30 1.15 0.58 0.29 0.144 0.072 0.036 0.018 
(Iso)-leucine 15.25 272.3 136.1 68.1 34.0 17.02 8.51 4.25 2.13 1.06 0.53 0.27 0.13 0.066 0.033 0.017 0.008 
Lysine 13.68 244.3 122.2 61.1 30.5 15.27 7.63 3.82 1.91 0.95 0.48 0.24 0.12 0.060 0.030 0.015 0.007 
Methionine 13.40 239.4 119.7 59.8 29.9 14.96 7.48 3.74 1.87 0.93 0.47 0.23 0.12 0.058 0.029 0.015 0.007 
Histidine 12.89 230.2 115.1 57.5 28.8 14.39 7.19 3.60 1.80 0.90 0.45 0.22 0.11 0.056 0.028 0.014 0.007 
Phenylalanine 12.11 216.2 108.1 54.1 27.0 13.51 6.76 3.38 1.69 0.84 0.42 0.21 0.11 0.053 0.026 0.013 0.007 
Tryptophan 9.79 174.9 87.4 43.7 21.9 10.93 5.46 2.73 1.37 0.68 0.34 0.17 0.09 0.043 0.021 0.011 0.005 
Tyrosine 11.04 197.1 98.6 49.3 24.6 12.32 6.16 3.08 1.54 0.77 0.38 0.19 0.10 0.048 0.024 0.012 0.006 
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Table 3: (Continued) 
Ornithine 15.13 
 
270.2 135.1 67.6 33.8 16.89 8.44 4.22 2.11 1.06 0.53 0.26 0.13 0.066 0.033 0.016 0.008 
Citrulline 11.42 203.9 101.9 51.0 25.5 12.74 6.37 3.19 1.59 0.80 0.40 0.20 0.10 0.050 0.025 0.012 0.006 
NAD 3.01 53.8 26.9 13.5 6.7 3.36 1.68 0.84 0.42 0.21 0.11 0.05 0.03 0.013 0.007 0.003 0.002 
NADH 3.01 53.7 26.8 13.4 6.7 3.35 1.68 0.84 0.42 0.21 0.10 0.05 0.03 0.013 0.007 0.003 0.002 
GSH 6.51 116.2 58.1 29.1 14.5 7.26 3.63 1.82 0.91 0.45 0.23 0.11 0.06 0.028 0.014 0.007 0.004 
GSSG 3.26 58.3 29.1 14.6 7.3 3.64 1.82 0.91 0.46 0.23 0.11 0.06 0.03 0.014 0.007 0.004 0.002 
NADP 2.69 48.0 24.0 12.0 6.0 3.00 1.50 0.75 0.38 0.19 0.09 0.05 0.02 0.012 0.006 0.003 0.001 
NADPH 2.68 47.9 24.0 12.0 6.0 2.99 1.50 0.75 0.37 0.19 0.09 0.05 0.02 0.012 0.006 0.003 0.001 
FAD 2.55 45.5 22.7 11.4 5.7 2.84 1.42 0.71 0.36 0.18 0.09 0.04 0.02 0.011 0.006 0.003 0.001 
UMP 6.17 110.2 55.1 27.5 13.8 6.89 3.44 1.72 0.86 0.43 0.22 0.11 0.05 0.027 0.013 0.007 0.003 
UDP 4.95 88.4 44.2 22.1 11.0 5.52 2.76 1.38 0.69 0.35 0.17 0.09 0.04 0.022 0.011 0.005 0.003 
UTP 4.13 73.8 36.9 18.4 9.2 4.61 2.31 1.15 0.58 0.29 0.14 0.07 0.04 0.018 0.009 0.005 0.002 
CTP 4.14 73.9 37.0 18.5 9.2 4.62 2.31 1.15 0.58 0.29 0.14 0.07 0.04 0.018 0.009 0.005 0.002 
TTP 4.15 74.1 37.0 18.5 9.3 4.63 2.31 1.16 0.58 0.29 0.14 0.07 0.04 0.018 0.009 0.005 0.002 
AMP 5.76 102.9 51.4 25.7 12.9 6.43 3.21 1.61 0.80 0.40 0.20 0.10 0.05 0.025 0.013 0.006 0.003 
ADP 4.68 83.6 41.8 20.9 10.5 5.23 2.61 1.31 0.65 0.33 0.16 0.08 0.04 0.020 0.010 0.005 0.003 
ATP 3.94 70.4 35.2 17.6 8.8 4.40 2.20 1.10 0.55 0.28 0.14 0.07 0.03 0.017 0.009 0.004 0.002 
GTP 3.82 68.3 34.1 17.1 8.5 4.27 2.13 1.07 0.53 0.27 0.13 0.07 0.03 0.017 0.008 0.004 0.002 
Carbamyl-L-
Aspartate 11.36 202.8 101.4 50.7 25.3 12.67 6.34 3.17 1.58 0.79 0.40 0.20 0.10 0.050 0.025 0.012 0.006 
Acetyl-CoA 12.35 220.6 110.3 55.1 27.6 13.79 6.89 3.45 1.72 0.86 0.43 0.22 0.11 0.054 0.027 0.013 0.007 
Succinyl-CoA 5.76 102.9 51.5 25.7 12.9 6.43 3.22 1.61 0.80 0.40 0.20 0.10 0.05 0.025 0.013 0.006 0.003 
Propionyl-CoA 6.07 108.4 54.2 27.1 13.6 6.78 3.39 1.69 0.85 0.42 0.21 0.11 0.05 0.026 0.013 0.007 0.003 
D-glucose 11.10 198.2 99.1 49.6 24.8 12.39 6.20 3.10 1.55 0.77 0.39 0.19 0.10 0.048 0.024 0.012 0.006 
Fumarate 17.23 307.7 153.8 76.9 38.5 19.23 9.62 4.81 2.40 1.20 0.60 0.30 0.15 0.075 0.038 0.019 0.009 
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Table 3: (Continued) 
Succinate 16.94 
 
302.4 151.2 75.6 37.8 18.90 9.45 4.73 2.36 1.18 0.59 0.30 0.15 0.074 0.037 0.018 0.009 
Malate 14.92 266.4 133.2 66.6 33.3 16.65 8.32 4.16 2.08 1.04 0.52 0.26 0.13 0.065 0.033 0.016 0.008 
2-Oxoglutarate 13.69 244.5 122.2 61.1 30.6 15.28 7.64 3.82 1.91 0.95 0.48 0.24 0.12 0.060 0.030 0.015 0.007 
(iso)-Citrate 10.42 186.0 93.0 46.5 23.3 11.63 5.81 2.91 1.45 0.73 0.36 0.18 0.09 0.045 0.023 0.011 0.006 
PEP 11.90 212.5 106.3 53.1 26.6 13.28 6.64 3.32 1.66 0.83 0.42 0.21 0.10 0.052 0.026 0.013 0.006 
PABA 14.58 260.4 130.2 65.1 32.6 16.28 8.14 4.07 2.03 1.02 0.51 0.25 0.13 0.064 0.032 0.016 0.008 
G-3-P 11.62 207.6 103.8 51.9 25.9 12.97 6.49 3.24 1.62 0.81 0.41 0.20 0.10 0.051 0.025 0.013 0.006 
Hypoxanthine 14.71 262.6 131.3 65.7 32.8 16.41 8.21 4.10 2.05 1.03 0.51 0.26 0.13 0.064 0.032 0.016 0.008 
Orotate 12.81 228.8 114.4 57.2 28.6 14.30 7.15 3.57 1.79 0.89 0.45 0.22 0.11 0.056 0.028 0.014 0.007 
Dihydroorotate 12.65 225.9 112.9 56.5 28.2 14.12 7.06 3.53 1.76 0.88 0.44 0.22 0.11 0.055 0.028 0.014 0.007 
Lactate 44.41 793.0 396.5 198.3 99.1 49.56 24.78 12.39 6.20 3.10 1.55 0.77 0.39 0.194 0.097 0.048 0.024 
DHAP 23.53 420.2 210.1 105.0 52.5 26.26 13.13 6.57 3.28 1.64 0.82 0.41 0.21 0.103 0.051 0.026 0.013 
Oxaloacetate 
151.4
3 
2704.
2 1352. 676.0 338.0 169.0 84.51 42.25 21.13 10.56 5.28 2.64 1.32 0.660 0.330 0.165 0.083 
Carbamoyl 
phosphate 
212.7
7 
3799.
4 1899. 949.8 474.9 237.4 118.7 59.37 29.68 14.84 7.42 3.71 1.86 0.928 0.464 0.232 0.116 
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Table 4: Mixture of standards concentration for preparing QC samples 
   
Serially diluted standard 
mixture concentration 
(uM) 
Metabolite 
Primary Stock 
Concentration 
(mM) 
 
HQC 
 
1:1 
MQC 
 
1:10  
LQC 
 
1:100 
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 400.9 40.09 4.01 
Asparagine 15.14 270.3 27.03 2.70 
Aspartate 15.03 268.3 26.83 2.68 
Glutamine 13.69 244.4 24.44 2.44 
Glutamate 13.59 242.7 24.27 2.43 
Arginine 11.48 205.0 20.50 2.05 
Proline 17.37 310.2 31.02 3.10 
Serine 19.03 339.8 33.98 3.40 
Valine 17.07 304.9 30.49 3.05 
Threonine 16.79 299.8 29.98 3.00 
Cysteine 33.03 589.7 58.97 5.90 
(Iso)-leucine 15.25 272.3 27.23 2.72 
Lysine 13.68 244.3 24.43 2.44 
Methionine 13.40 239.4 23.94 2.39 
Histidine 12.89 230.2 23.02 2.30 
Phenylalanine 12.11 216.2 21.62 2.16 
Tryptophan 9.79 174.9 17.49 1.75 
Tyrosine 11.04 197.1 19.71 1.97 
Ornithine 15.13 270.2 27.02 2.70 
Citrulline 11.42 203.9 20.39 2.04 
NAD 3.01 53.8 5.38 0.54 
NADH 3.01 53.7 5.37 0.54 
GSH 6.51 116.2 11.62 1.16 
GSSG 3.26 58.3 5.83 0.58 
NADP 2.69 48.0 4.80 0.48 
NADPH 2.68 47.9 4.79 0.48 
FAD 2.55 45.5 4.55 0.45 
UMP 6.17 110.2 11.02 1.10 
UDP 4.95 88.4 8.84 0.88 
UTP 4.13 73.8 7.38 0.74 
CTP 4.14 73.9 7.39 0.74 
TTP 4.15 74.1 7.41 0.74 
AMP 5.76 102.9 10.29 1.03 
ADP 4.68 83.6 8.36 0.84 
ATP 3.94 70.4 7.04 0.70 
GTP 3.82 68.3 6.83 0.68 
Carbamoyl-l-
Aspartate 11.36 
202.8 20.28 2.03 
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Table 4: (Contintued) 
Acetyl-CoA 12.35  220.6 22.06 2.21 
Succinyl-CoA 5.76  102.9 10.29 1.03 
Propionyl-CoA 6.07 
 
108.4 10.84 1.08 
Glucose 11.10 198.2 19.82 1.98 
Fumarate 17.23 307.7 30.77 3.08 
Succinate 16.94 302.4 30.24 3.02 
Malate 14.92 266.4 26.64 2.66 
2-Oxoglutarate 13.69 244.5 24.45 2.44 
(Iso)-Citrate 10.42 186.0 18.60 1.86 
PEP 11.90 212.5 21.25 2.13 
PABA 14.58 260.4 26.04 2.60 
G-3-P 11.62 207.6 20.76 2.08 
Hypoxanthine 14.71 262.6 26.26 2.63 
Orotate 12.81 228.8 22.88 2.29 
Dihydroorotate 12.65 225.9 22.59 2.26 
Lactate 44.41 793.0 79.30 7.93 
DHAP 23.53 420.2 42.02 4.20 
Oxaloacetate 151.43 2704.2 270.42 27.04 
Carbamyl-P 212.77 3799.4 379.94 37.99 
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APPENDIX II 
 
 
Figure 1: LC-MS/MS chromatogram of (iso)-leucine. A) Chromatographic separation of (iso)-leucine 
peak shows retention time (RT) at ~11min. B) SRM scan of ionized (iso)-leucine shows the detection of 
its product ion at mass-to-charge (m/z) of 86. 
 
 
Figure 2: LC-MS/MS chromatogram of phenylalanine. A) Chromatographic separation of 
phenylalanine peak shows retention time (RT) at ~11.6min. B) SRM scan of ionized phenylalanine shows 
the detection of its product ion at mass-to-charge (m/z) of 103. 
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Figure 3: LC-MS/MS chromatogram of tryptophan. A) Chromatographic separation of tryptophan 
peak shows retention time (RT) at ~11.9min. B) SRM scan of ionized tryptophan shows the detection of 
its product ion at mass-to-charge (m/z) of 146. 
 
 
Figure 4: LC-MS/MS chromatogram of proline. A) Chromatographic separation of proline peak shows 
retention time (RT) at ~12.4min. B) SRM scan of ionized proline shows the detection of its product ion at 
mass-to-charge (m/z) of 70. 
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Figure 5: LC-MS/MS chromatogram of methionine. A) Chromatographic separation of methionine 
peak shows retention time (RT) at ~12min. B) SRM scan of ionized methionine shows the detection of its 
product ion at mass-to-charge (m/z) of 133. 
 
 
Figure 6: LC-MS/MS chromatogram of citrulline. A) Chromatographic separation of citrulline peak 
shows retention time (RT) at ~12.9 min. B) SRM scan of ionized citrulline shows the detection of its 
product ion at mass-to-charge (m/z) of 159. 
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Figure 7: LC-MS/MS chromatogram of histidine. A) Chromatographic separation of histidine peak 
shows retention time (RT) at ~13.6 min. B) SRM scan of ionized histidine shows the detection of its 
product ion at mass-to-charge (m/z) of 110. 
 
 
Figure 8: LC-MS/MS chromatogram of asparagine. A) Chromatographic separation of asparagine 
peak shows retention time (RT) at ~13.4 min. B) SRM scan of ionized asparagine shows the detection of 
its product ion at mass-to-charge (m/z) of 74. 
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Figure 9: LC-MS/MS chromatogram of glutamine. A) Chromatographic separation of glutamine peak 
shows retention time (RT) at ~13.1 min. B) SRM scan of ionized glutamine shows the detection of its 
product ion at mass-to-charge (m/z) of 84. 
 
 
Figure 10: LC-MS/MS chromatogram of arginine. A) Chromatographic separation of arginine peak 
shows retention time (RT) at ~13.7 min. B) SRM scan of ionized arginine shows the detection of its 
product ion at mass-to-charge (m/z) of 60. 
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Figure 11: LC-MS/MS chromatogram of lysine. A) Chromatographic separation of lysine peak shows 
retention time (RT) at ~14.4min. B) SRM scan of ionized lysine shows the detection of its product ion at 
mass-to-charge (m/z) of 84. 
 
 
 
Figure 12: LC-MS/MS chromatogram of ornithine. A) Chromatographic separation of ornithine peak 
shows retention time (RT) at ~14.4 min. B) SRM scan of ionized ornithine shows the detection of its 
product ion at mass-to-charge (m/z) of 70. 
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Figure 13: LC-MS/MS chromatogram of aspartate. A) Chromatographic separation of aspartate peak 
shows retention time (RT) at ~16.4 min. B) SRM scan of ionized aspartate shows the detection of its 
product ion at mass-to-charge (m/z) of 74. 
 
 
Figure 14: LC-MS/MS chromatogram of glutamate. A) Chromatographic separation of glutamate peak 
shows retention time (RT) at ~16.5 min. B) SRM scan of ionized glutamate shows the detection of its 
product ion at mass-to-charge (m/z) of 84. 
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Figure 15: LC-MS/MS chromatogram of NAD. A) Chromatographic separation of NAD peak shows 
retention time (RT) at ~16.5 min. B) SRM scan of ionized NAD shows the detection of its product ion at 
mass-to-charge (m/z) of 428. 
 
 
Figure 16: LC-MS/MS chromatogram of GSH. A) Chromatographic separation of GSH peak shows 
retention time (RT) at ~19.7 min. B) SRM scan of ionized GSH shows the detection of its product ion at 
mass-to-charge (m/z) of 162. 
 
 
 
 
 
 
E:\mass spec data\...\OCT\11th\Pos\STD1 12/10/2012 05:12:18 STD1
RT: 0.00 - 45.03 SM: 5G
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44
Time (min)
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
RT: 16.54
23.34 26.5917.7714.16 24.78 42.6341.4819.149.10 20.45 30.35 31.362.88 11.48 38.154.542.23 5.27 36.06 44.6634.617.80 27.75
NL:
1.72E5
TIC F: + c ESI 
SRM ms2 
664.000@cid30.
00 
[427.500-
428.500]  MS 
STD1
STD1 #9341 RT: 16.47 AV: 1 NL: 1.49E5
F: + c ESI SRM ms2 664.000@cid30.00 [427.500-428.500]
427.5 427.6 427.7 427.8 427.9 428.0 428.1 428.2 428.3 428.4
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
427.96
E:\mass spec data\...\Pos\STD1 25/06/2012 21:29:20 STD1
RT: 0.00 - 45.03 SM: 7G
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44
Time (min)
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
RT: 19.70
23.17 23.82
22.45
24.91 27.29 27.87 29.68 32.7918.915.83 11.18 35.326.91 11.97 17.549.80 14.14 39.5136.26 41.82 44.490.77 2.00 8.724.823.22
NL:
1.12E5
TIC F: + c ESI 
SRM ms2 
308.000@cid19.
00 
[161.500-
162.500]  MS 
STD1
STD1 #11175 RT: 19.70 AV: 1 NL: 1.31E5
F: + c ESI SRM ms2 308.000@cid19.00 [161.500-162.500]
161.5 161.6 161.7 161.8 161.9 162.0 162.1 162.2 162.3 162.4 162.5
m/z
0
20
40
60
80
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
162.01
A) 
B) 
A) 
B) 
 310 
 
 
 
 
Figure 17: LC-MS/MS chromatogram of carbamoyl-l-aspartate. A) Chromatographic separation of 
carbamoyl-l-aspartate peak shows retention time (RT) at ~21.5 min. B) SRM scan of ionized carbamoyl-
l-aspartate shows the detection of its product ion at mass-to-charge (m/z) of 74. 
 
 
Figure 18: LC-MS/MS chromatogram of GSSG. A) Chromatographic separation of GSSG peak shows 
retention time (RT) at ~22 min. B) SRM scan of ionized GSSG shows the detection of its product ion at 
mass-to-charge (m/z) of 231. 
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Figure 19: LC-MS/MS chromatogram of UMP. A) Chromatographic separation of UMP peak shows 
retention time (RT) at ~22.3 min. B) SRM scan of ionized UMP shows the detection of its product ion at 
mass-to-charge (m/z) of 97. 
 
 
Figure 20: LC-MS/MS chromatogram of AMP. A) Chromatographic separation of AMP peak shows 
retention time (RT) at ~22.8 min. B) SRM scan of ionized AMP shows the detection of its product ion at 
mass-to-charge (m/z) of 136. 
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Figure 21: LC-MS/MS chromatogram of FAD. A) Chromatographic separation of FAD peak shows 
retention time (RT) at ~22.9 min. B) SRM scan of ionized FAD shows the detection of its product ion at 
mass-to-charge (m/z) of 348. 
 
 
Figure 22: LC-MS/MS chromatogram of NADP. A) Chromatographic separation of NADP peak 
shows retention time (RT) at ~22.9 min. B) SRM scan of ionized NADP shows the detection of its 
product ion at mass-to-charge (m/z) of 136. 
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Figure 23: LC-MS/MS chromatogram of UDP. A) Chromatographic separation of UDP peak shows 
retention time (RT) at ~23.1 min. B) SRM scan of ionized UDP shows the detection of its product ion at 
mass-to-charge (m/z) of 97. 
 
 
Figure 24: LC-MS/MS chromatogram of ADP. A) Chromatographic separation of ADP peak shows 
retention time (RT) at ~23.5 min. B) SRM scan of ionized ADP shows the detection of its product ion at 
mass-to-charge (m/z) of 136.  
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Figure 25: LC-MS/MS chromatogram of acetyl-CoA. A) Chromatographic separation of acetyl-CoA 
peak shows retention time (RT) at ~24 min. B) SRM scan of ionized acetyl-CoA shows the detection of 
its product ion at mass-to-charge (m/z) of 303.  
 
 
Figure 26: LC-MS/MS chromatogram of propionyl-CoA. A) Chromatographic separation of 
propionyl-CoA peak shows retention time (RT) at ~24.2 min. B) SRM scan of ionized propionyl-CoA 
shows the detection of its product ion at mass-to-charge (m/z) of 317.  
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Figure 27: LC-MS/MS chromatogram of succinyl-CoA. A) Chromatographic separation of succinyl-
CoA peak shows retention time (RT) at ~25 min. B) SRM scan of ionized succinyl-CoA shows the 
detection of its product ion at mass-to-charge (m/z) of 361.  
 
 
Figure 28: LC-MS/MS chromatogram of CTP. A) Chromatographic separation of CTP peak shows 
retention time (RT) at ~25.1 min. B) SRM scan of ionized CTP shows the detection of its product ion at 
mass-to-charge (m/z) of 112.  
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Figure 29: LC-MS/MS chromatogram of ATP. A) Chromatographic separation of ATP peak shows 
retention time (RT) at ~25.5 min. B) SRM scan of ionized ATP shows the detection of its product ion at 
mass-to-charge (m/z) of 136.  
 
 
Figure 30: LC-MS/MS chromatogram of GTP. A) Chromatographic separation of GTP peak shows 
retention time (RT) at ~27.8 min. B) SRM scan of ionized GTP shows the detection of its product ion at 
mass-to-charge (m/z) of 152.  
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Figure 31: LC-MS/MS chromatogram of alanine. A) Chromatographic separation of alanine peak 
shows retention time (RT) at ~12.8 min. B) SRM scan of ionized alanine shows the detection of its 
product ion at mass-to-charge (m/z) of 44.1.  
 
 
Figure 32: LC-MS/MS chromatogram of valine. A) Chromatographic separation of valine peak shows 
retention time (RT) at ~12.1 min. B) SRM scan of ionized valine shows the detection of its product ion at 
mass-to-charge (m/z) of 55.  
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Figure 33: LC-MS/MS chromatogram of tyrosine. A) Chromatographic separation of tyrosine peak 
shows retention time (RT) at ~13 min. B) SRM scan of ionized tyrosine shows the detection of its product 
ion at mass-to-charge (m/z) of 77.  
 
 
Figure 34: LC-MS/MS chromatogram of threonine. A) Chromatographic separation of threonine peak 
shows retention time (RT) at ~13.3 min. B) SRM scan of ionized threonine shows the detection of its 
product ion at mass-to-charge (m/z) of 74.  
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Figure 35: LC-MS/MS chromatogram of UTP. A) Chromatographic separation of UTP peak shows 
retention time (RT) at ~27.7 min. B) SRM scan of ionized UTP shows the detection of its product ion at 
mass-to-charge (m/z) of 97.  
 
 
Figure 36: LC-MS/MS chromatogram of TTP. A) Chromatographic separation of TTP peak shows 
retention time (RT) at ~27.3 min. B) SRM scan of ionized TTP shows the detection of its product ion at 
mass-to-charge (m/z) of 81.  
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Figure 37: LC-MS/MS chromatogram of NADH. A) Chromatographic separation of NADH peak 
shows retention time (RT) at ~27.1 min. B) SRM scan of ionized NADH shows the detection of its 
product ion at mass-to-charge (m/z) of 514.  
 
 
Figure 38: LC-MS/MS chromatogram of NADPH. A) Chromatographic separation of NADPH peak 
shows retention time (RT) at ~31.9 min. B) SRM scan of ionized NADPH shows the detection of its 
product ion at mass-to-charge (m/z) of 729.  
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Figure 39: LC-MS/MS chromatogram of serine. A) Chromatographic separation of serine peak shows 
retention time (RT) at ~13.1 min. B) SRM scan of ionized serine shows the detection of its product ion at 
mass-to-charge (m/z) of 60.  
 
 
Figure 40: LC-MS/MS chromatogram of cysteine. A) Chromatographic separation of cysteine peak 
shows retention time (RT) at ~26.1 min. B) SRM scan of ionized cysteine shows the detection of its 
product ion at mass-to-charge (m/z) of 59.  
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Figure 41: LC-MS/MS chromatogram of glucose. A) Chromatographic separation of glucose peak 
shows retention time (RT) at ~11.7 min. B) SRM scan of ionized glucose shows the detection of its 
product ion at mass-to-charge (m/z) of 59.  
 
 
 
Figure 42: LC-MS/MS chromatogram of hypoxanthine. A) Chromatographic separation of 
hypoxanthine peak shows retention time (RT) at ~13.4 min. B) SRM scan of ionized hypoxanthine shows 
the detection of its product ion at mass-to-charge (m/z) of 92.  
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Figure 43: LC-MS/MS chromatogram of lactate. A) Chromatographic separation of lactate peak shows 
retention time (RT) at ~14 min. B) SRM scan of ionized lactate shows the detection of its product ion at 
mass-to-charge (m/z) of 43.  
 
 
Figure 44: LC-MS/MS chromatogram of dihydroorotate. A) Chromatographic separation of 
dihydroorotate peak shows retention time (RT) at ~14.1 min. B) SRM scan of ionized dihydroorotate 
shows the detection of its product ion at mass-to-charge (m/z) of 113.  
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Figure 45: LC-MS/MS chromatogram of orotate. A) Chromatographic separation of orotate peak 
shows retention time (RT) at ~15.3 min. B) SRM scan of ionized orotate shows the detection of its 
product ion at mass-to-charge (m/z) of 111.  
 
 
Figure 46: LC-MS/MS chromatogram of succinate. A) Chromatographic separation of succinate peak 
shows retention time (RT) at ~21.5 min. B) SRM scan of ionized succinate shows the detection of its 
product ion at mass-to-charge (m/z) of 73.  
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Figure 47: LC-MS/MS chromatogram of malate. A) Chromatographic separation of malate peak 
shows retention time (RT) at ~21.6 min. B) SRM scan of ionized malate shows the detection of its 
product ion at mass-to-charge (m/z) of 115.  
 
 
Figure 48: LC-MS/MS chromatogram of glycerol-3-phosphate (G-3-P). A) Chromatographic 
separation of G-3-P peak shows retention time (RT) at ~21.8 min. B) SRM scan of ionized G-3-P shows 
the detection of its product ion at mass-to-charge (m/z) of 79.  
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Figure 49: LC-MS/MS chromatogram of 2-oxoglutrate. A) Chromatographic separation of 2-
oxoglutrate peak shows retention time (RT) at ~26.6 min. B) SRM scan of ionized 2-oxoglutrate shows 
the detection of its product ion at mass-to-charge (m/z) of 101.  
 
 
Figure 50: LC-MS/MS chromatogram of (iso)-citrate. A) Chromatographic separation of (iso)-citrate 
peak shows retention time (RT) at ~23.3 min. B) SRM scan of ionized (iso)-citrate shows the detection of 
its product ion at mass-to-charge (m/z) of 111.  
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Figure 51: LC-MS/MS chromatogram of phosphoenol pyruvate (PEP). A) Chromatographic 
separation of PEP peak shows retention time (RT) at ~23.3 min. B) SRM scan of ionized PEP shows the 
detection of its product ion at mass-to-charge (m/z) of 79.  
 
 
 
Figure 52: LC-MS/MS chromatogram of p-aminobenzoic acid (PABA). A) Chromatographic 
separation of PABA peak shows retention time (RT) at ~13.1 min. B) SRM scan of ionized PABA shows 
the detection of its product ion at mass-to-charge (m/z) of 92.  
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Figure 53: LC-MS/MS chromatogram of carbamoyl-phosphate. A) Chromatographic separation of 
carbamoyl-phosphate peak shows retention time (RT) at ~25.7 min. B) SRM scan of ionized carbamoyl-
phosphate shows the detection of its product ion at mass-to-charge (m/z) of 79.  
 
 
Figure 54: LC-MS/MS chromatogram of fumarate. A) Chromatographic separation of fumarate peak 
shows retention time (RT) at ~25.5 min. B) SRM scan of ionized fumarate shows the detection of its 
product ion at mass-to-charge (m/z) of 71.  
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Figure 55: LC-MS/MS chromatogram of oxaloacetate. A) Chromatographic separation of oxaloacetate 
peak shows retention time (RT) at ~24.2 min. B) SRM scan of ionized oxaloacetate shows the detection 
of its product ion at mass-to-charge (m/z) of 87.  
 
 
 
Figure 56: LC-MS/MS chromatogram of dihydroxyaceton phosphate (DHAP). A) Chromatographic 
separation of DHAP peak shows retention time (RT) at ~29 min. B) SRM scan of ionized DHAP shows 
the detection of its product ion at mass-to-charge (m/z) of 79.  
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Figure 57: LC-MS/MS chromatogram of β–alanine (Internal Standard). A) Chromatographic 
separation of β–alanine peak shows retention time (RT) at ~12.5 min. B) SRM scan of ionized β–alanine 
shows the detection of its product ion at mass-to-charge (m/z) of 71.8.  
 
 
Figure 58: LC-MS/MS chromatogram of DL-arabinose (Internal Standard). A) Chromatographic 
separation of DL-arabinose peak shows retention time (RT) at ~10.8 min. B) SRM scan of ionized DL-
arabinose shows the detection of its product ion at mass-to-charge (m/z) of 130.6.  
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Figure 59. Standard calibration curves for alanine, arginine and asparagine show  R
2 ≥0.99 .The line 
of best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples were calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 60. Standard calibration curves for aspartate, cysteine and glutamate show  R
2 ≥0.98 .The 
line of best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples was calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 61. Standard calibration curves for (iso)-leucine, lysine and methionine show  R
2 ≥0.99 .The 
line of best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples was calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 62. Standard calibration curves for proline, tryptophan and phenyalanine show  R
2 ≥0.99 
.The line of best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples was calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 63. Standard calibration curves for tyrosine, valine and threonine show  R
2 ≥0.99 .The line of 
best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples was calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 64. Standard calibration curves for serine, ornithine and citrulline show  R
2 ≥0.98 .The line 
of best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples was calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 65. Standard calibration curves for hypoxanthine, PABA and DHAP show  R
2 ≥0.98 .The 
line of best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples was calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
 
Hypoxanthine
Y = 0.126161*X   R^2 = 0.9958   W: Equal
0 50 100 150 200 250
uM
0
5
10
15
20
25
30
35
A
re
a
 R
a
tio
PABA
Y = 0.000885836*X   R^2 = 0.9848   W: Equal
0 50 100 150 200 250
uM
0.00
0.05
0.10
0.15
0.20
0.25
A
re
a
 R
a
tio
DHAP
Y = 0.000108554*X   R^2 = 0.9845   W: Equal
0 50 100 150 200 250 300 350 400 450
uM
0.000
0.005
0.010
0.015
0.020
0.025
0.030
0.035
0.040
0.045
0.050
A
re
a
 R
a
tio
 338 
 
 
 
 
 
Figure 66. Standard calibration curves for glycerol-3-phosphate, 2-oxoglutarate and malate show  
R
2 ≥0.99 .The line of best fit for each calibration curve was generated using equal weighted linear 
regression as the mathematical model of best fit. Metabolites concentration in QC and parasite samples 
was calculated from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 67. Standard calibration curves for succinate, fumarate and oxaloacetate show  R
2 ≥0.99 
.The line of best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples was calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 68. Standard calibration curves for (iso)-citrate, acetyl-CoA and succinyl-CoA show  R
2 
≥0.99 .The line of best fit for each calibration curve was generated using equal weighted linear regression 
as the mathematical model of best fit. Metabolites concentration in QC and parasite samples was 
calculated from the resulting area ratio and the regression equation of the calibration curve.    
 
 
(Iso)_Citrate
Y = 0.121448*X   R^2 = 0.9904   W: Equal
0 20 40 60 80 100 120 140 160 180 200
uM
0
5
10
15
20
A
re
a
 R
a
ti
o
Acetyl-CoA
Y = 0.0709522*X   R^2 = 0.9908   W: Equal
0 50 100 150 200
uM
0
2
4
6
8
10
12
14
16
A
re
a
 R
a
tio
Succinyl-CoA
Y = 0.00357221*X   R^2 = 0.9895   W: Equal
0 20 40 60 80 100
uM
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
0.40
A
re
a
 R
a
ti
o
 341 
 
 
 
 
 
Figure 69. Standard calibration curves for AMP, ADP and ATP show  R
2 ≥0.99 .The line of best fit 
for each calibration curve was generated using equal weighted linear regression as the mathematical 
model of best fit. Metabolites concentration in QC and parasite samples was calculated from the resulting 
area ratio and the regression equation of the calibration curve.    
 
 
AMP
Y = 0.0999809*X   R^2 = 0.9941   W: Equal
0 20 40 60 80 100
uM
0
1
2
3
4
5
6
7
8
9
10
11
A
re
a
 R
a
ti
o
ADP
Y = 0.0444041*X   R^2 = 0.9966   W: Equal
0 10 20 30 40 50 60 70 80 90
uM
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
A
re
a
 R
a
ti
o
ATP
Y = 0.0259697*X   R^2 = 0.9915   W: Equal
0 10 20 30 40 50 60 70
uM
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
A
re
a
 R
a
ti
o
 342 
 
 
 
 
 
Figure 70. Standard calibration curves for  CTP, UMP and UDP show  R
2 ≥0.99 .The line of best fit 
for each calibration curve was generated using equal weighted linear regression as the mathematical 
model of best fit. Metabolites concentration in QC and parasite samples was calculated from the resulting 
area ratio and the regression equation of the calibration curve.    
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Figure 71. Standard calibration curves for UTP, TTP and GTP show  R
2 ≥0.98 .The line of best fit 
for each calibration curve was generated using equal weighted linear regression as the mathematical 
model of best fit. Metabolites concentration in QC and parasite samples was calculated from the resulting 
area ratio and the regression equation of the calibration curve.    
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Figure 72. Standard calibration curves for FAD, GSH and GSSG show  R
2 ≥0.98 .The line of best fit 
for each calibration curve was generated using equal weighted linear regression as the mathematical 
model of best fit. Metabolites concentration in QC and parasite samples was calculated from the resulting 
area ratio and the regression equation of the calibration curve.    
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Figure 73. Standard calibration curves for NAD, NADH and NADP show  R
2 ≥0.99 .The line of best 
fit for each calibration curve was generated using equal weighted linear regression as the mathematical 
model of best fit. Metabolites concentration in QC and parasite samples was calculated from the resulting 
area ratio and the regression equation of the calibration curve.    
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Figure 74. Standard calibration curves for NADPH, glucose and lactate show  R
2 ≥0.99 .The line of 
best fit for each calibration curve was generated using equal weighted linear regression as the 
mathematical model of best fit. Metabolites concentration in QC and parasite samples was calculated 
from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 75. Standard calibration curves for dihydroorotate, orotate and carbamoyl-phosphate show  
R
2 ≥0.98 .The line of best fit for each calibration curve was generated using equal weighted linear 
regression as the mathematical model of best fit. Metabolites concentration in QC and parasite samples 
was calculated from the resulting area ratio and the regression equation of the calibration curve.    
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Figure 76. Standard calibration curves for carbamoyl-l-aspartate, propionyl-CoA and PEP show  
R
2 ≥0.99. The line of best fit for each calibration curve was generated using equal weighted linear 
regression as the mathematical model of best fit. Metabolites concentration in QC and parasite samples 
was calculated from the resulting area ratio and the regression equation of the calibration curve.   
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Figure 77. Standard calibration curves for histidine and glutamine show  R
2 ≥0.99. The line of best 
fit for each calibration curve was generated using equal weighted linear regression as the mathematical 
model of best fit. Metabolites concentration in QC and parasite samples was calculated from the resulting 
area ratio and the regression equation of the calibration curve.   
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